[
  {
    "id": "41412441",
    "title_en": "Sulforaphane ameliorates DSS-induced colitis and secondary liver injury in mice: Proposed mechanism in the SCFAs-FFAR2/3-macrophage polarization axis.",
    "pub_date": "2026 Apr",
    "journal": "The Journal of nutritional biochemistry",
    "abstract_en": "Sulforaphane (SFN), an isothiocyanate derived from cruciferous vegetables, has shown therapeutic potential in inflammatory diseases. Our previous studies demonstrated that SFN ameliorates ulcerative colitis (UC) and restores gut microbiota composition in dextran sulfate sodium (DSS)-induced mice. In the present study, we further investigate the protective effects and underlying mechanisms of SFN against secondary liver injury associated with UC. The results revealed that SFN significantly alleviated pathological damage in both the colon and liver, improved liver function parameters, upregulated intestinal tight junction proteins and Muc2 expression, and inhibited inflammation in DSS-induced colitis mice. Additionally, SFN significantly elevated short-chain fatty acid (SCFA) concentrations, enhanced the expression of SCFA receptors (free fatty acid receptors 2 and 3, FFAR2/3), and modulated macrophage polarization by inhibiting M1 and promoting M2 phenotypes in the colon and liver. Collectively, these findings suggest that SFN may alleviate colitis and secondary liver injury by enhancing intestinal barrier function and reducing inflammatory responses, potentially via the SCFAs-FFAR2/3-macrophage polarization signaling cascade. Thus, SFN may serve as a promising adjunctive therapeutic agent for the prevention and treatment of UC.",
    "para1": "è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®ä¾†è‡ªåå­—èŠ±ç§‘è”¬èœçš„åŒ–åˆç‰©ï¼Œå°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æœ‰æ½›åœ¨çš„å•Ÿç¤ºã€‚ç ”ç©¶é¡¯ç¤ºï¼Œé€™ç¨®ç‰©è³ªå¯èƒ½å°æŠ—ç™¼ç‚æ€§ç–¾ç—…ï¼Œç‰¹åˆ¥æ˜¯èˆ‡è…¸é“å¥åº·æœ‰é—œçš„å•é¡Œã€‚é€éæ”¹å–„è…¸é“å±éšœåŠŸèƒ½å’Œæ¸›å°‘ç™¼ç‚åæ‡‰ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½åœ¨é é˜²å’Œæ²»ç™‚æŸäº›è…¸é“ç–¾ç—…æ–¹é¢ç™¼æ®é‡è¦ä½œç”¨ï¼Œé€™å°æ–¼å¸Œæœ›æ”¹å–„è…¸é“å¥åº·çš„äººä¾†èªªï¼Œæä¾›äº†ä¸€å€‹æ–°çš„æ–¹å‘ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°æ–¼èˆ‡æ½°ç˜æ€§çµè…¸ç‚ç›¸é—œçš„æ¬¡ç´šè‚æå‚·çš„ä¿è­·ä½œç”¨ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œè˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿æ½°ç˜æ€§çµè…¸ç‚æ‚£è€…çš„è…¸é“å’Œè‚è‡Ÿå¥åº·ï¼Œä¸¦å¸Œæœ›äº†è§£å…¶èƒŒå¾Œçš„æ©Ÿåˆ¶ã€‚æ½°ç˜æ€§çµè…¸ç‚æ˜¯ä¸€ç¨®æ…¢æ€§è…¸é“ç–¾ç—…ï¼Œå¯èƒ½å°è‡´è…¸é“å’Œè‚è‡Ÿçš„ç—…ç†æå‚·ï¼Œå› æ­¤ç ”ç©¶è˜¿è””ç¡«ç´ çš„æ½›åœ¨ç™‚æ•ˆå…·æœ‰é‡è¦æ„ç¾©ã€‚",
    "para3": "åœ¨é€™é …ç ”ç©¶ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†ä»¥å³æ—‹ç³–é…ç¡«é…¸éˆ‰ï¼ˆDSSï¼‰èª˜å°çš„å‹•ç‰©æ¨¡å‹ï¼Œä¾†æ¨¡æ“¬æ½°ç˜æ€§çµè…¸ç‚çš„æƒ…æ³ã€‚å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…è§€å¯Ÿäº†è˜¿è””ç¡«ç´ å°é€™äº›å°é¼ çš„å½±éŸ¿ï¼Œè©•ä¼°å…¶å°è…¸é“å’Œè‚è‡Ÿçš„ç—…ç†æå‚·ã€è‚åŠŸèƒ½åƒæ•¸ã€è…¸é“ç·Šå¯†é€£æ¥è›‹ç™½åŠé»æ¶²è›‹ç™½çš„è¡¨é”ç­‰æ–¹é¢çš„æ”¹å–„ã€‚é€™æ¨£çš„è¨­è¨ˆæœ‰åŠ©æ–¼æ·±å…¥äº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶åŠå…¶æ½›åœ¨çš„æ²»ç™‚æ•ˆæœã€‚",
    "para4": "ç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½é¡¯è‘—æ¸›è¼•å°é¼ çš„è…¸é“å’Œè‚è‡Ÿç—…ç†æå‚·ï¼Œä¸¦æ”¹å–„è‚åŠŸèƒ½åƒæ•¸ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ é‚„èƒ½æé«˜çŸ­éˆè„‚è‚ªé…¸çš„æ¿ƒåº¦ï¼Œå¢å¼·çŸ­éˆè„‚è‚ªé…¸å—é«”çš„è¡¨é”ï¼Œä¸¦èª¿ç¯€å·¨å™¬ç´°èƒçš„æ¥µåŒ–ï¼Œé€™äº›éƒ½è¡¨æ˜è˜¿è””ç¡«ç´ å¯èƒ½é€éå¢å¼·è…¸é“å±éšœåŠŸèƒ½å’Œæ¸›å°‘ç™¼ç‚åæ‡‰ä¾†ç™¼æ®ä½œç”¨ã€‚é€™äº›ç™¼ç¾æš—ç¤ºè˜¿è””ç¡«ç´ å¯èƒ½æˆç‚ºæ½°ç˜æ€§çµè…¸ç‚çš„è¼”åŠ©æ²»ç™‚é¸æ“‡ï¼Œä½†ä»éœ€é€²ä¸€æ­¥ç ”ç©¶ä¾†ç¢ºèªå…¶æ•ˆæœã€‚",
    "explanation_zh": "è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®ä¾†è‡ªåå­—èŠ±ç§‘è”¬èœçš„åŒ–åˆç‰©ï¼Œå°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æœ‰æ½›åœ¨çš„å•Ÿç¤ºã€‚ç ”ç©¶é¡¯ç¤ºï¼Œé€™ç¨®ç‰©è³ªå¯èƒ½å°æŠ—ç™¼ç‚æ€§ç–¾ç—…ï¼Œç‰¹åˆ¥æ˜¯èˆ‡è…¸é“å¥åº·æœ‰é—œçš„å•é¡Œã€‚é€éæ”¹å–„è…¸é“å±éšœåŠŸèƒ½å’Œæ¸›å°‘ç™¼ç‚åæ‡‰ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½åœ¨é é˜²å’Œæ²»ç™‚æŸäº›è…¸é“ç–¾ç—…æ–¹é¢ç™¼æ®é‡è¦ä½œç”¨ï¼Œé€™å°æ–¼å¸Œæœ›æ”¹å–„è…¸é“å¥åº·çš„äººä¾†èªªï¼Œæä¾›äº†ä¸€å€‹æ–°çš„æ–¹å‘ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°æ–¼èˆ‡æ½°ç˜æ€§çµè…¸ç‚ç›¸é—œçš„æ¬¡ç´šè‚æå‚·çš„ä¿è­·ä½œç”¨ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œè˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿æ½°ç˜æ€§çµè…¸ç‚æ‚£è€…çš„è…¸é“å’Œè‚è‡Ÿå¥åº·ï¼Œä¸¦å¸Œæœ›äº†è§£å…¶èƒŒå¾Œçš„æ©Ÿåˆ¶ã€‚æ½°ç˜æ€§çµè…¸ç‚æ˜¯ä¸€ç¨®æ…¢æ€§è…¸é“ç–¾ç—…ï¼Œå¯èƒ½å°è‡´è…¸é“å’Œè‚è‡Ÿçš„ç—…ç†æå‚·ï¼Œå› æ­¤ç ”ç©¶è˜¿è””ç¡«ç´ çš„æ½›åœ¨ç™‚æ•ˆå…·æœ‰é‡è¦æ„ç¾©ã€‚\n\nåœ¨é€™é …ç ”ç©¶ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†ä»¥å³æ—‹ç³–é…ç¡«é…¸éˆ‰ï¼ˆDSSï¼‰èª˜å°çš„å‹•ç‰©æ¨¡å‹ï¼Œä¾†æ¨¡æ“¬æ½°ç˜æ€§çµè…¸ç‚çš„æƒ…æ³ã€‚å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…è§€å¯Ÿäº†è˜¿è””ç¡«ç´ å°é€™äº›å°é¼ çš„å½±éŸ¿ï¼Œè©•ä¼°å…¶å°è…¸é“å’Œè‚è‡Ÿçš„ç—…ç†æå‚·ã€è‚åŠŸèƒ½åƒæ•¸ã€è…¸é“ç·Šå¯†é€£æ¥è›‹ç™½åŠé»æ¶²è›‹ç™½çš„è¡¨é”ç­‰æ–¹é¢çš„æ”¹å–„ã€‚é€™æ¨£çš„è¨­è¨ˆæœ‰åŠ©æ–¼æ·±å…¥äº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶åŠå…¶æ½›åœ¨çš„æ²»ç™‚æ•ˆæœã€‚\n\nç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½é¡¯è‘—æ¸›è¼•å°é¼ çš„è…¸é“å’Œè‚è‡Ÿç—…ç†æå‚·ï¼Œä¸¦æ”¹å–„è‚åŠŸèƒ½åƒæ•¸ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ é‚„èƒ½æé«˜çŸ­éˆè„‚è‚ªé…¸çš„æ¿ƒåº¦ï¼Œå¢å¼·çŸ­éˆè„‚è‚ªé…¸å—é«”çš„è¡¨é”ï¼Œä¸¦èª¿ç¯€å·¨å™¬ç´°èƒçš„æ¥µåŒ–ï¼Œé€™äº›éƒ½è¡¨æ˜è˜¿è””ç¡«ç´ å¯èƒ½é€éå¢å¼·è…¸é“å±éšœåŠŸèƒ½å’Œæ¸›å°‘ç™¼ç‚åæ‡‰ä¾†ç™¼æ®ä½œç”¨ã€‚é€™äº›ç™¼ç¾æš—ç¤ºè˜¿è””ç¡«ç´ å¯èƒ½æˆç‚ºæ½°ç˜æ€§çµè…¸ç‚çš„è¼”åŠ©æ²»ç™‚é¸æ“‡ï¼Œä½†ä»éœ€é€²ä¸€æ­¥ç ”ç©¶ä¾†ç¢ºèªå…¶æ•ˆæœã€‚",
    "fb_post": "æ ¹æ“šã€ŠThe Journal of nutritional biochemistryã€‹æ–¼ 2026 å¹´ 4 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿè˜¿è””è£¡é¢ç«Ÿç„¶æœ‰ä¸€ç¨®ç¥å¥‡çš„æˆåˆ†å«è˜¿è””ç¡«ç´ ï¼é€™ç¨®æˆåˆ†ä¾†è‡ªåå­—èŠ±ç§‘çš„è”¬èœï¼Œå°æˆ‘å€‘çš„å¥åº·å¯æœ‰ä¸å°‘å¥½è™•å“¦ï¼æœ€è¿‘çš„ç ”ç©¶ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼å°æŠ—ç™¼ç‚ï¼Œç‰¹åˆ¥æ˜¯è·Ÿè…¸é“å¥åº·æœ‰é—œçš„å•é¡Œã€‚ é€™é …ç ”ç©¶ä¸»è¦é—œå¿ƒçš„æ˜¯è˜¿è””ç¡«ç´ å°æ½°ç˜æ€§çµè…¸ç‚æ‚£è€…çš„è…¸é“å’Œè‚è‡Ÿå¥åº·çš„å½±éŸ¿ã€‚æ½°ç˜æ€§çµè…¸ç‚æ˜¯ä¸€ç¨®æ…¢æ€§è…¸é“ç–¾ç—…ï¼Œæœƒé€ æˆè…¸é“å’Œè‚è‡Ÿçš„æå‚·ï¼Œå› æ­¤äº†è§£è˜¿è””ç¡«ç´ çš„æ½›åœ¨ç™‚æ•ˆéå¸¸é‡è¦ã€‚ ç ”ç©¶è€…ä½¿ç”¨äº†ä¸€ç¨®å‹•ç‰©æ¨¡å‹ä¾†æ¨¡æ“¬æ½°ç˜æ€§çµè…¸ç‚çš„æƒ…æ³ï¼Œä¸¦è§€å¯Ÿè˜¿è””ç¡«ç´ å°è…¸é“å’Œè‚è‡Ÿçš„å½±éŸ¿ã€‚çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½é¡¯è‘—æ¸›è¼•å°é¼ çš„ç—…ç†æå‚·ï¼Œæ”¹å–„è‚åŠŸèƒ½ï¼Œç”šè‡³é‚„èƒ½æå‡è…¸é“çš„å¥åº·ï¼é€™äº›ç™¼ç¾è®“æˆ‘å€‘çœ‹åˆ°è˜¿è””ç¡«ç´ æˆ–è¨±èƒ½æˆç‚ºæ½°ç˜æ€§çµè…¸ç‚çš„è¼”åŠ©æ²»ç™‚é¸æ“‡ï¼Œä½†é‚„éœ€è¦æ›´å¤šçš„ç ”ç©¶ä¾†ç¢ºèªã€‚ ç¸½çµä¸€ä¸‹ï¼š 1. è˜¿è””ç¡«ç´ ä¾†è‡ªåå­—èŠ±ç§‘è”¬èœï¼Œå°è…¸é“å¥åº·æœ‰å¹«åŠ©ã€‚ 2. ç ”ç©¶ç™¼ç¾å®ƒèƒ½æ¸›è¼•æ½°ç˜æ€§çµè…¸ç‚çš„ç—…ç†æå‚·ã€‚ 3. é€™å¯èƒ½æˆç‚ºæœªä¾†è…¸é“ç–¾ç—…çš„è¼”åŠ©æ²»ç™‚é¸æ“‡ï¼",
    "image_prompt": "Create a flat design infographic with a light background that explains the experiment and main results of a study on the protective effects of sulforaphane from cruciferous vegetables. Include simplified illustrations of broccoli and sulforaphane, animals used in the experiment, and arrows or flow lines to indicate the experimental steps. Add a section highlighting the main results, such as protection effects and changes observed.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "æ½°ç˜æ€§çµè…¸ç‚ Ulcerative Colitis",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41412441/"
  },
  {
    "id": "41511787",
    "title_en": "Sulforaphane attenuates DSS-induced ulcerative colitis <i>via</i> the Nrf2/STAT3 signaling pathway and gut microbiota modulation.",
    "pub_date": "2026 Jan",
    "journal": "Food & function",
    "abstract_en": "Sulforaphane (SFN) is an isothiocyanate derived from cruciferous vegetables. Our previous studies have shown that nuclear factor (erythroid-derived 2)-like 2 (Nrf2) and signal transducer and activator of transcription 3 (STAT3) may play roles in the protective effects of SFN against dextran sulfate sodium (DSS)-induced ulcerative colitis (UC) in mice. This study aims to elucidate the underlying mechanisms. GEO database analysis revealed that <i>Nrf2</i> expression was reduced, while <i>STAT3</i> expression was elevated in the colonic mucosa of UC patients compared to healthy controls (<i>P</i> < 0.01). In the DSS-induced Caco-2 cell model, <i>Nrf2</i> siRNA transfection abolished the effects of SFN on enhancing Nrf2 and tight junction protein expression, suppressing inflammatory factors and reducing the phosphorylated-STAT3/STAT3 ratio. In DSS-induced UC mice, SFN alleviated colitic symptoms in wide-type mice, including weight loss, colon edema and shortening, and inflammatory cell infiltration. SFN also reduced the levels of inflammatory cytokines and enhanced tight junction protein expression in wide-type mice with colitis. However, these protective effects were largely abolished in Nrf2 knockout mice. Moreover, in Nrf2 knockout colitis mice, SFN reduced the gut microbial diversity and decreased the relative abundance of <i>Firmicutes</i> at the phylum level, as well as <i>Muribaculaceae</i> and <i>Lachnospiraceae</i>_NK4A136 at the genus level. In conclusion, the protective effects of SFN against UC may involve the regulation of the Nrf2/STAT3 signaling pathway and modulation of the gut microbiota, highlighting Nrf2 as a key mediator of SFN's action.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨è…¸é“å¥åº·æ–¹é¢ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½å°æ½°ç˜æ€§çµè…¸ç‚ï¼ˆUCï¼‰æœ‰ä¿è­·ä½œç”¨ï¼Œé€™æ˜¯ä¸€ç¨®å½±éŸ¿è…¸é“çš„ç–¾ç—…ã€‚é€éäº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ï¼Œæˆ‘å€‘æˆ–è¨±èƒ½æ‰¾åˆ°æ–°çš„æ–¹æ³•ä¾†é é˜²æˆ–æ¸›è¼•é€™é¡ç–¾ç—…çš„ç—‡ç‹€ï¼Œé€²è€Œæ”¹å–„æ‚£è€…çš„ç”Ÿæ´»å“è³ªã€‚é€™å°æ–¼é‚£äº›æœ‰æ½°ç˜æ€§çµè…¸ç‚é¢¨éšªçš„äººä¾†èªªï¼Œç„¡ç–‘æ˜¯ä¸€å€‹å€¼å¾—é—œæ³¨çš„è©±é¡Œã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨æ½°ç˜æ€§çµè…¸ç‚ä¸­çš„ä½œç”¨åŠå…¶èƒŒå¾Œçš„æ©Ÿåˆ¶ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿èˆ‡è…¸é“ç‚ç—‡ç›¸é—œçš„ä¿¡è™Ÿå‚³å°è·¯å¾‘ï¼Œç‰¹åˆ¥æ˜¯Nrf2å’ŒSTAT3é€™å…©å€‹é—œéµå› å­ã€‚é€éåˆ†æé€™äº›å› å­çš„è¡¨ç¾è®ŠåŒ–ï¼Œç ”ç©¶è€…å¸Œæœ›èƒ½æ­ç¤ºè˜¿è””ç¡«ç´ åœ¨è…¸é“å¥åº·ä¸­çš„æ½›åœ¨ç›Šè™•ï¼Œä¸¦ç‚ºæœªä¾†çš„æ²»ç™‚ç­–ç•¥æä¾›ä¾æ“šã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†å°é¼ æ¨¡å‹å’Œç´°èƒæ¨¡å‹ä¾†æ¢è¨è˜¿è””ç¡«ç´ çš„æ•ˆæœã€‚é¦–å…ˆï¼Œä»–å€‘åˆ†æäº†æ½°ç˜æ€§çµè…¸ç‚æ‚£è€…çš„è…¸é“çµ„ç¹”ï¼Œç™¼ç¾Nrf2çš„è¡¨ç¾é™ä½ï¼Œè€ŒSTAT3çš„è¡¨ç¾å‰‡å‡é«˜ã€‚æ¥è‘—ï¼Œç ”ç©¶è€…åœ¨DSSèª˜å°çš„Caco-2ç´°èƒæ¨¡å‹ä¸­é€²è¡Œäº†å¯¦é©—ï¼Œä½¿ç”¨Nrf2çš„siRNAä¾†è§€å¯Ÿè˜¿è””ç¡«ç´ çš„ä½œç”¨ã€‚æœ€å¾Œï¼Œä»–å€‘åœ¨DSSèª˜å°çš„æ½°ç˜æ€§çµè…¸ç‚å°é¼ ä¸­æ¸¬è©¦äº†è˜¿è””ç¡«ç´ çš„æ•ˆæœï¼Œè§€å¯Ÿå…¶å°è…¸é“ç—‡ç‹€åŠç‚ç—‡å› å­çš„å½±éŸ¿ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ æ¸›è¼•æ½°ç˜æ€§çµè…¸ç‚å°é¼ çš„ç—‡ç‹€ï¼ŒåŒ…æ‹¬é«”é‡æ¸›è¼•ã€è…¸é“æ°´è…«å’Œç‚ç—‡ç´°èƒæµ¸æ½¤ç­‰ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ é‚„èƒ½é™ä½ç‚ç—‡ç´°èƒå› å­çš„æ°´å¹³ï¼Œä¸¦å¢å¼·ç·Šå¯†é€£æ¥è›‹ç™½çš„è¡¨ç¾ã€‚ç„¶è€Œï¼Œé€™äº›ä¿è­·æ•ˆæœåœ¨Nrf2åŸºå› ç¼ºå¤±çš„å°é¼ ä¸­å¤§å¹…æ¸›å¼±ï¼Œé¡¯ç¤ºNrf2åœ¨è˜¿è””ç¡«ç´ çš„ä½œç”¨ä¸­æ‰®æ¼”äº†é‡è¦è§’è‰²ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ é‚„å½±éŸ¿äº†è…¸é“å¾®ç”Ÿç‰©çš„å¤šæ¨£æ€§ï¼Œé€™å¯èƒ½é€²ä¸€æ­¥å½±éŸ¿è…¸é“å¥åº·ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨è…¸é“å¥åº·æ–¹é¢ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½å°æ½°ç˜æ€§çµè…¸ç‚ï¼ˆUCï¼‰æœ‰ä¿è­·ä½œç”¨ï¼Œé€™æ˜¯ä¸€ç¨®å½±éŸ¿è…¸é“çš„ç–¾ç—…ã€‚é€éäº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ï¼Œæˆ‘å€‘æˆ–è¨±èƒ½æ‰¾åˆ°æ–°çš„æ–¹æ³•ä¾†é é˜²æˆ–æ¸›è¼•é€™é¡ç–¾ç—…çš„ç—‡ç‹€ï¼Œé€²è€Œæ”¹å–„æ‚£è€…çš„ç”Ÿæ´»å“è³ªã€‚é€™å°æ–¼é‚£äº›æœ‰æ½°ç˜æ€§çµè…¸ç‚é¢¨éšªçš„äººä¾†èªªï¼Œç„¡ç–‘æ˜¯ä¸€å€‹å€¼å¾—é—œæ³¨çš„è©±é¡Œã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨æ½°ç˜æ€§çµè…¸ç‚ä¸­çš„ä½œç”¨åŠå…¶èƒŒå¾Œçš„æ©Ÿåˆ¶ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿èˆ‡è…¸é“ç‚ç—‡ç›¸é—œçš„ä¿¡è™Ÿå‚³å°è·¯å¾‘ï¼Œç‰¹åˆ¥æ˜¯Nrf2å’ŒSTAT3é€™å…©å€‹é—œéµå› å­ã€‚é€éåˆ†æé€™äº›å› å­çš„è¡¨ç¾è®ŠåŒ–ï¼Œç ”ç©¶è€…å¸Œæœ›èƒ½æ­ç¤ºè˜¿è””ç¡«ç´ åœ¨è…¸é“å¥åº·ä¸­çš„æ½›åœ¨ç›Šè™•ï¼Œä¸¦ç‚ºæœªä¾†çš„æ²»ç™‚ç­–ç•¥æä¾›ä¾æ“šã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†å°é¼ æ¨¡å‹å’Œç´°èƒæ¨¡å‹ä¾†æ¢è¨è˜¿è””ç¡«ç´ çš„æ•ˆæœã€‚é¦–å…ˆï¼Œä»–å€‘åˆ†æäº†æ½°ç˜æ€§çµè…¸ç‚æ‚£è€…çš„è…¸é“çµ„ç¹”ï¼Œç™¼ç¾Nrf2çš„è¡¨ç¾é™ä½ï¼Œè€ŒSTAT3çš„è¡¨ç¾å‰‡å‡é«˜ã€‚æ¥è‘—ï¼Œç ”ç©¶è€…åœ¨DSSèª˜å°çš„Caco-2ç´°èƒæ¨¡å‹ä¸­é€²è¡Œäº†å¯¦é©—ï¼Œä½¿ç”¨Nrf2çš„siRNAä¾†è§€å¯Ÿè˜¿è””ç¡«ç´ çš„ä½œç”¨ã€‚æœ€å¾Œï¼Œä»–å€‘åœ¨DSSèª˜å°çš„æ½°ç˜æ€§çµè…¸ç‚å°é¼ ä¸­æ¸¬è©¦äº†è˜¿è””ç¡«ç´ çš„æ•ˆæœï¼Œè§€å¯Ÿå…¶å°è…¸é“ç—‡ç‹€åŠç‚ç—‡å› å­çš„å½±éŸ¿ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ æ¸›è¼•æ½°ç˜æ€§çµè…¸ç‚å°é¼ çš„ç—‡ç‹€ï¼ŒåŒ…æ‹¬é«”é‡æ¸›è¼•ã€è…¸é“æ°´è…«å’Œç‚ç—‡ç´°èƒæµ¸æ½¤ç­‰ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ é‚„èƒ½é™ä½ç‚ç—‡ç´°èƒå› å­çš„æ°´å¹³ï¼Œä¸¦å¢å¼·ç·Šå¯†é€£æ¥è›‹ç™½çš„è¡¨ç¾ã€‚ç„¶è€Œï¼Œé€™äº›ä¿è­·æ•ˆæœåœ¨Nrf2åŸºå› ç¼ºå¤±çš„å°é¼ ä¸­å¤§å¹…æ¸›å¼±ï¼Œé¡¯ç¤ºNrf2åœ¨è˜¿è””ç¡«ç´ çš„ä½œç”¨ä¸­æ‰®æ¼”äº†é‡è¦è§’è‰²ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ é‚„å½±éŸ¿äº†è…¸é“å¾®ç”Ÿç‰©çš„å¤šæ¨£æ€§ï¼Œé€™å¯èƒ½é€²ä¸€æ­¥å½±éŸ¿è…¸é“å¥åº·ã€‚",
    "fb_post": "æ ¹æ“šã€ŠFood & functionã€‹æ–¼ 2026 å¹´ 1 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿè˜¿è””ä¸åƒ…å¥½åƒï¼Œé‚„å¯èƒ½å°æˆ‘å€‘çš„è…¸é“å¥åº·æœ‰å¹«åŠ©ï¼æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ ï¼ˆå°±æ˜¯è˜¿è””è£¡çš„é‚£å€‹æˆåˆ†ï¼‰å¯èƒ½å°æ½°ç˜æ€§çµè…¸ç‚ï¼ˆUCï¼‰æœ‰ä¿è­·ä½œç”¨ï¼Œé€™æ˜¯ä¸€ç¨®è®“è…¸é“ç™¼ç‚çš„ç–¾ç—…ã€‚ç ”ç©¶è€…å€‘æƒ³çŸ¥é“è˜¿è””ç¡«ç´ åˆ°åº•æ˜¯æ€éº¼å¹«åŠ©è…¸é“çš„ï¼Œæ–¼æ˜¯ä»–å€‘åšäº†ä¸€äº›å¯¦é©—ä¾†æ‰¾å‡ºç­”æ¡ˆã€‚  \n  \nä»–å€‘ä½¿ç”¨å°é¼ å’Œç´°èƒæ¨¡å‹ï¼Œè§€å¯Ÿæ½°ç˜æ€§çµè…¸ç‚æ‚£è€…çš„è…¸é“çµ„ç¹”ï¼Œç™¼ç¾æŸäº›é—œéµå› å­çš„è¡¨ç¾è®ŠåŒ–ï¼Œé€™äº›å› å­è·Ÿè…¸é“ç‚ç—‡æœ‰é—œã€‚æ¥è‘—ï¼Œä»–å€‘åœ¨å¯¦é©—ä¸­æ¸¬è©¦äº†è˜¿è””ç¡«ç´ çš„æ•ˆæœï¼Œçµæœé¡¯ç¤ºè˜¿è””ç¡«ç´ èƒ½æ¸›è¼•å°é¼ çš„æ½°ç˜æ€§çµè…¸ç‚ç—‡ç‹€ï¼Œåƒæ˜¯é«”é‡æ¸›è¼•å’Œè…¸é“æ°´è…«ç­‰å•é¡Œã€‚  \n  \næœ€é‡è¦çš„æ˜¯ï¼Œé€™äº›æ•ˆæœåœ¨ç¼ºå°‘æŸäº›åŸºå› çš„å°é¼ ä¸­å¤§å¹…æ¸›å¼±ï¼Œé¡¯ç¤ºé€™äº›åŸºå› å°è˜¿è””ç¡«ç´ çš„ä½œç”¨éå¸¸é—œéµã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ é‚„å¯èƒ½å½±éŸ¿è…¸é“è£¡çš„å¾®ç”Ÿç‰©ï¼Œé€²ä¸€æ­¥å½±éŸ¿å¥åº·ã€‚  \n  \nğŸ” ç ”ç©¶é‡é»ï¼š  \n1. è˜¿è””ç¡«ç´ æˆ–è¨±èƒ½å¹«åŠ©æ¸›è¼•æ½°ç˜æ€§çµè…¸ç‚çš„ç—‡ç‹€ã€‚  \n2. Nrf2é€™å€‹åŸºå› åœ¨è˜¿è””ç¡«ç´ çš„ä¿è­·ä½œç”¨ä¸­æ‰®æ¼”é‡è¦è§’è‰²ã€‚  \n3. è˜¿è””ç¡«ç´ å¯èƒ½å½±éŸ¿è…¸é“å¾®ç”Ÿç‰©çš„å¤šæ¨£æ€§ï¼Œé€²è€Œå½±éŸ¿è…¸é“å¥åº·ã€‚",
    "image_prompt": "Create a simple, flat design infographic on a light background that explains the experimental methods and main findings of a study on the effects of sulforaphane from radishes on ulcerative colitis. Include symbols representing sulforaphane (like radishes or broccoli), simplified illustrations of experimental subjects (like mice or cells), arrows or flow lines to show the experimental steps, and a section labeled 'Main Findings' highlighting protective effects and changes observed.",
    "is_human_study": true,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "æ½°ç˜æ€§çµè…¸ç‚ Ulcerative Colitis",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41511787/"
  },
  {
    "id": "41540706",
    "title_en": "[Sulforaphane reduces reactive astrocyte-mediated neuron apoptosis <i>in vitro</i> by inhibiting the MAPK/NF-ÎºB signaling pathway in AÎ²42 oligomer-activated astrocytes].",
    "pub_date": "2026 Jan",
    "journal": "Nan fang yi ke da xue xue bao = Journal of Southern Medical University",
    "abstract_en": "To explore the effects of sulforaphane (SFN) on AÎ²42-activated U87 astrocyte-mediated apoptosis of SH-SY5Y neurons <i>in vitro</i>. U87 cells treated with different concentrations of AÎ²42, SFN or both were examined for changes in cell activity, IL-6 and TNF-Î± mRNA expression, release of IL-6 and TNF-Î± proteins, and expressions of p-p38, p-p65 and GFAP using CCK-8 assay, RT-qPCR, ELISA and Western blotting. SH-SY5Y neurons were co-cultured with U87 astrocytes treated with AÎ²42 alone or in combination with SFN or SB203580 for 24 h, and the changes in Bax protein expression levels and viability of SH-SY5Y cells were examined. The effects of AÎ²42, SFN, and their combination were also observed in astrocytes isolated from mouse brain tissues, and the indirect effects of astrocyte treatmentt on viability of the co-cultured primary neurons were assessed. The viability of U87 astrocytes increased significantly following treatment with 1.25 Î¼mol/L AÎ²42 but decreased after AÎ²42 treatment above 5 Î¼mol/L. SFN treatments for 24 h below 5 Î¼mol/L did not significantly affect U87 cell viability. AÎ²42 treatment significantly increased protein expressions of p-p38, p-p65 and GFAP, mRNA expression levels of IL-6 and TNF-Î±, and IL-6 and TNF-Î± levels in culture supernatant of U87 cells. SH-SY5Y cells co-cultured with AÎ²42-treated U87 cells showed significantly increased protein expressions of Bax, and exhibited lowered viability following co-culture with 5 Î¼mol/L AÎ²42-treated U87 cells. The isolated mouse astrocytes showed lowered viability following AÎ²42 treatment above 10 Î¼mol/L, but SFN treatment below 5 Î¼mol/L for 24 did not obviously affect the cell viability. The primary neurons co-cultured with AÎ²42-treated mouse astrocytes showed significantly lower cell viability than those co-cultured with the astrocytes treated with AÎ²+SFN or AÎ²+SB203580. SFN attenuates astrocyte-mediated neuron apoptosis by inhibiting the MAPK/NF-ÎºB signaling pathway in AÎ²42 oligomer-activated astrocytes.",
    "para1": "é€™é …ç ”ç©¶å¯èƒ½å°å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨ç¥ç¶“é€€è¡Œæ€§ç–¾ç—…çš„èƒŒæ™¯ä¸‹ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œé’èŠ±æ¤°èœä¸­çš„è˜¿è””ç¡«ç´ å¯èƒ½å°ç¥ç¶“ç´°èƒçš„å­˜æ´»æœ‰æ­£é¢å½±éŸ¿ï¼Œé€™å°æ–¼é é˜²èˆ‡è€åŒ–ç›¸é—œçš„ç¥ç¶“ç–¾ç—…å¦‚é˜¿èŒ²ç½•é»˜ç—‡ç­‰ï¼Œå¯èƒ½å…·æœ‰æ½›åœ¨çš„æ„ç¾©ã€‚é€éäº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç¥ç¶“ç´°èƒçš„æ­»äº¡éç¨‹ï¼Œæˆ‘å€‘æˆ–è¨±èƒ½æ‰¾åˆ°æ–°çš„æ–¹æ³•ä¾†ä¿è­·å¤§è…¦å¥åº·ï¼Œæ¸›å°‘ç¥ç¶“ç´°èƒçš„æå‚·ï¼Œé€²è€Œæ”¹å–„ç”Ÿæ´»å“è³ªã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°æ–¼é˜¿èŒ²ç½•é»˜ç—‡ç›¸é—œçš„ç¥ç¶“ç´°èƒæ­»äº¡çš„å½±éŸ¿ã€‚å…·é«”ä¾†èªªï¼Œç ”ç©¶é—œæ³¨çš„æ˜¯é˜¿Î²42è›‹ç™½å¦‚ä½•å¼•ç™¼ç¥ç¶“ç´°èƒçš„å‡‹äº¡ï¼Œä»¥åŠè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½å¤ æ¸›å°‘é€™ç¨®å‡‹äº¡ç¾è±¡ã€‚é€éé€™äº›ç ”ç©¶ï¼Œç§‘å­¸å®¶å¸Œæœ›èƒ½å¤ æ›´æ·±å…¥äº†è§£ç¥ç¶“ç´°èƒæ­»äº¡çš„æ©Ÿåˆ¶ï¼Œä¸¦å°‹æ‰¾å¯èƒ½çš„å¹²é æ–¹æ³•ï¼Œä»¥æ”¹å–„ç¥ç¶“é€€è¡Œæ€§ç–¾ç—…çš„æ²»ç™‚ç­–ç•¥ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶äººå“¡ä½¿ç”¨äº†U87æ˜Ÿç‹€è† ç´°èƒå’ŒSH-SY5Yç¥ç¶“ç´°èƒé€²è¡Œäº†å…±åŒåŸ¹é¤Šï¼Œä¸¦å°ä¸åŒæ¿ƒåº¦çš„é˜¿Î²42å’Œè˜¿è””ç¡«ç´ é€²è¡Œäº†è™•ç†ã€‚ç ”ç©¶åœ˜éšŠä½¿ç”¨äº†å¤šç¨®æŠ€è¡“ä¾†è©•ä¼°ç´°èƒæ´»æ€§å’ŒåŸºå› è¡¨é”ï¼ŒåŒ…æ‹¬CCK-8æ¸¬è©¦ã€RT-qPCRã€ELISAå’Œè¥¿æ–¹å°è·¡æ³•ã€‚é€™äº›æ–¹æ³•å¹«åŠ©ä»–å€‘è§€å¯Ÿåˆ°åœ¨ä¸åŒè™•ç†ä¸‹ï¼Œç´°èƒçš„æ´»æ€§è®ŠåŒ–ä»¥åŠç›¸é—œçš„è›‹ç™½è³ªå’ŒåŸºå› è¡¨é”æƒ…æ³ï¼Œå¾è€Œäº†è§£è˜¿è””ç¡«ç´ å°ç¥ç¶“ç´°èƒçš„å½±éŸ¿ã€‚",
    "para4": "ä¸»è¦çš„ç™¼ç¾æ˜¯ï¼Œé˜¿Î²42çš„è™•ç†æœƒé¡¯è‘—å¢åŠ U87ç´°èƒä¸­æŸäº›è›‹ç™½è³ªçš„è¡¨é”ï¼Œä¸¦é™ä½SH-SY5Yç¥ç¶“ç´°èƒçš„å­˜æ´»ç‡ã€‚è€Œè˜¿è””ç¡«ç´ çš„è™•ç†å‰‡åœ¨ä¸€å®šæ¿ƒåº¦ä¸‹å°U87ç´°èƒçš„æ´»æ€§å½±éŸ¿ä¸å¤§ï¼Œä½†åœ¨èˆ‡é˜¿Î²42å…±åŒä½œç”¨æ™‚ï¼Œèƒ½å¤ æ¸›å°‘ç¥ç¶“ç´°èƒçš„å‡‹äº¡ã€‚é€™äº›çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€éæŠ‘åˆ¶ç‰¹å®šçš„ä¿¡è™Ÿé€šè·¯ä¾†æ¸›å°‘æ˜Ÿç‹€è† ç´°èƒå°ç¥ç¶“ç´°èƒçš„æå®³ï¼Œé€™ç‚ºæœªä¾†çš„ç ”ç©¶æä¾›äº†æ–°çš„æ–¹å‘ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å¯èƒ½å°å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨ç¥ç¶“é€€è¡Œæ€§ç–¾ç—…çš„èƒŒæ™¯ä¸‹ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œé’èŠ±æ¤°èœä¸­çš„è˜¿è””ç¡«ç´ å¯èƒ½å°ç¥ç¶“ç´°èƒçš„å­˜æ´»æœ‰æ­£é¢å½±éŸ¿ï¼Œé€™å°æ–¼é é˜²èˆ‡è€åŒ–ç›¸é—œçš„ç¥ç¶“ç–¾ç—…å¦‚é˜¿èŒ²ç½•é»˜ç—‡ç­‰ï¼Œå¯èƒ½å…·æœ‰æ½›åœ¨çš„æ„ç¾©ã€‚é€éäº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç¥ç¶“ç´°èƒçš„æ­»äº¡éç¨‹ï¼Œæˆ‘å€‘æˆ–è¨±èƒ½æ‰¾åˆ°æ–°çš„æ–¹æ³•ä¾†ä¿è­·å¤§è…¦å¥åº·ï¼Œæ¸›å°‘ç¥ç¶“ç´°èƒçš„æå‚·ï¼Œé€²è€Œæ”¹å–„ç”Ÿæ´»å“è³ªã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°æ–¼é˜¿èŒ²ç½•é»˜ç—‡ç›¸é—œçš„ç¥ç¶“ç´°èƒæ­»äº¡çš„å½±éŸ¿ã€‚å…·é«”ä¾†èªªï¼Œç ”ç©¶é—œæ³¨çš„æ˜¯é˜¿Î²42è›‹ç™½å¦‚ä½•å¼•ç™¼ç¥ç¶“ç´°èƒçš„å‡‹äº¡ï¼Œä»¥åŠè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½å¤ æ¸›å°‘é€™ç¨®å‡‹äº¡ç¾è±¡ã€‚é€éé€™äº›ç ”ç©¶ï¼Œç§‘å­¸å®¶å¸Œæœ›èƒ½å¤ æ›´æ·±å…¥äº†è§£ç¥ç¶“ç´°èƒæ­»äº¡çš„æ©Ÿåˆ¶ï¼Œä¸¦å°‹æ‰¾å¯èƒ½çš„å¹²é æ–¹æ³•ï¼Œä»¥æ”¹å–„ç¥ç¶“é€€è¡Œæ€§ç–¾ç—…çš„æ²»ç™‚ç­–ç•¥ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶äººå“¡ä½¿ç”¨äº†U87æ˜Ÿç‹€è† ç´°èƒå’ŒSH-SY5Yç¥ç¶“ç´°èƒé€²è¡Œäº†å…±åŒåŸ¹é¤Šï¼Œä¸¦å°ä¸åŒæ¿ƒåº¦çš„é˜¿Î²42å’Œè˜¿è””ç¡«ç´ é€²è¡Œäº†è™•ç†ã€‚ç ”ç©¶åœ˜éšŠä½¿ç”¨äº†å¤šç¨®æŠ€è¡“ä¾†è©•ä¼°ç´°èƒæ´»æ€§å’ŒåŸºå› è¡¨é”ï¼ŒåŒ…æ‹¬CCK-8æ¸¬è©¦ã€RT-qPCRã€ELISAå’Œè¥¿æ–¹å°è·¡æ³•ã€‚é€™äº›æ–¹æ³•å¹«åŠ©ä»–å€‘è§€å¯Ÿåˆ°åœ¨ä¸åŒè™•ç†ä¸‹ï¼Œç´°èƒçš„æ´»æ€§è®ŠåŒ–ä»¥åŠç›¸é—œçš„è›‹ç™½è³ªå’ŒåŸºå› è¡¨é”æƒ…æ³ï¼Œå¾è€Œäº†è§£è˜¿è””ç¡«ç´ å°ç¥ç¶“ç´°èƒçš„å½±éŸ¿ã€‚\n\nä¸»è¦çš„ç™¼ç¾æ˜¯ï¼Œé˜¿Î²42çš„è™•ç†æœƒé¡¯è‘—å¢åŠ U87ç´°èƒä¸­æŸäº›è›‹ç™½è³ªçš„è¡¨é”ï¼Œä¸¦é™ä½SH-SY5Yç¥ç¶“ç´°èƒçš„å­˜æ´»ç‡ã€‚è€Œè˜¿è””ç¡«ç´ çš„è™•ç†å‰‡åœ¨ä¸€å®šæ¿ƒåº¦ä¸‹å°U87ç´°èƒçš„æ´»æ€§å½±éŸ¿ä¸å¤§ï¼Œä½†åœ¨èˆ‡é˜¿Î²42å…±åŒä½œç”¨æ™‚ï¼Œèƒ½å¤ æ¸›å°‘ç¥ç¶“ç´°èƒçš„å‡‹äº¡ã€‚é€™äº›çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€éæŠ‘åˆ¶ç‰¹å®šçš„ä¿¡è™Ÿé€šè·¯ä¾†æ¸›å°‘æ˜Ÿç‹€è† ç´°èƒå°ç¥ç¶“ç´°èƒçš„æå®³ï¼Œé€™ç‚ºæœªä¾†çš„ç ”ç©¶æä¾›äº†æ–°çš„æ–¹å‘ã€‚",
    "fb_post": "æ ¹æ“šã€ŠNan fang yi ke da xue xue bao = Journal of Southern Medical Universityã€‹æ–¼ 2026 å¹´ 1 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ± ä½ çŸ¥é“å—ï¼Ÿé’èŠ±æ¤°èœè£¡çš„è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼ä¿è­·æˆ‘å€‘çš„å¤§è…¦ï¼é€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ å°ç¥ç¶“ç´°èƒçš„å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯åœ¨èˆ‡é˜¿èŒ²ç½•é»˜ç—‡ç›¸é—œçš„ç´°èƒæ­»äº¡éç¨‹ä¸­ã€‚ç ”ç©¶äººå“¡ä½¿ç”¨äº†ä¸åŒæ¿ƒåº¦çš„é˜¿Î²42ï¼ˆé€™æ˜¯ä¸€ç¨®èˆ‡é˜¿èŒ²ç½•é»˜ç—‡æœ‰é—œçš„è›‹ç™½è³ªï¼‰å’Œè˜¿è””ç¡«ç´ ï¼Œä¾†çœ‹çœ‹å®ƒå€‘å°ç¥ç¶“ç´°èƒçš„å½±éŸ¿ã€‚  \n\nåœ¨å¯¦é©—ä¸­ï¼Œä»–å€‘ç™¼ç¾é˜¿Î²42æœƒè®“æŸäº›ç´°èƒçš„å­˜æ´»ç‡ä¸‹é™ï¼Œè€Œè˜¿è””ç¡«ç´ åœ¨é©ç•¶çš„æ¿ƒåº¦ä¸‹ï¼Œç«Ÿç„¶èƒ½æ¸›å°‘ç¥ç¶“ç´°èƒçš„å‡‹äº¡ï¼é€™è¡¨ç¤ºè˜¿è””ç¡«ç´ å¯èƒ½é€éæŠ‘åˆ¶ç‰¹å®šçš„ä¿¡è™Ÿé€šè·¯ä¾†ä¿è­·ç¥ç¶“ç´°èƒï¼Œé€™å°æ–¼æœªä¾†çš„ç ”ç©¶å’Œæ²»ç™‚ç­–ç•¥éå¸¸é‡è¦ã€‚  \n\nğŸ” ä¸»è¦é‡é»ï¼š  \n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼ä¿è­·ç¥ç¶“ç´°èƒï¼Œå°æŠ—è€åŒ–ç›¸é—œçš„ç–¾ç—…ã€‚  \n2. é˜¿Î²42æœƒå¢åŠ ç¥ç¶“ç´°èƒçš„æ­»äº¡ï¼Œå½±éŸ¿å¤§è…¦å¥åº·ã€‚  \n3. é€²ä¸€æ­¥çš„ç ”ç©¶å¯èƒ½æœƒæ­ç¤ºæ–°çš„æ²»ç™‚æ–¹æ³•ï¼",
    "image_prompt": "Create a flat design infographic with a light background. Include symbols for broccoli or sulforaphane. Add simplified representations of experimental subjects like cells or simple human figures. Use arrows or flow lines to illustrate the experimental steps. Include a section labeled 'Main Results' highlighting protective effects and changes observed in the experiment.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "é˜¿èŒ²ç½•é»˜ç—‡ Alzheimer's Disease",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41540706/"
  },
  {
    "id": "41565088",
    "title_en": "Sulforaphane attenuates HFD-induced enteritis in yellow river carp by restoring immune homeostasis, repairing intestinal barrier, and modulating gut microbiota.",
    "pub_date": "2026 Jan",
    "journal": "Fish & shellfish immunology",
    "abstract_en": "High-fat diets (HFD) exacerbate intestinal health risks in aquaculture. This study evaluated effects of dietary sulforaphane (SFN) supplementation on intestinal morphology, biochemistry, microbiota, and metabolism in Yellow River carp (Cyprinus carpio haematopterus) fed HFD. Five isoprotein diets diets were formulated: control (CN, 6Â % lipid), HFD (12.29Â % lipid), and HFD with 10 (HS10), 15 (HS15), or 20 (HS20) mg/kg SFN. Results demonstrated that HFD induced marked intestinal inflammation featuring villi deformation, oxidative stress, epithelial exfoliation, mitochondrial swelling, significantly elevated pro-inflammatory cytokines (TNF-Î±/IL-1Î²/IL-6; pÂ <Â 0.05), and downregulated tight junction protein genes (Occludin/ZO-1/Claudin-3; pÂ <Â 0.05), concomitant with microbial dysbiosis (Proteobacteria dominance>70Â %, reduced Cetobacterium) and disrupted metabolic pathways (amino acid imbalance). SFN supplementation significantly enhanced antioxidant enzyme activities (SOD/CAT/GSH-Px, pÂ <Â 0.05), peaking in HS15, which also exhibited minimized pro-inflammatory cytokines and maximized tight junction expression (pÂ <Â 0.05). Furthermore, 16S rRNA gene sequencing of the gut microbiota indicated that SFN restored microbial homeostasis, notably by increasing the abundance of Cetobacterium. Metabolomic analysis based on KEGG enrichment revealed that these beneficial effects were associated with the activation of FoxO signaling, enhanced lysosomal function, and upregulation of coenzyme A biosynthesis. Critically, HS15 demonstrated optimal efficacy across all parameters. Therefore, 15Â mg/kg SFN is identified as the optimal dose to ameliorate intestinal health in Yellow River carp, providing a theoretical basis for functional aquafeed development.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›æœ‰é—œå¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨æ°´ç”¢é¤Šæ®–é ˜åŸŸã€‚é«˜è„‚é£²é£ŸæœƒåŠ é‡è…¸é“å¥åº·çš„é¢¨éšªï¼Œé€™å°æ–¼é¤Šæ®–é­šé¡çš„å¥åº·ç®¡ç†éå¸¸é‡è¦ã€‚é€éè£œå……è˜¿è””ç¡«ç´ ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„é­šé¡çš„è…¸é“å¥åº·ï¼Œæ¸›å°‘è…¸é“ç™¼ç‚å’Œå…¶ä»–ç›¸é—œå•é¡Œï¼Œé€™å°æ–¼æé«˜é¤Šæ®–é­šçš„ç”Ÿé•·å’Œå­˜æ´»ç‡å…·æœ‰æ½›åœ¨çš„å¥½è™•ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°æ–¼é»ƒæ²³é¯‰é­šåœ¨é«˜è„‚é£²é£Ÿä¸‹çš„è…¸é“å¥åº·å½±éŸ¿ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œç•¶é€™äº›é­šé¡æ”å–é«˜è„‚é£²é£Ÿæ™‚ï¼Œè…¸é“çš„å½¢æ…‹ã€ç”ŸåŒ–æŒ‡æ¨™ã€å¾®ç”Ÿç‰©ç¾¤è½åŠå…¶ä»£è¬æ˜¯å¦æœƒå—åˆ°å½±éŸ¿ï¼Œä»¥åŠè£œå……è˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æ”¹å–„é€™äº›ä¸è‰¯å½±éŸ¿ã€‚",
    "para3": "å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…è¨­è¨ˆäº†äº”ç¨®ä¸åŒçš„é£²é£Ÿé…æ–¹ï¼ŒåŒ…æ‹¬ä¸€ç¨®å°ç…§çµ„ï¼ˆè„‚è‚ªå«é‡6%ï¼‰å’Œå››ç¨®é«˜è„‚é£²é£Ÿï¼ˆè„‚è‚ªå«é‡12.29%ï¼‰ï¼Œå…¶ä¸­ä¸‰çµ„åˆ†åˆ¥æ·»åŠ äº†10ã€15å’Œ20æ¯«å…‹çš„è˜¿è””ç¡«ç´ ã€‚ç ”ç©¶å°è±¡ç‚ºé»ƒæ²³é¯‰é­šï¼Œé€šéè§€å¯Ÿå…¶è…¸é“å½¢æ…‹ã€ç‚ç—‡æŒ‡æ¨™ã€å¾®ç”Ÿç‰©çµ„æˆåŠä»£è¬è·¯å¾‘ä¾†è©•ä¼°è˜¿è””ç¡«ç´ çš„æ•ˆæœã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œé«˜è„‚é£²é£Ÿæœƒå°è‡´è…¸é“ç™¼ç‚ã€æ°§åŒ–å£“åŠ›å¢åŠ åŠå¾®ç”Ÿç‰©å¤±èª¿ï¼Œè€Œè£œå……è˜¿è””ç¡«ç´ èƒ½é¡¯è‘—æ”¹å–„é€™äº›æƒ…æ³ï¼Œç‰¹åˆ¥æ˜¯åœ¨15æ¯«å…‹çš„åŠ‘é‡ä¸‹æ•ˆæœæœ€ä½³ã€‚ç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½æé«˜æŠ—æ°§åŒ–é…¶æ´»æ€§ï¼Œæ¸›å°‘ä¿ƒç‚ç´°èƒå› å­çš„è¡¨é”ï¼Œä¸¦æ¢å¾©å¾®ç”Ÿç‰©çš„å¹³è¡¡ï¼Œé€™äº›éƒ½èˆ‡æ”¹å–„è…¸é“å¥åº·æœ‰é—œã€‚é€™äº›ç™¼ç¾ç‚ºæœªä¾†åŠŸèƒ½æ€§æ°´ç”¢é£¼æ–™çš„é–‹ç™¼æä¾›äº†ç†è«–åŸºç¤ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›æœ‰é—œå¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨æ°´ç”¢é¤Šæ®–é ˜åŸŸã€‚é«˜è„‚é£²é£ŸæœƒåŠ é‡è…¸é“å¥åº·çš„é¢¨éšªï¼Œé€™å°æ–¼é¤Šæ®–é­šé¡çš„å¥åº·ç®¡ç†éå¸¸é‡è¦ã€‚é€éè£œå……è˜¿è””ç¡«ç´ ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„é­šé¡çš„è…¸é“å¥åº·ï¼Œæ¸›å°‘è…¸é“ç™¼ç‚å’Œå…¶ä»–ç›¸é—œå•é¡Œï¼Œé€™å°æ–¼æé«˜é¤Šæ®–é­šçš„ç”Ÿé•·å’Œå­˜æ´»ç‡å…·æœ‰æ½›åœ¨çš„å¥½è™•ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°æ–¼é»ƒæ²³é¯‰é­šåœ¨é«˜è„‚é£²é£Ÿä¸‹çš„è…¸é“å¥åº·å½±éŸ¿ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œç•¶é€™äº›é­šé¡æ”å–é«˜è„‚é£²é£Ÿæ™‚ï¼Œè…¸é“çš„å½¢æ…‹ã€ç”ŸåŒ–æŒ‡æ¨™ã€å¾®ç”Ÿç‰©ç¾¤è½åŠå…¶ä»£è¬æ˜¯å¦æœƒå—åˆ°å½±éŸ¿ï¼Œä»¥åŠè£œå……è˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æ”¹å–„é€™äº›ä¸è‰¯å½±éŸ¿ã€‚\n\nå¯¦é©—ä¸­ï¼Œç ”ç©¶è€…è¨­è¨ˆäº†äº”ç¨®ä¸åŒçš„é£²é£Ÿé…æ–¹ï¼ŒåŒ…æ‹¬ä¸€ç¨®å°ç…§çµ„ï¼ˆè„‚è‚ªå«é‡6%ï¼‰å’Œå››ç¨®é«˜è„‚é£²é£Ÿï¼ˆè„‚è‚ªå«é‡12.29%ï¼‰ï¼Œå…¶ä¸­ä¸‰çµ„åˆ†åˆ¥æ·»åŠ äº†10ã€15å’Œ20æ¯«å…‹çš„è˜¿è””ç¡«ç´ ã€‚ç ”ç©¶å°è±¡ç‚ºé»ƒæ²³é¯‰é­šï¼Œé€šéè§€å¯Ÿå…¶è…¸é“å½¢æ…‹ã€ç‚ç—‡æŒ‡æ¨™ã€å¾®ç”Ÿç‰©çµ„æˆåŠä»£è¬è·¯å¾‘ä¾†è©•ä¼°è˜¿è””ç¡«ç´ çš„æ•ˆæœã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œé«˜è„‚é£²é£Ÿæœƒå°è‡´è…¸é“ç™¼ç‚ã€æ°§åŒ–å£“åŠ›å¢åŠ åŠå¾®ç”Ÿç‰©å¤±èª¿ï¼Œè€Œè£œå……è˜¿è””ç¡«ç´ èƒ½é¡¯è‘—æ”¹å–„é€™äº›æƒ…æ³ï¼Œç‰¹åˆ¥æ˜¯åœ¨15æ¯«å…‹çš„åŠ‘é‡ä¸‹æ•ˆæœæœ€ä½³ã€‚ç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½æé«˜æŠ—æ°§åŒ–é…¶æ´»æ€§ï¼Œæ¸›å°‘ä¿ƒç‚ç´°èƒå› å­çš„è¡¨é”ï¼Œä¸¦æ¢å¾©å¾®ç”Ÿç‰©çš„å¹³è¡¡ï¼Œé€™äº›éƒ½èˆ‡æ”¹å–„è…¸é“å¥åº·æœ‰é—œã€‚é€™äº›ç™¼ç¾ç‚ºæœªä¾†åŠŸèƒ½æ€§æ°´ç”¢é£¼æ–™çš„é–‹ç™¼æä¾›äº†ç†è«–åŸºç¤ã€‚",
    "fb_post": "æ ¹æ“šã€ŠFish & shellfish immunologyã€‹æ–¼ 2026 å¹´ 1 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿæˆ‘å€‘çš„æ°´ç”¢é¤Šæ®–é­šé¡ä¹Ÿéœ€è¦å¥åº·é£²é£Ÿï¼æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶å°ˆé–€æ¢è¨äº†è˜¿è””ç¡«ç´ å°é»ƒæ²³é¯‰é­šè…¸é“å¥åº·çš„å½±éŸ¿ã€‚ç ”ç©¶ç™¼ç¾ï¼Œé«˜è„‚é£²é£Ÿå¯èƒ½æœƒè®“é­šçš„è…¸é“å‡ºç¾å•é¡Œï¼Œåƒæ˜¯ç™¼ç‚å’Œå¾®ç”Ÿç‰©å¤±èª¿ï¼Œé€™å°é­šçš„ç”Ÿé•·å’Œå­˜æ´»ç‡éƒ½ä¸å¥½ã€‚  \n ç ”ç©¶è€…è¨­è¨ˆäº†äº”ç¨®ä¸åŒçš„é£²é£Ÿé…æ–¹ï¼ŒåŒ…å«ä¸€ç¨®æ­£å¸¸è„‚è‚ªçš„å°ç…§çµ„å’Œå››ç¨®é«˜è„‚é£²é£Ÿï¼Œä¸¦ä¸”åœ¨å…¶ä¸­ä¸‰çµ„æ·»åŠ äº†ä¸åŒåŠ‘é‡çš„è˜¿è””ç¡«ç´ ã€‚é€éè§€å¯Ÿé­šçš„è…¸é“ç‹€æ³ï¼Œç ”ç©¶è€…ç™¼ç¾ï¼Œè£œå……è˜¿è””ç¡«ç´ èƒ½é¡¯è‘—æ”¹å–„é€™äº›ä¸è‰¯å½±éŸ¿ï¼Œå°¤å…¶æ˜¯15æ¯«å…‹çš„åŠ‘é‡æ•ˆæœæœ€ä½³ã€‚  \n é€™äº›çµæœå‘Šè¨´æˆ‘å€‘ï¼š  \n1. é«˜è„‚é£²é£Ÿæœƒå°è‡´è…¸é“ç™¼ç‚å’Œå¾®ç”Ÿç‰©å¤±èª¿ã€‚  \n2. è˜¿è””ç¡«ç´ èƒ½æé«˜æŠ—æ°§åŒ–é…¶æ´»æ€§ï¼Œå¹«åŠ©è…¸é“å¥åº·ã€‚  \n3. é€™äº›ç™¼ç¾ç‚ºæœªä¾†çš„æ°´ç”¢é£¼æ–™é–‹ç™¼æä¾›äº†æ–°çš„æ€è·¯ã€‚  \nè®“æˆ‘å€‘ä¸€èµ·é—œå¿ƒæ°´ç”¢é¤Šæ®–çš„å¥åº·å§ï¼",
    "image_prompt": "Create a flat design infographic that explains the experiment and main results of a study on the effects of sulforaphane on the gut health of fish. Use a light background with soft colors. Include symbols of broccoli or sulforaphane, simplified illustrations of fish or cells, arrows or flow lines to indicate the experimental steps, and a section that highlights the main results, such as protective effects and changes observed in gut health.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41565088/"
  },
  {
    "id": "41594902",
    "title_en": "Sulforaphane as a Multi-Scale Mechano-Modulator in Cancer: An Integrative Perspective.",
    "pub_date": "2026 Jan",
    "journal": "Biology",
    "abstract_en": "Cancer progression is driven not only by biochemical signals but also by abnormal physical forces within a stiffened tumor microenvironment. This review re-examines the anticancer compound sulforaphane (SFN) through the integrative lens of tumor biomechanics. We propose SFN functions as a \"mechano-modulator,\" whose pleiotropic effects converge to disrupt pro-invasive mechanotransduction. SFN targets key force-sensitive pathways (e.g., YAP/TEAD, Rho/ROCK), destabilizes invasion machinery (cytoskeleton, invadopodia), and promotes tissue-level changes such as extracellular matrix remodeling. While preclinical evidence for this mechano-modulatory role is compelling, this perspective also highlights the critical need for clinical validation and discusses the key translational challenges. By systematically linking SFN's molecular actions to the biophysics of tumor progression, this synthesis provides a novel framework for understanding its efficacy and outlines a rational path for its future development as a mechano-inspired therapeutic.",
    "para1": "é€™ç¯‡ç ”ç©¶æä¾›äº†ä¸€äº›å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨ç™Œç—‡çš„æ²»ç™‚æ–¹é¢ã€‚ç ”ç©¶æŒ‡å‡ºï¼Œç™Œç—‡çš„é€²å±•ä¸åƒ…å—åˆ°ç”ŸåŒ–ä¿¡è™Ÿçš„å½±éŸ¿ï¼Œé‚„å—åˆ°è…«ç˜¤å¾®ç’°å¢ƒä¸­ç•°å¸¸ç‰©ç†åŠ›é‡çš„é©…å‹•ã€‚é€™æ„å‘³è‘—ï¼Œé™¤äº†å‚³çµ±çš„è—¥ç‰©æ²»ç™‚å¤–ï¼Œäº†è§£è…«ç˜¤çš„ç‰©ç†ç‰¹æ€§å’ŒåŠ›å­¸è¡Œç‚ºï¼Œå¯èƒ½æœ‰åŠ©æ–¼é–‹ç™¼æ–°çš„æ²»ç™‚æ–¹æ³•ã€‚ç‰¹åˆ¥æ˜¯è˜¿è””ç¡«ç´ é€™ç¨®åŒ–åˆç‰©ï¼Œå¯èƒ½é€éèª¿ç¯€è…«ç˜¤çš„æ©Ÿæ¢°ç’°å¢ƒä¾†å½±éŸ¿ç™Œç´°èƒçš„ä¾µè¥²æ€§ï¼Œé€™ç‚ºæœªä¾†çš„ç™Œç—‡æ²»ç™‚æä¾›äº†æ–°çš„æ€è·¯ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨ç™Œç—‡æ²»ç™‚ä¸­çš„ä½œç”¨ï¼Œç‰¹åˆ¥æ˜¯å®ƒå¦‚ä½•å½±éŸ¿è…«ç˜¤çš„ç”Ÿç‰©åŠ›å­¸ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½ä½œç‚ºä¸€ç¨®ã€Œæ©Ÿæ¢°èª¿ç¯€åŠ‘ã€ï¼Œé€éæ”¹è®Šè…«ç˜¤å¾®ç’°å¢ƒä¸­çš„ç‰©ç†åŠ›é‡ä¾†æŠ‘åˆ¶ç™Œç´°èƒçš„ä¾µè¥²æ€§ã€‚é€™ç¨®æ–°ç©çš„è§€é»ä¸åƒ…é—œæ³¨åŒ–å­¸æˆåˆ†çš„ä½œç”¨ï¼Œé‚„å¼·èª¿äº†è…«ç˜¤çš„ç‰©ç†ç‰¹æ€§åœ¨ç™Œç—‡é€²å±•ä¸­çš„é‡è¦æ€§ã€‚",
    "para3": "åœ¨é€™é …ç ”ç©¶ä¸­ï¼Œç ”ç©¶è€…å›é¡§äº†è˜¿è””ç¡«ç´ çš„ç›¸é—œæ–‡ç»ï¼Œä¸¦åˆ†æäº†å®ƒåœ¨è…«ç˜¤ç”Ÿç‰©åŠ›å­¸ä¸­çš„æ½›åœ¨ä½œç”¨ã€‚ç ”ç©¶è€…æ¢è¨äº†è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ä¸€äº›é—œéµçš„åŠ›æ•é€šè·¯ï¼Œä¾‹å¦‚YAP/TEADå’ŒRho/ROCKï¼Œä¸¦ä¸”ç ”ç©¶äº†å®ƒå°ç´°èƒéª¨æ¶å’Œä¾µè¥²æ©Ÿåˆ¶çš„å½±éŸ¿ã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„æåˆ°è˜¿è””ç¡«ç´ å¯èƒ½ä¿ƒé€²çµ„ç¹”å±¤é¢çš„è®ŠåŒ–ï¼Œä¾‹å¦‚ç´°èƒå¤–åŸºè³ªçš„é‡å¡‘ï¼Œé€™äº›éƒ½æ˜¯ç†è§£å…¶ä½œç”¨æ©Ÿåˆ¶çš„é‡è¦éƒ¨åˆ†ã€‚",
    "para4": "ä¸»è¦çš„ç™¼ç¾æ˜¯ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½åœ¨è…«ç˜¤é€²å±•ä¸­æ‰®æ¼”è‘—é‡è¦çš„æ©Ÿæ¢°èª¿ç¯€è§’è‰²ï¼Œé€éå½±éŸ¿è…«ç˜¤çš„ç‰©ç†ç’°å¢ƒä¾†æ”¹è®Šç™Œç´°èƒçš„è¡Œç‚ºã€‚é›–ç„¶ç›®å‰çš„å‰è‡¨åºŠè­‰æ“šé¡¯ç¤ºé€™ç¨®æ©Ÿåˆ¶çš„æ½›åŠ›ï¼Œä½†ç ”ç©¶è€…ä¹Ÿå¼·èª¿äº†è‡¨åºŠé©—è­‰çš„å¿…è¦æ€§ï¼Œä¸¦è¨è«–äº†åœ¨å°‡é€™äº›ç™¼ç¾è½‰åŒ–ç‚ºè‡¨åºŠæ‡‰ç”¨æ™‚å¯èƒ½é¢è‡¨çš„æŒ‘æˆ°ã€‚é€™äº›ç™¼ç¾ç‚ºæœªä¾†å°‡è˜¿è””ç¡«ç´ ç™¼å±•ç‚ºä¸€ç¨®æ–°çš„æ²»ç™‚æ–¹æ³•æä¾›äº†ç†è«–åŸºç¤ã€‚",
    "explanation_zh": "é€™ç¯‡ç ”ç©¶æä¾›äº†ä¸€äº›å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨ç™Œç—‡çš„æ²»ç™‚æ–¹é¢ã€‚ç ”ç©¶æŒ‡å‡ºï¼Œç™Œç—‡çš„é€²å±•ä¸åƒ…å—åˆ°ç”ŸåŒ–ä¿¡è™Ÿçš„å½±éŸ¿ï¼Œé‚„å—åˆ°è…«ç˜¤å¾®ç’°å¢ƒä¸­ç•°å¸¸ç‰©ç†åŠ›é‡çš„é©…å‹•ã€‚é€™æ„å‘³è‘—ï¼Œé™¤äº†å‚³çµ±çš„è—¥ç‰©æ²»ç™‚å¤–ï¼Œäº†è§£è…«ç˜¤çš„ç‰©ç†ç‰¹æ€§å’ŒåŠ›å­¸è¡Œç‚ºï¼Œå¯èƒ½æœ‰åŠ©æ–¼é–‹ç™¼æ–°çš„æ²»ç™‚æ–¹æ³•ã€‚ç‰¹åˆ¥æ˜¯è˜¿è””ç¡«ç´ é€™ç¨®åŒ–åˆç‰©ï¼Œå¯èƒ½é€éèª¿ç¯€è…«ç˜¤çš„æ©Ÿæ¢°ç’°å¢ƒä¾†å½±éŸ¿ç™Œç´°èƒçš„ä¾µè¥²æ€§ï¼Œé€™ç‚ºæœªä¾†çš„ç™Œç—‡æ²»ç™‚æä¾›äº†æ–°çš„æ€è·¯ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨ç™Œç—‡æ²»ç™‚ä¸­çš„ä½œç”¨ï¼Œç‰¹åˆ¥æ˜¯å®ƒå¦‚ä½•å½±éŸ¿è…«ç˜¤çš„ç”Ÿç‰©åŠ›å­¸ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½ä½œç‚ºä¸€ç¨®ã€Œæ©Ÿæ¢°èª¿ç¯€åŠ‘ã€ï¼Œé€éæ”¹è®Šè…«ç˜¤å¾®ç’°å¢ƒä¸­çš„ç‰©ç†åŠ›é‡ä¾†æŠ‘åˆ¶ç™Œç´°èƒçš„ä¾µè¥²æ€§ã€‚é€™ç¨®æ–°ç©çš„è§€é»ä¸åƒ…é—œæ³¨åŒ–å­¸æˆåˆ†çš„ä½œç”¨ï¼Œé‚„å¼·èª¿äº†è…«ç˜¤çš„ç‰©ç†ç‰¹æ€§åœ¨ç™Œç—‡é€²å±•ä¸­çš„é‡è¦æ€§ã€‚\n\nåœ¨é€™é …ç ”ç©¶ä¸­ï¼Œç ”ç©¶è€…å›é¡§äº†è˜¿è””ç¡«ç´ çš„ç›¸é—œæ–‡ç»ï¼Œä¸¦åˆ†æäº†å®ƒåœ¨è…«ç˜¤ç”Ÿç‰©åŠ›å­¸ä¸­çš„æ½›åœ¨ä½œç”¨ã€‚ç ”ç©¶è€…æ¢è¨äº†è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ä¸€äº›é—œéµçš„åŠ›æ•é€šè·¯ï¼Œä¾‹å¦‚YAP/TEADå’ŒRho/ROCKï¼Œä¸¦ä¸”ç ”ç©¶äº†å®ƒå°ç´°èƒéª¨æ¶å’Œä¾µè¥²æ©Ÿåˆ¶çš„å½±éŸ¿ã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„æåˆ°è˜¿è””ç¡«ç´ å¯èƒ½ä¿ƒé€²çµ„ç¹”å±¤é¢çš„è®ŠåŒ–ï¼Œä¾‹å¦‚ç´°èƒå¤–åŸºè³ªçš„é‡å¡‘ï¼Œé€™äº›éƒ½æ˜¯ç†è§£å…¶ä½œç”¨æ©Ÿåˆ¶çš„é‡è¦éƒ¨åˆ†ã€‚\n\nä¸»è¦çš„ç™¼ç¾æ˜¯ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½åœ¨è…«ç˜¤é€²å±•ä¸­æ‰®æ¼”è‘—é‡è¦çš„æ©Ÿæ¢°èª¿ç¯€è§’è‰²ï¼Œé€éå½±éŸ¿è…«ç˜¤çš„ç‰©ç†ç’°å¢ƒä¾†æ”¹è®Šç™Œç´°èƒçš„è¡Œç‚ºã€‚é›–ç„¶ç›®å‰çš„å‰è‡¨åºŠè­‰æ“šé¡¯ç¤ºé€™ç¨®æ©Ÿåˆ¶çš„æ½›åŠ›ï¼Œä½†ç ”ç©¶è€…ä¹Ÿå¼·èª¿äº†è‡¨åºŠé©—è­‰çš„å¿…è¦æ€§ï¼Œä¸¦è¨è«–äº†åœ¨å°‡é€™äº›ç™¼ç¾è½‰åŒ–ç‚ºè‡¨åºŠæ‡‰ç”¨æ™‚å¯èƒ½é¢è‡¨çš„æŒ‘æˆ°ã€‚é€™äº›ç™¼ç¾ç‚ºæœªä¾†å°‡è˜¿è””ç¡«ç´ ç™¼å±•ç‚ºä¸€ç¨®æ–°çš„æ²»ç™‚æ–¹æ³•æä¾›äº†ç†è«–åŸºç¤ã€‚",
    "fb_post": "æ ¹æ“šã€ŠBiologyã€‹æ–¼ 2026 å¹´ 1 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ± ä½ çŸ¥é“å—ï¼Ÿæˆ‘å€‘çš„é£²é£Ÿä¸­ç«Ÿç„¶æœ‰åŠ©æ–¼ç™Œç—‡æ²»ç™‚çš„æ½›åŠ›ï¼æœ€è¿‘ä¸€é …ç ”ç©¶èšç„¦æ–¼ä¸€ç¨®å«åšè˜¿è””ç¡«ç´ çš„åŒ–åˆç‰©ï¼Œç™¼ç¾å®ƒä¸åƒ…æ˜¯ç¾å‘³çš„è”¬èœæˆåˆ†ï¼Œé‚„å¯èƒ½åœ¨ç™Œç—‡æ²»ç™‚ä¸­ç™¼æ®é‡è¦ä½œç”¨ã€‚  \n  \né€™é …ç ”ç©¶çš„é‡é»åœ¨æ–¼æ¢ç´¢è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿è…«ç˜¤çš„ç‰©ç†ç’°å¢ƒï¼Œé€²è€Œæ”¹è®Šç™Œç´°èƒçš„è¡Œç‚ºã€‚ç ”ç©¶è€…å€‘ä»”ç´°åˆ†æäº†è˜¿è””ç¡«ç´ å°è…«ç˜¤å¾®ç’°å¢ƒä¸­çš„ç‰©ç†åŠ›é‡çš„å½±éŸ¿ï¼Œè©¦åœ–æ‰¾å‡ºå®ƒæ˜¯å¦èƒ½ä½œç‚ºä¸€ç¨®ã€Œæ©Ÿæ¢°èª¿ç¯€åŠ‘ã€ï¼Œå¹«åŠ©æŠ‘åˆ¶ç™Œç´°èƒçš„ä¾µè¥²æ€§ã€‚  \n  \nä»–å€‘å›é¡§äº†ç›¸é—œæ–‡ç»ï¼Œç ”ç©¶è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç´°èƒå…§çš„ä¸€äº›é‡è¦é€šè·¯ï¼Œé€™äº›é€šè·¯å°±åƒæ˜¯ç´°èƒçš„æŒ‡æ®ä¸­å¿ƒï¼Œæ±ºå®šè‘—ç´°èƒçš„è¡Œç‚ºã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„ç™¼ç¾è˜¿è””ç¡«ç´ å¯èƒ½ä¿ƒé€²çµ„ç¹”å±¤é¢çš„è®ŠåŒ–ï¼Œé€™äº›æ”¹è®Šå°æ–¼ç†è§£å®ƒçš„ä½œç”¨æ©Ÿåˆ¶è‡³é—œé‡è¦ã€‚  \n  \nğŸ” ä¸»è¦ç™¼ç¾ï¼š  \n1. è˜¿è””ç¡«ç´ å¯èƒ½åœ¨è…«ç˜¤é€²å±•ä¸­æ‰®æ¼”é‡è¦çš„è§’è‰²ï¼Œå½±éŸ¿ç™Œç´°èƒçš„è¡Œç‚ºã€‚  \n2. ç›®å‰çš„è­‰æ“šé¡¯ç¤ºé€™ç¨®æ©Ÿåˆ¶çš„æ½›åŠ›ï¼Œä½†ä»éœ€è‡¨åºŠé©—è­‰ã€‚  \n3. é€™äº›ç™¼ç¾ç‚ºæœªä¾†å°‡è˜¿è””ç¡«ç´ ç™¼å±•ç‚ºæ–°æ²»ç™‚æ–¹æ³•æä¾›äº†ç†è«–åŸºç¤ã€‚  \n  \nè®“æˆ‘å€‘ä¸€èµ·æœŸå¾…ç§‘å­¸çš„é€²æ­¥ï¼Œæˆ–è¨±æœªä¾†çš„é£²é£Ÿä¸­å°±èƒ½å¤šä¸€å€‹æŠ—ç™Œè‹±é›„ï¼",
    "image_prompt": "Create an infographic that explains the experimental approach and main findings of a study on sulforaphane, a compound found in vegetables like broccoli. Use a simple and clear layout with a white or light-colored background and soft color palette. Include symbols representing sulforaphane and experimental subjects like cells or animals. Use arrows or flow lines to indicate the steps of the experiment. Add a section highlighting the main results, such as protective effects or changes observed in cancer cell behavior.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "ç™Œç—‡ Cancer",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41594902/"
  },
  {
    "id": "41535692",
    "title_en": "Inhibiting autophagy enhances anti-cancer properties of sulforaphane.",
    "pub_date": "2026 Jan",
    "journal": "Scientific reports",
    "abstract_en": "Bladder cancer (BC) has an extremely low survival rate due to its tendency to metastasize. The antimalarial drug chloroquine (CQ) can inhibit BC progression and invasiveness by targeting basal autophagy. However, the mechanism by which CQ affects BC is not defined. Here, we revealed that although CQ showed an anticancer effect by reducing the migration and proliferation of the analyzed bladder cancer cells, it increased the expression of ICAM-1, a protein whose expression is associated with higher tumorigenic potential. Sulforaphane (SFN), a well-known ICAM-1 inhibitor, significantly contributed to the enhancement of anticancer effect of CQ, through regulation of both AKT/GSK-3Î² and mTOR/ULK pathways, which led to effective inhibition of autophagy, reduced proliferation level or inhibition of migration of the analyzed bladder cells. Moreover, regulation of pathways related to autophagy contributed to the reduction of mitochondrial membrane potential and regulation of ROS level. Nevertheless, the level of influence of CQ and SFN on the anticancer effects strongly depended on the molecular basis of the analyzed bladder cell lines. Our data indicate that although CQ exerts antitumor effects on bladder cancer cells, it should be noted that activation of some pro-tumor pathways may be associated with subsequent disease relapse or treatment resistance.",
    "para1": "è†€èƒ±ç™Œæ˜¯ä¸€ç¨®å­˜æ´»ç‡æ¥µä½çš„ç™Œç—‡ï¼Œå› ç‚ºå®ƒå®¹æ˜“è½‰ç§»ã€‚é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°è†€èƒ±ç™Œçš„æ²»ç™‚ã€‚ç ”ç©¶é¡¯ç¤ºï¼ŒæŸäº›è—¥ç‰©å¯èƒ½åœ¨æŠ‘åˆ¶ç™Œç´°èƒå¢é•·çš„åŒæ™‚ï¼Œå»ä¹Ÿå¯èƒ½æ¿€æ´»ä¸€äº›èˆ‡è…«ç˜¤å½¢æˆç›¸é—œçš„é€”å¾‘ã€‚å› æ­¤ï¼Œåœ¨æ²»ç™‚è†€èƒ±ç™Œæ™‚ï¼Œé™¤äº†è€ƒæ…®è—¥ç‰©çš„æŠ—ç™Œæ•ˆæœå¤–ï¼Œé‚„å¿…é ˆè¬¹æ…è©•ä¼°å…¶å¯èƒ½å¼•ç™¼çš„å‰¯ä½œç”¨ï¼Œä»¥é¿å…ç—…æƒ…æƒ¡åŒ–æˆ–æ²»ç™‚å¤±æ•—çš„é¢¨éšªã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨æŠ—ç˜§ç–¾è—¥ç‰©æ°¯å–¹ï¼ˆCQï¼‰å°è†€èƒ±ç™Œç´°èƒçš„å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯å®ƒå¦‚ä½•æŠ‘åˆ¶ç™Œç´°èƒçš„å¢æ®–å’Œé·ç§»ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œé›–ç„¶æ°¯å–¹åœ¨æŸäº›æƒ…æ³ä¸‹é¡¯ç¤ºå‡ºæŠ—ç™Œæ•ˆæœï¼Œä½†å…¶ä½œç”¨æ©Ÿåˆ¶å°šä¸æ˜ç¢ºï¼Œä¸¦ä¸”å¯èƒ½æœƒæ¿€æ´»ä¸€äº›ä¿ƒè…«ç˜¤çš„é€”å¾‘ã€‚ç ”ç©¶é‚„æ¢è¨äº†è˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰åœ¨å¢å¼·æ°¯å–¹æŠ—ç™Œæ•ˆæœä¸­çš„è§’è‰²ï¼Œé€™å°æ–¼ç†è§£è†€èƒ±ç™Œçš„æ²»ç™‚æœ‰é‡è¦æ„ç¾©ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…åˆ†æäº†ä¸åŒçš„è†€èƒ±ç™Œç´°èƒç³»ï¼Œè§€å¯Ÿæ°¯å–¹å’Œè˜¿è””ç¡«ç´ å°é€™äº›ç´°èƒçš„å½±éŸ¿ã€‚ç ”ç©¶æ–¹æ³•åŒ…æ‹¬æ¸¬é‡ç´°èƒçš„å¢æ®–ã€é·ç§»èƒ½åŠ›ï¼Œä»¥åŠç›¸é—œçš„ä¿¡è™Ÿå‚³å°é€”å¾‘ã€‚é€éé€™äº›å¯¦é©—ï¼Œç ”ç©¶è€…å¸Œæœ›èƒ½å¤ æ­ç¤ºæ°¯å–¹çš„æŠ—ç™Œæ©Ÿåˆ¶ï¼Œä¸¦äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•èª¿ç¯€èˆ‡è‡ªå™¬ç›¸é—œçš„é€”å¾‘ï¼Œé€²è€Œå½±éŸ¿ç™Œç´°èƒçš„è¡Œç‚ºã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œæ°¯å–¹èƒ½å¤ æ¸›å°‘è†€èƒ±ç™Œç´°èƒçš„é·ç§»å’Œå¢æ®–ï¼Œä½†åŒæ™‚ä¹Ÿæœƒå¢åŠ ICAM-1çš„è¡¨é”ï¼Œé€™èˆ‡è…«ç˜¤å½¢æˆæ½›åŠ›çš„æé«˜æœ‰é—œã€‚è˜¿è””ç¡«ç´ çš„åŠ å…¥é¡¯è‘—å¢å¼·äº†æ°¯å–¹çš„æŠ—ç™Œæ•ˆæœï¼Œé€šéèª¿ç¯€AKT/GSK-3Î²å’ŒmTOR/ULKé€”å¾‘ä¾†æœ‰æ•ˆæŠ‘åˆ¶è‡ªå™¬ï¼Œé™ä½ç´°èƒå¢æ®–å’Œé·ç§»ã€‚ç„¶è€Œï¼Œæ°¯å–¹å’Œè˜¿è””ç¡«ç´ çš„æŠ—ç™Œæ•ˆæœå—åˆ°æ‰€åˆ†æçš„è†€èƒ±ç™Œç´°èƒç³»çš„åˆ†å­åŸºç¤å½±éŸ¿ï¼Œå› æ­¤åœ¨è‡¨åºŠæ‡‰ç”¨ä¸­éœ€è¦è¬¹æ…è€ƒé‡å…¶æ½›åœ¨çš„å‰¯ä½œç”¨ã€‚",
    "explanation_zh": "è†€èƒ±ç™Œæ˜¯ä¸€ç¨®å­˜æ´»ç‡æ¥µä½çš„ç™Œç—‡ï¼Œå› ç‚ºå®ƒå®¹æ˜“è½‰ç§»ã€‚é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°è†€èƒ±ç™Œçš„æ²»ç™‚ã€‚ç ”ç©¶é¡¯ç¤ºï¼ŒæŸäº›è—¥ç‰©å¯èƒ½åœ¨æŠ‘åˆ¶ç™Œç´°èƒå¢é•·çš„åŒæ™‚ï¼Œå»ä¹Ÿå¯èƒ½æ¿€æ´»ä¸€äº›èˆ‡è…«ç˜¤å½¢æˆç›¸é—œçš„é€”å¾‘ã€‚å› æ­¤ï¼Œåœ¨æ²»ç™‚è†€èƒ±ç™Œæ™‚ï¼Œé™¤äº†è€ƒæ…®è—¥ç‰©çš„æŠ—ç™Œæ•ˆæœå¤–ï¼Œé‚„å¿…é ˆè¬¹æ…è©•ä¼°å…¶å¯èƒ½å¼•ç™¼çš„å‰¯ä½œç”¨ï¼Œä»¥é¿å…ç—…æƒ…æƒ¡åŒ–æˆ–æ²»ç™‚å¤±æ•—çš„é¢¨éšªã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨æŠ—ç˜§ç–¾è—¥ç‰©æ°¯å–¹ï¼ˆCQï¼‰å°è†€èƒ±ç™Œç´°èƒçš„å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯å®ƒå¦‚ä½•æŠ‘åˆ¶ç™Œç´°èƒçš„å¢æ®–å’Œé·ç§»ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œé›–ç„¶æ°¯å–¹åœ¨æŸäº›æƒ…æ³ä¸‹é¡¯ç¤ºå‡ºæŠ—ç™Œæ•ˆæœï¼Œä½†å…¶ä½œç”¨æ©Ÿåˆ¶å°šä¸æ˜ç¢ºï¼Œä¸¦ä¸”å¯èƒ½æœƒæ¿€æ´»ä¸€äº›ä¿ƒè…«ç˜¤çš„é€”å¾‘ã€‚ç ”ç©¶é‚„æ¢è¨äº†è˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰åœ¨å¢å¼·æ°¯å–¹æŠ—ç™Œæ•ˆæœä¸­çš„è§’è‰²ï¼Œé€™å°æ–¼ç†è§£è†€èƒ±ç™Œçš„æ²»ç™‚æœ‰é‡è¦æ„ç¾©ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…åˆ†æäº†ä¸åŒçš„è†€èƒ±ç™Œç´°èƒç³»ï¼Œè§€å¯Ÿæ°¯å–¹å’Œè˜¿è””ç¡«ç´ å°é€™äº›ç´°èƒçš„å½±éŸ¿ã€‚ç ”ç©¶æ–¹æ³•åŒ…æ‹¬æ¸¬é‡ç´°èƒçš„å¢æ®–ã€é·ç§»èƒ½åŠ›ï¼Œä»¥åŠç›¸é—œçš„ä¿¡è™Ÿå‚³å°é€”å¾‘ã€‚é€éé€™äº›å¯¦é©—ï¼Œç ”ç©¶è€…å¸Œæœ›èƒ½å¤ æ­ç¤ºæ°¯å–¹çš„æŠ—ç™Œæ©Ÿåˆ¶ï¼Œä¸¦äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•èª¿ç¯€èˆ‡è‡ªå™¬ç›¸é—œçš„é€”å¾‘ï¼Œé€²è€Œå½±éŸ¿ç™Œç´°èƒçš„è¡Œç‚ºã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œæ°¯å–¹èƒ½å¤ æ¸›å°‘è†€èƒ±ç™Œç´°èƒçš„é·ç§»å’Œå¢æ®–ï¼Œä½†åŒæ™‚ä¹Ÿæœƒå¢åŠ ICAM-1çš„è¡¨é”ï¼Œé€™èˆ‡è…«ç˜¤å½¢æˆæ½›åŠ›çš„æé«˜æœ‰é—œã€‚è˜¿è””ç¡«ç´ çš„åŠ å…¥é¡¯è‘—å¢å¼·äº†æ°¯å–¹çš„æŠ—ç™Œæ•ˆæœï¼Œé€šéèª¿ç¯€AKT/GSK-3Î²å’ŒmTOR/ULKé€”å¾‘ä¾†æœ‰æ•ˆæŠ‘åˆ¶è‡ªå™¬ï¼Œé™ä½ç´°èƒå¢æ®–å’Œé·ç§»ã€‚ç„¶è€Œï¼Œæ°¯å–¹å’Œè˜¿è””ç¡«ç´ çš„æŠ—ç™Œæ•ˆæœå—åˆ°æ‰€åˆ†æçš„è†€èƒ±ç™Œç´°èƒç³»çš„åˆ†å­åŸºç¤å½±éŸ¿ï¼Œå› æ­¤åœ¨è‡¨åºŠæ‡‰ç”¨ä¸­éœ€è¦è¬¹æ…è€ƒé‡å…¶æ½›åœ¨çš„å‰¯ä½œç”¨ã€‚",
    "fb_post": "æ ¹æ“šã€ŠScientific reportsã€‹æ–¼ 2026 å¹´ 1 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸ§ª ä½ çŸ¥é“å—ï¼Ÿè†€èƒ±ç™Œæ˜¯ä¸€ç¨®è½‰ç§»æ€§å¾ˆé«˜çš„ç™Œç—‡ï¼Œè®“äººæ“”å¿ƒï¼æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶æ¢è¨äº†æŠ—ç˜§ç–¾è—¥ç‰©æ°¯å–¹ï¼ˆCQï¼‰å°è†€èƒ±ç™Œç´°èƒçš„å½±éŸ¿ï¼Œä¸¦ä¸”ç™¼ç¾äº†ä¸€äº›æœ‰è¶£çš„çµæœï¼\n\né€™é …ç ”ç©¶çš„é‡é»åœ¨æ–¼æ°¯å–¹å¦‚ä½•æŠ‘åˆ¶ç™Œç´°èƒçš„å¢æ®–å’Œé·ç§»ã€‚ç ”ç©¶è€…å€‘ç™¼ç¾ï¼Œé›–ç„¶æ°¯å–¹åœ¨æŸäº›æƒ…æ³ä¸‹å¯ä»¥å°æŠ—ç™Œç—‡ï¼Œä½†å®ƒä¹Ÿå¯èƒ½æ¿€æ´»ä¸€äº›ä¿ƒè…«ç˜¤çš„é€”å¾‘ï¼Œé€™å°±éœ€è¦æˆ‘å€‘æ›´åŠ è¬¹æ…äº†ï¼\n\nåœ¨å¯¦é©—ä¸­ï¼Œç§‘å­¸å®¶å€‘åˆ†æäº†ä¸åŒçš„è†€èƒ±ç™Œç´°èƒç³»ï¼Œè§€å¯Ÿæ°¯å–¹å’Œè˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰å°é€™äº›ç´°èƒçš„å½±éŸ¿ã€‚çµæœç™¼ç¾ï¼Œæ°¯å–¹èƒ½æ¸›å°‘ç™Œç´°èƒçš„é·ç§»å’Œå¢æ®–ï¼Œä½†ä¹Ÿæœƒæé«˜æŸäº›èˆ‡è…«ç˜¤å½¢æˆç›¸é—œçš„è¡¨é”ã€‚è€Œç•¶åŠ å…¥è˜¿è””ç¡«ç´ å¾Œï¼Œæ°¯å–¹çš„æŠ—ç™Œæ•ˆæœé¡¯è‘—å¢å¼·ï¼Œèƒ½æœ‰æ•ˆæŠ‘åˆ¶è‡ªå™¬ï¼Œé™ä½ç´°èƒçš„å¢æ®–å’Œé·ç§»ã€‚\n\nğŸ” é€™è£¡æœ‰å¹¾å€‹é‡é»ï¼š\n1. æ°¯å–¹å°è†€èƒ±ç™Œç´°èƒæœ‰æŠ‘åˆ¶æ•ˆæœï¼Œä½†ä¹Ÿå¯èƒ½å¼•ç™¼å‰¯ä½œç”¨ã€‚\n2. è˜¿è””ç¡«ç´ èƒ½å¢å¼·æ°¯å–¹çš„æŠ—ç™Œæ•ˆæœã€‚\n3. æ¯ç¨®è†€èƒ±ç™Œç´°èƒçš„åæ‡‰å¯èƒ½ä¸åŒï¼Œè‡¨åºŠæ‡‰ç”¨éœ€è¬¹æ…è€ƒé‡ï¼",
    "image_prompt": "Create a flat design infographic on a light background that visually explains the experimental method and main findings of a study on bladder cancer treatment. Include simplified icons representing broccoli or sulforaphane, simplified representations of experimental subjects like cells or humans, arrows or flow lines indicating the experimental steps, and a section highlighting the main results, such as protective effects and changes in cell behavior.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "è†€èƒ±ç™Œ Bladder Cancer",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41535692/"
  },
  {
    "id": "41543290",
    "title_en": "Elucidation of Sulforaphane-Mediated Effects on the Cellular Human Metabolome Using Metabolic Profiling.",
    "pub_date": "2026 Jan",
    "journal": "Molecular nutrition & food research",
    "abstract_en": "Sulforaphane (SFN) is an isothiocyanate derived from glucoraphanin, which occurs in broccoli. Several human health-promoting effects are attributed to the consumption of cruciferous vegetables or food supplements containing SFN. Its described cancer-preventive, chemoprotective, and antioxidant properties made SFN an increasingly important research topic. The antioxidant properties have previously been connected to stimulation of the Nuclear factor erythroid-2-related factor 2 (Nrf2)/Kelch-like ECH-associated protein 1 (Keap1) signaling pathway. However, the global effects of SFN on the primary metabolic pathways have yet to be fully unraveled. Therefore metabolic profiling was used to elucidate the effects of SFN on the cellular metabolome. For this purpose, human hepatoblastoma cells (HepG2) were incubated with SFN and the changes of primary metabolite levels were determined by targeted hydrophilic interaction liquid chromatography tandem mass spectrometry (HILIC-MS/MS) analysis. Metabolic profiling revealed that SFN affects the tricarboxylic acid cycle, the urea cycle and their related amino acids. Furthermore, effects on glycolysis, pentose phosphate pathway and glutathione (GSH) levels were observed. This profound impact on nearly all primary metabolic pathways indicates a high bioactive potential of this natural compound. Especially elevated GSH levels underline the commonly described antioxidant potential of SFN.",
    "para1": "è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®ä¾†è‡ªé’èŠ±æ¤°èœçš„å¤©ç„¶åŒ–åˆç‰©ï¼Œè¿‘å¹´ä¾†å—åˆ°è¶Šä¾†è¶Šå¤šçš„é—œæ³¨ï¼Œå› ç‚ºå®ƒå¯èƒ½å°å¥åº·æœ‰è¨±å¤šå¥½è™•ï¼Œç‰¹åˆ¥æ˜¯åœ¨ç–¾ç—…é é˜²æ–¹é¢ã€‚è¨±å¤šç ”ç©¶æŒ‡å‡ºï¼Œé£Ÿç”¨å«æœ‰è˜¿è””ç¡«ç´ çš„åå­—èŠ±ç§‘è”¬èœï¼Œå¯èƒ½æœ‰åŠ©æ–¼é™ä½æŸäº›ç™Œç—‡çš„é¢¨éšªï¼Œä¸¦æä¾›æŠ—æ°§åŒ–å’Œä¿è­·ç´°èƒçš„æ•ˆæœã€‚é€™äº›æ½›åœ¨çš„å¥åº·ç›Šè™•ä½¿å¾—è˜¿è””ç¡«ç´ æˆç‚ºç§‘å­¸ç ”ç©¶çš„é‡è¦ä¸»é¡Œï¼Œå°¤å…¶æ˜¯åœ¨äº†è§£å®ƒå¦‚ä½•å½±éŸ¿èº«é«”çš„ä»£è¬éç¨‹æ–¹é¢ï¼Œé€™å°æ–¼æœªä¾†çš„å¥åº·ä¿ƒé€²å’Œç–¾ç—…é é˜²ç­–ç•¥å¯èƒ½æœ‰é‡è¦å•Ÿç¤ºã€‚",
    "para2": "é€™é …ç ”ç©¶ä¸»è¦é—œæ³¨è˜¿è””ç¡«ç´ å°ç´°èƒä»£è¬çš„å½±éŸ¿ã€‚å„˜ç®¡å…ˆå‰çš„ç ”ç©¶å·²ç¶“æ¢è¨äº†è˜¿è””ç¡«ç´ çš„æŠ—æ°§åŒ–ç‰¹æ€§å’Œå…¶åœ¨ç™Œç—‡é é˜²ä¸­çš„æ½›åŠ›ï¼Œä½†å°æ–¼å®ƒå¦‚ä½•å½±éŸ¿èº«é«”å…§éƒ¨çš„ä¸»è¦ä»£è¬é€”å¾‘ä»ç„¶äº†è§£ä¸å¤ ã€‚å› æ­¤ï¼Œç ”ç©¶è€…å¸Œæœ›é€šéä»£è¬åˆ†æä¾†æ­ç¤ºè˜¿è””ç¡«ç´ å°ç´°èƒä»£è¬çµ„çš„å…·é«”å½±éŸ¿ï¼Œé€²ä¸€æ­¥äº†è§£é€™ç¨®å¤©ç„¶åŒ–åˆç‰©çš„ç”Ÿç‰©æ´»æ€§ã€‚",
    "para3": "åœ¨é€™é …ç ”ç©¶ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†äººé¡è‚æ¯ç´°èƒç™Œç´°èƒï¼ˆHepG2ï¼‰ä½œç‚ºå¯¦é©—å°è±¡ï¼Œå°‡é€™äº›ç´°èƒèˆ‡è˜¿è””ç¡«ç´ é€²è¡ŒåŸ¹é¤Šã€‚æ¥è‘—ï¼Œç ”ç©¶åœ˜éšŠåˆ©ç”¨ç›®æ¨™æ€§è¦ªæ°´æ€§ç›¸äº’ä½œç”¨æ¶²ç›¸è‰²è­œä¸²è¯è³ªè­œï¼ˆHILIC-MS/MSï¼‰åˆ†æï¼Œä¾†æ¸¬é‡ç´°èƒå…§ä¸»è¦ä»£è¬ç‰©çš„è®ŠåŒ–ã€‚é€™ç¨®æ–¹æ³•ä½¿ä»–å€‘èƒ½å¤ è©³ç´°äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç´°èƒçš„ä»£è¬éç¨‹ï¼Œç‰¹åˆ¥æ˜¯èˆ‡èƒ½é‡ç”Ÿæˆå’Œæ°¨åŸºé…¸ä»£è¬ç›¸é—œçš„é€”å¾‘ã€‚",
    "para4": "ç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å°å¤šå€‹ä¸»è¦ä»£è¬é€”å¾‘ç”¢ç”Ÿäº†é¡¯è‘—å½±éŸ¿ï¼ŒåŒ…æ‹¬ä¸‰ç¾§é…¸å¾ªç’°ã€å°¿ç´ å¾ªç’°åŠå…¶ç›¸é—œçš„æ°¨åŸºé…¸ã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„è§€å¯Ÿåˆ°å°ç³–è§£ä½œç”¨ã€ç£·é…¸æˆŠç³–é€”å¾‘ä»¥åŠè°·èƒ±ç”˜è‚½ï¼ˆGSHï¼‰æ°´å¹³çš„å½±éŸ¿ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å…·æœ‰å¾ˆé«˜çš„ç”Ÿç‰©æ´»æ€§æ½›åŠ›ï¼Œå°¤å…¶æ˜¯æå‡çš„GSHæ°´å¹³é€²ä¸€æ­¥å¼·èª¿äº†å…¶æŠ—æ°§åŒ–ç‰¹æ€§ï¼Œé€™äº›ç™¼ç¾ç‚ºæœªä¾†çš„å¥åº·ç ”ç©¶æä¾›äº†é‡è¦çš„åŸºç¤ã€‚",
    "explanation_zh": "è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®ä¾†è‡ªé’èŠ±æ¤°èœçš„å¤©ç„¶åŒ–åˆç‰©ï¼Œè¿‘å¹´ä¾†å—åˆ°è¶Šä¾†è¶Šå¤šçš„é—œæ³¨ï¼Œå› ç‚ºå®ƒå¯èƒ½å°å¥åº·æœ‰è¨±å¤šå¥½è™•ï¼Œç‰¹åˆ¥æ˜¯åœ¨ç–¾ç—…é é˜²æ–¹é¢ã€‚è¨±å¤šç ”ç©¶æŒ‡å‡ºï¼Œé£Ÿç”¨å«æœ‰è˜¿è””ç¡«ç´ çš„åå­—èŠ±ç§‘è”¬èœï¼Œå¯èƒ½æœ‰åŠ©æ–¼é™ä½æŸäº›ç™Œç—‡çš„é¢¨éšªï¼Œä¸¦æä¾›æŠ—æ°§åŒ–å’Œä¿è­·ç´°èƒçš„æ•ˆæœã€‚é€™äº›æ½›åœ¨çš„å¥åº·ç›Šè™•ä½¿å¾—è˜¿è””ç¡«ç´ æˆç‚ºç§‘å­¸ç ”ç©¶çš„é‡è¦ä¸»é¡Œï¼Œå°¤å…¶æ˜¯åœ¨äº†è§£å®ƒå¦‚ä½•å½±éŸ¿èº«é«”çš„ä»£è¬éç¨‹æ–¹é¢ï¼Œé€™å°æ–¼æœªä¾†çš„å¥åº·ä¿ƒé€²å’Œç–¾ç—…é é˜²ç­–ç•¥å¯èƒ½æœ‰é‡è¦å•Ÿç¤ºã€‚\n\né€™é …ç ”ç©¶ä¸»è¦é—œæ³¨è˜¿è””ç¡«ç´ å°ç´°èƒä»£è¬çš„å½±éŸ¿ã€‚å„˜ç®¡å…ˆå‰çš„ç ”ç©¶å·²ç¶“æ¢è¨äº†è˜¿è””ç¡«ç´ çš„æŠ—æ°§åŒ–ç‰¹æ€§å’Œå…¶åœ¨ç™Œç—‡é é˜²ä¸­çš„æ½›åŠ›ï¼Œä½†å°æ–¼å®ƒå¦‚ä½•å½±éŸ¿èº«é«”å…§éƒ¨çš„ä¸»è¦ä»£è¬é€”å¾‘ä»ç„¶äº†è§£ä¸å¤ ã€‚å› æ­¤ï¼Œç ”ç©¶è€…å¸Œæœ›é€šéä»£è¬åˆ†æä¾†æ­ç¤ºè˜¿è””ç¡«ç´ å°ç´°èƒä»£è¬çµ„çš„å…·é«”å½±éŸ¿ï¼Œé€²ä¸€æ­¥äº†è§£é€™ç¨®å¤©ç„¶åŒ–åˆç‰©çš„ç”Ÿç‰©æ´»æ€§ã€‚\n\nåœ¨é€™é …ç ”ç©¶ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†äººé¡è‚æ¯ç´°èƒç™Œç´°èƒï¼ˆHepG2ï¼‰ä½œç‚ºå¯¦é©—å°è±¡ï¼Œå°‡é€™äº›ç´°èƒèˆ‡è˜¿è””ç¡«ç´ é€²è¡ŒåŸ¹é¤Šã€‚æ¥è‘—ï¼Œç ”ç©¶åœ˜éšŠåˆ©ç”¨ç›®æ¨™æ€§è¦ªæ°´æ€§ç›¸äº’ä½œç”¨æ¶²ç›¸è‰²è­œä¸²è¯è³ªè­œï¼ˆHILIC-MS/MSï¼‰åˆ†æï¼Œä¾†æ¸¬é‡ç´°èƒå…§ä¸»è¦ä»£è¬ç‰©çš„è®ŠåŒ–ã€‚é€™ç¨®æ–¹æ³•ä½¿ä»–å€‘èƒ½å¤ è©³ç´°äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç´°èƒçš„ä»£è¬éç¨‹ï¼Œç‰¹åˆ¥æ˜¯èˆ‡èƒ½é‡ç”Ÿæˆå’Œæ°¨åŸºé…¸ä»£è¬ç›¸é—œçš„é€”å¾‘ã€‚\n\nç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å°å¤šå€‹ä¸»è¦ä»£è¬é€”å¾‘ç”¢ç”Ÿäº†é¡¯è‘—å½±éŸ¿ï¼ŒåŒ…æ‹¬ä¸‰ç¾§é…¸å¾ªç’°ã€å°¿ç´ å¾ªç’°åŠå…¶ç›¸é—œçš„æ°¨åŸºé…¸ã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„è§€å¯Ÿåˆ°å°ç³–è§£ä½œç”¨ã€ç£·é…¸æˆŠç³–é€”å¾‘ä»¥åŠè°·èƒ±ç”˜è‚½ï¼ˆGSHï¼‰æ°´å¹³çš„å½±éŸ¿ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å…·æœ‰å¾ˆé«˜çš„ç”Ÿç‰©æ´»æ€§æ½›åŠ›ï¼Œå°¤å…¶æ˜¯æå‡çš„GSHæ°´å¹³é€²ä¸€æ­¥å¼·èª¿äº†å…¶æŠ—æ°§åŒ–ç‰¹æ€§ï¼Œé€™äº›ç™¼ç¾ç‚ºæœªä¾†çš„å¥åº·ç ”ç©¶æä¾›äº†é‡è¦çš„åŸºç¤ã€‚",
    "fb_post": "æ ¹æ“šã€ŠMolecular nutrition & food researchã€‹æ–¼ 2026 å¹´ 1 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸ¥¦ä½ çŸ¥é“é’èŠ±æ¤°èœè£¡æœ‰å€‹ç§˜å¯†æ­¦å™¨å—ï¼Ÿé‚£å°±æ˜¯è˜¿è””ç¡«ç´ ï¼é€™ç¨®å¤©ç„¶åŒ–åˆç‰©æœ€è¿‘å¼•èµ·äº†ä¸å°‘é—œæ³¨ï¼Œå› ç‚ºå®ƒå¯èƒ½å°æˆ‘å€‘çš„å¥åº·æœ‰å¾ˆå¤šå¥½è™•ï¼Œå°¤å…¶æ˜¯åœ¨é é˜²ç–¾ç—…æ–¹é¢ï¼\n\næœ€è¿‘æœ‰ä¸€é …ç ”ç©¶å°ˆé–€æ¢è¨è˜¿è””ç¡«ç´ å°ç´°èƒä»£è¬çš„å½±éŸ¿ã€‚ç ”ç©¶äººå“¡æƒ³çŸ¥é“é€™ç¨®åŒ–åˆç‰©å¦‚ä½•å½±éŸ¿æˆ‘å€‘èº«é«”è£¡çš„ä¸»è¦ä»£è¬é€”å¾‘ã€‚ç‚ºäº†äº†è§£é€™ä¸€é»ï¼Œä»–å€‘ç”¨äººé¡è‚æ¯ç´°èƒç™Œç´°èƒï¼ˆç°¡ç¨±HepG2ï¼‰ä¾†é€²è¡Œå¯¦é©—ï¼Œä¸¦ä½¿ç”¨å…ˆé€²çš„åˆ†ææŠ€è¡“ä¾†æ¸¬é‡ç´°èƒå…§çš„ä»£è¬è®ŠåŒ–ã€‚\n\nçµæœç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ å°å¤šå€‹é‡è¦çš„ä»£è¬é€”å¾‘ç”¢ç”Ÿäº†é¡¯è‘—å½±éŸ¿ï¼Œåƒæ˜¯èƒ½é‡ç”Ÿæˆå’Œæ°¨åŸºé…¸ä»£è¬ç­‰ã€‚æ­¤å¤–ï¼Œå®ƒé‚„æé«˜äº†æˆ‘å€‘èº«é«”è£¡çš„æŠ—æ°§åŒ–ç‰©è³ªæ°´å¹³ï¼Œé€™æ„å‘³è‘—å®ƒå¯èƒ½æœ‰åŠ©æ–¼ä¿è­·æˆ‘å€‘çš„ç´°èƒï¼\n\nğŸ” ç¸½çµä¸€ä¸‹é€™é …ç ”ç©¶çš„é‡é»ï¼š  \n1ï¸âƒ£ è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼é™ä½æŸäº›ç™Œç—‡é¢¨éšªã€‚  \n2ï¸âƒ£ å®ƒå°ç´°èƒçš„èƒ½é‡å’Œæ°¨åŸºé…¸ä»£è¬æœ‰é¡¯è‘—å½±éŸ¿ã€‚  \n3ï¸âƒ£ æå‡çš„æŠ—æ°§åŒ–ç‰©è³ªæ°´å¹³ï¼Œå¯èƒ½æœ‰åŠ©æ–¼ä¿è­·ç´°èƒï¼\n\nè®“æˆ‘å€‘ä¸€èµ·å¤šåƒé’èŠ±æ¤°èœï¼Œç‚ºå¥åº·åŠ åˆ†ï¼",
    "image_prompt": "Create an infographic that explains the experiment and main results of a study on sulforaphane, a compound found in broccoli. Use a flat design style with a white or light-colored background and soft colors. Include symbols representing broccoli or sulforaphane, simplified illustrations of human or cell subjects, arrows or flow lines indicating the steps of the experiment, and a section highlighting the main results, such as protective effects and changes observed in metabolism.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "è‚ç™Œ Hepatocellular Carcinoma",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41543290/"
  },
  {
    "id": "41438577",
    "title_en": "Sulforaphane-cysteine elicits apoptosis through JNK-mediated caspase activation in oral squamous cell carcinoma cells.",
    "pub_date": "2026",
    "journal": "Journal of Cancer",
    "abstract_en": "Sulforaphane-cysteine (SFN-Cys) is a naturally-occurring form of plant-derived isothiocyanate metabolites that displays several tumor-suppressive properties. However, the oncostatic potential of SFN-Cys on oral squamous cell carcinoma (OSCC) is mostly elusive. In this study, we tried to test whether SFN-Cys affects OSCC to progress and further explored the underlying array of molecular cues that SFN-Cys mediates. Our results demonstrate that SFN-Cys was an effective inducer of cytotoxicity to OSCC cells, accompanied with blockage of cell cycling and promotion of apoptotic events. Moreover, treatment of OSCC cells with SFN-Cys attuned an apoptosis-associated protein regulatory program, underlined by downregulation of apoptosis suppressors (cIAP-1 and XIAP) and activation of caspase cascades. Furthermore, caspase activations in SFN-Cys-treated OSCC cells were affected by the pre-incubation with a specific c-Jun N-terminal kinase (JNK) inhibitor, suggesting a functional link of JNK pathway to SFN-Cys's actions in OSCC cells. Collectively, our data revealed that SFN-Cys hampered cell cycle progression and elicited apoptotic responses in OSCC via a JNK-mediated activation of caspase pathways. These findings provide possible avenues for the application of a natural compound in the management of oral malignancies.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨å£è…”ç™Œçš„ç®¡ç†ä¸Šã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ é€™ç¨®å¤©ç„¶åŒ–åˆç‰©å¯èƒ½å°å£è…”é±—ç‹€ç´°èƒç™Œï¼ˆOSCCï¼‰æœ‰æ½›åœ¨çš„æŠ‘åˆ¶æ•ˆæœã€‚é€™æ„å‘³è‘—ï¼Œé€éé£²é£Ÿä¸­æ”å–å¯Œå«è˜¿è””ç¡«ç´ çš„é£Ÿç‰©ï¼Œä¾‹å¦‚é’èŠ±æ¤°èœï¼Œå¯èƒ½æœ‰åŠ©æ–¼é™ä½æŸäº›ç™Œç—‡çš„é¢¨éšªï¼Œä¸¦ç‚ºæœªä¾†çš„ç™Œç—‡æ²»ç™‚æä¾›æ–°çš„æ€è·¯ã€‚é€™æ¨£çš„ç™¼ç¾ä¸åƒ…å°æ‚£è€…æœ‰å¹«åŠ©ï¼Œä¹Ÿå¯èƒ½å¼•å°å¥åº·ä¿ƒé€²çš„é£²é£Ÿå»ºè­°ï¼Œé¼“å‹µäººå€‘å¤šæ”å–é€™é¡æ¤ç‰©æ€§é£Ÿç‰©ä»¥å¢å¼·å¥åº·ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°å£è…”é±—ç‹€ç´°èƒç™Œï¼ˆOSCCï¼‰çš„å½±éŸ¿ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£é€™ç¨®å¤©ç„¶åŒ–åˆç‰©æ˜¯å¦èƒ½å¤ æŠ‘åˆ¶ç™Œç´°èƒçš„å¢é•·ï¼Œä¸¦é€²ä¸€æ­¥æ¢è¨å…¶èƒŒå¾Œçš„åˆ†å­æ©Ÿåˆ¶ã€‚ç”±æ–¼å£è…”ç™Œæ˜¯ä¸€ç¨®å¸¸è¦‹çš„æƒ¡æ€§è…«ç˜¤ï¼Œäº†è§£å¦‚ä½•åˆ©ç”¨å¤©ç„¶æˆåˆ†ä¾†å°æŠ—é€™ç¨®ç–¾ç—…ï¼Œå°æ–¼æ”¹å–„æ‚£è€…çš„é å¾Œå’Œç”Ÿæ´»å“è³ªå…·æœ‰é‡è¦æ„ç¾©ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†å£è…”é±—ç‹€ç´°èƒç™Œç´°èƒä½œç‚ºç ”ç©¶å°è±¡ï¼Œä¸¦æ–½åŠ äº†è˜¿è””ç¡«ç´ ä¾†è§€å¯Ÿå…¶æ•ˆæœã€‚ç ”ç©¶ä¸»è¦é›†ä¸­åœ¨è˜¿è””ç¡«ç´ å°ç™Œç´°èƒçš„ç´°èƒæ¯’æ€§å½±éŸ¿ï¼Œä»¥åŠå®ƒå¦‚ä½•å½±éŸ¿ç´°èƒé€±æœŸå’Œä¿ƒé€²ç´°èƒå‡‹äº¡çš„éç¨‹ã€‚ç ”ç©¶è€…é‚„æ¢è¨äº†èˆ‡ç´°èƒå‡‹äº¡ç›¸é—œçš„è›‹ç™½è³ªèª¿æ§ç¨‹åºï¼Œä¸¦ä½¿ç”¨ç‰¹å®šçš„æŠ‘åˆ¶åŠ‘ä¾†åˆ†æä¸åŒä¿¡è™Ÿé€šè·¯çš„ä½œç”¨ï¼Œç‰¹åˆ¥æ˜¯c-Jun N-terminal kinaseï¼ˆJNKï¼‰é€šè·¯çš„å½±éŸ¿ã€‚",
    "para4": "ç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½æœ‰æ•ˆèª˜å°å£è…”é±—ç‹€ç´°èƒç™Œç´°èƒçš„ç´°èƒæ¯’æ€§ï¼Œä¸¦é˜»ç¤™ç´°èƒé€±æœŸçš„é€²è¡Œï¼ŒåŒæ™‚ä¿ƒé€²ç´°èƒå‡‹äº¡ã€‚å…·é«”ä¾†èªªï¼Œè˜¿è””ç¡«ç´ çš„è™•ç†å°è‡´äº†èˆ‡å‡‹äº¡ç›¸é—œçš„è›‹ç™½è³ªçš„ä¸‹èª¿å’Œcaspaseç´šè¯åæ‡‰çš„æ¿€æ´»ã€‚æ­¤å¤–ï¼Œç•¶ä½¿ç”¨JNKæŠ‘åˆ¶åŠ‘é€²è¡Œé è™•ç†æ™‚ï¼Œç™¼ç¾caspaseçš„æ´»åŒ–å—åˆ°å½±éŸ¿ï¼Œé€™è¡¨æ˜JNKé€šè·¯åœ¨è˜¿è””ç¡«ç´ çš„ä½œç”¨ä¸­æ‰®æ¼”äº†é‡è¦è§’è‰²ã€‚é€™äº›ç™¼ç¾ç‚ºåˆ©ç”¨å¤©ç„¶åŒ–åˆç‰©ä¾†ç®¡ç†å£è…”æƒ¡æ€§è…«ç˜¤æä¾›äº†æ–°çš„å¯èƒ½æ€§ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨å£è…”ç™Œçš„ç®¡ç†ä¸Šã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ é€™ç¨®å¤©ç„¶åŒ–åˆç‰©å¯èƒ½å°å£è…”é±—ç‹€ç´°èƒç™Œï¼ˆOSCCï¼‰æœ‰æ½›åœ¨çš„æŠ‘åˆ¶æ•ˆæœã€‚é€™æ„å‘³è‘—ï¼Œé€éé£²é£Ÿä¸­æ”å–å¯Œå«è˜¿è””ç¡«ç´ çš„é£Ÿç‰©ï¼Œä¾‹å¦‚é’èŠ±æ¤°èœï¼Œå¯èƒ½æœ‰åŠ©æ–¼é™ä½æŸäº›ç™Œç—‡çš„é¢¨éšªï¼Œä¸¦ç‚ºæœªä¾†çš„ç™Œç—‡æ²»ç™‚æä¾›æ–°çš„æ€è·¯ã€‚é€™æ¨£çš„ç™¼ç¾ä¸åƒ…å°æ‚£è€…æœ‰å¹«åŠ©ï¼Œä¹Ÿå¯èƒ½å¼•å°å¥åº·ä¿ƒé€²çš„é£²é£Ÿå»ºè­°ï¼Œé¼“å‹µäººå€‘å¤šæ”å–é€™é¡æ¤ç‰©æ€§é£Ÿç‰©ä»¥å¢å¼·å¥åº·ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°å£è…”é±—ç‹€ç´°èƒç™Œï¼ˆOSCCï¼‰çš„å½±éŸ¿ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£é€™ç¨®å¤©ç„¶åŒ–åˆç‰©æ˜¯å¦èƒ½å¤ æŠ‘åˆ¶ç™Œç´°èƒçš„å¢é•·ï¼Œä¸¦é€²ä¸€æ­¥æ¢è¨å…¶èƒŒå¾Œçš„åˆ†å­æ©Ÿåˆ¶ã€‚ç”±æ–¼å£è…”ç™Œæ˜¯ä¸€ç¨®å¸¸è¦‹çš„æƒ¡æ€§è…«ç˜¤ï¼Œäº†è§£å¦‚ä½•åˆ©ç”¨å¤©ç„¶æˆåˆ†ä¾†å°æŠ—é€™ç¨®ç–¾ç—…ï¼Œå°æ–¼æ”¹å–„æ‚£è€…çš„é å¾Œå’Œç”Ÿæ´»å“è³ªå…·æœ‰é‡è¦æ„ç¾©ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†å£è…”é±—ç‹€ç´°èƒç™Œç´°èƒä½œç‚ºç ”ç©¶å°è±¡ï¼Œä¸¦æ–½åŠ äº†è˜¿è””ç¡«ç´ ä¾†è§€å¯Ÿå…¶æ•ˆæœã€‚ç ”ç©¶ä¸»è¦é›†ä¸­åœ¨è˜¿è””ç¡«ç´ å°ç™Œç´°èƒçš„ç´°èƒæ¯’æ€§å½±éŸ¿ï¼Œä»¥åŠå®ƒå¦‚ä½•å½±éŸ¿ç´°èƒé€±æœŸå’Œä¿ƒé€²ç´°èƒå‡‹äº¡çš„éç¨‹ã€‚ç ”ç©¶è€…é‚„æ¢è¨äº†èˆ‡ç´°èƒå‡‹äº¡ç›¸é—œçš„è›‹ç™½è³ªèª¿æ§ç¨‹åºï¼Œä¸¦ä½¿ç”¨ç‰¹å®šçš„æŠ‘åˆ¶åŠ‘ä¾†åˆ†æä¸åŒä¿¡è™Ÿé€šè·¯çš„ä½œç”¨ï¼Œç‰¹åˆ¥æ˜¯c-Jun N-terminal kinaseï¼ˆJNKï¼‰é€šè·¯çš„å½±éŸ¿ã€‚\n\nç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½æœ‰æ•ˆèª˜å°å£è…”é±—ç‹€ç´°èƒç™Œç´°èƒçš„ç´°èƒæ¯’æ€§ï¼Œä¸¦é˜»ç¤™ç´°èƒé€±æœŸçš„é€²è¡Œï¼ŒåŒæ™‚ä¿ƒé€²ç´°èƒå‡‹äº¡ã€‚å…·é«”ä¾†èªªï¼Œè˜¿è””ç¡«ç´ çš„è™•ç†å°è‡´äº†èˆ‡å‡‹äº¡ç›¸é—œçš„è›‹ç™½è³ªçš„ä¸‹èª¿å’Œcaspaseç´šè¯åæ‡‰çš„æ¿€æ´»ã€‚æ­¤å¤–ï¼Œç•¶ä½¿ç”¨JNKæŠ‘åˆ¶åŠ‘é€²è¡Œé è™•ç†æ™‚ï¼Œç™¼ç¾caspaseçš„æ´»åŒ–å—åˆ°å½±éŸ¿ï¼Œé€™è¡¨æ˜JNKé€šè·¯åœ¨è˜¿è””ç¡«ç´ çš„ä½œç”¨ä¸­æ‰®æ¼”äº†é‡è¦è§’è‰²ã€‚é€™äº›ç™¼ç¾ç‚ºåˆ©ç”¨å¤©ç„¶åŒ–åˆç‰©ä¾†ç®¡ç†å£è…”æƒ¡æ€§è…«ç˜¤æä¾›äº†æ–°çš„å¯èƒ½æ€§ã€‚",
    "fb_post": "æ ¹æ“šã€ŠJournal of Cancerã€‹æ–¼ 2026 å¹´ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸ½ï¸ä½ çŸ¥é“å—ï¼Ÿæœ‰äº›é£Ÿç‰©å¯èƒ½å°æˆ‘å€‘çš„å¥åº·æœ‰ç¥å¥‡çš„å½±éŸ¿ï¼æœ€è¿‘ä¸€é …ç ”ç©¶ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ é€™ç¨®å¤©ç„¶åŒ–åˆç‰©ï¼Œå¯èƒ½å°å£è…”ç™Œæœ‰æŠ‘åˆ¶æ•ˆæœï¼\n\né€™é …ç ”ç©¶ä¸»è¦åœ¨æ¢è¨è˜¿è””ç¡«ç´ æ˜¯å¦èƒ½å¹«åŠ©æ¸›å°‘å£è…”é±—ç‹€ç´°èƒç™Œï¼ˆOSCCï¼‰çš„å¢é•·ã€‚ç ”ç©¶è€…å€‘ä½¿ç”¨äº†ç™Œç´°èƒä¾†é€²è¡Œå¯¦é©—ï¼Œè§€å¯Ÿè˜¿è””ç¡«ç´ å°é€™äº›ç´°èƒçš„å½±éŸ¿ã€‚ä»–å€‘ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ ä¸åƒ…èƒ½æ®ºæ­»ç™Œç´°èƒï¼Œé‚„èƒ½é˜»æ­¢å®ƒå€‘çš„å¢é•·ï¼Œç”šè‡³ä¿ƒé€²ç´°èƒçš„è‡ªç„¶æ­»äº¡ã€‚\n\né€™äº›çµæœè®“æˆ‘å€‘çœ‹åˆ°ï¼Œæ—¥å¸¸é£²é£Ÿä¸­åŠ å…¥å¯Œå«è˜¿è””ç¡«ç´ çš„é£Ÿç‰©ï¼Œå¦‚é’èŠ±æ¤°èœï¼Œæˆ–è¨±èƒ½é™ä½æŸäº›ç™Œç—‡çš„é¢¨éšªï¼\n\nğŸ” ç¸½çµä¸€ä¸‹é€™é …ç ”ç©¶çš„é‡é»ï¼š  \n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æŠ‘åˆ¶å£è…”ç™Œç´°èƒå¢é•·ã€‚  \n2. å®ƒèƒ½ä¿ƒé€²ç™Œç´°èƒçš„è‡ªç„¶æ­»äº¡ï¼Œè®“èº«é«”æ›´å¥åº·ã€‚  \n3. å¤šåƒé’èŠ±æ¤°èœç­‰æ¤ç‰©æ€§é£Ÿç‰©ï¼Œå°å¥åº·æœ‰ç›Šï¼",
    "image_prompt": "Create an infographic that illustrates the experiment and main results of a study on the effects of sulforaphane on oral squamous cell carcinoma. The design should be flat and simple, with a light background and soft colors. Include symbols representing broccoli or sulforaphane, simplified illustrations of experimental subjects like cells, and arrows or flow lines to show the experimental steps. Add a section that highlights the main results, such as protective effects or changes observed.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "å£è…”é±—ç‹€ç´°èƒç™Œ Oral Squamous Cell Carcinoma",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41438577/"
  },
  {
    "id": "41352012",
    "title_en": "Protection against deoxynivalenol (DON)-induced intestinal injury by sulforaphane via modulation of lysosomal function.",
    "pub_date": "2026 Jan",
    "journal": "Journal of hazardous materials",
    "abstract_en": "Deoxynivalenol (DON) is a prevalent mycotoxin commonly detected in both human and animal diets, representing a significant health risk. Sulforaphane (SFN), a bioactive compound from cruciferous vegetables known for its antioxidant. This study aimed to confirm SFN's protective effect against DON-induced intestinal injury and clarify its underlying molecular mechanism. In vivo, C57BL/6 male mice (nâ€¯=â€¯8/group) were treated with DON (2â€¯mg/kg BW) and SFN (10â€¯mg/kg BW) to assess the overall protective effects of SFN; in vitro, intestinal porcine epithelial cells (IPEC-J2) and pig intestinal organoids were treated with DON (1â€¯Î¼g/mL) and SFN (2â€¯Î¼M) to investigate the protective mechanism of SFN. Hematoxylin-eosin staining, western blot and flow cytometry were used to confirm the protective effects of SFN. RNA-seq, CETSA, ITDRF and non-targeted metabolomics was employed to investigate the mechanism of SFN supplementation. This study demonstrated that SFN significantly alleviated DON-induced intestinal toxicity: in vivo, SFN restored jejunal villus height/crypt depth and restored the balance of redox homeostasis (decreased MDA, LDH, SOD and CAT); in vitro, SFN lowered DON-induced cell apoptosis and ROS accumulation. Mechanistically, lysosomal function was critical for SFN's protection-SFN directly targeted ATP6AP1 to enhance lysosomal acidification Moreover, ATP supplementation further potentiated this acidification and SFN's cytoprotective effect. This study identified ATP6AP1-mediated lysosomal acidification as a novel mechanism for SFN to mitigate DON-induced intestinal injury. Therefore, investigating the crosstalk between the SFN-ATP6AP1 axis and gut microbiota warrants further investigation to elucidate a broader protective mechanism.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°é£Ÿç‰©ä¸­å¸¸è¦‹çš„éœ‰èŒæ¯’ç´ â€”â€”å»æ°§é†‹é…¸ï¼ˆDONï¼‰ã€‚é€™ç¨®æ¯’ç´ åœ¨æˆ‘å€‘çš„é£²é£Ÿä¸­å¾ˆå¸¸è¦‹ï¼Œå°äººé«”å¥åº·æ§‹æˆæ½›åœ¨é¢¨éšªã€‚ç ”ç©¶ç™¼ç¾ï¼Œä¾†è‡ªåå­—èŠ±ç§‘è”¬èœçš„è˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰å¯èƒ½å°æŠ—é€™ç¨®æ¯’ç´ å¼•èµ·çš„è…¸é“æå‚·ï¼Œé€™å°æ–¼æ”¹å–„é£²é£Ÿå®‰å…¨å’Œä¿ƒé€²è…¸é“å¥åº·æœ‰é‡è¦æ„ç¾©ã€‚é€éé€™é …ç ”ç©¶ï¼Œæˆ‘å€‘å¯ä»¥æ›´æ·±å…¥äº†è§£å¦‚ä½•åˆ©ç”¨å¤©ç„¶é£Ÿæä¾†å¢å¼·äººé«”æŠµæŠ—åŠ›ï¼Œä¸¦æ¸›å°‘é£²é£Ÿä¸­æœ‰å®³ç‰©è³ªçš„å½±éŸ¿ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°å»æ°§é†‹é…¸ï¼ˆDONï¼‰å¼•èµ·çš„è…¸é“æå‚·çš„ä¿è­·ä½œç”¨ï¼Œä»¥åŠå…¶èƒŒå¾Œçš„åˆ†å­æ©Ÿåˆ¶ã€‚ç ”ç©¶è€…å¸Œæœ›ç¢ºèªè˜¿è””ç¡«ç´ åœ¨æ¸›è¼•DONå¼•èµ·çš„è…¸é“æ¯’æ€§æ–¹é¢çš„æ•ˆæœï¼Œä¸¦æ­ç¤ºå…¶å¦‚ä½•åœ¨ç´°èƒå±¤é¢ç™¼æ®ä½œç”¨ã€‚é€™ä¸åƒ…æœ‰åŠ©æ–¼äº†è§£è˜¿è””ç¡«ç´ çš„å¥åº·ç›Šè™•ï¼Œä¹Ÿèƒ½ç‚ºæœªä¾†çš„é£²é£Ÿå»ºè­°æä¾›ç§‘å­¸ä¾æ“šã€‚",
    "para3": "åœ¨å¯¦é©—è¨­è¨ˆä¸Šï¼Œç ”ç©¶è€…ä½¿ç”¨äº†å°é¼ å’Œè±¬è…¸é“ç´°èƒé€²è¡Œæ¸¬è©¦ã€‚åœ¨å°é¼ å¯¦é©—ä¸­ï¼ŒC57BL/6é›„æ€§å°é¼ è¢«åˆ†ç‚ºå…©çµ„ï¼Œåˆ†åˆ¥æ¥å—DONå’Œè˜¿è””ç¡«ç´ çš„è™•ç†ï¼Œä»¥è©•ä¼°è˜¿è””ç¡«ç´ çš„ä¿è­·æ•ˆæœã€‚åœ¨é«”å¤–å¯¦é©—ä¸­ï¼Œå‰‡ä½¿ç”¨è±¬è…¸é“ä¸Šçš®ç´°èƒï¼ˆIPEC-J2ï¼‰å’Œè±¬è…¸é“å™¨å®˜æ¨£æœ¬ï¼Œè§€å¯Ÿè˜¿è””ç¡«ç´ å°DONçš„å½±éŸ¿ã€‚ç ”ç©¶è€…é‚„ä½¿ç”¨äº†å¤šç¨®æŠ€è¡“ï¼Œå¦‚çµ„ç¹”æŸ“è‰²ã€è›‹ç™½è³ªå°è·¡å’Œæµå¼ç´°èƒè¡“ï¼Œä¾†ç¢ºèªè˜¿è””ç¡«ç´ çš„ä¿è­·æ•ˆæœåŠå…¶æ©Ÿåˆ¶ã€‚",
    "para4": "ç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½é¡¯è‘—æ¸›è¼•DONå¼•èµ·çš„è…¸é“æ¯’æ€§ã€‚åœ¨å°é¼ å¯¦é©—ä¸­ï¼Œè˜¿è””ç¡«ç´ æ¢å¾©äº†è…¸é“çµ¨æ¯›çš„é«˜åº¦å’Œè…ºé«”çš„æ·±åº¦ï¼Œä¸¦æ”¹å–„äº†æ°§åŒ–é‚„åŸå¹³è¡¡ã€‚åœ¨é«”å¤–å¯¦é©—ä¸­ï¼Œè˜¿è””ç¡«ç´ é™ä½äº†DONå¼•èµ·çš„ç´°èƒå‡‹äº¡å’Œæ´»æ€§æ°§çš„ç©ç´¯ã€‚æ©Ÿåˆ¶æ–¹é¢ï¼Œç ”ç©¶ç™¼ç¾è˜¿è””ç¡«ç´ é€šéç›´æ¥ä½œç”¨æ–¼ATP6AP1ä¾†å¢å¼·æº¶é…¶é«”çš„é…¸åŒ–ï¼Œé€™å°å…¶ä¿è­·ä½œç”¨è‡³é—œé‡è¦ã€‚æ­¤å¤–ï¼ŒATPçš„è£œå……é€²ä¸€æ­¥å¢å¼·äº†é€™ç¨®é…¸åŒ–åŠå…¶ç´°èƒä¿è­·æ•ˆæœã€‚é€™é …ç ”ç©¶æ­ç¤ºäº†ATP6AP1ä»‹å°çš„æº¶é…¶é«”é…¸åŒ–ä½œç‚ºè˜¿è””ç¡«ç´ æ¸›è¼•DONå¼•èµ·çš„è…¸é“æå‚·çš„æ–°æ©Ÿåˆ¶ï¼Œæœªä¾†é‚„éœ€é€²ä¸€æ­¥æ¢è¨è˜¿è””ç¡«ç´ èˆ‡è…¸é“å¾®ç”Ÿç‰©ä¹‹é–“çš„ç›¸äº’ä½œç”¨ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°é£Ÿç‰©ä¸­å¸¸è¦‹çš„éœ‰èŒæ¯’ç´ â€”â€”å»æ°§é†‹é…¸ï¼ˆDONï¼‰ã€‚é€™ç¨®æ¯’ç´ åœ¨æˆ‘å€‘çš„é£²é£Ÿä¸­å¾ˆå¸¸è¦‹ï¼Œå°äººé«”å¥åº·æ§‹æˆæ½›åœ¨é¢¨éšªã€‚ç ”ç©¶ç™¼ç¾ï¼Œä¾†è‡ªåå­—èŠ±ç§‘è”¬èœçš„è˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰å¯èƒ½å°æŠ—é€™ç¨®æ¯’ç´ å¼•èµ·çš„è…¸é“æå‚·ï¼Œé€™å°æ–¼æ”¹å–„é£²é£Ÿå®‰å…¨å’Œä¿ƒé€²è…¸é“å¥åº·æœ‰é‡è¦æ„ç¾©ã€‚é€éé€™é …ç ”ç©¶ï¼Œæˆ‘å€‘å¯ä»¥æ›´æ·±å…¥äº†è§£å¦‚ä½•åˆ©ç”¨å¤©ç„¶é£Ÿæä¾†å¢å¼·äººé«”æŠµæŠ—åŠ›ï¼Œä¸¦æ¸›å°‘é£²é£Ÿä¸­æœ‰å®³ç‰©è³ªçš„å½±éŸ¿ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°å»æ°§é†‹é…¸ï¼ˆDONï¼‰å¼•èµ·çš„è…¸é“æå‚·çš„ä¿è­·ä½œç”¨ï¼Œä»¥åŠå…¶èƒŒå¾Œçš„åˆ†å­æ©Ÿåˆ¶ã€‚ç ”ç©¶è€…å¸Œæœ›ç¢ºèªè˜¿è””ç¡«ç´ åœ¨æ¸›è¼•DONå¼•èµ·çš„è…¸é“æ¯’æ€§æ–¹é¢çš„æ•ˆæœï¼Œä¸¦æ­ç¤ºå…¶å¦‚ä½•åœ¨ç´°èƒå±¤é¢ç™¼æ®ä½œç”¨ã€‚é€™ä¸åƒ…æœ‰åŠ©æ–¼äº†è§£è˜¿è””ç¡«ç´ çš„å¥åº·ç›Šè™•ï¼Œä¹Ÿèƒ½ç‚ºæœªä¾†çš„é£²é£Ÿå»ºè­°æä¾›ç§‘å­¸ä¾æ“šã€‚\n\nåœ¨å¯¦é©—è¨­è¨ˆä¸Šï¼Œç ”ç©¶è€…ä½¿ç”¨äº†å°é¼ å’Œè±¬è…¸é“ç´°èƒé€²è¡Œæ¸¬è©¦ã€‚åœ¨å°é¼ å¯¦é©—ä¸­ï¼ŒC57BL/6é›„æ€§å°é¼ è¢«åˆ†ç‚ºå…©çµ„ï¼Œåˆ†åˆ¥æ¥å—DONå’Œè˜¿è””ç¡«ç´ çš„è™•ç†ï¼Œä»¥è©•ä¼°è˜¿è””ç¡«ç´ çš„ä¿è­·æ•ˆæœã€‚åœ¨é«”å¤–å¯¦é©—ä¸­ï¼Œå‰‡ä½¿ç”¨è±¬è…¸é“ä¸Šçš®ç´°èƒï¼ˆIPEC-J2ï¼‰å’Œè±¬è…¸é“å™¨å®˜æ¨£æœ¬ï¼Œè§€å¯Ÿè˜¿è””ç¡«ç´ å°DONçš„å½±éŸ¿ã€‚ç ”ç©¶è€…é‚„ä½¿ç”¨äº†å¤šç¨®æŠ€è¡“ï¼Œå¦‚çµ„ç¹”æŸ“è‰²ã€è›‹ç™½è³ªå°è·¡å’Œæµå¼ç´°èƒè¡“ï¼Œä¾†ç¢ºèªè˜¿è””ç¡«ç´ çš„ä¿è­·æ•ˆæœåŠå…¶æ©Ÿåˆ¶ã€‚\n\nç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½é¡¯è‘—æ¸›è¼•DONå¼•èµ·çš„è…¸é“æ¯’æ€§ã€‚åœ¨å°é¼ å¯¦é©—ä¸­ï¼Œè˜¿è””ç¡«ç´ æ¢å¾©äº†è…¸é“çµ¨æ¯›çš„é«˜åº¦å’Œè…ºé«”çš„æ·±åº¦ï¼Œä¸¦æ”¹å–„äº†æ°§åŒ–é‚„åŸå¹³è¡¡ã€‚åœ¨é«”å¤–å¯¦é©—ä¸­ï¼Œè˜¿è””ç¡«ç´ é™ä½äº†DONå¼•èµ·çš„ç´°èƒå‡‹äº¡å’Œæ´»æ€§æ°§çš„ç©ç´¯ã€‚æ©Ÿåˆ¶æ–¹é¢ï¼Œç ”ç©¶ç™¼ç¾è˜¿è””ç¡«ç´ é€šéç›´æ¥ä½œç”¨æ–¼ATP6AP1ä¾†å¢å¼·æº¶é…¶é«”çš„é…¸åŒ–ï¼Œé€™å°å…¶ä¿è­·ä½œç”¨è‡³é—œé‡è¦ã€‚æ­¤å¤–ï¼ŒATPçš„è£œå……é€²ä¸€æ­¥å¢å¼·äº†é€™ç¨®é…¸åŒ–åŠå…¶ç´°èƒä¿è­·æ•ˆæœã€‚é€™é …ç ”ç©¶æ­ç¤ºäº†ATP6AP1ä»‹å°çš„æº¶é…¶é«”é…¸åŒ–ä½œç‚ºè˜¿è””ç¡«ç´ æ¸›è¼•DONå¼•èµ·çš„è…¸é“æå‚·çš„æ–°æ©Ÿåˆ¶ï¼Œæœªä¾†é‚„éœ€é€²ä¸€æ­¥æ¢è¨è˜¿è””ç¡«ç´ èˆ‡è…¸é“å¾®ç”Ÿç‰©ä¹‹é–“çš„ç›¸äº’ä½œç”¨ã€‚",
    "fb_post": "æ ¹æ“šã€ŠJournal of hazardous materialsã€‹æ–¼ 2026 å¹´ 1 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿæˆ‘å€‘çš„é£²é£Ÿä¸­å¯èƒ½éš±è—è‘—ä¸€ç¨®å«åšå»æ°§é†‹é…¸ï¼ˆDONï¼‰çš„æ¯’ç´ ï¼Œå°æˆ‘å€‘çš„è…¸é“å¥åº·æœ‰æ½›åœ¨å¨è„…ï¼ä¸éï¼Œåˆ¥æ“”å¿ƒï¼Œæœ€è¿‘çš„ç ”ç©¶ç™¼ç¾ï¼Œä¾†è‡ªé’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘è”¬èœçš„è˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰æˆ–è¨±å¯ä»¥å¹«åŠ©æˆ‘å€‘æŠµæŠ—é€™ç¨®æ¯’ç´ çš„å½±éŸ¿ã€‚  \n é€™é …ç ”ç©¶çš„ç›®çš„æ˜¯äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•ä¿è­·è…¸é“å…å—DONçš„å‚·å®³ã€‚ç ”ç©¶è€…å€‘é€²è¡Œäº†å°é¼ å’Œè±¬è…¸é“ç´°èƒçš„å¯¦é©—ï¼Œè§€å¯Ÿè˜¿è””ç¡«ç´ çš„æ•ˆæœã€‚çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½æœ‰æ•ˆæ¸›è¼•DONé€ æˆçš„è…¸é“æå‚·ï¼Œæ”¹å–„è…¸é“çš„å¥åº·ç‹€æ³ã€‚  \n å…·é«”ä¾†èªªï¼Œè˜¿è””ç¡«ç´ èƒ½æ¢å¾©è…¸é“ç´°èƒçš„çµæ§‹ï¼Œé™ä½ç´°èƒæ­»äº¡ï¼Œä¸¦æ”¹å–„ç´°èƒå…§çš„æ°§åŒ–é‚„åŸå¹³è¡¡ã€‚é€™äº›ç™¼ç¾è®“æˆ‘å€‘æ›´äº†è§£å¦‚ä½•é€éé£²é£Ÿä¾†å¢å¼·èº«é«”çš„æŠµæŠ—åŠ›ï¼Œæœªä¾†æˆ–è¨±èƒ½æä¾›æˆ‘å€‘æ›´å¥½çš„é£²é£Ÿå»ºè­°ï¼  \n  **é‡é»æ•´ç†ï¼š**  \n 1. è˜¿è””ç¡«ç´ ä¾†è‡ªé’èŠ±æ¤°èœï¼Œå¯èƒ½å°æŠ—é£²é£Ÿä¸­çš„æ¯’ç´ ã€‚  \n 2. ç ”ç©¶é¡¯ç¤ºè˜¿è””ç¡«ç´ èƒ½æ¸›è¼•è…¸é“æå‚·ã€‚  \n 3. é€™æˆ–è¨±èƒ½æˆç‚ºæœªä¾†é£²é£Ÿå»ºè­°çš„ç§‘å­¸åŸºç¤ã€‚",
    "image_prompt": "Create an informative flat design illustration that explains the experimental methods and main results of a study on sulforaphane (SFN) and its protective effects against deoxynivalenol (DON) toxicity. Include simplified icons representing broccoli or sulforaphane, experimental subjects like mice and intestinal cells, and arrows or flow lines indicating the experimental steps. Add a section highlighting the main results, such as protective effects and improvements in gut health.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "è…¸é“æå‚· Intestinal Injury",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41352012/"
  },
  {
    "id": "41265122",
    "title_en": "Synergistic strategies of sulforaphane biosynthesis and functional properties in broccoli sprouts powder obtained from sucrose stress modulation coupled with vacuum freeze-drying.",
    "pub_date": "2026 Jan",
    "journal": "Food chemistry",
    "abstract_en": "This study investigated methionine-sucrose stress treatments on glucoraphanin biosynthesis in broccoli sprouts and the impact of vacuum freeze-drying (VFD) on sprout powder quality. Results showed that sucrose treatment elevated glucoraphanin content by 316.30Â % in 4-day sprouts compared to the control (9.72Â mg/g), accompanied by increases of 42.65Â % in total isothiocyanates (ITCs) and 70.00Â % in anthocyanins. The treatment enhanced myrosinase activity and upregulated osmotic regulators. PCA confirmed that sucrose stress optimized the nutritional quality of broccoli sprouts and exhibited potential in sulforaphane enrichment. The VFD broccoli sprout powder exhibited high retention of sulforaphane (6.00Â mg/g dw) and total ITCs (7.00Â mg/g dw), with optimal water-holding capacity, oil-holding capacity, and swelling capacity. The sulforaphane extract exhibited significant antimicrobial activity against E. coli (16.00Â mm inhibition zone) and Staphylococcus aureus (10.02Â mm). The synergistic application of sucrose stress and VFD presents a promising approach for developing functional foods.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é’èŠ±æ¤°èœçš„ç‡Ÿé¤Šæˆåˆ†å¦‚ä½•å—åˆ°ä¸åŒè™•ç†æ–¹å¼çš„å½±éŸ¿ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œé€éç‰¹å®šçš„å£“åŠ›è™•ç†ï¼Œå¯ä»¥æå‡é’èŠ±æ¤°èœèŠ½ä¸­çš„é‡è¦æˆåˆ†ï¼Œé€™äº›æˆåˆ†å¯èƒ½æœ‰åŠ©æ–¼å¢å¼·äººé«”çš„å…ç–«ç³»çµ±ï¼Œä¸¦å°æŠ—æŸäº›ç´°èŒæ„ŸæŸ“ã€‚é€™æ„å‘³è‘—ï¼Œé€éèª¿æ•´é£²é£Ÿä¸­çš„æŸäº›é£Ÿææˆ–å…¶è™•ç†æ–¹å¼ï¼Œå¯èƒ½èƒ½å¤ æœ‰æ•ˆåœ°æé«˜æˆ‘å€‘çš„å¥åº·æ°´å¹³ï¼Œä¸¦åœ¨æŸç¨®ç¨‹åº¦ä¸Šé é˜²ç–¾ç—…çš„ç™¼ç”Ÿã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨ç”²ç¡«æ°¨é…¸-è”—ç³–å£“åŠ›è™•ç†å°é’èŠ±æ¤°èœèŠ½ä¸­è‘¡è„ç³–æ‹‰æ³•å¯§ï¼ˆglucoraphaninï¼‰åˆæˆçš„å½±éŸ¿ï¼Œä»¥åŠçœŸç©ºå†·å‡ä¹¾ç‡¥ï¼ˆVFDï¼‰å°èŠ½ç²‰å“è³ªçš„å½±éŸ¿ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯å¦‚ä½•é€éé€™äº›è™•ç†æ–¹å¼ä¾†æå‡é’èŠ±æ¤°èœèŠ½çš„ç‡Ÿé¤Šåƒ¹å€¼ï¼Œç‰¹åˆ¥æ˜¯å…¶å°å¥åº·æœ‰ç›Šçš„æˆåˆ†ï¼Œä¸¦è©•ä¼°é€™äº›è™•ç†å°é’èŠ±æ¤°èœèŠ½ç²‰çš„å“è³ªæ˜¯å¦æœ‰æ­£é¢çš„å½±éŸ¿ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†é’èŠ±æ¤°èœèŠ½ä½œç‚ºå°è±¡ï¼Œä¸¦å°å…¶é€²è¡Œäº†ç”²ç¡«æ°¨é…¸-è”—ç³–çš„å£“åŠ›è™•ç†ï¼Œè§€å¯Ÿå…¶å°è‘¡è„ç³–æ‹‰æ³•å¯§åˆæˆçš„å½±éŸ¿ã€‚ç ”ç©¶è€…é‚„é€²è¡Œäº†çœŸç©ºå†·å‡ä¹¾ç‡¥ï¼Œä»¥è©•ä¼°é€™ç¨®è™•ç†å°é’èŠ±æ¤°èœèŠ½ç²‰çš„å“è³ªï¼ŒåŒ…æ‹¬å…¶æ°´åˆ†ä¿æŒèƒ½åŠ›å’Œæ²¹è„‚ä¿æŒèƒ½åŠ›ç­‰ã€‚é€™äº›æ–¹æ³•çš„è¨­è¨ˆæ—¨åœ¨æ‰¾å‡ºæœ€ä½³çš„è™•ç†æ–¹å¼ï¼Œä»¥æå‡é’èŠ±æ¤°èœèŠ½çš„ç‡Ÿé¤Šæˆåˆ†ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè”—ç³–è™•ç†ä½¿é’èŠ±æ¤°èœèŠ½ä¸­çš„è‘¡è„ç³–æ‹‰æ³•å¯§å«é‡æå‡äº†316.30%ï¼Œä¸¦ä¸”ç¸½ç•°ç¡«æ°°é…¸é¹½å’ŒèŠ±é’ç´ çš„å«é‡ä¹Ÿæœ‰é¡¯è‘—å¢åŠ ã€‚æ­¤å¤–ï¼Œé€™ç¨®è™•ç†é‚„å¢å¼·äº†é…µç´ æ´»æ€§ï¼Œä¸¦ä¿ƒé€²äº†æ»²é€èª¿ç¯€å› å­çš„ä¸Šèª¿ã€‚çœŸç©ºå†·å‡ä¹¾ç‡¥çš„é’èŠ±æ¤°èœèŠ½ç²‰åœ¨ä¿ç•™è˜¿è””ç¡«ç´ å’Œç¸½ç•°ç¡«æ°°é…¸é¹½æ–¹é¢è¡¨ç¾è‰¯å¥½ï¼Œä¸¦ä¸”å…·æœ‰å„ªè‰¯çš„æ°´åˆ†å’Œæ²¹è„‚ä¿æŒèƒ½åŠ›ã€‚é€™äº›çµæœé¡¯ç¤ºï¼Œçµåˆè”—ç³–å£“åŠ›å’ŒçœŸç©ºå†·å‡ä¹¾ç‡¥çš„æ‡‰ç”¨ï¼Œå¯èƒ½ç‚ºé–‹ç™¼åŠŸèƒ½æ€§é£Ÿå“æä¾›äº†ä¸€å€‹æœ‰å‰æ™¯çš„æ–¹å‘ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é’èŠ±æ¤°èœçš„ç‡Ÿé¤Šæˆåˆ†å¦‚ä½•å—åˆ°ä¸åŒè™•ç†æ–¹å¼çš„å½±éŸ¿ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œé€éç‰¹å®šçš„å£“åŠ›è™•ç†ï¼Œå¯ä»¥æå‡é’èŠ±æ¤°èœèŠ½ä¸­çš„é‡è¦æˆåˆ†ï¼Œé€™äº›æˆåˆ†å¯èƒ½æœ‰åŠ©æ–¼å¢å¼·äººé«”çš„å…ç–«ç³»çµ±ï¼Œä¸¦å°æŠ—æŸäº›ç´°èŒæ„ŸæŸ“ã€‚é€™æ„å‘³è‘—ï¼Œé€éèª¿æ•´é£²é£Ÿä¸­çš„æŸäº›é£Ÿææˆ–å…¶è™•ç†æ–¹å¼ï¼Œå¯èƒ½èƒ½å¤ æœ‰æ•ˆåœ°æé«˜æˆ‘å€‘çš„å¥åº·æ°´å¹³ï¼Œä¸¦åœ¨æŸç¨®ç¨‹åº¦ä¸Šé é˜²ç–¾ç—…çš„ç™¼ç”Ÿã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨ç”²ç¡«æ°¨é…¸-è”—ç³–å£“åŠ›è™•ç†å°é’èŠ±æ¤°èœèŠ½ä¸­è‘¡è„ç³–æ‹‰æ³•å¯§ï¼ˆglucoraphaninï¼‰åˆæˆçš„å½±éŸ¿ï¼Œä»¥åŠçœŸç©ºå†·å‡ä¹¾ç‡¥ï¼ˆVFDï¼‰å°èŠ½ç²‰å“è³ªçš„å½±éŸ¿ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯å¦‚ä½•é€éé€™äº›è™•ç†æ–¹å¼ä¾†æå‡é’èŠ±æ¤°èœèŠ½çš„ç‡Ÿé¤Šåƒ¹å€¼ï¼Œç‰¹åˆ¥æ˜¯å…¶å°å¥åº·æœ‰ç›Šçš„æˆåˆ†ï¼Œä¸¦è©•ä¼°é€™äº›è™•ç†å°é’èŠ±æ¤°èœèŠ½ç²‰çš„å“è³ªæ˜¯å¦æœ‰æ­£é¢çš„å½±éŸ¿ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†é’èŠ±æ¤°èœèŠ½ä½œç‚ºå°è±¡ï¼Œä¸¦å°å…¶é€²è¡Œäº†ç”²ç¡«æ°¨é…¸-è”—ç³–çš„å£“åŠ›è™•ç†ï¼Œè§€å¯Ÿå…¶å°è‘¡è„ç³–æ‹‰æ³•å¯§åˆæˆçš„å½±éŸ¿ã€‚ç ”ç©¶è€…é‚„é€²è¡Œäº†çœŸç©ºå†·å‡ä¹¾ç‡¥ï¼Œä»¥è©•ä¼°é€™ç¨®è™•ç†å°é’èŠ±æ¤°èœèŠ½ç²‰çš„å“è³ªï¼ŒåŒ…æ‹¬å…¶æ°´åˆ†ä¿æŒèƒ½åŠ›å’Œæ²¹è„‚ä¿æŒèƒ½åŠ›ç­‰ã€‚é€™äº›æ–¹æ³•çš„è¨­è¨ˆæ—¨åœ¨æ‰¾å‡ºæœ€ä½³çš„è™•ç†æ–¹å¼ï¼Œä»¥æå‡é’èŠ±æ¤°èœèŠ½çš„ç‡Ÿé¤Šæˆåˆ†ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè”—ç³–è™•ç†ä½¿é’èŠ±æ¤°èœèŠ½ä¸­çš„è‘¡è„ç³–æ‹‰æ³•å¯§å«é‡æå‡äº†316.30%ï¼Œä¸¦ä¸”ç¸½ç•°ç¡«æ°°é…¸é¹½å’ŒèŠ±é’ç´ çš„å«é‡ä¹Ÿæœ‰é¡¯è‘—å¢åŠ ã€‚æ­¤å¤–ï¼Œé€™ç¨®è™•ç†é‚„å¢å¼·äº†é…µç´ æ´»æ€§ï¼Œä¸¦ä¿ƒé€²äº†æ»²é€èª¿ç¯€å› å­çš„ä¸Šèª¿ã€‚çœŸç©ºå†·å‡ä¹¾ç‡¥çš„é’èŠ±æ¤°èœèŠ½ç²‰åœ¨ä¿ç•™è˜¿è””ç¡«ç´ å’Œç¸½ç•°ç¡«æ°°é…¸é¹½æ–¹é¢è¡¨ç¾è‰¯å¥½ï¼Œä¸¦ä¸”å…·æœ‰å„ªè‰¯çš„æ°´åˆ†å’Œæ²¹è„‚ä¿æŒèƒ½åŠ›ã€‚é€™äº›çµæœé¡¯ç¤ºï¼Œçµåˆè”—ç³–å£“åŠ›å’ŒçœŸç©ºå†·å‡ä¹¾ç‡¥çš„æ‡‰ç”¨ï¼Œå¯èƒ½ç‚ºé–‹ç™¼åŠŸèƒ½æ€§é£Ÿå“æä¾›äº†ä¸€å€‹æœ‰å‰æ™¯çš„æ–¹å‘ã€‚",
    "fb_post": "æ ¹æ“šã€ŠFood chemistryã€‹æ–¼ 2026 å¹´ 1 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ±ä½ çŸ¥é“é’èŠ±æ¤°èœèŠ½è£¡æœ‰ä»€éº¼ç§˜å¯†å—ï¼Ÿæœ€è¿‘æœ‰ä¸€é …ç ”ç©¶ç™¼ç¾ï¼Œé€éç‰¹å®šçš„è™•ç†æ–¹å¼ï¼Œæˆ‘å€‘å¯ä»¥è®“é’èŠ±æ¤°èœèŠ½è®Šå¾—æ›´æœ‰ç‡Ÿé¤Šï¼Œç”šè‡³å¯èƒ½å¹«åŠ©å¢å¼·å…ç–«ç³»çµ±ï¼é€™é …ç ”ç©¶ä¸»è¦æ¢è¨äº†ç”¨è”—ç³–é€²è¡Œçš„å£“åŠ›è™•ç†ï¼Œçœ‹çœ‹å®ƒå¦‚ä½•å½±éŸ¿é’èŠ±æ¤°èœèŠ½ä¸­çš„ä¸€ç¨®é‡è¦æˆåˆ†â€”â€”è‘¡è„ç³–æ‹‰æ³•å¯§ï¼Œé€™ç¨®æˆåˆ†å°å¥åº·éå¸¸æœ‰ç›Šã€‚ ç ”ç©¶è€…å€‘ä½¿ç”¨é’èŠ±æ¤°èœèŠ½é€²è¡Œäº†å¯¦é©—ï¼Œè§€å¯Ÿé€™ç¨®è™•ç†å°å…¶ç‡Ÿé¤Šåƒ¹å€¼çš„æå‡æ•ˆæœï¼Œé‚„é€²è¡Œäº†çœŸç©ºå†·å‡ä¹¾ç‡¥ä¾†è©•ä¼°èŠ½ç²‰çš„å“è³ªã€‚ çµæœé¡¯ç¤ºï¼Œç¶“éè”—ç³–è™•ç†å¾Œï¼Œé’èŠ±æ¤°èœèŠ½ä¸­çš„è‘¡è„ç³–æ‹‰æ³•å¯§å«é‡ç«Ÿç„¶æå‡äº†316.30%ï¼è€Œä¸”ï¼ŒèŠ½ç²‰çš„æ°´åˆ†å’Œæ²¹è„‚ä¿æŒèƒ½åŠ›ä¹Ÿè¡¨ç¾å¾—ç›¸ç•¶ä¸éŒ¯ã€‚é€™äº›ç™¼ç¾è®“æˆ‘å€‘çœ‹åˆ°äº†é’èŠ±æ¤°èœèŠ½åœ¨å¥åº·é£²é£Ÿä¸­çš„æ½›åŠ›ï¼  âœ… ä¸»è¦é‡é»ï¼š 1. è”—ç³–è™•ç†èƒ½é¡¯è‘—æå‡é’èŠ±æ¤°èœèŠ½çš„ç‡Ÿé¤Šæˆåˆ†ã€‚ 2. çœŸç©ºå†·å‡ä¹¾ç‡¥æœ‰åŠ©æ–¼ä¿æŒé’èŠ±æ¤°èœèŠ½ç²‰çš„å“è³ªã€‚ 3. èª¿æ•´é£Ÿæè™•ç†æ–¹å¼å¯èƒ½å°å¥åº·æœ‰æ­£é¢å½±éŸ¿ï¼",
    "image_prompt": "Create a flat design infographic on a light background explaining the experiment and main results of a study on broccoli sprouts. Include simplified icons of broccoli sprouts and glucoraphanin, along with simplified illustrations of experimental subjects like humans or cells. Use arrows or flow lines to show the experimental steps. Add a section labeled 'Main Results' highlighting the significant increase in glucoraphanin and the quality of freeze-dried broccoli sprout powder.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41265122/"
  },
  {
    "id": "40580757",
    "title_en": "The effect of graphene oxide-polyethylene glycol on lung cell and treatment of sulforaphane.",
    "pub_date": "2026 Jan",
    "journal": "Talanta",
    "abstract_en": "This study explores the cytotoxic and biochemical effects of PEGylated graphene oxide (GO-PEG) nanoparticles, sulforaphane, and Raphanus sativus L. (black radish) juice on BEAS-2B human bronchial epithelial cells. Sulforaphane was extracted from radish juice through pH-adjusted aqueous treatment followed by organic solvent extraction, and quantified via high-performance liquid chromatography (HPLC) at 202Â nm, with a retention time of 11.0Â min. GO-PEG nanoparticles produced from graphites (50Â nm and 400Â nm) were tested at concentrations ranging from 50-225 Î¼gÂ mL<sup>-1</sup> and 100-1000 Î¼gÂ mL<sup>-1</sup> to have IC<sub>50</sub> values, respectively. Sulforaphane and black radish juice were also administered. The MTT assay revealed IC<sub>50</sub> values of 8.7Â Î¼gÂ mL<sup>-1</sup> for sulforaphane, 197.0 mgÂ mL<sup>-1</sup> for black radish juice, 175.8Â Î¼gÂ mL<sup>-1</sup> for GO-PEG (50Â nm), and 650.6Â Î¼gÂ mL<sup>-1</sup> for GO-PEG (400Â nm). Biochemical analyses showed that sulforaphane and radish juice decreased IL-6 levels and increased antioxidant enzyme activities (GSH-Px and CAT). These results highlight the therapeutic potential of GO-PEG, sulforaphane, and black radish juice for anti-inflammatory and antioxidant applications.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–çš„é ˜åŸŸã€‚ç ”ç©¶é¡¯ç¤ºï¼ŒæŸäº›å¤©ç„¶ç‰©è³ªå¦‚è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±å¯èƒ½å°å‘¼å¸é“ç´°èƒæœ‰ä¿è­·ä½œç”¨ï¼Œé€™å°æ–¼é é˜²èˆ‡ç‚ç—‡ç›¸é—œçš„ç–¾ç—…ï¼Œå¦‚æ°£å–˜æˆ–æ…¢æ€§é˜»å¡æ€§è‚ºç—…ï¼Œå¯èƒ½æœ‰æ½›åœ¨çš„å¥½è™•ã€‚é€™äº›ç™¼ç¾é¼“å‹µäººå€‘è€ƒæ…®åœ¨é£²é£Ÿä¸­åŠ å…¥é€™äº›å¤©ç„¶æˆåˆ†ï¼Œä»¥ä¿ƒé€²å¥åº·å’Œå¢å¼·å…ç–«ç³»çµ±çš„åŠŸèƒ½ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨PEGåŒ–çŸ³å¢¨çƒ¯æ°§åŒ–ç‰©ï¼ˆGO-PEGï¼‰å¥ˆç±³é¡†ç²’ã€è˜¿è””ç¡«ç´ ä»¥åŠé»‘è˜¿è””æ±å°äººé¡æ”¯æ°£ç®¡ä¸Šçš®ç´°èƒBEAS-2Bçš„ç´°èƒæ¯’æ€§å’Œç”ŸåŒ–æ•ˆæ‡‰ã€‚ç ”ç©¶è€…é—œå¿ƒé€™äº›ç‰©è³ªå¦‚ä½•å½±éŸ¿ç´°èƒçš„å¥åº·ï¼Œç‰¹åˆ¥æ˜¯åœ¨æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–çš„æ•ˆæœä¸Šã€‚é€™äº›å•é¡Œçš„ç ”ç©¶ä¸åƒ…æœ‰åŠ©æ–¼ç†è§£é€™äº›æˆåˆ†çš„ç”Ÿç‰©å­¸ä½œç”¨ï¼Œé‚„å¯èƒ½ç‚ºç›¸é—œç–¾ç—…çš„æ²»ç™‚æä¾›æ–°çš„æ€è·¯ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…é¦–å…ˆå¾é»‘è˜¿è””æ±ä¸­æå–è˜¿è””ç¡«ç´ ï¼Œä¸¦ä½¿ç”¨é«˜æ•ˆæ¶²ç›¸è‰²è­œæ³•é€²è¡Œå®šé‡åˆ†æã€‚æ¥è‘—ï¼Œç ”ç©¶åœ˜éšŠæ¸¬è©¦äº†ä¸åŒæ¿ƒåº¦çš„GO-PEGå¥ˆç±³é¡†ç²’ï¼Œä¸¦è©•ä¼°å…¶å°BEAS-2Bç´°èƒçš„å½±éŸ¿ã€‚ä½¿ç”¨MTTæ³•ä¾†æ¸¬é‡ç´°èƒå­˜æ´»ç‡ï¼Œä¸¦é€²è¡Œç”ŸåŒ–åˆ†æä»¥è©•ä¼°ç´°èƒå…§çš„æŠ—æ°§åŒ–é…¶æ´»æ€§å’Œç‚ç—‡æŒ‡æ¨™çš„è®ŠåŒ–ã€‚é€™äº›æ–¹æ³•çš„çµåˆä½¿ç ”ç©¶è€…èƒ½å¤ å…¨é¢äº†è§£é€™äº›ç‰©è³ªçš„ç”Ÿç‰©æ•ˆæ‡‰ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±èƒ½æœ‰æ•ˆé™ä½IL-6çš„æ°´å¹³ï¼Œä¸¦æé«˜æŠ—æ°§åŒ–é…¶çš„æ´»æ€§ï¼ˆå¦‚GSH-Pxå’ŒCATï¼‰ã€‚é€™äº›çµæœè¡¨æ˜ï¼ŒGO-PEGã€è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±åœ¨æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–æ–¹é¢å…·æœ‰æ½›åœ¨çš„æ‡‰ç”¨åƒ¹å€¼ï¼Œé›–ç„¶é€™äº›çµæœéœ€è¦é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†ç¢ºèªå…¶å…·é«”æ•ˆæœå’Œæ©Ÿåˆ¶ï¼Œä½†å·²ç¶“é¡¯ç¤ºå‡ºé€™äº›å¤©ç„¶æˆåˆ†åœ¨ä¿ƒé€²ç´°èƒå¥åº·æ–¹é¢çš„æ½›åŠ›ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–çš„é ˜åŸŸã€‚ç ”ç©¶é¡¯ç¤ºï¼ŒæŸäº›å¤©ç„¶ç‰©è³ªå¦‚è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±å¯èƒ½å°å‘¼å¸é“ç´°èƒæœ‰ä¿è­·ä½œç”¨ï¼Œé€™å°æ–¼é é˜²èˆ‡ç‚ç—‡ç›¸é—œçš„ç–¾ç—…ï¼Œå¦‚æ°£å–˜æˆ–æ…¢æ€§é˜»å¡æ€§è‚ºç—…ï¼Œå¯èƒ½æœ‰æ½›åœ¨çš„å¥½è™•ã€‚é€™äº›ç™¼ç¾é¼“å‹µäººå€‘è€ƒæ…®åœ¨é£²é£Ÿä¸­åŠ å…¥é€™äº›å¤©ç„¶æˆåˆ†ï¼Œä»¥ä¿ƒé€²å¥åº·å’Œå¢å¼·å…ç–«ç³»çµ±çš„åŠŸèƒ½ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨PEGåŒ–çŸ³å¢¨çƒ¯æ°§åŒ–ç‰©ï¼ˆGO-PEGï¼‰å¥ˆç±³é¡†ç²’ã€è˜¿è””ç¡«ç´ ä»¥åŠé»‘è˜¿è””æ±å°äººé¡æ”¯æ°£ç®¡ä¸Šçš®ç´°èƒBEAS-2Bçš„ç´°èƒæ¯’æ€§å’Œç”ŸåŒ–æ•ˆæ‡‰ã€‚ç ”ç©¶è€…é—œå¿ƒé€™äº›ç‰©è³ªå¦‚ä½•å½±éŸ¿ç´°èƒçš„å¥åº·ï¼Œç‰¹åˆ¥æ˜¯åœ¨æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–çš„æ•ˆæœä¸Šã€‚é€™äº›å•é¡Œçš„ç ”ç©¶ä¸åƒ…æœ‰åŠ©æ–¼ç†è§£é€™äº›æˆåˆ†çš„ç”Ÿç‰©å­¸ä½œç”¨ï¼Œé‚„å¯èƒ½ç‚ºç›¸é—œç–¾ç—…çš„æ²»ç™‚æä¾›æ–°çš„æ€è·¯ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…é¦–å…ˆå¾é»‘è˜¿è””æ±ä¸­æå–è˜¿è””ç¡«ç´ ï¼Œä¸¦ä½¿ç”¨é«˜æ•ˆæ¶²ç›¸è‰²è­œæ³•é€²è¡Œå®šé‡åˆ†æã€‚æ¥è‘—ï¼Œç ”ç©¶åœ˜éšŠæ¸¬è©¦äº†ä¸åŒæ¿ƒåº¦çš„GO-PEGå¥ˆç±³é¡†ç²’ï¼Œä¸¦è©•ä¼°å…¶å°BEAS-2Bç´°èƒçš„å½±éŸ¿ã€‚ä½¿ç”¨MTTæ³•ä¾†æ¸¬é‡ç´°èƒå­˜æ´»ç‡ï¼Œä¸¦é€²è¡Œç”ŸåŒ–åˆ†æä»¥è©•ä¼°ç´°èƒå…§çš„æŠ—æ°§åŒ–é…¶æ´»æ€§å’Œç‚ç—‡æŒ‡æ¨™çš„è®ŠåŒ–ã€‚é€™äº›æ–¹æ³•çš„çµåˆä½¿ç ”ç©¶è€…èƒ½å¤ å…¨é¢äº†è§£é€™äº›ç‰©è³ªçš„ç”Ÿç‰©æ•ˆæ‡‰ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±èƒ½æœ‰æ•ˆé™ä½IL-6çš„æ°´å¹³ï¼Œä¸¦æé«˜æŠ—æ°§åŒ–é…¶çš„æ´»æ€§ï¼ˆå¦‚GSH-Pxå’ŒCATï¼‰ã€‚é€™äº›çµæœè¡¨æ˜ï¼ŒGO-PEGã€è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±åœ¨æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–æ–¹é¢å…·æœ‰æ½›åœ¨çš„æ‡‰ç”¨åƒ¹å€¼ï¼Œé›–ç„¶é€™äº›çµæœéœ€è¦é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†ç¢ºèªå…¶å…·é«”æ•ˆæœå’Œæ©Ÿåˆ¶ï¼Œä½†å·²ç¶“é¡¯ç¤ºå‡ºé€™äº›å¤©ç„¶æˆåˆ†åœ¨ä¿ƒé€²ç´°èƒå¥åº·æ–¹é¢çš„æ½›åŠ›ã€‚",
    "fb_post": "æ ¹æ“šã€ŠTalantaã€‹æ–¼ 2026 å¹´ 1 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸ€ ä½ çŸ¥é“å—ï¼Ÿæœ‰äº›å¤©ç„¶é£Ÿæå¯èƒ½å°æˆ‘å€‘çš„å¥åº·æœ‰æ„æƒ³ä¸åˆ°çš„å¥½è™•ï¼æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±å°å‘¼å¸é“ç´°èƒæœ‰ä¿è­·ä½œç”¨ï¼Œé€™å°æ–¼åƒæ°£å–˜æˆ–æ…¢æ€§é˜»å¡æ€§è‚ºç—…é€™é¡èˆ‡ç‚ç—‡ç›¸é—œçš„ç–¾ç—…å¯èƒ½æœ‰å¹«åŠ©ã€‚ç ”ç©¶åœ˜éšŠå°ˆæ³¨æ–¼æ¢è¨é€™äº›å¤©ç„¶æˆåˆ†å¦‚ä½•å½±éŸ¿ç´°èƒå¥åº·ï¼Œå°¤å…¶æ˜¯åœ¨æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–çš„æ•ˆæœä¸Šã€‚  \n  \nä»–å€‘å¾é»‘è˜¿è””æ±ä¸­æå–è˜¿è””ç¡«ç´ ï¼Œç„¶å¾Œé€²è¡Œäº†ä¸€ç³»åˆ—å¯¦é©—ï¼ŒæŸ¥çœ‹ä¸åŒæ¿ƒåº¦çš„å¥ˆç±³é¡†ç²’å°ç´°èƒçš„å½±éŸ¿ã€‚ä½¿ç”¨MTTæ³•æ¸¬é‡ç´°èƒå­˜æ´»ç‡ï¼Œä¸¦åˆ†æç´°èƒå…§çš„æŠ—æ°§åŒ–é…¶æ´»æ€§å’Œç‚ç—‡æŒ‡æ¨™ã€‚  \n  \nçµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±èƒ½æœ‰æ•ˆé™ä½ä¸€ç¨®ç‚ç—‡æŒ‡æ¨™IL-6çš„æ°´å¹³ï¼Œä¸¦æé«˜æŠ—æ°§åŒ–é…¶çš„æ´»æ€§ã€‚é›–ç„¶é€™äº›çµæœéœ€è¦é€²ä¸€æ­¥ç ”ç©¶ä¾†ç¢ºèªï¼Œä½†é€™äº›å¤©ç„¶æˆåˆ†åœ¨ä¿ƒé€²ç´°èƒå¥åº·æ–¹é¢çš„æ½›åŠ›å·²ç¶“é¡¯ç¾å‡ºä¾†ï¼  \n  \nğŸ” ä¸»è¦é‡é»ï¼š  \n1. è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±å¯èƒ½æœ‰åŠ©æ–¼é™ä½ç‚ç—‡ã€‚  \n2. é€™äº›å¤©ç„¶æˆåˆ†èƒ½æé«˜æŠ—æ°§åŒ–é…¶çš„æ´»æ€§ã€‚  \n3. é€²ä¸€æ­¥çš„ç ”ç©¶å°‡å¹«åŠ©æˆ‘å€‘æ›´äº†è§£å®ƒå€‘çš„å¥åº·ç›Šè™•ã€‚",
    "image_prompt": "Create a flat design infographic on a light background explaining the experiment and main results of the study. Include simple icons representing sulforaphane (like broccoli or radish) and human or cell figures as experimental subjects. Use arrows or flow lines to indicate the steps of the experiment. Include a section that highlights the main results, such as protective effects and changes in inflammation markers.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "å‘¼å¸é“ç–¾ç—… Respiratory Diseases",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40580757/"
  },
  {
    "id": "41487499",
    "title_en": "The dietary phytochemicals carnosic acid and sulforaphane regulate inflammatory markers in ulcerative colitis patient-derived colonoids.",
    "pub_date": "2025",
    "journal": "Frontiers in pharmacology",
    "abstract_en": "The inflammatory bowel disease (IBD) ulcerative colitis (UC) is characterized by continuous inflammation of the colon with erosion and ulcers. Diagnosis typically occurs in patients between their late teens and mid-30s with no cure. Available therapeutics are efficient at controlling symptoms however, they have many serious adverse effects. Thus, additional therapies with limited adverse effects are needed to complement these drugs. In this study, we evaluated the anti-inflammatory potential of carnosic acid (CA), the most abundant diterpene in rosemary (<i>Salvia rosmarinus</i>) and sulforaphane (SFN), an isothiocyanate found in cruciferous vegetables. We used colonic epithelial organoids (colonoids) derived from non-IBD and UC patients as a physiologically relevant testing platform for both phytochemicals. These patient-derived colonoids are a representative model that recapitulates the parent epithelial tissue including its cellular composition and 3D structure. Moreover, we cultured the colonoids at 2% O<sub>2</sub> to better approximate the low oxygen level (physioxia) observed in the colon crypts. To assess the effects of CA and SFN in the nuclear factor erythroid 2-related factor 2 (NRF2) and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-ÎºB) pathways, we studied modulation of inflammatory cytokines through a 40-plex chemokine assay and ELISA, as well as gene and protein expression of target genes with qPCR and western blot, respectively. Through these techniques, we observed that CA and SFN decreased inflammatory markers and promoted NRF2 activity in patient-derived colonoids. Additionally, SFN and CA modulated the expression and secretion of the NF-ÎºB promoted antibacterial peptide neutrophil gelatinase-associated lipocalin which is highly expressed in the inflamed colonic epithelium and has been suggested as a biomarker for active UC. Together, the results validated the use of colonoids as a pharmacological testing platform for phytochemicals, and that CA and SFN promote NRF2 activation and decrease inflammation in a human physiologically relevant UC model.",
    "para1": "é€™é …ç ”ç©¶å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°ç‚ç—‡æ€§è…¸ç—…ï¼ˆIBDï¼‰ä¸­çš„æ½°ç˜æ€§çµè…¸ç‚ï¼ˆUCï¼‰ã€‚é€™ç¨®ç–¾ç—…ç›®å‰æ²’æœ‰æ²»ç™’çš„æ–¹æ³•ï¼Œç¾æœ‰çš„æ²»ç™‚é›–ç„¶èƒ½æ§åˆ¶ç—‡ç‹€ï¼Œä½†å¾€å¾€ä¼´éš¨è‘—åš´é‡çš„å‰¯ä½œç”¨ã€‚å› æ­¤ï¼Œå°‹æ‰¾æ–°çš„ç™‚æ³•ï¼Œå°¤å…¶æ˜¯é‚£äº›å‰¯ä½œç”¨è¼ƒå°‘çš„é¸æ“‡ï¼Œå°æ–¼æ”¹å–„æ‚£è€…çš„ç”Ÿæ´»å“è³ªéå¸¸é‡è¦ã€‚é€™é …ç ”ç©¶æ¢ç´¢äº†å…©ç¨®æ¤ç‰©åŒ–å­¸ç‰©è³ªçš„æŠ—ç‚æ½›åŠ›ï¼Œå¯èƒ½ç‚ºæœªä¾†çš„æ²»ç™‚æä¾›æ–°çš„æ–¹å‘ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯è©•ä¼°è¿·è¿­é¦™ä¸­çš„ä¸»è¦äºŒèœé¡åŒ–åˆç‰©â€”â€”è¿·è¿­é¦™é…¸ï¼ˆcarnosic acid, CAï¼‰å’Œåœ¨åå­—èŠ±ç§‘è”¬èœä¸­ç™¼ç¾çš„è˜¿è””ç¡«ç´ ï¼ˆsulforaphane, SFNï¼‰å°æ½°ç˜æ€§çµè…¸ç‚çš„æŠ—ç‚æ•ˆæœã€‚ç ”ç©¶è€…é—œæ³¨é€™äº›åŒ–åˆç‰©å¦‚ä½•å½±éŸ¿èˆ‡ç‚ç—‡ç›¸é—œçš„ç”Ÿç‰©æ¨™è¨˜ï¼Œä¸¦å¸Œæœ›èƒ½æ‰¾åˆ°æœ‰æ•ˆçš„è¼”åŠ©ç™‚æ³•ä¾†æ¸›å°‘ç‚ç—‡ï¼Œæ”¹å–„æ½°ç˜æ€§çµè…¸ç‚æ‚£è€…çš„ç—‡ç‹€ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†ä¾†è‡ªéç‚ç—‡æ€§è…¸ç—…å’Œæ½°ç˜æ€§çµè…¸ç‚æ‚£è€…çš„çµè…¸ä¸Šçš®å™¨å®˜é¡ï¼ˆcolonoidsï¼‰ä½œç‚ºæ¸¬è©¦å¹³å°ã€‚é€™äº›çµè…¸ä¸Šçš®å™¨å®˜é¡èƒ½å¤ æ¨¡æ“¬çœŸå¯¦çš„è…¸é“çµ„ç¹”ï¼ŒåŒ…æ‹¬å…¶ç´°èƒçµ„æˆå’Œä¸‰ç¶­çµæ§‹ã€‚ç‚ºäº†æ›´å¥½åœ°æ¨¡æ“¬çµè…¸éš±çª©ä¸­çš„ä½æ°§ç’°å¢ƒï¼Œç ”ç©¶è€…å°‡é€™äº›çµè…¸ä¸Šçš®å™¨å®˜é¡åœ¨2%çš„æ°§æ°£æ¿ƒåº¦ä¸‹åŸ¹é¤Šã€‚æ¥è‘—ï¼Œä»–å€‘è©•ä¼°äº†CAå’ŒSFNå°æ–¼æ ¸å› å­ç´…ç´°èƒ2ç›¸é—œå› å­2ï¼ˆNRF2ï¼‰å’Œæ ¸å› å­ÎºBï¼ˆNF-ÎºBï¼‰é€šè·¯çš„å½±éŸ¿ï¼Œä¸¦ä½¿ç”¨å¤šé‡åŒ–å­¸å› å­æª¢æ¸¬å’ŒELISAç­‰æ–¹æ³•ä¾†æ¸¬é‡ç‚ç—‡ç´°èƒå› å­çš„è®ŠåŒ–ã€‚",
    "para4": "ç ”ç©¶çš„ä¸»è¦ç™¼ç¾æ˜¯ï¼Œè¿·è¿­é¦™é…¸å’Œè˜¿è””ç¡«ç´ èƒ½é™ä½ç‚ç—‡æ¨™è¨˜ç‰©ï¼Œä¸¦ä¿ƒé€²NRF2çš„æ´»æ€§ã€‚æ­¤å¤–ï¼Œé€™å…©ç¨®åŒ–åˆç‰©é‚„èª¿ç¯€äº†NF-ÎºBä¿ƒé€²çš„æŠ—èŒè‚½ä¸­æ€§ç²’ç´°èƒæ˜è† é…¶ç›¸é—œè„‚è›‹ç™½çš„è¡¨é”å’Œåˆ†æ³Œï¼Œé€™ç¨®æŠ—èŒè‚½åœ¨ç™¼ç‚çš„çµè…¸ä¸Šçš®ä¸­è¡¨é”é‡å¾ˆé«˜ï¼Œä¸¦è¢«å»ºè­°ä½œç‚ºæ½°ç˜æ€§çµè…¸ç‚çš„æ´»èºç”Ÿç‰©æ¨™è¨˜ã€‚é€™äº›çµæœé©—è­‰äº†çµè…¸ä¸Šçš®å™¨å®˜é¡ä½œç‚ºæ¤ç‰©åŒ–å­¸ç‰©è³ªè—¥ç†æ¸¬è©¦å¹³å°çš„å¯è¡Œæ€§ï¼Œä¸¦é¡¯ç¤ºCAå’ŒSFNåœ¨äººé«”ç›¸é—œçš„æ½°ç˜æ€§çµè…¸ç‚æ¨¡å‹ä¸­å…·æœ‰é™ä½ç‚ç—‡çš„æ½›åŠ›ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°ç‚ç—‡æ€§è…¸ç—…ï¼ˆIBDï¼‰ä¸­çš„æ½°ç˜æ€§çµè…¸ç‚ï¼ˆUCï¼‰ã€‚é€™ç¨®ç–¾ç—…ç›®å‰æ²’æœ‰æ²»ç™’çš„æ–¹æ³•ï¼Œç¾æœ‰çš„æ²»ç™‚é›–ç„¶èƒ½æ§åˆ¶ç—‡ç‹€ï¼Œä½†å¾€å¾€ä¼´éš¨è‘—åš´é‡çš„å‰¯ä½œç”¨ã€‚å› æ­¤ï¼Œå°‹æ‰¾æ–°çš„ç™‚æ³•ï¼Œå°¤å…¶æ˜¯é‚£äº›å‰¯ä½œç”¨è¼ƒå°‘çš„é¸æ“‡ï¼Œå°æ–¼æ”¹å–„æ‚£è€…çš„ç”Ÿæ´»å“è³ªéå¸¸é‡è¦ã€‚é€™é …ç ”ç©¶æ¢ç´¢äº†å…©ç¨®æ¤ç‰©åŒ–å­¸ç‰©è³ªçš„æŠ—ç‚æ½›åŠ›ï¼Œå¯èƒ½ç‚ºæœªä¾†çš„æ²»ç™‚æä¾›æ–°çš„æ–¹å‘ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯è©•ä¼°è¿·è¿­é¦™ä¸­çš„ä¸»è¦äºŒèœé¡åŒ–åˆç‰©â€”â€”è¿·è¿­é¦™é…¸ï¼ˆcarnosic acid, CAï¼‰å’Œåœ¨åå­—èŠ±ç§‘è”¬èœä¸­ç™¼ç¾çš„è˜¿è””ç¡«ç´ ï¼ˆsulforaphane, SFNï¼‰å°æ½°ç˜æ€§çµè…¸ç‚çš„æŠ—ç‚æ•ˆæœã€‚ç ”ç©¶è€…é—œæ³¨é€™äº›åŒ–åˆç‰©å¦‚ä½•å½±éŸ¿èˆ‡ç‚ç—‡ç›¸é—œçš„ç”Ÿç‰©æ¨™è¨˜ï¼Œä¸¦å¸Œæœ›èƒ½æ‰¾åˆ°æœ‰æ•ˆçš„è¼”åŠ©ç™‚æ³•ä¾†æ¸›å°‘ç‚ç—‡ï¼Œæ”¹å–„æ½°ç˜æ€§çµè…¸ç‚æ‚£è€…çš„ç—‡ç‹€ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†ä¾†è‡ªéç‚ç—‡æ€§è…¸ç—…å’Œæ½°ç˜æ€§çµè…¸ç‚æ‚£è€…çš„çµè…¸ä¸Šçš®å™¨å®˜é¡ï¼ˆcolonoidsï¼‰ä½œç‚ºæ¸¬è©¦å¹³å°ã€‚é€™äº›çµè…¸ä¸Šçš®å™¨å®˜é¡èƒ½å¤ æ¨¡æ“¬çœŸå¯¦çš„è…¸é“çµ„ç¹”ï¼ŒåŒ…æ‹¬å…¶ç´°èƒçµ„æˆå’Œä¸‰ç¶­çµæ§‹ã€‚ç‚ºäº†æ›´å¥½åœ°æ¨¡æ“¬çµè…¸éš±çª©ä¸­çš„ä½æ°§ç’°å¢ƒï¼Œç ”ç©¶è€…å°‡é€™äº›çµè…¸ä¸Šçš®å™¨å®˜é¡åœ¨2%çš„æ°§æ°£æ¿ƒåº¦ä¸‹åŸ¹é¤Šã€‚æ¥è‘—ï¼Œä»–å€‘è©•ä¼°äº†CAå’ŒSFNå°æ–¼æ ¸å› å­ç´…ç´°èƒ2ç›¸é—œå› å­2ï¼ˆNRF2ï¼‰å’Œæ ¸å› å­ÎºBï¼ˆNF-ÎºBï¼‰é€šè·¯çš„å½±éŸ¿ï¼Œä¸¦ä½¿ç”¨å¤šé‡åŒ–å­¸å› å­æª¢æ¸¬å’ŒELISAç­‰æ–¹æ³•ä¾†æ¸¬é‡ç‚ç—‡ç´°èƒå› å­çš„è®ŠåŒ–ã€‚\n\nç ”ç©¶çš„ä¸»è¦ç™¼ç¾æ˜¯ï¼Œè¿·è¿­é¦™é…¸å’Œè˜¿è””ç¡«ç´ èƒ½é™ä½ç‚ç—‡æ¨™è¨˜ç‰©ï¼Œä¸¦ä¿ƒé€²NRF2çš„æ´»æ€§ã€‚æ­¤å¤–ï¼Œé€™å…©ç¨®åŒ–åˆç‰©é‚„èª¿ç¯€äº†NF-ÎºBä¿ƒé€²çš„æŠ—èŒè‚½ä¸­æ€§ç²’ç´°èƒæ˜è† é…¶ç›¸é—œè„‚è›‹ç™½çš„è¡¨é”å’Œåˆ†æ³Œï¼Œé€™ç¨®æŠ—èŒè‚½åœ¨ç™¼ç‚çš„çµè…¸ä¸Šçš®ä¸­è¡¨é”é‡å¾ˆé«˜ï¼Œä¸¦è¢«å»ºè­°ä½œç‚ºæ½°ç˜æ€§çµè…¸ç‚çš„æ´»èºç”Ÿç‰©æ¨™è¨˜ã€‚é€™äº›çµæœé©—è­‰äº†çµè…¸ä¸Šçš®å™¨å®˜é¡ä½œç‚ºæ¤ç‰©åŒ–å­¸ç‰©è³ªè—¥ç†æ¸¬è©¦å¹³å°çš„å¯è¡Œæ€§ï¼Œä¸¦é¡¯ç¤ºCAå’ŒSFNåœ¨äººé«”ç›¸é—œçš„æ½°ç˜æ€§çµè…¸ç‚æ¨¡å‹ä¸­å…·æœ‰é™ä½ç‚ç—‡çš„æ½›åŠ›ã€‚",
    "fb_post": "æ ¹æ“šã€ŠFrontiers in pharmacologyã€‹æ–¼ 2025 å¹´ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ±ä½ çŸ¥é“å—ï¼Ÿæˆ‘å€‘çš„é£²é£Ÿè£¡æœ‰äº›æˆåˆ†å¯èƒ½å°å¥åº·æœ‰æ„æƒ³ä¸åˆ°çš„å¹«åŠ©ï¼æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶ç™¼ç¾ï¼Œè¿·è¿­é¦™å’ŒæŸäº›åå­—èŠ±ç§‘è”¬èœä¸­çš„å¤©ç„¶æˆåˆ†ï¼Œå°æ½°ç˜æ€§çµè…¸ç‚ï¼ˆUCï¼‰é€™ç¨®å›°æ“¾è¨±å¤šäººçš„ç–¾ç—…ï¼Œå¯èƒ½æœ‰æŠ—ç‚æ•ˆæœã€‚\n\né€™é …ç ”ç©¶çš„ç§‘å­¸å®¶å€‘ï¼Œå°ˆæ³¨æ–¼è¿·è¿­é¦™ä¸­çš„è¿·è¿­é¦™é…¸å’Œé’èŠ±èœä¸­çš„è˜¿è””ç¡«ç´ ã€‚ä»–å€‘ä½¿ç”¨äº†æ¨¡æ“¬è…¸é“çµ„ç¹”çš„ç´°èƒæ¨¡å‹ï¼Œä¸¦åœ¨ç‰¹å®šçš„ç’°å¢ƒä¸­è§€å¯Ÿé€™äº›æˆåˆ†å°ç‚ç—‡çš„å½±éŸ¿ã€‚ä»–å€‘ç™¼ç¾ï¼Œé€™å…©ç¨®æˆåˆ†èƒ½å¤ é™ä½é«”å…§çš„ç‚ç—‡æ¨™è¨˜ï¼Œä¸¦ä¿ƒé€²ä¸€ç¨®æœ‰åŠ©æ–¼æŠ—ç‚çš„è›‹ç™½è³ªçš„æ´»æ€§ã€‚\n\né€™äº›ç™¼ç¾ä¸åƒ…é¡¯ç¤ºäº†é€™äº›æ¤ç‰©æˆåˆ†çš„æ½›åŠ›ï¼Œä¹Ÿç‚ºæœªä¾†é–‹ç™¼æ–°ç™‚æ³•æä¾›äº†æ–°çš„æ–¹å‘ï¼\n\nğŸ” ä¸»è¦é‡é»ï¼š\n1. è¿·è¿­é¦™é…¸å’Œè˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘æ½°ç˜æ€§çµè…¸ç‚çš„ç‚ç—‡ã€‚\n2. é€™äº›æˆåˆ†ä¿ƒé€²äº†æŠ—ç‚è›‹ç™½è³ªçš„æ´»æ€§ã€‚\n3. ç ”ç©¶ç‚ºæœªä¾†çš„ç™‚æ³•æ¢ç´¢æä¾›äº†æ–°æ€è·¯ã€‚",
    "image_prompt": "Create a flat design infographic illustrating the experimental approach and main findings of a study on rosemary acid and sulforaphane. Use a light background with soft colors. Include symbols representing broccoli or sulforaphane, simplified illustrations of experimental subjects (like humans or cells), arrows or flow lines to indicate the experimental steps, and a section labeled 'Main Findings' highlighting protective effects or changes observed.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "æ½°ç˜æ€§çµè…¸ç‚ Ulcerative Colitis",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41487499/"
  },
  {
    "id": "41340527",
    "title_en": "Metabolomics and Transcriptomics Analyses Reveal the Mechanisms of Sulforaphane Conversion and Adaptive Strategies in the Absence of Glucose by <i>Lactiplantibacillus plantarum</i>.",
    "pub_date": "2025 Dec",
    "journal": "Journal of agricultural and food chemistry",
    "abstract_en": "Sulforaphane is a beneficial but unstable bioactive compound that can be converted from glucoraphanin by <i>Lactiplantibacillus plantarum</i>. However, the sulforaphane conversion rate is low, and the conversion mechanism of <i>L. plantarum</i> remains unclear. This research utilized the adaptive laboratory evolution technology to enhance the sulforaphane conversion rate of <i>L. plantarum</i>. The results showed that an increase in the glucose replacement ratio significantly downregulated carbohydrate metabolism and upregulated amino acid metabolism. Transcriptomic analysis showed that the ALE-adapted strain significantly upregulated carbohydrate metabolism and amino acid metabolism. In the conversion pathway, glucoraphanin is imported into <i>L. plantarum</i> cells, and its glucose moiety is phosphorylated by bglF (the phosphate group may be derived from phosphoenolpyruvate via the phosphotransferase system). Subsequently, the S-glycosidic bond of phosphorylated glucoraphanin is hydrolyzed by bglA (6-phospho-Î²-glucosidase), followed by nonenzymatic rearrangement and sulfate elimination, ultimately yielding sulforaphane. This research can contribute to revealing the interaction mechanism between microorganisms and natural active substances.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°è˜¿è””ç¡«ç´ é€™ç¨®æœ‰ç›Šçš„ç”Ÿç‰©æ´»æ€§åŒ–åˆç‰©ã€‚è˜¿è””ç¡«ç´ è¢«èªç‚ºå…·æœ‰å¤šç¨®å¥åº·ç›Šè™•ï¼ŒåŒ…æ‹¬æŠ—æ°§åŒ–å’ŒæŠ—ç™¼ç‚çš„ç‰¹æ€§ï¼Œå¯èƒ½å°é é˜²æŸäº›ç–¾ç—…æœ‰å¹«åŠ©ã€‚ç„¶è€Œï¼Œé€™ç¨®åŒ–åˆç‰©çš„ç©©å®šæ€§è¼ƒå·®ï¼Œè½‰åŒ–ç‡ä¹Ÿä¸é«˜ï¼Œå› æ­¤äº†è§£å¦‚ä½•æé«˜å…¶è½‰åŒ–ç‡å°æ–¼å¥åº·ä¿ƒé€²å’Œç–¾ç—…é é˜²çš„æ½›åŠ›æ˜¯ç›¸ç•¶é‡è¦çš„ã€‚é€éé€™é …ç ”ç©¶ï¼Œæˆ‘å€‘å¯ä»¥æ›´æ·±å…¥äº†è§£å¾®ç”Ÿç‰©èˆ‡å¤©ç„¶æ´»æ€§ç‰©è³ªä¹‹é–“çš„äº’å‹•æ©Ÿåˆ¶ï¼Œé€™å¯èƒ½æœƒç‚ºæœªä¾†çš„å¥åº·ç”¢å“é–‹ç™¼æä¾›æ–°çš„æ–¹å‘ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨å¦‚ä½•æé«˜é’èŠ±æ¤°èœä¸­çš„è˜¿è””ç¡«ç´ è½‰åŒ–ç‡ï¼Œç‰¹åˆ¥æ˜¯åˆ©ç”¨ä¸€ç¨®åç‚ºLactiplantibacillus plantarumçš„ç´°èŒã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œé€™ç¨®ç´°èŒåœ¨è½‰åŒ–é’èŠ±æ¤°èœä¸­çš„ä¸€ç¨®å‰é«”ç‰©è³ªâ€”â€”è‘¡è„ç³–è‹·é…¸ï¼ˆglucoraphaninï¼‰ç‚ºè˜¿è””ç¡«ç´ çš„éç¨‹ä¸­ï¼Œè½‰åŒ–ç‡ä½çš„åŸå› ä»¥åŠå¦‚ä½•æ”¹å–„é€™ä¸€éç¨‹ã€‚é€™ä¸åƒ…æ¶‰åŠåˆ°ç´°èŒçš„ä»£è¬é€”å¾‘ï¼Œä¹Ÿé—œä¹å¦‚ä½•æœ‰æ•ˆåˆ©ç”¨é’èŠ±æ¤°èœä¸­çš„ç‡Ÿé¤Šæˆåˆ†ï¼Œé€²ä¸€æ­¥ä¿ƒé€²å¥åº·ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†é©æ‡‰æ€§å¯¦é©—å®¤é€²åŒ–æŠ€è¡“ä¾†å¢å¼·Lactiplantibacillus plantarumçš„è˜¿è””ç¡«ç´ è½‰åŒ–ç‡ã€‚ç ”ç©¶å°è±¡æ˜¯é€™ç¨®ç´°èŒï¼Œä¸¦é€éèª¿æ•´å…¶ç’°å¢ƒæ¢ä»¶ä¾†ä¿ƒé€²å…¶ä»£è¬éç¨‹ã€‚å…·é«”ä¾†èªªï¼Œç ”ç©¶è€…æ”¹è®Šäº†è‘¡è„ç³–çš„æ›¿ä»£æ¯”ä¾‹ï¼Œè§€å¯Ÿå…¶å°ç´°èŒç¢³æ°´åŒ–åˆç‰©å’Œæ°¨åŸºé…¸ä»£è¬çš„å½±éŸ¿ã€‚é€™æ¨£çš„å¯¦é©—è¨­è¨ˆæ—¨åœ¨æ­ç¤ºç´°èŒåœ¨è½‰åŒ–éç¨‹ä¸­çš„å…·é«”æ©Ÿåˆ¶ï¼Œä¸¦ç‚ºæé«˜è˜¿è””ç¡«ç´ çš„ç”¢é‡æä¾›ç§‘å­¸ä¾æ“šã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œç•¶è‘¡è„ç³–æ›¿ä»£æ¯”ä¾‹å¢åŠ æ™‚ï¼Œç´°èŒçš„ç¢³æ°´åŒ–åˆç‰©ä»£è¬é¡¯è‘—ä¸‹èª¿ï¼Œè€Œæ°¨åŸºé…¸ä»£è¬å‰‡ä¸Šèª¿ã€‚æ­¤å¤–ï¼Œè½‰éŒ„çµ„åˆ†æçµæœè¡¨æ˜ï¼Œç¶“éé©æ‡‰æ€§å¯¦é©—å®¤é€²åŒ–çš„ç´°èŒæ ªåœ¨ç¢³æ°´åŒ–åˆç‰©å’Œæ°¨åŸºé…¸ä»£è¬æ–¹é¢éƒ½æœ‰é¡¯è‘—çš„ä¸Šèª¿ã€‚é€™äº›çµæœæš—ç¤ºäº†åœ¨è˜¿è””ç¡«ç´ çš„è½‰åŒ–è·¯å¾‘ä¸­ï¼Œè‘¡è„ç³–è‹·é…¸å¦‚ä½•è¢«ç´°èŒå¸æ”¶ä¸¦è½‰åŒ–ç‚ºè˜¿è””ç¡«ç´ çš„éç¨‹ï¼Œä¸¦ä¸”é€™ä¸€éç¨‹å¯èƒ½æ¶‰åŠå¤šç¨®é…¶çš„ä½œç”¨ã€‚é€™äº›ç™¼ç¾å°æ–¼ç†è§£å¾®ç”Ÿç‰©èˆ‡å¤©ç„¶æ´»æ€§ç‰©è³ªçš„äº’å‹•æ©Ÿåˆ¶å…·æœ‰é‡è¦æ„ç¾©ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°è˜¿è””ç¡«ç´ é€™ç¨®æœ‰ç›Šçš„ç”Ÿç‰©æ´»æ€§åŒ–åˆç‰©ã€‚è˜¿è””ç¡«ç´ è¢«èªç‚ºå…·æœ‰å¤šç¨®å¥åº·ç›Šè™•ï¼ŒåŒ…æ‹¬æŠ—æ°§åŒ–å’ŒæŠ—ç™¼ç‚çš„ç‰¹æ€§ï¼Œå¯èƒ½å°é é˜²æŸäº›ç–¾ç—…æœ‰å¹«åŠ©ã€‚ç„¶è€Œï¼Œé€™ç¨®åŒ–åˆç‰©çš„ç©©å®šæ€§è¼ƒå·®ï¼Œè½‰åŒ–ç‡ä¹Ÿä¸é«˜ï¼Œå› æ­¤äº†è§£å¦‚ä½•æé«˜å…¶è½‰åŒ–ç‡å°æ–¼å¥åº·ä¿ƒé€²å’Œç–¾ç—…é é˜²çš„æ½›åŠ›æ˜¯ç›¸ç•¶é‡è¦çš„ã€‚é€éé€™é …ç ”ç©¶ï¼Œæˆ‘å€‘å¯ä»¥æ›´æ·±å…¥äº†è§£å¾®ç”Ÿç‰©èˆ‡å¤©ç„¶æ´»æ€§ç‰©è³ªä¹‹é–“çš„äº’å‹•æ©Ÿåˆ¶ï¼Œé€™å¯èƒ½æœƒç‚ºæœªä¾†çš„å¥åº·ç”¢å“é–‹ç™¼æä¾›æ–°çš„æ–¹å‘ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨å¦‚ä½•æé«˜é’èŠ±æ¤°èœä¸­çš„è˜¿è””ç¡«ç´ è½‰åŒ–ç‡ï¼Œç‰¹åˆ¥æ˜¯åˆ©ç”¨ä¸€ç¨®åç‚ºLactiplantibacillus plantarumçš„ç´°èŒã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œé€™ç¨®ç´°èŒåœ¨è½‰åŒ–é’èŠ±æ¤°èœä¸­çš„ä¸€ç¨®å‰é«”ç‰©è³ªâ€”â€”è‘¡è„ç³–è‹·é…¸ï¼ˆglucoraphaninï¼‰ç‚ºè˜¿è””ç¡«ç´ çš„éç¨‹ä¸­ï¼Œè½‰åŒ–ç‡ä½çš„åŸå› ä»¥åŠå¦‚ä½•æ”¹å–„é€™ä¸€éç¨‹ã€‚é€™ä¸åƒ…æ¶‰åŠåˆ°ç´°èŒçš„ä»£è¬é€”å¾‘ï¼Œä¹Ÿé—œä¹å¦‚ä½•æœ‰æ•ˆåˆ©ç”¨é’èŠ±æ¤°èœä¸­çš„ç‡Ÿé¤Šæˆåˆ†ï¼Œé€²ä¸€æ­¥ä¿ƒé€²å¥åº·ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†é©æ‡‰æ€§å¯¦é©—å®¤é€²åŒ–æŠ€è¡“ä¾†å¢å¼·Lactiplantibacillus plantarumçš„è˜¿è””ç¡«ç´ è½‰åŒ–ç‡ã€‚ç ”ç©¶å°è±¡æ˜¯é€™ç¨®ç´°èŒï¼Œä¸¦é€éèª¿æ•´å…¶ç’°å¢ƒæ¢ä»¶ä¾†ä¿ƒé€²å…¶ä»£è¬éç¨‹ã€‚å…·é«”ä¾†èªªï¼Œç ”ç©¶è€…æ”¹è®Šäº†è‘¡è„ç³–çš„æ›¿ä»£æ¯”ä¾‹ï¼Œè§€å¯Ÿå…¶å°ç´°èŒç¢³æ°´åŒ–åˆç‰©å’Œæ°¨åŸºé…¸ä»£è¬çš„å½±éŸ¿ã€‚é€™æ¨£çš„å¯¦é©—è¨­è¨ˆæ—¨åœ¨æ­ç¤ºç´°èŒåœ¨è½‰åŒ–éç¨‹ä¸­çš„å…·é«”æ©Ÿåˆ¶ï¼Œä¸¦ç‚ºæé«˜è˜¿è””ç¡«ç´ çš„ç”¢é‡æä¾›ç§‘å­¸ä¾æ“šã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œç•¶è‘¡è„ç³–æ›¿ä»£æ¯”ä¾‹å¢åŠ æ™‚ï¼Œç´°èŒçš„ç¢³æ°´åŒ–åˆç‰©ä»£è¬é¡¯è‘—ä¸‹èª¿ï¼Œè€Œæ°¨åŸºé…¸ä»£è¬å‰‡ä¸Šèª¿ã€‚æ­¤å¤–ï¼Œè½‰éŒ„çµ„åˆ†æçµæœè¡¨æ˜ï¼Œç¶“éé©æ‡‰æ€§å¯¦é©—å®¤é€²åŒ–çš„ç´°èŒæ ªåœ¨ç¢³æ°´åŒ–åˆç‰©å’Œæ°¨åŸºé…¸ä»£è¬æ–¹é¢éƒ½æœ‰é¡¯è‘—çš„ä¸Šèª¿ã€‚é€™äº›çµæœæš—ç¤ºäº†åœ¨è˜¿è””ç¡«ç´ çš„è½‰åŒ–è·¯å¾‘ä¸­ï¼Œè‘¡è„ç³–è‹·é…¸å¦‚ä½•è¢«ç´°èŒå¸æ”¶ä¸¦è½‰åŒ–ç‚ºè˜¿è””ç¡«ç´ çš„éç¨‹ï¼Œä¸¦ä¸”é€™ä¸€éç¨‹å¯èƒ½æ¶‰åŠå¤šç¨®é…¶çš„ä½œç”¨ã€‚é€™äº›ç™¼ç¾å°æ–¼ç†è§£å¾®ç”Ÿç‰©èˆ‡å¤©ç„¶æ´»æ€§ç‰©è³ªçš„äº’å‹•æ©Ÿåˆ¶å…·æœ‰é‡è¦æ„ç¾©ã€‚",
    "fb_post": "æ ¹æ“šã€ŠJournal of agricultural and food chemistryã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸ½ï¸ å¤§å®¶çŸ¥é“é’èŠ±æ¤°èœè£¡é¢æœ‰ä¸€ç¨®å«è˜¿è””ç¡«ç´ çš„å¥½æ±è¥¿å—ï¼Ÿå®ƒä¸åƒ…æœ‰åŠ©æ–¼æŠ—æ°§åŒ–ï¼Œé‚„å¯èƒ½å°å¥åº·æœ‰å¾ˆå¤šå¥½è™•ï¼ä¸éï¼Œè˜¿è””ç¡«ç´ çš„è½‰åŒ–ç‡ä¸é«˜ï¼Œé€™è®“å®ƒçš„å¥åº·æ½›åŠ›ç„¡æ³•å®Œå…¨ç™¼æ®ã€‚æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶å°ˆé–€æ¢è¨å¦‚ä½•æé«˜é’èŠ±æ¤°èœä¸­çš„è˜¿è””ç¡«ç´ è½‰åŒ–ç‡ï¼Œç‰¹åˆ¥æ˜¯åˆ©ç”¨ä¸€ç¨®å« Lactiplantibacillus plantarum çš„ç´°èŒã€‚ ç ”ç©¶è€…å€‘æƒ³çŸ¥é“ï¼Œé€™ç¨®ç´°èŒåœ¨æŠŠé’èŠ±æ¤°èœä¸­çš„ä¸€ç¨®å‰é«”ç‰©è³ªï¼ˆè‘¡è„ç³–è‹·é…¸ï¼‰è½‰æ›æˆè˜¿è””ç¡«ç´ æ™‚ï¼Œè½‰åŒ–ç‡ä½çš„åŸå› æ˜¯ä»€éº¼ï¼Œä»¥åŠå¦‚ä½•æ”¹å–„é€™ä¸€éç¨‹ã€‚ \n\nåœ¨å¯¦é©—ä¸­ï¼Œä»–å€‘ç”¨äº†ä¸€ç¨®å«é©æ‡‰æ€§å¯¦é©—å®¤é€²åŒ–çš„æŠ€è¡“ï¼Œèª¿æ•´äº†ç´°èŒçš„ç’°å¢ƒæ¢ä»¶ï¼Œåƒæ˜¯æ”¹è®Šè‘¡è„ç³–çš„æ¯”ä¾‹ï¼Œè§€å¯Ÿç´°èŒçš„ä»£è¬è®ŠåŒ–ã€‚çµæœé¡¯ç¤ºï¼Œç•¶è‘¡è„ç³–çš„æ¯”ä¾‹å¢åŠ æ™‚ï¼Œç´°èŒçš„ç¢³æ°´åŒ–åˆç‰©ä»£è¬é™ä½ï¼Œè€Œæ°¨åŸºé…¸çš„ä»£è¬å‰‡æé«˜ï¼é€™æ„å‘³è‘—ç´°èŒåœ¨è½‰åŒ–è˜¿è””ç¡«ç´ çš„éç¨‹ä¸­ï¼Œå¯èƒ½æ¶‰åŠå¤šç¨®é…¶çš„ä½œç”¨ã€‚\n\nğŸ” ä¸»è¦ç™¼ç¾ï¼š  \n1. å¢åŠ è‘¡è„ç³–æ¯”ä¾‹æœƒæ”¹è®Šç´°èŒçš„ä»£è¬æ–¹å¼ã€‚  \n2. è˜¿è””ç¡«ç´ çš„è½‰åŒ–éç¨‹å¯èƒ½éœ€è¦å¤šç¨®é…¶çš„åƒèˆ‡ã€‚  \n3. é€™é …ç ”ç©¶ç‚ºæå‡å¥åº·ç”¢å“çš„é–‹ç™¼æä¾›äº†æ–°çš„æ–¹å‘ï¼",
    "image_prompt": "Create a flat design infographic that explains the experiment and main findings of a study on increasing the conversion rate of sulforaphane from broccoli. Include symbols for broccoli and sulforaphane, simplified illustrations of the experiment subjects (like people or cells), arrows or flow lines to indicate experimental steps, and a section labeled 'Main Findings' that highlights key results such as changes in metabolic pathways.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": false,
    "disease_name": "",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41340527/"
  },
  {
    "id": "40961586",
    "title_en": "Design, synthesis and biological evaluation of magnolol-sulforaphane hybrid analogues as potential therapeutics of triple-negative breast cancer.",
    "pub_date": "2025 Dec",
    "journal": "European journal of medicinal chemistry",
    "abstract_en": "Triple-negative breast cancer (TNBC) is an aggressive subtype that primarily relies on chemotherapy. Natural products like magnolol and sulforaphane, especially their synthetic hybrid, have shown promising antitumor activity. To develop more potent agents, we designed and synthesized 15 novel magnolol-sulforaphane hybrid analogues and evaluated their anticancer efficacy. Among them, compound 17a demonstrated the highest potency, exhibiting an average 7.4-fold increase in antiproliferative activity with IC<sub>50</sub> values ranging from 0.85Â Â±Â 0.04Â Î¼M to 1.34Â Â±Â 0.02Â Î¼M in TNBC cell lines compared to the parent hybrid CT1-3. In vitro, 17a significantly suppressed TNBC cell proliferation, colony formation, migration, and invasion while inducing apoptosis. In vivo, administration of 17a effectively inhibited tumor growth without apparent toxicity in an MDA-MB-231 xenograft model, as evidenced by normal organ morphology. Mechanistically, RNA sequencing revealed that 17a downregulated the nucleotide excision repair (NER) and NF-ÎºB pathways, suppressing expression of NER-related genes (ERCC2, POLE2, LIG1, GTF2H3, and DDB2) at mRNA and protein levels and inhibiting phosphorylation of IKKÎ± and p65. These findings position 17a as a potent therapeutic candidate for TNBC treatment, warranting further clinical investigation.",
    "para1": "é€™é …ç ”ç©¶å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°ä¸‰é™°æ€§ä¹³ç™Œé€™ç¨®ä¾µç•¥æ€§å¼·çš„ç™Œç—‡é¡å‹ã€‚ä¸‰é™°æ€§ä¹³ç™Œé€šå¸¸ä¾è³´åŒ–ç™‚ä¾†æ²»ç™‚ï¼Œä½†é€™ç¨®æ–¹æ³•å¯èƒ½æœƒæœ‰å‰¯ä½œç”¨ï¼Œå› æ­¤å°‹æ‰¾æ–°çš„æ²»ç™‚é¸æ“‡æ˜¯éå¸¸é‡è¦çš„ã€‚ç ”ç©¶ä¸­æåˆ°çš„å¤©ç„¶ç”¢å“ï¼Œå¦‚è˜¿è””ç¡«ç´ å’Œæœ¨è˜­é†‡ï¼Œé¡¯ç¤ºå‡ºè‰¯å¥½çš„æŠ—è…«ç˜¤æ´»æ€§ï¼Œé€™å¯èƒ½ç‚ºæœªä¾†çš„ç™Œç—‡æ²»ç™‚æä¾›æ–°çš„æ–¹å‘ã€‚é€éé–‹ç™¼æ›´æœ‰æ•ˆçš„è—¥ç‰©ï¼Œæˆ–è¨±èƒ½æ”¹å–„æ‚£è€…çš„é å¾Œï¼Œæ¸›å°‘å°å‚³çµ±åŒ–ç™‚çš„ä¾è³´ï¼Œä¸¦æå‡æ²»ç™‚æ•ˆæœã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯é–‹ç™¼æ–°å‹çš„æŠ—ç™Œè—¥ç‰©ï¼Œç‰¹åˆ¥æ˜¯é‡å°ä¸‰é™°æ€§ä¹³ç™Œçš„æ²»ç™‚ã€‚ç ”ç©¶è€…è¨­è¨ˆä¸¦åˆæˆäº†15ç¨®æ–°çš„æœ¨è˜­é†‡-è˜¿è””ç¡«ç´ æ··åˆç‰©ï¼Œä¸¦è©•ä¼°å®ƒå€‘çš„æŠ—ç™Œæ•ˆæœã€‚é€™å€‹ç ”ç©¶é—œå¿ƒçš„å•é¡Œæ˜¯å¦‚ä½•æé«˜é€™äº›å¤©ç„¶ç”¢å“çš„æŠ—è…«ç˜¤æ´»æ€§ï¼Œä»¥ä¾¿æ‰¾åˆ°æ›´æœ‰æ•ˆçš„æ²»ç™‚é¸æ“‡ï¼Œå°¤å…¶æ˜¯åœ¨é¢å°é›£æ²»çš„ä¸‰é™°æ€§ä¹³ç™Œæ™‚ã€‚",
    "para3": "å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…é¦–å…ˆåˆæˆäº†15ç¨®æ–°å‹çš„æœ¨è˜­é†‡-è˜¿è””ç¡«ç´ æ··åˆç‰©ï¼Œç„¶å¾Œåœ¨å¯¦é©—å®¤ä¸­æ¸¬è©¦å®ƒå€‘å°ä¸‰é™°æ€§ä¹³ç™Œç´°èƒçš„å½±éŸ¿ã€‚é€™äº›æ¸¬è©¦åŒ…æ‹¬è©•ä¼°ç´°èƒå¢æ®–ã€é›†è½å½¢æˆã€é·ç§»å’Œä¾µè¥²èƒ½åŠ›ç­‰æ–¹é¢çš„è®ŠåŒ–ã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„åœ¨å°é¼ æ¨¡å‹ä¸­é€²è¡Œäº†é«”å…§å¯¦é©—ï¼Œä»¥è§€å¯Ÿé€™äº›åŒ–åˆç‰©å°è…«ç˜¤ç”Ÿé•·çš„æŠ‘åˆ¶æ•ˆæœï¼Œä¸¦æª¢æŸ¥å…¶å°æ­£å¸¸å™¨å®˜çš„å½±éŸ¿ï¼Œä»¥è©•ä¼°æ½›åœ¨çš„æ¯’æ€§ã€‚",
    "para4": "ä¸»è¦çš„ç™¼ç¾æ˜¯ï¼ŒåŒ–åˆç‰©17aåœ¨æŠ—å¢æ®–æ´»æ€§æ–¹é¢è¡¨ç¾å‡ºæœ€é«˜çš„æ•ˆèƒ½ï¼Œé¡¯ç¤ºå‡ºé¡¯è‘—æŠ‘åˆ¶ä¸‰é™°æ€§ä¹³ç™Œç´°èƒå¢æ®–çš„èƒ½åŠ›ï¼Œä¸¦èƒ½èª˜å°ç´°èƒå‡‹äº¡ã€‚åœ¨å°é¼ æ¨¡å‹ä¸­ï¼Œ17aæœ‰æ•ˆæŠ‘åˆ¶è…«ç˜¤ç”Ÿé•·ï¼Œä¸”æœªè§€å¯Ÿåˆ°æ˜é¡¯çš„æ¯’æ€§åæ‡‰ã€‚é€²ä¸€æ­¥çš„æ©Ÿåˆ¶ç ”ç©¶é¡¯ç¤ºï¼Œ17aèƒ½ä¸‹èª¿èˆ‡æ ¸è‹·é…¸åˆ‡é™¤ä¿®å¾©å’ŒNF-ÎºBé€šè·¯ç›¸é—œçš„åŸºå› è¡¨é”ï¼Œé€™äº›çµæœé¡¯ç¤º17aæœ‰æ½›åŠ›æˆç‚ºä¸‰é™°æ€§ä¹³ç™Œçš„æ²»ç™‚å€™é¸è—¥ç‰©ï¼Œå€¼å¾—é€²ä¸€æ­¥çš„è‡¨åºŠç ”ç©¶ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°ä¸‰é™°æ€§ä¹³ç™Œé€™ç¨®ä¾µç•¥æ€§å¼·çš„ç™Œç—‡é¡å‹ã€‚ä¸‰é™°æ€§ä¹³ç™Œé€šå¸¸ä¾è³´åŒ–ç™‚ä¾†æ²»ç™‚ï¼Œä½†é€™ç¨®æ–¹æ³•å¯èƒ½æœƒæœ‰å‰¯ä½œç”¨ï¼Œå› æ­¤å°‹æ‰¾æ–°çš„æ²»ç™‚é¸æ“‡æ˜¯éå¸¸é‡è¦çš„ã€‚ç ”ç©¶ä¸­æåˆ°çš„å¤©ç„¶ç”¢å“ï¼Œå¦‚è˜¿è””ç¡«ç´ å’Œæœ¨è˜­é†‡ï¼Œé¡¯ç¤ºå‡ºè‰¯å¥½çš„æŠ—è…«ç˜¤æ´»æ€§ï¼Œé€™å¯èƒ½ç‚ºæœªä¾†çš„ç™Œç—‡æ²»ç™‚æä¾›æ–°çš„æ–¹å‘ã€‚é€éé–‹ç™¼æ›´æœ‰æ•ˆçš„è—¥ç‰©ï¼Œæˆ–è¨±èƒ½æ”¹å–„æ‚£è€…çš„é å¾Œï¼Œæ¸›å°‘å°å‚³çµ±åŒ–ç™‚çš„ä¾è³´ï¼Œä¸¦æå‡æ²»ç™‚æ•ˆæœã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯é–‹ç™¼æ–°å‹çš„æŠ—ç™Œè—¥ç‰©ï¼Œç‰¹åˆ¥æ˜¯é‡å°ä¸‰é™°æ€§ä¹³ç™Œçš„æ²»ç™‚ã€‚ç ”ç©¶è€…è¨­è¨ˆä¸¦åˆæˆäº†15ç¨®æ–°çš„æœ¨è˜­é†‡-è˜¿è””ç¡«ç´ æ··åˆç‰©ï¼Œä¸¦è©•ä¼°å®ƒå€‘çš„æŠ—ç™Œæ•ˆæœã€‚é€™å€‹ç ”ç©¶é—œå¿ƒçš„å•é¡Œæ˜¯å¦‚ä½•æé«˜é€™äº›å¤©ç„¶ç”¢å“çš„æŠ—è…«ç˜¤æ´»æ€§ï¼Œä»¥ä¾¿æ‰¾åˆ°æ›´æœ‰æ•ˆçš„æ²»ç™‚é¸æ“‡ï¼Œå°¤å…¶æ˜¯åœ¨é¢å°é›£æ²»çš„ä¸‰é™°æ€§ä¹³ç™Œæ™‚ã€‚\n\nå¯¦é©—ä¸­ï¼Œç ”ç©¶è€…é¦–å…ˆåˆæˆäº†15ç¨®æ–°å‹çš„æœ¨è˜­é†‡-è˜¿è””ç¡«ç´ æ··åˆç‰©ï¼Œç„¶å¾Œåœ¨å¯¦é©—å®¤ä¸­æ¸¬è©¦å®ƒå€‘å°ä¸‰é™°æ€§ä¹³ç™Œç´°èƒçš„å½±éŸ¿ã€‚é€™äº›æ¸¬è©¦åŒ…æ‹¬è©•ä¼°ç´°èƒå¢æ®–ã€é›†è½å½¢æˆã€é·ç§»å’Œä¾µè¥²èƒ½åŠ›ç­‰æ–¹é¢çš„è®ŠåŒ–ã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„åœ¨å°é¼ æ¨¡å‹ä¸­é€²è¡Œäº†é«”å…§å¯¦é©—ï¼Œä»¥è§€å¯Ÿé€™äº›åŒ–åˆç‰©å°è…«ç˜¤ç”Ÿé•·çš„æŠ‘åˆ¶æ•ˆæœï¼Œä¸¦æª¢æŸ¥å…¶å°æ­£å¸¸å™¨å®˜çš„å½±éŸ¿ï¼Œä»¥è©•ä¼°æ½›åœ¨çš„æ¯’æ€§ã€‚\n\nä¸»è¦çš„ç™¼ç¾æ˜¯ï¼ŒåŒ–åˆç‰©17aåœ¨æŠ—å¢æ®–æ´»æ€§æ–¹é¢è¡¨ç¾å‡ºæœ€é«˜çš„æ•ˆèƒ½ï¼Œé¡¯ç¤ºå‡ºé¡¯è‘—æŠ‘åˆ¶ä¸‰é™°æ€§ä¹³ç™Œç´°èƒå¢æ®–çš„èƒ½åŠ›ï¼Œä¸¦èƒ½èª˜å°ç´°èƒå‡‹äº¡ã€‚åœ¨å°é¼ æ¨¡å‹ä¸­ï¼Œ17aæœ‰æ•ˆæŠ‘åˆ¶è…«ç˜¤ç”Ÿé•·ï¼Œä¸”æœªè§€å¯Ÿåˆ°æ˜é¡¯çš„æ¯’æ€§åæ‡‰ã€‚é€²ä¸€æ­¥çš„æ©Ÿåˆ¶ç ”ç©¶é¡¯ç¤ºï¼Œ17aèƒ½ä¸‹èª¿èˆ‡æ ¸è‹·é…¸åˆ‡é™¤ä¿®å¾©å’ŒNF-ÎºBé€šè·¯ç›¸é—œçš„åŸºå› è¡¨é”ï¼Œé€™äº›çµæœé¡¯ç¤º17aæœ‰æ½›åŠ›æˆç‚ºä¸‰é™°æ€§ä¹³ç™Œçš„æ²»ç™‚å€™é¸è—¥ç‰©ï¼Œå€¼å¾—é€²ä¸€æ­¥çš„è‡¨åºŠç ”ç©¶ã€‚",
    "fb_post": "æ ¹æ“šã€ŠEuropean journal of medicinal chemistryã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ± å¤§å®¶çŸ¥é“å—ï¼Ÿå…¶å¯¦æˆ‘å€‘çš„é£²é£Ÿè£¡æœ‰ä¸€äº›å¤©ç„¶æˆåˆ†å¯èƒ½å°å¥åº·æœ‰å¾ˆå¤§çš„å¹«åŠ©ï¼Œå°¤å…¶æ˜¯åœ¨å°æŠ—ç™Œç—‡æ–¹é¢ï¼æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶å°ˆæ³¨æ–¼ä¸‰é™°æ€§ä¹³ç™Œï¼Œé€™æ˜¯ä¸€ç¨®ç‰¹åˆ¥é›£ä»¥æ²»ç™‚çš„ç™Œç—‡é¡å‹ã€‚ç ”ç©¶è€…å€‘ç™¼ç¾ï¼Œåƒè˜¿è””ç¡«ç´ å’Œæœ¨è˜­é†‡é€™äº›å¤©ç„¶æˆåˆ†ï¼Œå¯èƒ½æœƒæˆç‚ºæœªä¾†æ²»ç™‚çš„æ–°é¸æ“‡ï¼\n\né€™é …ç ”ç©¶çš„é‡é»æ˜¯é–‹ç™¼æ–°å‹çš„æŠ—ç™Œè—¥ç‰©ï¼Œç‰¹åˆ¥æ˜¯é‡å°ä¸‰é™°æ€§ä¹³ç™Œã€‚ä»–å€‘åˆæˆäº†15ç¨®æ–°çš„æœ¨è˜­é†‡-è˜¿è””ç¡«ç´ æ··åˆç‰©ï¼Œä¸¦åœ¨å¯¦é©—å®¤è£¡æ¸¬è©¦é€™äº›åŒ–åˆç‰©å°ç™Œç´°èƒçš„å½±éŸ¿ã€‚çµæœç™¼ç¾ï¼Œé€™äº›å¤©ç„¶æ··åˆç‰©èƒ½æœ‰æ•ˆæŠ‘åˆ¶ç™Œç´°èƒçš„å¢é•·ï¼Œä¸¦ä¸”åœ¨å°é¼ æ¨¡å‹ä¸­ä¹Ÿé¡¯ç¤ºå‡ºè‰¯å¥½çš„æ•ˆæœï¼\n\nä¸»è¦ç™¼ç¾æ˜¯æœ‰ä¸€ç¨®åŒ–åˆç‰©ï¼ˆ17aï¼‰ç‰¹åˆ¥æœ‰æ•ˆï¼Œèƒ½é¡¯è‘—æŠ‘åˆ¶ç™Œç´°èƒå¢æ®–ï¼Œä¸¦ä¸”æ²’æœ‰æ˜é¡¯çš„æ¯’æ€§åæ‡‰ã€‚é€™äº›çµæœè®“ç ”ç©¶è€…å€‘å°æœªä¾†çš„ç™Œç—‡æ²»ç™‚å……æ»¿å¸Œæœ›ï¼\n\nğŸ” é‡é»æ•´ç†ï¼š\n1. è˜¿è””ç¡«ç´ å’Œæœ¨è˜­é†‡å¯èƒ½æˆç‚ºæ–°å‹æŠ—ç™Œè—¥ç‰©ã€‚\n2. ç ”ç©¶å±•ç¤ºäº†15ç¨®æ–°æ··åˆç‰©çš„æŠ—ç™Œæ•ˆæœã€‚\n3. åŒ–åˆç‰©17aé¡¯ç¤ºå‡ºè‰¯å¥½çš„è…«ç˜¤æŠ‘åˆ¶æ•ˆæœï¼Œæœªè¦‹æ˜é¡¯æ¯’æ€§ã€‚  \n\nè®“æˆ‘å€‘æœŸå¾…é€™äº›å¤©ç„¶æˆåˆ†åœ¨ç™Œç—‡æ²»ç™‚ä¸­çš„æœªä¾†ç™¼å±•å§ï¼",
    "image_prompt": "Create a flat design infographic with a light background that explains the experimental process and main results of a study on natural compounds for cancer treatment. Include symbols representing broccoli or sulforaphane, simplified illustrations of experimental subjects (like humans, animals, and cells), and arrows or flow lines indicating the experimental steps. Add a section labeled 'Main Results' highlighting key findings, such as protective effects and changes observed.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "ä¸‰é™°æ€§ä¹³ç™Œ Triple-negative Breast Cancer",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40961586/"
  },
  {
    "id": "41399453",
    "title_en": "Dual effect of sulforaphane on multi-walled carbon nanotube-induced lung inflammation in mice.",
    "pub_date": "2025 Dec",
    "journal": "Toxicology research",
    "abstract_en": "A previous study demonstrated that Nrf2, a transcription factor, unexpectedly promoted multi-walled carbon nanotube (MWCNT)-induced lung inflammation in mice. This finding contrasts with the well-established role of Nrf2 in suppressing inflammatory responses induced by environmental chemicals, highlighting a critical knowledge gap. The present study investigated the effect of sulforaphane, a known activator of Nrf2, on MWCNT-induced lung inflammation in mice, in order to better understand the underlying mechanisms of this response. Each of 48 C57BL/6Â J male mouse was anesthetized and exposed once via pharyngeal aspiration to MWCNTs (Mitsui-7) at doses of 0, 10, or 20Â Î¼g in 40Â Î¼l of dispersion medium per mouse and treated thereafter with subcutaneous 25Â mg/kg/day sulforaphane or vehicle for 14Â days. Bronchoalveolar lavage fluid (BALF) was collected for differential cell counts. Lung tissues were processed for histopathological analysis and quantification of cytokine or chemokine mRNA expression and Nrf2 protein in nuclear extracts. MWCNTs exposure increased lung weight, BALF lymphocytes, and lung IL-6 expression. Sulforaphane attenuated MWCNTs-induced lung weight gain, lymphocytic infiltration, and upregulation of IL-6 expression, but paradoxically enhanced low-dose MWCNT-induced neutrophil infiltration in BALF, MIP-2 expression, and histopathological inflammation scores. These effects were accompanied by increased levels of active Nrf2 protein in nuclear extracts from lung tissue. Overall, the results indicate that sulforaphane suppresses lymphocyte infiltration while promoting neutrophil recruitment in response to low-dose MWCNTs, suggesting a dual effect of sulforaphane on MWCNT-induced lung inflammation mediated through Nrf2 activation.",
    "para1": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œé›–ç„¶è˜¿è””ç¡«ç´ è¢«èªç‚ºæœ‰åŠ©æ–¼æŠ—ç™¼ç‚ï¼Œä½†åœ¨æŸäº›æƒ…æ³ä¸‹ï¼Œå®ƒçš„æ•ˆæœå¯èƒ½æ˜¯è¤‡é›œçš„ã€‚ç‰¹åˆ¥æ˜¯åœ¨æ¥è§¸åˆ°å¤šå£ç¢³ç´ç±³ç®¡ï¼ˆMWCNTï¼‰é€™é¡ç’°å¢ƒæ±¡æŸ“ç‰©æ™‚ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½æœƒå¼•ç™¼ä¸åŒçš„å…ç–«åæ‡‰ï¼Œé€™æé†’æˆ‘å€‘åœ¨ä½¿ç”¨å¤©ç„¶ç‰©è³ªä½œç‚ºä¿å¥å“æ™‚ï¼Œå¿…é ˆè€ƒæ…®å…¶æ½›åœ¨çš„é›™é¢æ€§ã€‚é€™æ¨£çš„ç ”ç©¶çµæœå°æ–¼æœªä¾†çš„å¥åº·å¹²é æªæ–½å’Œç–¾ç—…é é˜²ç­–ç•¥æä¾›äº†é‡è¦çš„åƒè€ƒï¼Œå°¤å…¶æ˜¯åœ¨é¢å°ç’°å¢ƒæ±¡æŸ“çš„æŒ‘æˆ°æ™‚ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°å¤šå£ç¢³ç´ç±³ç®¡å¼•èµ·çš„è‚ºéƒ¨ç™¼ç‚åæ‡‰çš„å½±éŸ¿ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£åœ¨æ¥è§¸é€™ç¨®ç’°å¢ƒæ±¡æŸ“ç‰©å¾Œï¼Œè˜¿è””ç¡«ç´ å¦‚ä½•é€éæ¿€æ´»Nrf2é€™ä¸€è½‰éŒ„å› å­ä¾†å½±éŸ¿è‚ºéƒ¨çš„å…ç–«åæ‡‰ã€‚é€™å€‹å•é¡Œçš„é—œéµåœ¨æ–¼ï¼Œå…ˆå‰çš„ç ”ç©¶é¡¯ç¤ºNrf2åœ¨æŸäº›æƒ…æ³ä¸‹å¯èƒ½ä¿ƒé€²è‚ºéƒ¨çš„ç™¼ç‚ï¼Œè€Œä¸æ˜¯æŠ‘åˆ¶å®ƒï¼Œå› æ­¤éœ€è¦é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†é‡æ¸…é€™ä¸€çŸ›ç›¾çš„ç¾è±¡ã€‚",
    "para3": "å¯¦é©—ä¸­ä½¿ç”¨äº†48éš»C57BL/6 Jé›„æ€§å°é¼ ï¼Œé€™äº›å°é¼ åœ¨éº»é†‰å¾Œè¢«å–®æ¬¡é€šéå’½å–‰å¸å…¥ä¸åŒåŠ‘é‡çš„å¤šå£ç¢³ç´ç±³ç®¡ï¼ˆ0ã€10æˆ–20å¾®å…‹ï¼‰ï¼Œä¸¦åœ¨éš¨å¾Œçš„14å¤©å…§æ¥å—æ¯æ—¥25æ¯«å…‹æ¯å…¬æ–¤é«”é‡çš„è˜¿è””ç¡«ç´ æˆ–å°ç…§è™•ç†ã€‚ç ”ç©¶è€…æ”¶é›†äº†å°é¼ çš„æ”¯æ°£ç®¡è‚ºæ³¡çŒæ´—æ¶²ï¼Œä»¥é€²è¡Œç´°èƒè¨ˆæ•¸ï¼Œä¸¦å°è‚ºçµ„ç¹”é€²è¡Œçµ„ç¹”ç—…ç†å­¸åˆ†æåŠç´°èƒå› å­æˆ–è¶¨åŒ–å› å­mRNAè¡¨é”å’ŒNrf2è›‹ç™½çš„å®šé‡æª¢æ¸¬ï¼Œå¾è€Œè©•ä¼°è˜¿è””ç¡«ç´ å°è‚ºéƒ¨ç™¼ç‚çš„å½±éŸ¿ã€‚",
    "para4": "ä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œæ¥è§¸å¤šå£ç¢³ç´ç±³ç®¡å¾Œï¼Œå°é¼ çš„è‚ºéƒ¨é‡é‡å¢åŠ ã€æ”¯æ°£ç®¡è‚ºæ³¡çŒæ´—æ¶²ä¸­çš„æ·‹å·´ç´°èƒæ•¸é‡ä¸Šå‡ä»¥åŠè‚ºéƒ¨IL-6çš„è¡¨é”ä¸Šå‡ã€‚è€Œè˜¿è””ç¡«ç´ å‰‡æ¸›å°‘äº†å¤šå£ç¢³ç´ç±³ç®¡å¼•èµ·çš„è‚ºéƒ¨é‡é‡å¢åŠ å’Œæ·‹å·´ç´°èƒæµ¸æ½¤ï¼Œä¸¦é™ä½IL-6çš„è¡¨é”ã€‚ç„¶è€Œï¼Œä»¤äººæ„å¤–çš„æ˜¯ï¼Œè˜¿è””ç¡«ç´ åœ¨ä½åŠ‘é‡çš„å¤šå£ç¢³ç´ç±³ç®¡è™•ç†ä¸‹å»ä¿ƒé€²äº†ä¸­æ€§ç²’ç´°èƒçš„æµ¸æ½¤ï¼Œé€™è¡¨æ˜è˜¿è””ç¡«ç´ å°æ–¼å¤šå£ç¢³ç´ç±³ç®¡å¼•èµ·çš„è‚ºéƒ¨ç™¼ç‚åæ‡‰å…·æœ‰é›™é‡ä½œç”¨ï¼Œé€™ä¸€åˆ‡éƒ½èˆ‡Nrf2çš„æ´»åŒ–æœ‰é—œã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œé›–ç„¶è˜¿è””ç¡«ç´ è¢«èªç‚ºæœ‰åŠ©æ–¼æŠ—ç™¼ç‚ï¼Œä½†åœ¨æŸäº›æƒ…æ³ä¸‹ï¼Œå®ƒçš„æ•ˆæœå¯èƒ½æ˜¯è¤‡é›œçš„ã€‚ç‰¹åˆ¥æ˜¯åœ¨æ¥è§¸åˆ°å¤šå£ç¢³ç´ç±³ç®¡ï¼ˆMWCNTï¼‰é€™é¡ç’°å¢ƒæ±¡æŸ“ç‰©æ™‚ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½æœƒå¼•ç™¼ä¸åŒçš„å…ç–«åæ‡‰ï¼Œé€™æé†’æˆ‘å€‘åœ¨ä½¿ç”¨å¤©ç„¶ç‰©è³ªä½œç‚ºä¿å¥å“æ™‚ï¼Œå¿…é ˆè€ƒæ…®å…¶æ½›åœ¨çš„é›™é¢æ€§ã€‚é€™æ¨£çš„ç ”ç©¶çµæœå°æ–¼æœªä¾†çš„å¥åº·å¹²é æªæ–½å’Œç–¾ç—…é é˜²ç­–ç•¥æä¾›äº†é‡è¦çš„åƒè€ƒï¼Œå°¤å…¶æ˜¯åœ¨é¢å°ç’°å¢ƒæ±¡æŸ“çš„æŒ‘æˆ°æ™‚ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°å¤šå£ç¢³ç´ç±³ç®¡å¼•èµ·çš„è‚ºéƒ¨ç™¼ç‚åæ‡‰çš„å½±éŸ¿ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£åœ¨æ¥è§¸é€™ç¨®ç’°å¢ƒæ±¡æŸ“ç‰©å¾Œï¼Œè˜¿è””ç¡«ç´ å¦‚ä½•é€éæ¿€æ´»Nrf2é€™ä¸€è½‰éŒ„å› å­ä¾†å½±éŸ¿è‚ºéƒ¨çš„å…ç–«åæ‡‰ã€‚é€™å€‹å•é¡Œçš„é—œéµåœ¨æ–¼ï¼Œå…ˆå‰çš„ç ”ç©¶é¡¯ç¤ºNrf2åœ¨æŸäº›æƒ…æ³ä¸‹å¯èƒ½ä¿ƒé€²è‚ºéƒ¨çš„ç™¼ç‚ï¼Œè€Œä¸æ˜¯æŠ‘åˆ¶å®ƒï¼Œå› æ­¤éœ€è¦é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†é‡æ¸…é€™ä¸€çŸ›ç›¾çš„ç¾è±¡ã€‚\n\nå¯¦é©—ä¸­ä½¿ç”¨äº†48éš»C57BL/6 Jé›„æ€§å°é¼ ï¼Œé€™äº›å°é¼ åœ¨éº»é†‰å¾Œè¢«å–®æ¬¡é€šéå’½å–‰å¸å…¥ä¸åŒåŠ‘é‡çš„å¤šå£ç¢³ç´ç±³ç®¡ï¼ˆ0ã€10æˆ–20å¾®å…‹ï¼‰ï¼Œä¸¦åœ¨éš¨å¾Œçš„14å¤©å…§æ¥å—æ¯æ—¥25æ¯«å…‹æ¯å…¬æ–¤é«”é‡çš„è˜¿è””ç¡«ç´ æˆ–å°ç…§è™•ç†ã€‚ç ”ç©¶è€…æ”¶é›†äº†å°é¼ çš„æ”¯æ°£ç®¡è‚ºæ³¡çŒæ´—æ¶²ï¼Œä»¥é€²è¡Œç´°èƒè¨ˆæ•¸ï¼Œä¸¦å°è‚ºçµ„ç¹”é€²è¡Œçµ„ç¹”ç—…ç†å­¸åˆ†æåŠç´°èƒå› å­æˆ–è¶¨åŒ–å› å­mRNAè¡¨é”å’ŒNrf2è›‹ç™½çš„å®šé‡æª¢æ¸¬ï¼Œå¾è€Œè©•ä¼°è˜¿è””ç¡«ç´ å°è‚ºéƒ¨ç™¼ç‚çš„å½±éŸ¿ã€‚\n\nä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œæ¥è§¸å¤šå£ç¢³ç´ç±³ç®¡å¾Œï¼Œå°é¼ çš„è‚ºéƒ¨é‡é‡å¢åŠ ã€æ”¯æ°£ç®¡è‚ºæ³¡çŒæ´—æ¶²ä¸­çš„æ·‹å·´ç´°èƒæ•¸é‡ä¸Šå‡ä»¥åŠè‚ºéƒ¨IL-6çš„è¡¨é”ä¸Šå‡ã€‚è€Œè˜¿è””ç¡«ç´ å‰‡æ¸›å°‘äº†å¤šå£ç¢³ç´ç±³ç®¡å¼•èµ·çš„è‚ºéƒ¨é‡é‡å¢åŠ å’Œæ·‹å·´ç´°èƒæµ¸æ½¤ï¼Œä¸¦é™ä½IL-6çš„è¡¨é”ã€‚ç„¶è€Œï¼Œä»¤äººæ„å¤–çš„æ˜¯ï¼Œè˜¿è””ç¡«ç´ åœ¨ä½åŠ‘é‡çš„å¤šå£ç¢³ç´ç±³ç®¡è™•ç†ä¸‹å»ä¿ƒé€²äº†ä¸­æ€§ç²’ç´°èƒçš„æµ¸æ½¤ï¼Œé€™è¡¨æ˜è˜¿è””ç¡«ç´ å°æ–¼å¤šå£ç¢³ç´ç±³ç®¡å¼•èµ·çš„è‚ºéƒ¨ç™¼ç‚åæ‡‰å…·æœ‰é›™é‡ä½œç”¨ï¼Œé€™ä¸€åˆ‡éƒ½èˆ‡Nrf2çš„æ´»åŒ–æœ‰é—œã€‚",
    "fb_post": "æ ¹æ“šã€ŠToxicology researchã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ± è½èªªè˜¿è””ç¡«ç´ å°å¥åº·æœ‰å¹«åŠ©ï¼Œä½†ä½ çŸ¥é“å®ƒä¹Ÿæœ‰å¯èƒ½å¸¶ä¾†æ„æƒ³ä¸åˆ°çš„æ•ˆæœå—ï¼Ÿé€™ç¯‡ç ”ç©¶å°±å‘Šè¨´æˆ‘å€‘ï¼Œè˜¿è””ç¡«ç´ åœ¨æŸäº›æƒ…æ³ä¸‹å¯èƒ½æœƒå¼•ç™¼è¤‡é›œçš„å…ç–«åæ‡‰ï¼Œå°¤å…¶æ˜¯åœ¨æ¥è§¸åˆ°ç’°å¢ƒæ±¡æŸ“ç‰©æ™‚ã€‚  \n  \nç ”ç©¶è€…å€‘å°ˆæ³¨æ–¼æ¢è¨è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿å› å¤šå£ç¢³ç´ç±³ç®¡ï¼ˆé€™æ˜¯ä¸€ç¨®ç’°å¢ƒæ±¡æŸ“ç‰©ï¼‰å¼•èµ·çš„è‚ºéƒ¨ç™¼ç‚åæ‡‰ã€‚ä»–å€‘ç™¼ç¾ï¼Œé›–ç„¶è˜¿è””ç¡«ç´ åœ¨æŸäº›æƒ…æ³ä¸‹èƒ½æ¸›å°‘è‚ºéƒ¨çš„ç‚ç—‡ï¼Œä½†åœ¨ä½åŠ‘é‡çš„æ±¡æŸ“ç‰©ä¸­ï¼Œå»å¯èƒ½ä¿ƒé€²æŸäº›å…ç–«ç´°èƒçš„æ´»åŒ–ã€‚é€™è®“æˆ‘å€‘å°å¤©ç„¶ä¿å¥å“çš„ä½¿ç”¨æ›´åŠ è¬¹æ…ï¼  \n  \nğŸ” é€™è£¡æœ‰å¹¾å€‹é‡è¦çš„ç™¼ç¾ï¼š  \n1. è˜¿è””ç¡«ç´ å¯èƒ½æ¸›å°‘å› æ±¡æŸ“ç‰©å¼•èµ·çš„è‚ºéƒ¨ç‚ç—‡ã€‚  \n2. åœ¨ä½åŠ‘é‡æ±¡æŸ“ç‰©çš„æƒ…æ³ä¸‹ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½ä¿ƒé€²æŸäº›å…ç–«åæ‡‰ã€‚  \n3. é€™äº›çµæœæé†’æˆ‘å€‘ï¼Œåœ¨ä½¿ç”¨å¤©ç„¶ç”¢å“æ™‚è¦è€ƒæ…®åˆ°å¯èƒ½çš„é›™é¢æ€§ã€‚  \n  \nè®“æˆ‘å€‘ä¸€èµ·é—œæ³¨å¥åº·ï¼Œè¬¹æ…é¸æ“‡ä¿å¥å“ï¼",
    "image_prompt": "Create a flat design infographic explaining the experiment and main findings of a study on sulforaphane's effects on lung inflammation caused by multi-walled carbon nanotubes. Include symbols for broccoli or sulforaphane, simplified representations of experimental subjects like mice or cells, arrows or flow lines to show the experimental process, and a section highlighting the main results such as protective effects and changes observed.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "è‚ºéƒ¨ç™¼ç‚ Lung Inflammation",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41399453/"
  },
  {
    "id": "41409171",
    "title_en": "Investigating the Anticancer Effects of Sulforaphane in an In Vitro Coculture Model of Prostate Cancer Cells with Engineered Heart Tissue.",
    "pub_date": "2025 Dec",
    "journal": "ACS pharmacology & translational science",
    "abstract_en": "Sulforaphane (SFN) is a phytoderived compound abundant in cruciferous plants that possesses a broad spectrum of anticancer properties. We showed that SFN-induced caspase-mediated apoptosis in grade IV bone metastasis-derived androgen-insensitive PC-3 (IC<sub>50</sub> = 4.2 Î¼M), and lymph node metastasis-derived androgen-sensitive LNCaP (IC<sub>50</sub> = 2.8 Î¼M) prostate adenocarcinoma cells. SFN-mediated cardiotoxic side effects were tested in a preclinical in vitro model that enables the study simultaneously of the impact of drugs on cancer cell death and contractile properties of engineered heart tissues generated from human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CM EHT). Thereby, SFN exposure induced PC-3 cell death without affecting the contractile force of hiPSC-CM EHT. Interestingly, the irregular beating pattern of hiPSC-CM EHT observed in the presence of PC-3 coculture was normalized compared to vehicle treatment. Overall, this in vitro coculture model of hiPSC-CM EHT and cancer cells could facilitate the study of cardiotoxic cancer drug side-effects.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨ç™Œç—‡æ²»ç™‚æ–¹é¢ã€‚è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å­˜åœ¨æ–¼åå­—èŠ±ç§‘æ¤ç‰©ä¸­çš„åŒ–åˆç‰©ï¼Œå·²çŸ¥å…·æœ‰æŠ—ç™Œç‰¹æ€§ã€‚é€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ å°å‰åˆ—è…ºç™Œç´°èƒçš„å½±éŸ¿ï¼Œä¸¦ä¸”åœ¨å¯¦é©—ä¸­é¡¯ç¤ºå‡ºå®ƒèƒ½å¤ ä¿ƒé€²ç™Œç´°èƒçš„æ­»äº¡ï¼Œé€™å¯èƒ½ç‚ºæœªä¾†çš„ç™Œç—‡æ²»ç™‚æä¾›æ–°çš„æ€è·¯ï¼Œå°¤å…¶æ˜¯åœ¨å¦‚ä½•æ¸›å°‘ç™Œç´°èƒå­˜æ´»çš„åŒæ™‚ï¼Œé™ä½å°å¿ƒè‡Ÿçš„å‰¯ä½œç”¨æ–¹é¢ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°å‰åˆ—è…ºç™Œç´°èƒçš„å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯å…¶åœ¨ä¸åŒé¡å‹çš„å‰åˆ—è…ºç™Œç´°èƒä¸­çš„ä½œç”¨ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æœ‰æ•ˆèª˜å°ç™Œç´°èƒæ­»äº¡ï¼Œä»¥åŠåœ¨é€™å€‹éç¨‹ä¸­æ˜¯å¦æœƒå°å¿ƒè‡Ÿç´°èƒé€ æˆä¸è‰¯å½±éŸ¿ã€‚é€™å°æ–¼ç™Œç—‡æ‚£è€…çš„æ²»ç™‚æ–¹æ¡ˆè¨­è¨ˆè‡³é—œé‡è¦ï¼Œå› ç‚ºè¨±å¤šç™Œç—‡æ²»ç™‚è—¥ç‰©éƒ½å¯èƒ½å°å¿ƒè‡Ÿé€ æˆæå®³ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†ä¾†è‡ªä¸åŒä¾†æºçš„å‰åˆ—è…ºç™Œç´°èƒï¼ŒåŒ…æ‹¬å°é›„æ¿€ç´ ä¸æ•æ„Ÿçš„PC-3ç´°èƒå’Œå°é›„æ¿€ç´ æ•æ„Ÿçš„LNCaPç´°èƒã€‚ä»–å€‘æ¡ç”¨äº†ä¸€ç¨®é è‡¨åºŠçš„é«”å¤–æ¨¡å‹ï¼Œé€™å€‹æ¨¡å‹å¯ä»¥åŒæ™‚ç ”ç©¶è—¥ç‰©å°ç™Œç´°èƒæ­»äº¡çš„å½±éŸ¿ä»¥åŠå°ç”±äººé¡èª˜å°å¤šèƒ½å¹¹ç´°èƒè¡ç”Ÿçš„å¿ƒè‚Œç´°èƒçµ„ç¹”çš„æ”¶ç¸®ç‰¹æ€§ã€‚é€™æ¨£çš„è¨­è¨ˆä½¿å¾—ç ”ç©¶è€…èƒ½å¤ æ›´å…¨é¢åœ°äº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½æœ‰æ•ˆèª˜å°PC-3ç´°èƒæ­»äº¡ï¼Œä¸”å…¶IC<sub>50</sub>å€¼ç‚º4.2 Î¼Mï¼Œè€Œå°LNCaPç´°èƒçš„IC<sub>50</sub>å€¼ç‚º2.8 Î¼Mã€‚æ›´é‡è¦çš„æ˜¯ï¼Œè˜¿è””ç¡«ç´ çš„ä½¿ç”¨ä¸¦æœªå½±éŸ¿å¿ƒè‚Œç´°èƒçµ„ç¹”çš„æ”¶ç¸®åŠ›ï¼Œé€™æ„å‘³è‘—åœ¨æ²»ç™‚ç™Œç—‡çš„åŒæ™‚ï¼Œå¯èƒ½ä¸æœƒå°å¿ƒè‡Ÿé€ æˆé¡¯è‘—çš„æå®³ã€‚æ­¤å¤–ï¼Œç ”ç©¶ä¸­è§€å¯Ÿåˆ°çš„å¿ƒè‚Œç´°èƒçµ„ç¹”çš„ç•°å¸¸è·³å‹•æ¨¡å¼åœ¨èˆ‡PC-3ç´°èƒå…±åŒåŸ¹é¤Šå¾Œå¾—åˆ°äº†æ”¹å–„ï¼Œé€™ç‚ºæœªä¾†çš„ç ”ç©¶æä¾›äº†æ–°çš„æ–¹å‘ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨ç™Œç—‡æ²»ç™‚æ–¹é¢ã€‚è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å­˜åœ¨æ–¼åå­—èŠ±ç§‘æ¤ç‰©ä¸­çš„åŒ–åˆç‰©ï¼Œå·²çŸ¥å…·æœ‰æŠ—ç™Œç‰¹æ€§ã€‚é€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ å°å‰åˆ—è…ºç™Œç´°èƒçš„å½±éŸ¿ï¼Œä¸¦ä¸”åœ¨å¯¦é©—ä¸­é¡¯ç¤ºå‡ºå®ƒèƒ½å¤ ä¿ƒé€²ç™Œç´°èƒçš„æ­»äº¡ï¼Œé€™å¯èƒ½ç‚ºæœªä¾†çš„ç™Œç—‡æ²»ç™‚æä¾›æ–°çš„æ€è·¯ï¼Œå°¤å…¶æ˜¯åœ¨å¦‚ä½•æ¸›å°‘ç™Œç´°èƒå­˜æ´»çš„åŒæ™‚ï¼Œé™ä½å°å¿ƒè‡Ÿçš„å‰¯ä½œç”¨æ–¹é¢ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°å‰åˆ—è…ºç™Œç´°èƒçš„å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯å…¶åœ¨ä¸åŒé¡å‹çš„å‰åˆ—è…ºç™Œç´°èƒä¸­çš„ä½œç”¨ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æœ‰æ•ˆèª˜å°ç™Œç´°èƒæ­»äº¡ï¼Œä»¥åŠåœ¨é€™å€‹éç¨‹ä¸­æ˜¯å¦æœƒå°å¿ƒè‡Ÿç´°èƒé€ æˆä¸è‰¯å½±éŸ¿ã€‚é€™å°æ–¼ç™Œç—‡æ‚£è€…çš„æ²»ç™‚æ–¹æ¡ˆè¨­è¨ˆè‡³é—œé‡è¦ï¼Œå› ç‚ºè¨±å¤šç™Œç—‡æ²»ç™‚è—¥ç‰©éƒ½å¯èƒ½å°å¿ƒè‡Ÿé€ æˆæå®³ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†ä¾†è‡ªä¸åŒä¾†æºçš„å‰åˆ—è…ºç™Œç´°èƒï¼ŒåŒ…æ‹¬å°é›„æ¿€ç´ ä¸æ•æ„Ÿçš„PC-3ç´°èƒå’Œå°é›„æ¿€ç´ æ•æ„Ÿçš„LNCaPç´°èƒã€‚ä»–å€‘æ¡ç”¨äº†ä¸€ç¨®é è‡¨åºŠçš„é«”å¤–æ¨¡å‹ï¼Œé€™å€‹æ¨¡å‹å¯ä»¥åŒæ™‚ç ”ç©¶è—¥ç‰©å°ç™Œç´°èƒæ­»äº¡çš„å½±éŸ¿ä»¥åŠå°ç”±äººé¡èª˜å°å¤šèƒ½å¹¹ç´°èƒè¡ç”Ÿçš„å¿ƒè‚Œç´°èƒçµ„ç¹”çš„æ”¶ç¸®ç‰¹æ€§ã€‚é€™æ¨£çš„è¨­è¨ˆä½¿å¾—ç ”ç©¶è€…èƒ½å¤ æ›´å…¨é¢åœ°äº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½æœ‰æ•ˆèª˜å°PC-3ç´°èƒæ­»äº¡ï¼Œä¸”å…¶IC<sub>50</sub>å€¼ç‚º4.2 Î¼Mï¼Œè€Œå°LNCaPç´°èƒçš„IC<sub>50</sub>å€¼ç‚º2.8 Î¼Mã€‚æ›´é‡è¦çš„æ˜¯ï¼Œè˜¿è””ç¡«ç´ çš„ä½¿ç”¨ä¸¦æœªå½±éŸ¿å¿ƒè‚Œç´°èƒçµ„ç¹”çš„æ”¶ç¸®åŠ›ï¼Œé€™æ„å‘³è‘—åœ¨æ²»ç™‚ç™Œç—‡çš„åŒæ™‚ï¼Œå¯èƒ½ä¸æœƒå°å¿ƒè‡Ÿé€ æˆé¡¯è‘—çš„æå®³ã€‚æ­¤å¤–ï¼Œç ”ç©¶ä¸­è§€å¯Ÿåˆ°çš„å¿ƒè‚Œç´°èƒçµ„ç¹”çš„ç•°å¸¸è·³å‹•æ¨¡å¼åœ¨èˆ‡PC-3ç´°èƒå…±åŒåŸ¹é¤Šå¾Œå¾—åˆ°äº†æ”¹å–„ï¼Œé€™ç‚ºæœªä¾†çš„ç ”ç©¶æä¾›äº†æ–°çš„æ–¹å‘ã€‚",
    "fb_post": "æ ¹æ“šã€ŠACS pharmacology & translational scienceã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸ€ ä½ çŸ¥é“å—ï¼Ÿæˆ‘å€‘çš„æ—¥å¸¸é£²é£Ÿä¸­ï¼Œå…¶å¯¦éš±è—è‘—å°æŠ—ç™Œç—‡çš„ç§˜å¯†æ­¦å™¨ï¼é€™æ¬¡çš„ç ”ç©¶èšç„¦æ–¼ä¸€ç¨®å«åšè˜¿è””ç¡«ç´ çš„å¤©ç„¶åŒ–åˆç‰©ï¼Œå®ƒä¸»è¦å­˜åœ¨æ–¼é’èŠ±èœç­‰åå­—èŠ±ç§‘çš„è”¬èœä¸­ã€‚ç ”ç©¶è€…å€‘æƒ³çŸ¥é“ï¼Œè˜¿è””ç¡«ç´ å°å‰åˆ—è…ºç™Œç´°èƒçš„å½±éŸ¿å¦‚ä½•ï¼Œå°¤å…¶æ˜¯åœ¨æ²»ç™‚éç¨‹ä¸­ï¼Œæ˜¯å¦æœƒå°å¿ƒè‡Ÿé€ æˆè² æ“”ã€‚  \n  \nä»–å€‘çš„å¯¦é©—é¸ç”¨äº†ä¸åŒé¡å‹çš„å‰åˆ—è…ºç™Œç´°èƒï¼Œä¸¦æ¸¬è©¦è˜¿è””ç¡«ç´ çš„æ•ˆæœã€‚çµæœç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ èƒ½æœ‰æ•ˆä¿ƒé€²ä¸€ç¨®ç™Œç´°èƒçš„æ­»äº¡ï¼Œè€Œå°å¦ä¸€ç¨®ç™Œç´°èƒçš„å½±éŸ¿ä¹Ÿå¾ˆé¡¯è‘—ï¼æ›´ä»¤äººé«˜èˆˆçš„æ˜¯ï¼Œé€™å€‹åŒ–åˆç‰©å°å¿ƒè‡Ÿç´°èƒçš„å½±éŸ¿éå¸¸å°ï¼Œç”šè‡³æ²’æœ‰å½±éŸ¿åˆ°å¿ƒè‡Ÿçš„æ”¶ç¸®åŠ›ã€‚é€™ç‚ºæœªä¾†çš„ç™Œç—‡æ²»ç™‚æä¾›äº†æ–°çš„å¸Œæœ›ï¼  \n  \nğŸ” ä¸»è¦ç™¼ç¾ï¼š  \n- è˜¿è””ç¡«ç´ èƒ½æœ‰æ•ˆèª˜å°å‰åˆ—è…ºç™Œç´°èƒæ­»äº¡  \n- å°å¿ƒè‡Ÿç´°èƒæ²’æœ‰é¡¯è‘—æå®³  \n- ç‚ºæœªä¾†ç™Œç—‡æ²»ç™‚æä¾›æ–°çš„æ–¹å‘  \n  \nå¸Œæœ›å¤§å®¶åœ¨é£²é£Ÿä¸­å¤šå¤šæ”å–é€™äº›å¥åº·çš„è”¬èœï¼Œè®“æˆ‘å€‘ä¸€èµ·ç‚ºå¥åº·åŠ æ²¹ï¼",
    "image_prompt": "Create an infographic that explains the experiment and main findings of a study on the effects of sulforaphane on prostate cancer cells. The image should have a simple and clear design with a light background and soft color palette. Include symbols representing broccoli or sulforaphane, simplified illustrations of human, animal, or cell subjects, arrows or flow lines indicating the experimental steps, and a section labeled 'Main Findings' that highlights protective effects or changes observed.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "å‰åˆ—è…ºç™Œ Prostate Cancer",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41409171/"
  },
  {
    "id": "41387309",
    "title_en": "Monovalent mannose-glycoconjugates of sulforaphane reprogram human dendritic cells via NFATc1 to induce immune tolerance under inflammatory conditions.",
    "pub_date": "2025 Dec",
    "journal": "British journal of pharmacology",
    "abstract_en": "Immune tolerance prevents inflammation and autoimmunity, with dendritic cells (DCs) playing a key role. Reprogramming DCs towards a tolerogenic state represents a promising therapeutic strategy. Sulforaphane (SFN) has known immunomodulatory effects, but its clinical application is limited by poor stability and bioavailability. To enhance its therapeutic potential, SFN was conjugated with mannose (SFNMan) or fucose (SFNFuc), aiming to induce a tolerogenic phenotype in human monocyte-derived DCs (moDCs) under inflammation and to explore NFATc1's involvement. moDCs were exposed to inflammatory conditions and treated with SFN, SFNMan or SFNFuc. Their phenotype, cytokine profile, T cell-modulating capacity and NFATc1 signalling were evaluated. SFNMan selectively induced a tolerogenic phenotype, characterised by an increased PD-L1/CD86 ratio and IL-10 production; up-regulation of SOCS1 and IDO transcripts; and Treg expansion and reduced proliferation of cytotoxic T cell proliferation. Functional assays and confocal microscopy revealed that SFNMan, but not SFNFuc, promoted NFATc1 nuclear translocation. Pharmacological inhibition of NFATc1 with cyclosporin A (CsA) abolished these effects, confirming NFATc1 as a central mediator of SFNMan-induced immune tolerance. Our findings identify NFATc1 as a key transcriptional switch in moDCs tolerogenic programming and highlight the carbohydrate-dependent specificity of SFN conjugates. SFNMan represents a novel carbohydrate-engineered immunomodulator capable of driving immune tolerance through NFATc1 activation. These results provide a mechanistic framework for the development of precision therapies targeting inflammatory and autoimmune diseases.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨å…ç–«è€å—æ€§æ–¹é¢ã€‚å…ç–«è€å—æ€§èƒ½å¤ é˜²æ­¢ç‚ç—‡å’Œè‡ªé«”å…ç–«åæ‡‰ï¼Œé€™å°æ–¼ç¶­æŒèº«é«”å¥åº·è‡³é—œé‡è¦ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œé€éèª¿æ•´æ¨¹çªç´°èƒçš„åŠŸèƒ½ï¼Œå¯ä»¥ä¿ƒé€²å…ç–«è€å—ï¼Œé€™å¯èƒ½æˆç‚ºæœªä¾†æ²»ç™‚ç›¸é—œç–¾ç—…çš„ä¸€ç¨®æ–°ç­–ç•¥ã€‚é€™æ„å‘³è‘—ï¼Œé€éç‰¹å®šçš„åŒ–åˆç‰©ä¾†æ”¹è®Šå…ç–«ç³»çµ±çš„åæ‡‰ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘ç‚ç—‡å’Œè‡ªé«”å…ç–«ç–¾ç—…çš„ç™¼ç”Ÿï¼Œé€²è€Œæ”¹å–„æ‚£è€…çš„ç”Ÿæ´»å“è³ªã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰åœ¨ä¿ƒé€²å…ç–«è€å—æ€§æ–¹é¢çš„æ½›åŠ›ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œå¦‚ä½•é€éæ”¹è®Šæ¨¹çªç´°èƒçš„ç‹€æ…‹ä¾†é”æˆå…ç–«è€å—ï¼Œä¸¦ä¸”å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ çš„è¡ç”Ÿç‰©ï¼ˆå¦‚èˆ‡ç”˜éœ²ç³–æˆ–å‘‹å–ƒç³–çµåˆçš„å½¢å¼ï¼‰åœ¨é€™ä¸€éç¨‹ä¸­çš„ä½œç”¨ã€‚é€™äº›åŒ–åˆç‰©çš„ç›®çš„æ˜¯åœ¨ç‚ç—‡ç‹€æ…‹ä¸‹èª˜å°æ¨¹çªç´°èƒç”¢ç”Ÿè€å—æ€§è¡¨å‹ï¼Œå¾è€Œæ¸›å°‘å…ç–«ç³»çµ±çš„éåº¦åæ‡‰ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†ä¾†è‡ªäººé¡å–®æ ¸ç´°èƒè¡ç”Ÿçš„æ¨¹çªç´°èƒï¼ˆmoDCsï¼‰ä½œç‚ºç ”ç©¶å°è±¡ã€‚é€™äº›ç´°èƒåœ¨ç‚ç—‡æ¢ä»¶ä¸‹è¢«è™•ç†ï¼Œä¸¦åˆ†åˆ¥æ¥å—äº†ä¸åŒçš„è™•ç†ï¼ŒåŒ…æ‹¬è˜¿è””ç¡«ç´ ã€è˜¿è””ç¡«ç´ èˆ‡ç”˜éœ²ç³–çµåˆçš„å½¢å¼ï¼ˆSFNManï¼‰å’Œè˜¿è””ç¡«ç´ èˆ‡å‘‹å–ƒç³–çµåˆçš„å½¢å¼ï¼ˆSFNFucï¼‰ã€‚ç ”ç©¶è€…è©•ä¼°äº†é€™äº›è™•ç†å°æ¨¹çªç´°èƒè¡¨å‹ã€ç´°èƒå› å­ç”¢ç”Ÿã€èª¿ç¯€Tç´°èƒçš„èƒ½åŠ›ä»¥åŠNFATc1ä¿¡è™Ÿå‚³å°çš„å½±éŸ¿ï¼Œä»¥äº†è§£é€™äº›åŒ–åˆç‰©çš„ä½œç”¨æ©Ÿåˆ¶ã€‚",
    "para4": "ä¸»è¦çš„ç™¼ç¾æ˜¯ï¼ŒSFNManèƒ½å¤ é¸æ“‡æ€§åœ°èª˜å°æ¨¹çªç´°èƒç”¢ç”Ÿè€å—æ€§è¡¨å‹ï¼Œé€™è¡¨ç¾ç‚ºPD-L1/CD86æ¯”ç‡çš„å¢åŠ å’ŒIL-10çš„ç”¢ç”Ÿä¸Šå‡ã€‚æ­¤å¤–ï¼ŒSFNMané‚„ä¿ƒé€²äº†SOCS1å’ŒIDOè½‰éŒ„æœ¬çš„ä¸Šèª¿ï¼Œä¸¦æ“´å¤§äº†èª¿ç¯€æ€§Tç´°èƒçš„æ•¸é‡ï¼ŒåŒæ™‚æ¸›å°‘äº†ç´°èƒæ¯’æ€§Tç´°èƒçš„å¢æ®–ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼ŒSFNManä¿ƒé€²äº†NFATc1çš„æ ¸è½‰ä½ï¼Œè€Œé€™ä¸€éç¨‹åœ¨ä½¿ç”¨ç’°å­¢ç´ AæŠ‘åˆ¶NFATc1å¾Œè¢«é˜»æ­¢ï¼Œé¡¯ç¤ºNFATc1åœ¨SFNManèª˜å°å…ç–«è€å—ä¸­çš„é—œéµä½œç”¨ã€‚é€™äº›çµæœç‚ºé‡å°ç‚ç—‡å’Œè‡ªé«”å…ç–«ç–¾ç—…çš„ç²¾æº–æ²»ç™‚æä¾›äº†æ©Ÿåˆ¶åŸºç¤ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨å…ç–«è€å—æ€§æ–¹é¢ã€‚å…ç–«è€å—æ€§èƒ½å¤ é˜²æ­¢ç‚ç—‡å’Œè‡ªé«”å…ç–«åæ‡‰ï¼Œé€™å°æ–¼ç¶­æŒèº«é«”å¥åº·è‡³é—œé‡è¦ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œé€éèª¿æ•´æ¨¹çªç´°èƒçš„åŠŸèƒ½ï¼Œå¯ä»¥ä¿ƒé€²å…ç–«è€å—ï¼Œé€™å¯èƒ½æˆç‚ºæœªä¾†æ²»ç™‚ç›¸é—œç–¾ç—…çš„ä¸€ç¨®æ–°ç­–ç•¥ã€‚é€™æ„å‘³è‘—ï¼Œé€éç‰¹å®šçš„åŒ–åˆç‰©ä¾†æ”¹è®Šå…ç–«ç³»çµ±çš„åæ‡‰ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘ç‚ç—‡å’Œè‡ªé«”å…ç–«ç–¾ç—…çš„ç™¼ç”Ÿï¼Œé€²è€Œæ”¹å–„æ‚£è€…çš„ç”Ÿæ´»å“è³ªã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰åœ¨ä¿ƒé€²å…ç–«è€å—æ€§æ–¹é¢çš„æ½›åŠ›ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œå¦‚ä½•é€éæ”¹è®Šæ¨¹çªç´°èƒçš„ç‹€æ…‹ä¾†é”æˆå…ç–«è€å—ï¼Œä¸¦ä¸”å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ çš„è¡ç”Ÿç‰©ï¼ˆå¦‚èˆ‡ç”˜éœ²ç³–æˆ–å‘‹å–ƒç³–çµåˆçš„å½¢å¼ï¼‰åœ¨é€™ä¸€éç¨‹ä¸­çš„ä½œç”¨ã€‚é€™äº›åŒ–åˆç‰©çš„ç›®çš„æ˜¯åœ¨ç‚ç—‡ç‹€æ…‹ä¸‹èª˜å°æ¨¹çªç´°èƒç”¢ç”Ÿè€å—æ€§è¡¨å‹ï¼Œå¾è€Œæ¸›å°‘å…ç–«ç³»çµ±çš„éåº¦åæ‡‰ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†ä¾†è‡ªäººé¡å–®æ ¸ç´°èƒè¡ç”Ÿçš„æ¨¹çªç´°èƒï¼ˆmoDCsï¼‰ä½œç‚ºç ”ç©¶å°è±¡ã€‚é€™äº›ç´°èƒåœ¨ç‚ç—‡æ¢ä»¶ä¸‹è¢«è™•ç†ï¼Œä¸¦åˆ†åˆ¥æ¥å—äº†ä¸åŒçš„è™•ç†ï¼ŒåŒ…æ‹¬è˜¿è””ç¡«ç´ ã€è˜¿è””ç¡«ç´ èˆ‡ç”˜éœ²ç³–çµåˆçš„å½¢å¼ï¼ˆSFNManï¼‰å’Œè˜¿è””ç¡«ç´ èˆ‡å‘‹å–ƒç³–çµåˆçš„å½¢å¼ï¼ˆSFNFucï¼‰ã€‚ç ”ç©¶è€…è©•ä¼°äº†é€™äº›è™•ç†å°æ¨¹çªç´°èƒè¡¨å‹ã€ç´°èƒå› å­ç”¢ç”Ÿã€èª¿ç¯€Tç´°èƒçš„èƒ½åŠ›ä»¥åŠNFATc1ä¿¡è™Ÿå‚³å°çš„å½±éŸ¿ï¼Œä»¥äº†è§£é€™äº›åŒ–åˆç‰©çš„ä½œç”¨æ©Ÿåˆ¶ã€‚\n\nä¸»è¦çš„ç™¼ç¾æ˜¯ï¼ŒSFNManèƒ½å¤ é¸æ“‡æ€§åœ°èª˜å°æ¨¹çªç´°èƒç”¢ç”Ÿè€å—æ€§è¡¨å‹ï¼Œé€™è¡¨ç¾ç‚ºPD-L1/CD86æ¯”ç‡çš„å¢åŠ å’ŒIL-10çš„ç”¢ç”Ÿä¸Šå‡ã€‚æ­¤å¤–ï¼ŒSFNMané‚„ä¿ƒé€²äº†SOCS1å’ŒIDOè½‰éŒ„æœ¬çš„ä¸Šèª¿ï¼Œä¸¦æ“´å¤§äº†èª¿ç¯€æ€§Tç´°èƒçš„æ•¸é‡ï¼ŒåŒæ™‚æ¸›å°‘äº†ç´°èƒæ¯’æ€§Tç´°èƒçš„å¢æ®–ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼ŒSFNManä¿ƒé€²äº†NFATc1çš„æ ¸è½‰ä½ï¼Œè€Œé€™ä¸€éç¨‹åœ¨ä½¿ç”¨ç’°å­¢ç´ AæŠ‘åˆ¶NFATc1å¾Œè¢«é˜»æ­¢ï¼Œé¡¯ç¤ºNFATc1åœ¨SFNManèª˜å°å…ç–«è€å—ä¸­çš„é—œéµä½œç”¨ã€‚é€™äº›çµæœç‚ºé‡å°ç‚ç—‡å’Œè‡ªé«”å…ç–«ç–¾ç—…çš„ç²¾æº–æ²»ç™‚æä¾›äº†æ©Ÿåˆ¶åŸºç¤ã€‚",
    "fb_post": "æ ¹æ“šã€ŠBritish journal of pharmacologyã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ±ä½ çŸ¥é“å—ï¼Ÿæˆ‘å€‘çš„å…ç–«ç³»çµ±å…¶å¯¦å¯ä»¥é€éä¸€äº›å¤©ç„¶åŒ–åˆç‰©ä¾†èª¿æ•´ï¼Œè®“èº«é«”æ›´å¥åº·ï¼æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶æ¢è¨äº†ä¸€ç¨®å«è˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰çš„ç‰©è³ªï¼Œç™¼ç¾å®ƒåœ¨ä¿ƒé€²å…ç–«è€å—æ€§æ–¹é¢æœ‰å¾ˆå¤§çš„æ½›åŠ›ã€‚\n\né€™é …ç ”ç©¶ä¸»è¦é—œå¿ƒçš„æ˜¯ï¼Œå¦‚ä½•åˆ©ç”¨è˜¿è””ç¡«ç´ ä¾†å¹«åŠ©èº«é«”çš„æ¨¹çªç´°èƒï¼ˆé€™æ˜¯ä¸€ç¨®å¯ä»¥å•Ÿå‹•å…ç–«åæ‡‰çš„ç´°èƒï¼‰è®Šå¾—æ›´æœ‰è€å—æ€§ï¼Œå¾è€Œæ¸›å°‘éåº¦çš„å…ç–«åæ‡‰ã€‚ç ”ç©¶è€…å€‘æ¡ç”¨äº†ä¾†è‡ªäººé¡çš„æ¨¹çªç´°èƒï¼Œä¸¦è§€å¯Ÿäº†ä¸åŒçš„è™•ç†æ–¹å¼ï¼ŒåŒ…æ‹¬è˜¿è””ç¡«ç´ æœ¬èº«ä»¥åŠèˆ‡å…¶ä»–ç³–é¡çµåˆçš„å½¢å¼ã€‚\n\nçµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ çš„æŸç¨®è¡ç”Ÿç‰©ï¼ˆSFNManï¼‰èƒ½å¤ æœ‰æ•ˆåœ°å¹«åŠ©æ¨¹çªç´°èƒç”¢ç”Ÿè€å—æ€§ï¼Œé€™æ„å‘³è‘—å®ƒèƒ½æé«˜èº«é«”å°ç‚ç—‡çš„æŠµæŠ—åŠ›ï¼Œä¸¦ä¸”ä¿ƒé€²ä¸€äº›æœ‰ç›Šçš„ç´°èƒå› å­çš„ç”¢ç”Ÿã€‚é€™äº›ç™¼ç¾ç‚ºæœªä¾†é‡å°ç‚ç—‡å’Œè‡ªé«”å…ç–«ç–¾ç—…çš„æ²»ç™‚æä¾›äº†æ–°çš„æ€è·¯ã€‚\n\nğŸ”é‡é»æ•´ç†ï¼š  \n1. è˜¿è””ç¡«ç´ æœ‰åŠ©æ–¼ä¿ƒé€²å…ç–«è€å—æ€§ï¼Œæ¸›å°‘éåº¦åæ‡‰ã€‚  \n2. SFNManèƒ½æé«˜æ¨¹çªç´°èƒçš„è€å—æ€§ï¼Œä¸¦ä¿ƒé€²æœ‰ç›Šå› å­çš„ç”¢ç”Ÿã€‚  \n3. é€™äº›çµæœå¯èƒ½æˆç‚ºæœªä¾†æ²»ç™‚ç›¸é—œç–¾ç—…çš„æ–°ç­–ç•¥ï¼",
    "image_prompt": "Create a flat design infographic on a light background explaining the experiment and main findings of a study on sulforaphane (SFN). Include simplified illustrations of broccoli or symbols representing sulforaphane, human-derived dendritic cells, and arrows or flow lines showing the experimental steps. Include a section that highlights the main results, such as the protective effects and changes observed in dendritic cells.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "è‡ªé«”å…ç–«ç–¾ç—… Autoimmune Diseases",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41387309/"
  },
  {
    "id": "41108925",
    "title_en": "Enhancing myocardial injury recovery: Nrf2 activation by sulforaphane regulates ferroptosis and oxidative stress in takotsubo-like models.",
    "pub_date": "2025 Dec",
    "journal": "International immunopharmacology",
    "abstract_en": "Takotsubo syndrome (TTS), once considered benign, can cause life-threatening myocardial injury. Although oxidative stress and ferroptosis are implicated in its pathogenesis, targeted therapies are not available for TTS. We demonstrate that sulforaphane (SFN), a natural Nrf2 activator, mitigates TTS-related injury in isoproterenol-induced rat models and AC16 cardiomyocytes. Isoproterenol induced ferroptosis and oxidative stress by impairing Nrf2 signaling. SFN treatment restored myocardial structure and function while enhancing antioxidant capacity, reducing mitochondrial damage, and suppressing ferroptosis markers. Additionally, similar to Fer-1 (a ferroptosis inhibitor), SFN reduced intracellular ferrous levels but uniquely activated Nrf2-driven endogenous defenses. Notably, Nrf2 inhibition abrogated the benefits of SFN in both in vitro and in vivo experiments. These findings highlight SFN as a dual-action therapeutic for TTS, simultaneously targeting oxidative stress and ferroptosis via Nrf2 activation. The therapeutic efficacy of SFN, combined with endogenous pathway modulation, underscores its translational potential for improving TTS outcomes.",
    "para1": "é«˜å£“æ€§å¿ƒè‡Ÿç—…ï¼ˆTakotsubo syndrome, TTSï¼‰æ›¾è¢«èªç‚ºæ˜¯è‰¯æ€§çš„ï¼Œä½†å¯¦éš›ä¸Šå¯èƒ½å°è‡´å±åŠç”Ÿå‘½çš„å¿ƒè‚Œæå‚·ã€‚é€™é …ç ”ç©¶çš„çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½åœ¨é é˜²å’Œæ”¹å–„é€™ç¨®ç–¾ç—…çš„éç¨‹ä¸­æ‰®æ¼”é‡è¦è§’è‰²ã€‚é€éæ¸›å°‘æ°§åŒ–å£“åŠ›å’Œç´°èƒæ­»äº¡ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼ä¿è­·å¿ƒè‡Ÿï¼Œé€™å°æ–¼å¸Œæœ›é™ä½å¿ƒè‡Ÿç—…é¢¨éšªçš„äººä¾†èªªï¼Œæä¾›äº†ä¸€å€‹æ–°çš„æ€è·¯ã€‚é€™äº›ç™¼ç¾å¯èƒ½æœƒä¿ƒé€²æœªä¾†é‡å°TTSçš„æ²»ç™‚æ–¹æ³•ï¼Œè®“æ‚£è€…ç²å¾—æ›´å¥½çš„å¥åº·çµæœã€‚",
    "para2": "é€™é …ç ”ç©¶ä¸»è¦é—œæ³¨é«˜å£“æ€§å¿ƒè‡Ÿç—…ï¼ˆTTSï¼‰çš„ç—…ç†æ©Ÿåˆ¶åŠå…¶æ½›åœ¨æ²»ç™‚æ–¹æ³•ã€‚ç ”ç©¶è€…å€‘ç‰¹åˆ¥é—œæ³¨æ°§åŒ–å£“åŠ›å’Œéµæ­»äº¡ï¼ˆferroptosisï¼‰åœ¨TTSä¸­çš„è§’è‰²ï¼Œä¸¦æ¢ç´¢å¦‚ä½•åˆ©ç”¨å¤©ç„¶åŒ–åˆç‰©ä¾†æ”¹å–„å¿ƒè‡ŸåŠŸèƒ½ã€‚ç”±æ–¼ç›®å‰å°æ–¼TTSçš„é‡å°æ€§æ²»ç™‚ä»ç„¶ç¼ºä¹ï¼Œé€™é …ç ”ç©¶çš„ç›®çš„æ˜¯å°‹æ‰¾æ–°çš„æ²»ç™‚é¸æ“‡ï¼Œä»¥æ¸›å°‘å¿ƒè‡Ÿæå‚·ä¸¦æ”¹å–„æ‚£è€…çš„é å¾Œã€‚",
    "para3": "ç ”ç©¶ä¸­ä½¿ç”¨äº†å¤§é¼ æ¨¡å‹å’Œå¿ƒè‡Ÿç´°èƒç³»ï¼ˆAC16ï¼‰ä¾†æ¨¡æ“¬TTSçš„ç—…ç†ç‹€æ³ã€‚ç ”ç©¶è€…å€‘ä½¿ç”¨ç•°ä¸™è…ä¸Šè…ºç´ ä¾†èª˜å°å¿ƒè‡Ÿçš„æ°§åŒ–å£“åŠ›å’Œéµæ­»äº¡ï¼Œç„¶å¾Œè§€å¯Ÿè˜¿è””ç¡«ç´ çš„æ²»ç™‚æ•ˆæœã€‚é€éé€™äº›å¯¦é©—ï¼Œç ”ç©¶è€…å€‘è©•ä¼°äº†è˜¿è””ç¡«ç´ å°å¿ƒè‚Œçµæ§‹å’ŒåŠŸèƒ½çš„å½±éŸ¿ï¼Œä¸¦æª¢æ¸¬äº†æŠ—æ°§åŒ–èƒ½åŠ›å’Œç´°èƒæå‚·æ¨™è¨˜çš„è®ŠåŒ–ï¼Œå¾è€Œäº†è§£å…¶æ½›åœ¨çš„æ²»ç™‚æ©Ÿåˆ¶ã€‚",
    "para4": "ç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ æ”¹å–„å¿ƒè‚Œçš„çµæ§‹å’ŒåŠŸèƒ½ï¼Œä¸¦å¢å¼·æŠ—æ°§åŒ–èƒ½åŠ›ï¼Œæ¸›å°‘ç·šç²’é«”æå‚·å’Œéµæ­»äº¡çš„æ¨™è¨˜ã€‚èˆ‡éµæ­»äº¡æŠ‘åˆ¶åŠ‘Fer-1ç›¸æ¯”ï¼Œè˜¿è””ç¡«ç´ çš„ç¨ç‰¹ä¹‹è™•åœ¨æ–¼å®ƒèƒ½æ¿€æ´»Nrf2é©…å‹•çš„å…§æºæ€§é˜²ç¦¦æ©Ÿåˆ¶ã€‚å€¼å¾—æ³¨æ„çš„æ˜¯ï¼Œç•¶æŠ‘åˆ¶Nrf2æ™‚ï¼Œè˜¿è””ç¡«ç´ çš„ç™‚æ•ˆæœƒå—åˆ°å½±éŸ¿ï¼Œé€™è¡¨æ˜Nrf2åœ¨å…¶æ²»ç™‚ä½œç”¨ä¸­æ‰®æ¼”äº†é—œéµè§’è‰²ã€‚é€™äº›ç™¼ç¾å¼·èª¿äº†è˜¿è””ç¡«ç´ ä½œç‚ºä¸€ç¨®é›™é‡ä½œç”¨ç™‚æ³•çš„æ½›åŠ›ï¼Œèƒ½åŒæ™‚é‡å°æ°§åŒ–å£“åŠ›å’Œéµæ­»äº¡ï¼Œç‚ºæ”¹å–„TTSçš„çµæœæä¾›äº†æ–°çš„å¸Œæœ›ã€‚",
    "explanation_zh": "é«˜å£“æ€§å¿ƒè‡Ÿç—…ï¼ˆTakotsubo syndrome, TTSï¼‰æ›¾è¢«èªç‚ºæ˜¯è‰¯æ€§çš„ï¼Œä½†å¯¦éš›ä¸Šå¯èƒ½å°è‡´å±åŠç”Ÿå‘½çš„å¿ƒè‚Œæå‚·ã€‚é€™é …ç ”ç©¶çš„çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½åœ¨é é˜²å’Œæ”¹å–„é€™ç¨®ç–¾ç—…çš„éç¨‹ä¸­æ‰®æ¼”é‡è¦è§’è‰²ã€‚é€éæ¸›å°‘æ°§åŒ–å£“åŠ›å’Œç´°èƒæ­»äº¡ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼ä¿è­·å¿ƒè‡Ÿï¼Œé€™å°æ–¼å¸Œæœ›é™ä½å¿ƒè‡Ÿç—…é¢¨éšªçš„äººä¾†èªªï¼Œæä¾›äº†ä¸€å€‹æ–°çš„æ€è·¯ã€‚é€™äº›ç™¼ç¾å¯èƒ½æœƒä¿ƒé€²æœªä¾†é‡å°TTSçš„æ²»ç™‚æ–¹æ³•ï¼Œè®“æ‚£è€…ç²å¾—æ›´å¥½çš„å¥åº·çµæœã€‚\n\né€™é …ç ”ç©¶ä¸»è¦é—œæ³¨é«˜å£“æ€§å¿ƒè‡Ÿç—…ï¼ˆTTSï¼‰çš„ç—…ç†æ©Ÿåˆ¶åŠå…¶æ½›åœ¨æ²»ç™‚æ–¹æ³•ã€‚ç ”ç©¶è€…å€‘ç‰¹åˆ¥é—œæ³¨æ°§åŒ–å£“åŠ›å’Œéµæ­»äº¡ï¼ˆferroptosisï¼‰åœ¨TTSä¸­çš„è§’è‰²ï¼Œä¸¦æ¢ç´¢å¦‚ä½•åˆ©ç”¨å¤©ç„¶åŒ–åˆç‰©ä¾†æ”¹å–„å¿ƒè‡ŸåŠŸèƒ½ã€‚ç”±æ–¼ç›®å‰å°æ–¼TTSçš„é‡å°æ€§æ²»ç™‚ä»ç„¶ç¼ºä¹ï¼Œé€™é …ç ”ç©¶çš„ç›®çš„æ˜¯å°‹æ‰¾æ–°çš„æ²»ç™‚é¸æ“‡ï¼Œä»¥æ¸›å°‘å¿ƒè‡Ÿæå‚·ä¸¦æ”¹å–„æ‚£è€…çš„é å¾Œã€‚\n\nç ”ç©¶ä¸­ä½¿ç”¨äº†å¤§é¼ æ¨¡å‹å’Œå¿ƒè‡Ÿç´°èƒç³»ï¼ˆAC16ï¼‰ä¾†æ¨¡æ“¬TTSçš„ç—…ç†ç‹€æ³ã€‚ç ”ç©¶è€…å€‘ä½¿ç”¨ç•°ä¸™è…ä¸Šè…ºç´ ä¾†èª˜å°å¿ƒè‡Ÿçš„æ°§åŒ–å£“åŠ›å’Œéµæ­»äº¡ï¼Œç„¶å¾Œè§€å¯Ÿè˜¿è””ç¡«ç´ çš„æ²»ç™‚æ•ˆæœã€‚é€éé€™äº›å¯¦é©—ï¼Œç ”ç©¶è€…å€‘è©•ä¼°äº†è˜¿è””ç¡«ç´ å°å¿ƒè‚Œçµæ§‹å’ŒåŠŸèƒ½çš„å½±éŸ¿ï¼Œä¸¦æª¢æ¸¬äº†æŠ—æ°§åŒ–èƒ½åŠ›å’Œç´°èƒæå‚·æ¨™è¨˜çš„è®ŠåŒ–ï¼Œå¾è€Œäº†è§£å…¶æ½›åœ¨çš„æ²»ç™‚æ©Ÿåˆ¶ã€‚\n\nç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ æ”¹å–„å¿ƒè‚Œçš„çµæ§‹å’ŒåŠŸèƒ½ï¼Œä¸¦å¢å¼·æŠ—æ°§åŒ–èƒ½åŠ›ï¼Œæ¸›å°‘ç·šç²’é«”æå‚·å’Œéµæ­»äº¡çš„æ¨™è¨˜ã€‚èˆ‡éµæ­»äº¡æŠ‘åˆ¶åŠ‘Fer-1ç›¸æ¯”ï¼Œè˜¿è””ç¡«ç´ çš„ç¨ç‰¹ä¹‹è™•åœ¨æ–¼å®ƒèƒ½æ¿€æ´»Nrf2é©…å‹•çš„å…§æºæ€§é˜²ç¦¦æ©Ÿåˆ¶ã€‚å€¼å¾—æ³¨æ„çš„æ˜¯ï¼Œç•¶æŠ‘åˆ¶Nrf2æ™‚ï¼Œè˜¿è””ç¡«ç´ çš„ç™‚æ•ˆæœƒå—åˆ°å½±éŸ¿ï¼Œé€™è¡¨æ˜Nrf2åœ¨å…¶æ²»ç™‚ä½œç”¨ä¸­æ‰®æ¼”äº†é—œéµè§’è‰²ã€‚é€™äº›ç™¼ç¾å¼·èª¿äº†è˜¿è””ç¡«ç´ ä½œç‚ºä¸€ç¨®é›™é‡ä½œç”¨ç™‚æ³•çš„æ½›åŠ›ï¼Œèƒ½åŒæ™‚é‡å°æ°§åŒ–å£“åŠ›å’Œéµæ­»äº¡ï¼Œç‚ºæ”¹å–„TTSçš„çµæœæä¾›äº†æ–°çš„å¸Œæœ›ã€‚",
    "fb_post": "æ ¹æ“šã€ŠInternational immunopharmacologyã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ æœ‰è½éé«˜å£“æ€§å¿ƒè‡Ÿç—…ï¼ˆTTSï¼‰å—ï¼Ÿé€™æ˜¯ä¸€ç¨®çœ‹ä¼¼è‰¯æ€§ï¼Œä½†å»å¯èƒ½å°å¿ƒè‡Ÿé€ æˆåš´é‡æå‚·çš„ç–¾ç—…ã€‚æœ€è¿‘çš„ç ”ç©¶ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ é€™ç¨®å¤©ç„¶åŒ–åˆç‰©ï¼Œå¯èƒ½åœ¨é é˜²å’Œæ”¹å–„TTSæ–¹é¢ç™¼æ®é‡è¦ä½œç”¨ï¼\n\né€™é …ç ”ç©¶å°ˆæ³¨æ–¼TTSçš„ç—…ç†æ©Ÿåˆ¶ï¼Œç‰¹åˆ¥æ˜¯æ°§åŒ–å£“åŠ›å’Œç´°èƒæ­»äº¡çš„å½±éŸ¿ã€‚ç ”ç©¶è€…å€‘ä½¿ç”¨å¤§é¼ æ¨¡å‹ä¾†æ¨¡æ“¬é€™ç¨®ç–¾ç—…ï¼Œä¸¦è§€å¯Ÿè˜¿è””ç¡«ç´ å°å¿ƒè‡Ÿçš„ä¿è­·æ•ˆæœã€‚ä»–å€‘ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ ä¸åƒ…èƒ½æ”¹å–„å¿ƒè‚Œçµæ§‹ï¼Œé‚„èƒ½å¢å¼·æŠ—æ°§åŒ–èƒ½åŠ›ï¼Œæ¸›å°‘å¿ƒè‡Ÿç´°èƒçš„æå‚·ã€‚\n\næœ€æœ‰è¶£çš„æ˜¯ï¼Œè˜¿è””ç¡«ç´ èƒ½å•Ÿå‹•èº«é«”çš„è‡ªæˆ‘é˜²ç¦¦æ©Ÿåˆ¶ï¼Œé€™è®“å®ƒåœ¨å°æŠ—å¿ƒè‡Ÿç—…æ–¹é¢å±•ç¾å‡ºé›™é‡ä½œç”¨çš„æ½›åŠ›ï¼\n\nğŸ” ç ”ç©¶é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ æœ‰åŠ©æ–¼ä¿è­·å¿ƒè‡Ÿï¼Œæ”¹å–„å¿ƒè‚Œçµæ§‹å’ŒåŠŸèƒ½ã€‚\n2. å®ƒèƒ½æ¸›å°‘æ°§åŒ–å£“åŠ›å’Œç´°èƒæ­»äº¡ï¼Œç‰¹åˆ¥æ˜¯éµæ­»äº¡ã€‚\n3. è˜¿è””ç¡«ç´ çš„ç™‚æ•ˆå¯èƒ½èˆ‡å•Ÿå‹•å…§æºæ€§é˜²ç¦¦æ©Ÿåˆ¶æœ‰é—œï¼Œè®“æˆ‘å€‘å°æœªä¾†çš„æ²»ç™‚å……æ»¿å¸Œæœ›ï¼",
    "image_prompt": "Create an infographic style image explaining the experiment and main results of the study on Takotsubo syndrome and the effects of sulforaphane. Include simplified illustrations of broccoli or sulforaphane as symbols, along with simplified representations of experimental subjects like rats and heart cells. Use arrows or flow lines to indicate the experimental steps, and create a section highlighting the main results, such as protective effects and changes observed in the heart structure and function. Use a flat design style with a white or light-colored background and soft color palette.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "é«˜å£“æ€§å¿ƒè‡Ÿç—… Takotsubo Syndrome",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41108925/"
  },
  {
    "id": "41341174",
    "title_en": "Sulforaphane attenuates oxidative stress, senescence, and ferroptosis induced by cigarette smoke extract <i>in vitro</i> and <i>in vivo via</i> upregulating the expression of SIRT1.",
    "pub_date": "2025 Dec",
    "journal": "Research in pharmaceutical sciences",
    "abstract_en": "Cigarette smoking induces lung toxicity by triggering oxidative stress, leading to apoptosis, ferroptosis, and senescence. Sulforaphane (SFN), a potent antioxidant, activates the SIRT1 pathway, enhancing cellular stress resistance and survival. This study aimed to evaluate the protective effects of SFN against cigarette smoke extract (CSE)-induced damage in human airway epithelial cells (BEAS-2B) and in mouse lungs, focusing on its role in upregulating SIRT1 expression. BEAS-2B cells were treated with CSE and SFN, and cell viability was assessed using the MTT assay. Cellular senescence was assessed using the SA-Î²-gal assay and the expression of genes associated with senescence (p16 and p21). The expression levels of SIRT1, senescence-associated secretory phenotype (SASP) cytokines (IL-1Î², IL-6, IL-8, TNF-Î±), GPX4, and SLC7A11 were quantified using qRT-PCR. Additionally, ROS production, GSH and MDA levels, and iron content were measured. An emphysema mouse model was induced by intraperitoneal administration of CSE (7.2 mg/kg) alone or in combination with SFN (10.2 mg/kg) over 28 days, and subsequent histopathological changes were evaluated. Our findings revealed that SFN co-treatment effectively mitigated CSE-induced cytotoxicity, senescence, and SASP cytokine secretion, as well as the pronounced emphysematous changes in lung tissues. Furthermore, SFN reversed CSE-induced downregulation of SIRT1 and upregulation of NF-ÎºB. Notably, SFN also inhibited CSE-induced ferroptosis by increasing GPX4 and SLC7A11 expression while reducing iron and MDA levels. The findings of the present study demonstrated that sulforaphane offers protective effects against CSE-induced toxicity by mitigating oxidative stress, ferroptosis, and cellular senescence.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°å¸ç…™æ‰€é€ æˆçš„è‚ºéƒ¨æå‚·ã€‚å¸ç…™æœƒå¼•ç™¼æ°§åŒ–å£“åŠ›ï¼Œå°è‡´ç´°èƒæ­»äº¡å’Œè€åŒ–ï¼Œè€Œç ”ç©¶é¡¯ç¤ºè˜¿è””ç¡«ç´ ä½œç‚ºä¸€ç¨®å¼·æ•ˆæŠ—æ°§åŒ–åŠ‘ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ¸›è¼•é€™äº›æå®³ã€‚é€éå¢å¼·ç´°èƒçš„æŠ—å£“èƒ½åŠ›ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½æˆç‚ºä¸€ç¨®æ½›åœ¨çš„ä¿è­·åŠ‘ï¼Œå¹«åŠ©æˆ‘å€‘æŠµæŠ—å¸ç…™å¸¶ä¾†çš„å¥åº·é¢¨éšªï¼Œé€™å°æ–¼å¸ç…™è€…å’ŒäºŒæ‰‹ç…™æš´éœ²è€…ä¾†èªªï¼Œéƒ½æ˜¯ä¸€å€‹å€¼å¾—é—œæ³¨çš„è­°é¡Œã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°å¸ç…™å¼•èµ·çš„è‚ºéƒ¨æå‚·çš„ä¿è­·ä½œç”¨ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯å¸ç…™å¦‚ä½•é€éæ°§åŒ–å£“åŠ›å½±éŸ¿è‚ºéƒ¨ç´°èƒçš„å¥åº·ï¼Œä»¥åŠè˜¿è””ç¡«ç´ åœ¨é€™å€‹éç¨‹ä¸­æ‰€æ‰®æ¼”çš„è§’è‰²ã€‚ç‰¹åˆ¥æ˜¯ï¼Œç ”ç©¶è‘—é‡æ–¼è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ä¸€ç¨®åç‚ºSIRT1çš„è›‹ç™½è³ªçš„è¡¨é”ï¼Œé€™èˆ‡ç´°èƒçš„å£“åŠ›æŠµæŠ—å’Œç”Ÿå­˜èƒ½åŠ›æœ‰é—œã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†äººé¡æ°£é“ä¸Šçš®ç´°èƒï¼ˆBEAS-2Bï¼‰å’Œå°é¼ ä½œç‚ºç ”ç©¶å°è±¡ã€‚BEAS-2Bç´°èƒè¢«è™•ç†ä»¥æ¨¡æ“¬å¸ç…™çš„å½±éŸ¿ï¼Œä¸¦èˆ‡è˜¿è””ç¡«ç´ å…±åŒè™•ç†ã€‚ç ”ç©¶è€…ä½¿ç”¨MTTæ¸¬è©¦ä¾†è©•ä¼°ç´°èƒçš„å­˜æ´»ç‡ï¼Œä¸¦é€éSA-Î²-galæ¸¬è©¦ä¾†è©•ä¼°ç´°èƒçš„è€åŒ–æƒ…æ³ã€‚æ­¤å¤–ï¼Œé‚„æ¸¬é‡äº†èˆ‡è€åŒ–ç›¸é—œçš„åŸºå› è¡¨é”ï¼Œä»¥åŠæ°§åŒ–å£“åŠ›æŒ‡æ¨™å’Œç´°èƒå…§çš„éµå«é‡ã€‚åœ¨å°é¼ æ¨¡å‹ä¸­ï¼Œç ”ç©¶è€…é€šéæ³¨å°„å¸ç…™æå–ç‰©ä¾†èª˜å°è‚ºæ°£è…«ï¼Œä¸¦è§€å¯Ÿè˜¿è””ç¡«ç´ çš„æ•ˆæœã€‚",
    "para4": "ç ”ç©¶çš„ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ çš„å…±åŒè™•ç†èƒ½æœ‰æ•ˆæ¸›è¼•å¸ç…™æå–ç‰©å¼•èµ·çš„ç´°èƒæ¯’æ€§ã€è€åŒ–åŠèˆ‡è€åŒ–ç›¸é—œçš„ç´°èƒå› å­åˆ†æ³Œã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ é‚„èƒ½æ”¹å–„å°é¼ è‚ºéƒ¨çš„ç—…ç†è®ŠåŒ–ï¼Œä¸¦é€†è½‰å¸ç…™æå–ç‰©å°SIRT1çš„æŠ‘åˆ¶ä½œç”¨ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ èƒ½æŠ‘åˆ¶å¸ç…™å¼•èµ·çš„éµæ­»äº¡ï¼Œé€™æ˜¯é€šéæé«˜GPX4å’ŒSLC7A11çš„è¡¨é”ä¾†å¯¦ç¾çš„ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½å°æŠ—å¸ç…™å¼•èµ·çš„æ°§åŒ–å£“åŠ›å’Œç´°èƒè€åŒ–å…·æœ‰ä¿è­·ä½œç”¨ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°å¸ç…™æ‰€é€ æˆçš„è‚ºéƒ¨æå‚·ã€‚å¸ç…™æœƒå¼•ç™¼æ°§åŒ–å£“åŠ›ï¼Œå°è‡´ç´°èƒæ­»äº¡å’Œè€åŒ–ï¼Œè€Œç ”ç©¶é¡¯ç¤ºè˜¿è””ç¡«ç´ ä½œç‚ºä¸€ç¨®å¼·æ•ˆæŠ—æ°§åŒ–åŠ‘ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ¸›è¼•é€™äº›æå®³ã€‚é€éå¢å¼·ç´°èƒçš„æŠ—å£“èƒ½åŠ›ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½æˆç‚ºä¸€ç¨®æ½›åœ¨çš„ä¿è­·åŠ‘ï¼Œå¹«åŠ©æˆ‘å€‘æŠµæŠ—å¸ç…™å¸¶ä¾†çš„å¥åº·é¢¨éšªï¼Œé€™å°æ–¼å¸ç…™è€…å’ŒäºŒæ‰‹ç…™æš´éœ²è€…ä¾†èªªï¼Œéƒ½æ˜¯ä¸€å€‹å€¼å¾—é—œæ³¨çš„è­°é¡Œã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°å¸ç…™å¼•èµ·çš„è‚ºéƒ¨æå‚·çš„ä¿è­·ä½œç”¨ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯å¸ç…™å¦‚ä½•é€éæ°§åŒ–å£“åŠ›å½±éŸ¿è‚ºéƒ¨ç´°èƒçš„å¥åº·ï¼Œä»¥åŠè˜¿è””ç¡«ç´ åœ¨é€™å€‹éç¨‹ä¸­æ‰€æ‰®æ¼”çš„è§’è‰²ã€‚ç‰¹åˆ¥æ˜¯ï¼Œç ”ç©¶è‘—é‡æ–¼è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ä¸€ç¨®åç‚ºSIRT1çš„è›‹ç™½è³ªçš„è¡¨é”ï¼Œé€™èˆ‡ç´°èƒçš„å£“åŠ›æŠµæŠ—å’Œç”Ÿå­˜èƒ½åŠ›æœ‰é—œã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†äººé¡æ°£é“ä¸Šçš®ç´°èƒï¼ˆBEAS-2Bï¼‰å’Œå°é¼ ä½œç‚ºç ”ç©¶å°è±¡ã€‚BEAS-2Bç´°èƒè¢«è™•ç†ä»¥æ¨¡æ“¬å¸ç…™çš„å½±éŸ¿ï¼Œä¸¦èˆ‡è˜¿è””ç¡«ç´ å…±åŒè™•ç†ã€‚ç ”ç©¶è€…ä½¿ç”¨MTTæ¸¬è©¦ä¾†è©•ä¼°ç´°èƒçš„å­˜æ´»ç‡ï¼Œä¸¦é€éSA-Î²-galæ¸¬è©¦ä¾†è©•ä¼°ç´°èƒçš„è€åŒ–æƒ…æ³ã€‚æ­¤å¤–ï¼Œé‚„æ¸¬é‡äº†èˆ‡è€åŒ–ç›¸é—œçš„åŸºå› è¡¨é”ï¼Œä»¥åŠæ°§åŒ–å£“åŠ›æŒ‡æ¨™å’Œç´°èƒå…§çš„éµå«é‡ã€‚åœ¨å°é¼ æ¨¡å‹ä¸­ï¼Œç ”ç©¶è€…é€šéæ³¨å°„å¸ç…™æå–ç‰©ä¾†èª˜å°è‚ºæ°£è…«ï¼Œä¸¦è§€å¯Ÿè˜¿è””ç¡«ç´ çš„æ•ˆæœã€‚\n\nç ”ç©¶çš„ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ çš„å…±åŒè™•ç†èƒ½æœ‰æ•ˆæ¸›è¼•å¸ç…™æå–ç‰©å¼•èµ·çš„ç´°èƒæ¯’æ€§ã€è€åŒ–åŠèˆ‡è€åŒ–ç›¸é—œçš„ç´°èƒå› å­åˆ†æ³Œã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ é‚„èƒ½æ”¹å–„å°é¼ è‚ºéƒ¨çš„ç—…ç†è®ŠåŒ–ï¼Œä¸¦é€†è½‰å¸ç…™æå–ç‰©å°SIRT1çš„æŠ‘åˆ¶ä½œç”¨ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ èƒ½æŠ‘åˆ¶å¸ç…™å¼•èµ·çš„éµæ­»äº¡ï¼Œé€™æ˜¯é€šéæé«˜GPX4å’ŒSLC7A11çš„è¡¨é”ä¾†å¯¦ç¾çš„ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½å°æŠ—å¸ç…™å¼•èµ·çš„æ°§åŒ–å£“åŠ›å’Œç´°èƒè€åŒ–å…·æœ‰ä¿è­·ä½œç”¨ã€‚",
    "fb_post": "æ ¹æ“šã€ŠResearch in pharmaceutical sciencesã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ± è½èªªéè˜¿è””ç¡«ç´ å—ï¼Ÿé€™å¯ä¸æ˜¯ä»€éº¼ç¥ç§˜çš„æ±è¥¿ï¼Œå…¶å¯¦å®ƒæ˜¯ä¸€ç¨®ä¾†è‡ªé’èŠ±æ¤°èœçš„å¤©ç„¶æˆåˆ†ï¼æœ€è¿‘æœ‰ç ”ç©¶ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ å°æ–¼å¸ç…™é€ æˆçš„è‚ºéƒ¨æå‚·æœ‰ä¸€äº›é©šäººçš„ä¿è­·æ•ˆæœã€‚\n\né€™é …ç ”ç©¶ä¸»è¦åœ¨æ¢è¨å¸ç…™å¦‚ä½•å½±éŸ¿æˆ‘å€‘çš„è‚ºéƒ¨ç´°èƒï¼Œå°¤å…¶æ˜¯å¸ç…™æœƒå¼•ç™¼æ°§åŒ–å£“åŠ›ï¼Œå°è‡´ç´°èƒè€åŒ–å’Œæ­»äº¡ã€‚è€Œè˜¿è””ç¡«ç´ ä½œç‚ºä¸€ç¨®å¼·æ•ˆçš„æŠ—æ°§åŒ–åŠ‘ï¼Œå¯èƒ½å¯ä»¥å¹«åŠ©æˆ‘å€‘æŠµæŠ—é€™äº›æå®³ã€‚\n\nç ”ç©¶è€…å€‘ä½¿ç”¨äº†äººé¡æ°£é“ç´°èƒå’Œå°é¼ ä¾†é€²è¡Œå¯¦é©—ã€‚ä»–å€‘æ¨¡æ“¬äº†å¸ç…™çš„å½±éŸ¿ï¼Œç„¶å¾Œè§€å¯Ÿè˜¿è””ç¡«ç´ çš„æ•ˆæœã€‚çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ä¸åƒ…èƒ½æ¸›è¼•ç´°èƒçš„æå‚·ï¼Œé‚„èƒ½æ”¹å–„å°é¼ çš„è‚ºéƒ¨å¥åº·ï¼Œç”šè‡³é€†è½‰å¸ç…™å°ä¸€ç¨®é‡è¦è›‹ç™½è³ªçš„æŠ‘åˆ¶ä½œç”¨ã€‚\n\nğŸ” ç¸½çµä¸€ä¸‹ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ¸›è¼•å¸ç…™é€ æˆçš„è‚ºéƒ¨æå‚·ã€‚\n2. å®ƒèƒ½æ”¹å–„ç´°èƒçš„å­˜æ´»ç‡ï¼Œä¸¦æ¸›å°‘è€åŒ–çš„æƒ…æ³ã€‚\n3. è˜¿è””ç¡«ç´ å°æ–¼æŠµæŠ—æ°§åŒ–å£“åŠ›æœ‰æ½›åœ¨çš„ä¿è­·ä½œç”¨ã€‚\n\né€™äº›ç™¼ç¾è®“æˆ‘å€‘å°æŠ—å¸ç…™çš„å¥åº·é¢¨éšªæœ‰äº†æ–°çš„å¸Œæœ›ï¼",
    "image_prompt": "Create an infographic that explains the experimental methods and main findings of a study on the protective effects of sulforaphane (found in broccoli) against smoking-induced lung damage. Use a flat design style with a white or light-colored background and soft color palette. Include simplified illustrations of broccoli and sulforaphane, human airway epithelial cells, and mice as experimental subjects. Use arrows or flow lines to represent the experimental steps. Include a section labeled 'Main Findings' highlighting protective effects and changes observed.",
    "is_human_study": true,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "è‚ºæ°£è…« Emphysema",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41341174/"
  },
  {
    "id": "41039785",
    "title_en": "Integrative Network Pharmacology and Proteomics Decipher the Immunomodulatory Mechanism of Sulforaphane Against Intrinsic Skin Aging.",
    "pub_date": "2025 Dec",
    "journal": "Molecular nutrition & food research",
    "abstract_en": "Skin aging is characterized by declines in structural functions, contributing to age-associated frailty. Sulforaphane (SFN), a natural anti-inflammatory substance, has been widely applied in multiple types of cancer therapies. However, its role in alleviating intrinsic skin aging remains to be elucidated. Integrative network pharmacology and proteomics were utilized to investigate the underlying mechanisms of SFN in intrinsic skin aging. Fifty-one anti-aging targets of SFN were identified, highlighting its promising regulatory impact on the aging process. Based on an 18-month-old natural aging mouse model, significant alleviation in skin structure, redox homeostasis, and immune cell composition was noted after 2 months of SFN supplementation. Additionally, proteomic analysis demonstrated that SFN reversed the proteomic profile of intrinsic skin aging, with 233 differentially expressed proteins (DEPs) identified in SFN-fed aging mice. Of note, the up-regulated DEPs were highly enriched in the apelin signaling pathway (pÂ =Â 0.010). Furthermore, immune cell infiltration and whole blood cell analysis revealed that SFN rescued T cells depletion in dermal tissue, which was strongly correlated with DEPs enriched in the SFN-activated apelin signaling pathway. SFN improves skin morphology and immune functions via activating the apelin signaling pathway, suggesting new prime targets in counteracting intrinsic skin aging.",
    "para1": "éš¨è‘—å¹´é½¡å¢é•·ï¼Œçš®è†šæœƒå‡ºç¾è€åŒ–ç¾è±¡ï¼Œé€™ä¸åƒ…å½±éŸ¿å¤–è§€ï¼Œé‚„å¯èƒ½å°è‡´èº«é«”çš„è„†å¼±æ„Ÿã€‚é€™é …ç ”ç©¶æ¢è¨äº†ä¸€ç¨®åç‚ºè˜¿è””ç¡«ç´ çš„å¤©ç„¶æŠ—ç™¼ç‚ç‰©è³ªï¼Œé€™ç¨®ç‰©è³ªåœ¨å¤šç¨®ç™Œç—‡æ²»ç™‚ä¸­å·²è¢«å»£æ³›æ‡‰ç”¨ã€‚ç ”ç©¶çš„é‡é»åœ¨æ–¼è˜¿è””ç¡«ç´ æ˜¯å¦èƒ½å¤ å¹«åŠ©æ¸›ç·©çš®è†šçš„å…§åœ¨è€åŒ–ï¼Œé€™å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æœ‰è‘—æ½›åœ¨çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨æ”¹å–„çš®è†šçµæ§‹å’Œå…ç–«åŠŸèƒ½æ–¹é¢ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨å…§åœ¨çš®è†šè€åŒ–ä¸­çš„ä½œç”¨ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£é€™ç¨®ç‰©è³ªå¦‚ä½•å½±éŸ¿çš®è†šçš„çµæ§‹åŠŸèƒ½ï¼Œä¸¦æ‰¾å‡ºå…¶å¯èƒ½çš„æ©Ÿåˆ¶ã€‚ç”±æ–¼çš®è†šè€åŒ–èˆ‡å¤šç¨®å¥åº·å•é¡Œæœ‰é—œï¼Œå› æ­¤äº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨å¯èƒ½å°æ–¼æœªä¾†çš„æŠ—è€åŒ–ç™‚æ³•æä¾›æ–°çš„æ€è·¯ã€‚",
    "para3": "ç ”ç©¶ä¸­ä½¿ç”¨äº†ä¸€ç¨®18å€‹æœˆå¤§çš„è‡ªç„¶è€åŒ–å°é¼ æ¨¡å‹ï¼Œä¾†æ¨¡æ“¬çš®è†šè€åŒ–çš„éç¨‹ã€‚ç ”ç©¶è€…å°é€™äº›å°é¼ é€²è¡Œäº†è˜¿è””ç¡«ç´ çš„è£œå……ï¼Œä¸¦è§€å¯Ÿå…¶å°çš®è†šçµæ§‹ã€æ°§åŒ–é‚„åŸå¹³è¡¡å’Œå…ç–«ç´°èƒçµ„æˆçš„å½±éŸ¿ã€‚é€éæ•´åˆæ€§ç¶²çµ¡è—¥ç†å­¸å’Œè›‹ç™½è³ªçµ„å­¸çš„åˆ†æï¼Œç ”ç©¶è€…è­˜åˆ¥äº†51å€‹èˆ‡æŠ—è€åŒ–ç›¸é—œçš„ç›®æ¨™ï¼Œé€™äº›ç›®æ¨™å¹«åŠ©æ­ç¤ºäº†è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ã€‚",
    "para4": "ä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œç¶“éå…©å€‹æœˆçš„è˜¿è””ç¡«ç´ è£œå……å¾Œï¼Œå°é¼ çš„çš®è†šçµæ§‹å’Œå…ç–«åŠŸèƒ½æœ‰é¡¯è‘—æ”¹å–„ã€‚è›‹ç™½è³ªçµ„å­¸åˆ†æç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ é€†è½‰å…§åœ¨çš®è†šè€åŒ–çš„è›‹ç™½è³ªè¡¨ç¾å‹ï¼Œä¸¦è­˜åˆ¥å‡º233å€‹å·®ç•°è¡¨é”çš„è›‹ç™½è³ªã€‚ç‰¹åˆ¥æ˜¯ï¼Œé€™äº›ä¸Šèª¿çš„è›‹ç™½è³ªåœ¨apelinä¿¡è™Ÿé€šè·¯ä¸­é«˜åº¦å¯Œé›†ï¼Œé¡¯ç¤ºè˜¿è””ç¡«ç´ å¯èƒ½é€éæ¿€æ´»é€™ä¸€ä¿¡è™Ÿé€šè·¯ä¾†æ”¹å–„çš®è†šçš„å½¢æ…‹å’Œå…ç–«åŠŸèƒ½ï¼Œç‚ºå°æŠ—å…§åœ¨çš®è†šè€åŒ–æä¾›äº†æ–°çš„ç ”ç©¶æ–¹å‘ã€‚",
    "explanation_zh": "éš¨è‘—å¹´é½¡å¢é•·ï¼Œçš®è†šæœƒå‡ºç¾è€åŒ–ç¾è±¡ï¼Œé€™ä¸åƒ…å½±éŸ¿å¤–è§€ï¼Œé‚„å¯èƒ½å°è‡´èº«é«”çš„è„†å¼±æ„Ÿã€‚é€™é …ç ”ç©¶æ¢è¨äº†ä¸€ç¨®åç‚ºè˜¿è””ç¡«ç´ çš„å¤©ç„¶æŠ—ç™¼ç‚ç‰©è³ªï¼Œé€™ç¨®ç‰©è³ªåœ¨å¤šç¨®ç™Œç—‡æ²»ç™‚ä¸­å·²è¢«å»£æ³›æ‡‰ç”¨ã€‚ç ”ç©¶çš„é‡é»åœ¨æ–¼è˜¿è””ç¡«ç´ æ˜¯å¦èƒ½å¤ å¹«åŠ©æ¸›ç·©çš®è†šçš„å…§åœ¨è€åŒ–ï¼Œé€™å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æœ‰è‘—æ½›åœ¨çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨æ”¹å–„çš®è†šçµæ§‹å’Œå…ç–«åŠŸèƒ½æ–¹é¢ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨å…§åœ¨çš®è†šè€åŒ–ä¸­çš„ä½œç”¨ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£é€™ç¨®ç‰©è³ªå¦‚ä½•å½±éŸ¿çš®è†šçš„çµæ§‹åŠŸèƒ½ï¼Œä¸¦æ‰¾å‡ºå…¶å¯èƒ½çš„æ©Ÿåˆ¶ã€‚ç”±æ–¼çš®è†šè€åŒ–èˆ‡å¤šç¨®å¥åº·å•é¡Œæœ‰é—œï¼Œå› æ­¤äº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨å¯èƒ½å°æ–¼æœªä¾†çš„æŠ—è€åŒ–ç™‚æ³•æä¾›æ–°çš„æ€è·¯ã€‚\n\nç ”ç©¶ä¸­ä½¿ç”¨äº†ä¸€ç¨®18å€‹æœˆå¤§çš„è‡ªç„¶è€åŒ–å°é¼ æ¨¡å‹ï¼Œä¾†æ¨¡æ“¬çš®è†šè€åŒ–çš„éç¨‹ã€‚ç ”ç©¶è€…å°é€™äº›å°é¼ é€²è¡Œäº†è˜¿è””ç¡«ç´ çš„è£œå……ï¼Œä¸¦è§€å¯Ÿå…¶å°çš®è†šçµæ§‹ã€æ°§åŒ–é‚„åŸå¹³è¡¡å’Œå…ç–«ç´°èƒçµ„æˆçš„å½±éŸ¿ã€‚é€éæ•´åˆæ€§ç¶²çµ¡è—¥ç†å­¸å’Œè›‹ç™½è³ªçµ„å­¸çš„åˆ†æï¼Œç ”ç©¶è€…è­˜åˆ¥äº†51å€‹èˆ‡æŠ—è€åŒ–ç›¸é—œçš„ç›®æ¨™ï¼Œé€™äº›ç›®æ¨™å¹«åŠ©æ­ç¤ºäº†è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ã€‚\n\nä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œç¶“éå…©å€‹æœˆçš„è˜¿è””ç¡«ç´ è£œå……å¾Œï¼Œå°é¼ çš„çš®è†šçµæ§‹å’Œå…ç–«åŠŸèƒ½æœ‰é¡¯è‘—æ”¹å–„ã€‚è›‹ç™½è³ªçµ„å­¸åˆ†æç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ é€†è½‰å…§åœ¨çš®è†šè€åŒ–çš„è›‹ç™½è³ªè¡¨ç¾å‹ï¼Œä¸¦è­˜åˆ¥å‡º233å€‹å·®ç•°è¡¨é”çš„è›‹ç™½è³ªã€‚ç‰¹åˆ¥æ˜¯ï¼Œé€™äº›ä¸Šèª¿çš„è›‹ç™½è³ªåœ¨apelinä¿¡è™Ÿé€šè·¯ä¸­é«˜åº¦å¯Œé›†ï¼Œé¡¯ç¤ºè˜¿è””ç¡«ç´ å¯èƒ½é€éæ¿€æ´»é€™ä¸€ä¿¡è™Ÿé€šè·¯ä¾†æ”¹å–„çš®è†šçš„å½¢æ…‹å’Œå…ç–«åŠŸèƒ½ï¼Œç‚ºå°æŠ—å…§åœ¨çš®è†šè€åŒ–æä¾›äº†æ–°çš„ç ”ç©¶æ–¹å‘ã€‚",
    "fb_post": "æ ¹æ“šã€ŠMolecular nutrition & food researchã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ± ä½ çŸ¥é“å—ï¼Ÿéš¨è‘—å¹´é½¡å¢é•·ï¼Œæˆ‘å€‘çš„çš®è†šæœƒè®Šå¾—è¶Šä¾†è¶Šè„†å¼±ï¼Œé€™å¯ä¸åƒ…åƒ…æ˜¯å¤–è¡¨çš„å•é¡Œå“¦ï¼æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ é€™ç¨®å¤©ç„¶ç‰©è³ªå¯èƒ½å°æŠ—çš®è†šè€åŒ–æœ‰å¹«åŠ©ï¼\n\né€™é …ç ”ç©¶ä¸»è¦é—œæ³¨è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿çš®è†šçš„å¥åº·ã€‚ç ”ç©¶äººå“¡ä½¿ç”¨18å€‹æœˆå¤§çš„è€é¼ ä¾†æ¨¡æ“¬çš®è†šè€åŒ–çš„éç¨‹ï¼Œä¸¦çµ¦å®ƒå€‘è£œå……è˜¿è””ç¡«ç´ ã€‚çµæœé¡¯ç¤ºï¼Œé€™ç¨®ç‰©è³ªèƒ½æ”¹å–„çš®è†šçµæ§‹å’Œå…ç–«åŠŸèƒ½ï¼Œç”šè‡³é€†è½‰ä¸€äº›è€åŒ–çš„è·¡è±¡ï¼\n\nç ”ç©¶ç™¼ç¾ï¼Œç¶“éå…©å€‹æœˆçš„è£œå……å¾Œï¼Œå°é¼ çš„çš®è†šç‹€æ³æœ‰äº†é¡¯è‘—çš„æ”¹å–„ï¼Œä¸¦ä¸”ä¸€äº›é‡è¦çš„è›‹ç™½è³ªè¡¨ç¾ä¹Ÿç™¼ç”Ÿäº†è®ŠåŒ–ï¼Œç‰¹åˆ¥æ˜¯èˆ‡å…ç–«ç³»çµ±æœ‰é—œçš„éƒ¨åˆ†ã€‚\n\nğŸ” ç¸½çµä¾†èªªï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ¸›ç·©çš®è†šè€åŒ–ã€‚\n2. ç ”ç©¶ä½¿ç”¨è€é¼ æ¨¡å‹ä¾†æ¨¡æ“¬è€åŒ–éç¨‹ã€‚\n3. è£œå……å¾Œçš„çš®è†šçµæ§‹å’Œå…ç–«åŠŸèƒ½éƒ½æœ‰æ˜é¡¯æ”¹å–„ã€‚\n\né€™äº›ç™¼ç¾ç‚ºæœªä¾†çš„æŠ—è€åŒ–ç™‚æ³•æä¾›äº†æ–°çš„æ€è·¯ï¼Œè®“æˆ‘å€‘å°çš®è†šå¥åº·çš„ç®¡ç†æ›´æœ‰ä¿¡å¿ƒï¼",
    "image_prompt": "Create a flat design infographic on the effects of sulforaphane on skin aging. Include symbols of broccoli or sulforaphane, simplified illustrations of experimental subjects like mice, and arrows or flow lines showing the experimental process. Highlight a section with the main results, such as improvements in skin structure and immune function. Use a light background with soft colors, making it easy to understand and visually appealing.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "çš®è†šè€åŒ– Skin Aging",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41039785/"
  },
  {
    "id": "41027171",
    "title_en": "Multi-omics analysis of gut-liver axis reveals the mechanism by which sulforaphane alleviates liver injury in Cyprinus carpio exposed to triphenyltin.",
    "pub_date": "2025 Dec",
    "journal": "Comparative biochemistry and physiology. Part D, Genomics & proteomics",
    "abstract_en": "This study investigates the protective effects of sulforaphane (SFN) against triphenyltin (TPT)-induced hepatotoxicity, immune dysfunction and gut microbiota dysbiosis in Cyprinus carpio. Cyprinus carpio were divided into three groups and exposed for 8Â weeks, including control, 10Â Î¼g/L TPT and 10Â Î¼g/L TPTÂ +Â 10Â mg/kg SFN group. This result showed that TPT exposure induced significantly (PÂ <Â 0.05) hepatotoxicity, evidenced by increasing hepatic total bile acid (TBA) and total cholesterol levels, while upregulating Hsp70/90 and downregulating lysozyme gene expression. SFN supplementation reduced TBA accumulation, normalized Hsp90 and lysozyme expression, mitigating TPT-induced lipid dysregulation and immunosuppression. Transcriptomic analysis revealed that TPT exposure activated lipid metabolism pathways (PPAR signaling and cholesterol metabolism), but suppressed immune-related pathways. SFN supplementation restored metabolic homeostasis by enriching glucose and amino acid metabolism pathways and activating AMPK signaling, while also modulating the expression of key genes (PLIN1, ME1, CPT1B). The microbiota composition were changed in SFNÂ +Â TPT, including the increased of beneficial Fusobacteriota and Cetobacterium, and the decreased of pathogenic Proteobacteria and Aeromonas. The gut transcriptome dysregulation were restored in SFNÂ +Â TPT by enhancing immune pathways in Toll-like/NOD-like receptors. The significant correlations linked were found in gut microbes (Kaistia, Vagococcus) to hepatic/intestinal gene expression in SFNÂ +Â TPT. Overall, these findings elucidate novel mechanisms underlying TPT-induced immunotoxicity in liver and intestine and demonstrate the protective role of SFN, providing a theoretical foundation for its application in toxicity mitigation strategies.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†é—œæ–¼å¦‚ä½•ä¿è­·è‚è‡Ÿå’Œå…ç–«ç³»çµ±çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°æŸäº›åŒ–å­¸ç‰©è³ªå¼•èµ·çš„æ¯’æ€§å½±éŸ¿ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘ç”±ä¸‰è‹¯éŒ«å¼•èµ·çš„è‚è‡Ÿæå‚·å’Œå…ç–«åŠŸèƒ½å¤±èª¿ï¼Œé€™å°æ–¼æœªä¾†çš„å¥åº·ä¿è­·å’Œç–¾ç—…é é˜²ç­–ç•¥å…·æœ‰æ½›åœ¨çš„æ„ç¾©ã€‚é€éäº†è§£é€™äº›æ©Ÿåˆ¶ï¼Œæˆ‘å€‘æˆ–è¨±èƒ½å¤ æ‰¾åˆ°æ›´æœ‰æ•ˆçš„æ–¹å¼ä¾†æ¸›å°‘ç’°å¢ƒæ¯’ç´ å°äººé«”çš„å½±éŸ¿ï¼Œé€²è€Œä¿ƒé€²æ•´é«”å¥åº·ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°ä¸‰è‹¯éŒ«å¼•èµ·çš„è‚è‡Ÿæ¯’æ€§ã€å…ç–«åŠŸèƒ½å¤±èª¿åŠè…¸é“å¾®ç”Ÿç‰©å¤±èª¿çš„ä¿è­·æ•ˆæœã€‚ä¸‰è‹¯éŒ«æ˜¯ä¸€ç¨®ç’°å¢ƒæ±¡æŸ“ç‰©ï¼Œå¯èƒ½å°ç”Ÿç‰©é«”é€ æˆå¤šé‡å¥åº·å¨è„…ã€‚ç ”ç©¶è€…å¸Œæœ›é€éé€™é …ç ”ç©¶ï¼Œäº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿é€™äº›ä¸è‰¯åæ‡‰ï¼Œä¸¦å°‹æ‰¾å¯èƒ½çš„è§£æ±ºæ–¹æ¡ˆï¼Œä»¥æ”¹å–„å› ç’°å¢ƒæ¯’ç´ å¼•èµ·çš„å¥åº·å•é¡Œã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…å°‡é¯‰é­šï¼ˆCyprinus carpioï¼‰åˆ†æˆä¸‰çµ„ï¼Œé€²è¡Œç‚ºæœŸå…«é€±çš„å¯¦é©—ã€‚é€™ä¸‰çµ„åˆ†åˆ¥æ˜¯å°ç…§çµ„ã€æ¥è§¸10å¾®å…‹/å‡çš„ä¸‰è‹¯éŒ«çµ„ï¼Œä»¥åŠæ¥è§¸10å¾®å…‹/å‡çš„ä¸‰è‹¯éŒ«åŠ ä¸Š10æ¯«å…‹/å…¬æ–¤çš„è˜¿è””ç¡«ç´ çµ„ã€‚ç ”ç©¶è€…é€šéè§€å¯Ÿé€™äº›é­šçš„è‚è‡Ÿå¥åº·ã€å…ç–«åŠŸèƒ½å’Œè…¸é“å¾®ç”Ÿç‰©çµ„æˆï¼Œä¾†è©•ä¼°è˜¿è””ç¡«ç´ çš„ä¿è­·ä½œç”¨ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œä¸‰è‹¯éŒ«çš„æ¥è§¸ç¢ºå¯¦æœƒå¼•èµ·è‚è‡Ÿæ¯’æ€§å’Œå…ç–«åŠŸèƒ½çš„ä¸‹é™ï¼Œè€Œè˜¿è””ç¡«ç´ çš„è£œå……å‰‡èƒ½æ¸›å°‘é€™äº›ä¸è‰¯å½±éŸ¿ã€‚ç ”ç©¶çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ æ”¹å–„è‚è‡Ÿçš„ä»£è¬å¹³è¡¡ï¼Œä¸¦ä¿ƒé€²æœ‰ç›Šè…¸é“å¾®ç”Ÿç‰©çš„å¢é•·ï¼ŒåŒæ™‚æŠ‘åˆ¶æœ‰å®³å¾®ç”Ÿç‰©çš„ç¹æ®–ã€‚é€™äº›ç™¼ç¾ç‚ºç†è§£ä¸‰è‹¯éŒ«å¼•èµ·çš„å…ç–«æ¯’æ€§æä¾›äº†æ–°çš„è¦‹è§£ï¼Œä¸¦é¡¯ç¤ºäº†è˜¿è””ç¡«ç´ åœ¨æ¸›è¼•æ¯’æ€§å½±éŸ¿æ–¹é¢çš„æ½›åœ¨ä½œç”¨ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†é—œæ–¼å¦‚ä½•ä¿è­·è‚è‡Ÿå’Œå…ç–«ç³»çµ±çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°æŸäº›åŒ–å­¸ç‰©è³ªå¼•èµ·çš„æ¯’æ€§å½±éŸ¿ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘ç”±ä¸‰è‹¯éŒ«å¼•èµ·çš„è‚è‡Ÿæå‚·å’Œå…ç–«åŠŸèƒ½å¤±èª¿ï¼Œé€™å°æ–¼æœªä¾†çš„å¥åº·ä¿è­·å’Œç–¾ç—…é é˜²ç­–ç•¥å…·æœ‰æ½›åœ¨çš„æ„ç¾©ã€‚é€éäº†è§£é€™äº›æ©Ÿåˆ¶ï¼Œæˆ‘å€‘æˆ–è¨±èƒ½å¤ æ‰¾åˆ°æ›´æœ‰æ•ˆçš„æ–¹å¼ä¾†æ¸›å°‘ç’°å¢ƒæ¯’ç´ å°äººé«”çš„å½±éŸ¿ï¼Œé€²è€Œä¿ƒé€²æ•´é«”å¥åº·ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°ä¸‰è‹¯éŒ«å¼•èµ·çš„è‚è‡Ÿæ¯’æ€§ã€å…ç–«åŠŸèƒ½å¤±èª¿åŠè…¸é“å¾®ç”Ÿç‰©å¤±èª¿çš„ä¿è­·æ•ˆæœã€‚ä¸‰è‹¯éŒ«æ˜¯ä¸€ç¨®ç’°å¢ƒæ±¡æŸ“ç‰©ï¼Œå¯èƒ½å°ç”Ÿç‰©é«”é€ æˆå¤šé‡å¥åº·å¨è„…ã€‚ç ”ç©¶è€…å¸Œæœ›é€éé€™é …ç ”ç©¶ï¼Œäº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿é€™äº›ä¸è‰¯åæ‡‰ï¼Œä¸¦å°‹æ‰¾å¯èƒ½çš„è§£æ±ºæ–¹æ¡ˆï¼Œä»¥æ”¹å–„å› ç’°å¢ƒæ¯’ç´ å¼•èµ·çš„å¥åº·å•é¡Œã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…å°‡é¯‰é­šï¼ˆCyprinus carpioï¼‰åˆ†æˆä¸‰çµ„ï¼Œé€²è¡Œç‚ºæœŸå…«é€±çš„å¯¦é©—ã€‚é€™ä¸‰çµ„åˆ†åˆ¥æ˜¯å°ç…§çµ„ã€æ¥è§¸10å¾®å…‹/å‡çš„ä¸‰è‹¯éŒ«çµ„ï¼Œä»¥åŠæ¥è§¸10å¾®å…‹/å‡çš„ä¸‰è‹¯éŒ«åŠ ä¸Š10æ¯«å…‹/å…¬æ–¤çš„è˜¿è””ç¡«ç´ çµ„ã€‚ç ”ç©¶è€…é€šéè§€å¯Ÿé€™äº›é­šçš„è‚è‡Ÿå¥åº·ã€å…ç–«åŠŸèƒ½å’Œè…¸é“å¾®ç”Ÿç‰©çµ„æˆï¼Œä¾†è©•ä¼°è˜¿è””ç¡«ç´ çš„ä¿è­·ä½œç”¨ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œä¸‰è‹¯éŒ«çš„æ¥è§¸ç¢ºå¯¦æœƒå¼•èµ·è‚è‡Ÿæ¯’æ€§å’Œå…ç–«åŠŸèƒ½çš„ä¸‹é™ï¼Œè€Œè˜¿è””ç¡«ç´ çš„è£œå……å‰‡èƒ½æ¸›å°‘é€™äº›ä¸è‰¯å½±éŸ¿ã€‚ç ”ç©¶çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ æ”¹å–„è‚è‡Ÿçš„ä»£è¬å¹³è¡¡ï¼Œä¸¦ä¿ƒé€²æœ‰ç›Šè…¸é“å¾®ç”Ÿç‰©çš„å¢é•·ï¼ŒåŒæ™‚æŠ‘åˆ¶æœ‰å®³å¾®ç”Ÿç‰©çš„ç¹æ®–ã€‚é€™äº›ç™¼ç¾ç‚ºç†è§£ä¸‰è‹¯éŒ«å¼•èµ·çš„å…ç–«æ¯’æ€§æä¾›äº†æ–°çš„è¦‹è§£ï¼Œä¸¦é¡¯ç¤ºäº†è˜¿è””ç¡«ç´ åœ¨æ¸›è¼•æ¯’æ€§å½±éŸ¿æ–¹é¢çš„æ½›åœ¨ä½œç”¨ã€‚",
    "fb_post": "æ ¹æ“šã€ŠComparative biochemistry and physiology. Part D, Genomics & proteomicsã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ±ä½ çŸ¥é“å—ï¼Ÿè˜¿è””è£¡çš„æˆåˆ†å¯èƒ½å°æˆ‘å€‘çš„è‚è‡Ÿå’Œå…ç–«ç³»çµ±æœ‰å¤§å¹«åŠ©ï¼é€™é …ç ”ç©¶å°ˆæ³¨æ–¼ä¸€ç¨®å«åšè˜¿è””ç¡«ç´ çš„ç‰©è³ªï¼Œçœ‹çœ‹å®ƒå¦‚ä½•å¹«åŠ©æˆ‘å€‘æŠµæŠ—ç’°å¢ƒä¸­çš„æ¯’ç´ ï¼Œç‰¹åˆ¥æ˜¯ä¸‰è‹¯éŒ«é€™ç¨®æ±¡æŸ“ç‰©ã€‚ä¸‰è‹¯éŒ«å°å¥åº·æœ‰ä¸å°‘å¨è„…ï¼Œç ”ç©¶è€…å¸Œæœ›é€éé€™é …ç ”ç©¶æ‰¾åˆ°è§£æ±ºä¹‹é“ã€‚\n\nå¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ç”¨é¯‰é­šé€²è¡Œæ¸¬è©¦ï¼Œåˆ†æˆä¸‰çµ„ï¼šä¸€çµ„ä¸æ¥è§¸ä¸‰è‹¯éŒ«ï¼Œå¦ä¸€çµ„æ¥è§¸ä¸‰è‹¯éŒ«ï¼Œæœ€å¾Œä¸€çµ„åœ¨æ¥è§¸ä¸‰è‹¯éŒ«çš„åŒæ™‚é‚„è£œå……äº†è˜¿è””ç¡«ç´ ã€‚é€éè§€å¯Ÿé€™äº›é­šçš„è‚è‡Ÿå¥åº·å’Œå…ç–«åŠŸèƒ½ï¼Œç ”ç©¶è€…ç™¼ç¾è˜¿è””ç¡«ç´ èƒ½æœ‰æ•ˆæ¸›å°‘ä¸‰è‹¯éŒ«å¸¶ä¾†çš„è² é¢å½±éŸ¿ã€‚\n\nğŸ”ä¸»è¦ç™¼ç¾ï¼š\n1. ä¸‰è‹¯éŒ«æœƒå°è‡´è‚è‡Ÿæå‚·å’Œå…ç–«åŠŸèƒ½ä¸‹é™ã€‚\n2. è˜¿è””ç¡«ç´ èƒ½æ”¹å–„è‚è‡Ÿçš„ä»£è¬ï¼Œä¸¦ä¿ƒé€²æœ‰ç›Šè…¸é“å¾®ç”Ÿç‰©çš„å¢é•·ã€‚\n3. é€™äº›çµæœè®“æˆ‘å€‘å°æŠ—ç’°å¢ƒæ¯’ç´ çš„æ–¹å¼æœ‰äº†æ–°çš„ç†è§£ï¼",
    "image_prompt": "Create a flat design infographic illustrating the experiment and main results of a study on the protective effects of sulforaphane from radishes against toxicity caused by tributyltin. Include simplified icons representing radishes or sulforaphane, experimental subjects like fish, and arrows or flow lines to indicate the experimental steps. Add a section highlighting the main results, such as protective effects and changes observed in liver health and gut microbiota.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41027171/"
  },
  {
    "id": "40714240",
    "title_en": "Gut microbiota-related glutathione metabolism is key mechanism for sulforaphane ameliorating ulcerative colitis.",
    "pub_date": "2025 Dec",
    "journal": "The Journal of nutritional biochemistry",
    "abstract_en": "Gut barrier dysfunction is associated with dysbiosis of the gut microbiota and its metabolites, which is closely linked to the pathogenesis of ulcerative colitis (UC). Recent studies have demonstrated that Sulforaphane (SFN) exerts beneficial effects on UC. However, the role of the gut microbiota and microbial metabolism in the anti-UC mechanisms of SFN remains inadequately understood. In this study, we observed that SFN administration significantly improved the pathological phenotype, restored gut barrier integrity, and reduced colon inflammation in dextran sulfate sodium (DSS)-induced colitis mice. Gut microbiota analysis illustrated that SFN administration rebalances the alterations in gut microbiota composition, including genera such as Turicibacter, Lactobacillus and Bacteroides, in DSS-induced mice. Furthermore, untargeted metabolomics analysis indicated that the levels of microbial arachidonic acid metabolism, as well as the metabolism of alanine, aspartate, and glutamate, and glutathione metabolism in the gastrointestinal tract, were significantly altered in DSS-induced mice. Interestingly, SFN treatment significantly restore the alterations in glutathione metabolism and the levels of associated metabolites. Additionally, we observed that the MAPK/NF-ÎºB signaling pathway, regulated by glutathione metabolism, was inhibited in the colon of DSS-induced mice following SFN treatment. Collectively, these results suggest that SFN can alleviate DSS-induced colitis in mice by restoring dysregulated gut microbiota and glutathione metabolism, thereby modulating the MAPK/NF-ÎºB signaling pathway, enhancing intestinal barrier function and reducing colonic inflammation. Importantly, our findings elucidate a novel mechanism by which SFN improves gut barrier function, highlighting its potential to advance the development of SFN-derived therapeutics for the clinical management of colitis.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨è…¸é“å¥åº·æ–¹é¢ã€‚è…¸é“å±éšœåŠŸèƒ½çš„å¤±èª¿èˆ‡è…¸é“å¾®ç”Ÿç‰©ç¾¤çš„å¤±è¡¡æœ‰é—œï¼Œé€™å¯èƒ½æœƒå°è‡´æ½°ç˜æ€§çµè…¸ç‚ç­‰ç–¾ç—…çš„ç™¼å±•ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„è…¸é“å±éšœçš„åŠŸèƒ½ï¼Œé€™å°æ–¼é é˜²ç›¸é—œç–¾ç—…å…·æœ‰æ½›åœ¨çš„æ„ç¾©ã€‚é€éèª¿æ•´è…¸é“å¾®ç”Ÿç‰©ç¾¤å’Œæ”¹å–„è…¸é“ä»£è¬ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½æˆç‚ºæœªä¾†æ²»ç™‚è…¸é“ç–¾ç—…çš„ä¸€å€‹é‡è¦æ–¹å‘ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨æ½°ç˜æ€§çµè…¸ç‚ä¸­çš„ä½œç”¨ï¼Œç‰¹åˆ¥æ˜¯å®ƒå¦‚ä½•å½±éŸ¿è…¸é“å¾®ç”Ÿç‰©ç¾¤å’Œå¾®ç”Ÿç‰©ä»£è¬ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æ”¹å–„è…¸é“å±éšœåŠŸèƒ½ï¼Œä¸¦æ¸›å°‘ç”±æ–¼è…¸é“å¾®ç”Ÿç‰©å¤±è¡¡æ‰€å¼•èµ·çš„ç‚ç—‡åæ‡‰ã€‚é€™äº›å•é¡Œçš„è§£ç­”ä¸åƒ…æœ‰åŠ©æ–¼ç†è§£è˜¿è””ç¡«ç´ çš„æ©Ÿåˆ¶ï¼Œé‚„å¯èƒ½ç‚ºæ½°ç˜æ€§çµè…¸ç‚çš„æ²»ç™‚æä¾›æ–°çš„æ€è·¯ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†èª˜å°æ½°ç˜æ€§çµè…¸ç‚çš„å°é¼ æ¨¡å‹ï¼Œé€™äº›å°é¼ æ˜¯é€šéçµ¦äºˆç¡«é…¸å³æ—‹ç³–é…ä¾†èª˜å°è…¸é“ç‚ç—‡ã€‚ç ”ç©¶åœ˜éšŠçµ¦äºˆå°é¼ è˜¿è””ç¡«ç´ ï¼Œä¸¦è§€å¯Ÿå…¶å°è…¸é“ç—…ç†è¡¨ç¾ã€è…¸é“å±éšœå®Œæ•´æ€§åŠçµè…¸ç‚ç—‡çš„å½±éŸ¿ã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„é€²è¡Œäº†è…¸é“å¾®ç”Ÿç‰©ç¾¤çš„åˆ†æï¼Œä¸¦ä½¿ç”¨ä»£è¬çµ„å­¸æŠ€è¡“ä¾†è©•ä¼°è…¸é“å…§çš„ä»£è¬è®ŠåŒ–ï¼Œä»¥äº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ã€‚",
    "para4": "ä¸»è¦çš„ç™¼ç¾æ˜¯ï¼Œè˜¿è””ç¡«ç´ çš„çµ¦äºˆé¡¯è‘—æ”¹å–„äº†å°é¼ çš„è…¸é“ç—…ç†è¡¨ç¾ï¼Œæ¢å¾©äº†è…¸é“å±éšœçš„å®Œæ•´æ€§ï¼Œä¸¦æ¸›å°‘äº†çµè…¸çš„ç‚ç—‡ã€‚æ­¤å¤–ï¼Œè…¸é“å¾®ç”Ÿç‰©ç¾¤çš„åˆ†æé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ èª¿æ•´è…¸é“å¾®ç”Ÿç‰©çš„çµ„æˆï¼Œä¸¦æ”¹å–„èˆ‡è…¸é“ä»£è¬ç›¸é—œçš„è®ŠåŒ–ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ èª¿ç¯€èˆ‡è°·èƒ±ç”˜è‚½ä»£è¬ç›¸é—œçš„ä¿¡è™Ÿé€šè·¯ï¼Œé€™å¯èƒ½æ˜¯å…¶æ”¹å–„è…¸é“åŠŸèƒ½çš„æ©Ÿåˆ¶ä¹‹ä¸€ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ åœ¨æ½°ç˜æ€§çµè…¸ç‚çš„æ²»ç™‚ä¸­å…·æœ‰æ½›åœ¨çš„æ‡‰ç”¨åƒ¹å€¼ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨è…¸é“å¥åº·æ–¹é¢ã€‚è…¸é“å±éšœåŠŸèƒ½çš„å¤±èª¿èˆ‡è…¸é“å¾®ç”Ÿç‰©ç¾¤çš„å¤±è¡¡æœ‰é—œï¼Œé€™å¯èƒ½æœƒå°è‡´æ½°ç˜æ€§çµè…¸ç‚ç­‰ç–¾ç—…çš„ç™¼å±•ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„è…¸é“å±éšœçš„åŠŸèƒ½ï¼Œé€™å°æ–¼é é˜²ç›¸é—œç–¾ç—…å…·æœ‰æ½›åœ¨çš„æ„ç¾©ã€‚é€éèª¿æ•´è…¸é“å¾®ç”Ÿç‰©ç¾¤å’Œæ”¹å–„è…¸é“ä»£è¬ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½æˆç‚ºæœªä¾†æ²»ç™‚è…¸é“ç–¾ç—…çš„ä¸€å€‹é‡è¦æ–¹å‘ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨æ½°ç˜æ€§çµè…¸ç‚ä¸­çš„ä½œç”¨ï¼Œç‰¹åˆ¥æ˜¯å®ƒå¦‚ä½•å½±éŸ¿è…¸é“å¾®ç”Ÿç‰©ç¾¤å’Œå¾®ç”Ÿç‰©ä»£è¬ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æ”¹å–„è…¸é“å±éšœåŠŸèƒ½ï¼Œä¸¦æ¸›å°‘ç”±æ–¼è…¸é“å¾®ç”Ÿç‰©å¤±è¡¡æ‰€å¼•èµ·çš„ç‚ç—‡åæ‡‰ã€‚é€™äº›å•é¡Œçš„è§£ç­”ä¸åƒ…æœ‰åŠ©æ–¼ç†è§£è˜¿è””ç¡«ç´ çš„æ©Ÿåˆ¶ï¼Œé‚„å¯èƒ½ç‚ºæ½°ç˜æ€§çµè…¸ç‚çš„æ²»ç™‚æä¾›æ–°çš„æ€è·¯ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†èª˜å°æ½°ç˜æ€§çµè…¸ç‚çš„å°é¼ æ¨¡å‹ï¼Œé€™äº›å°é¼ æ˜¯é€šéçµ¦äºˆç¡«é…¸å³æ—‹ç³–é…ä¾†èª˜å°è…¸é“ç‚ç—‡ã€‚ç ”ç©¶åœ˜éšŠçµ¦äºˆå°é¼ è˜¿è””ç¡«ç´ ï¼Œä¸¦è§€å¯Ÿå…¶å°è…¸é“ç—…ç†è¡¨ç¾ã€è…¸é“å±éšœå®Œæ•´æ€§åŠçµè…¸ç‚ç—‡çš„å½±éŸ¿ã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„é€²è¡Œäº†è…¸é“å¾®ç”Ÿç‰©ç¾¤çš„åˆ†æï¼Œä¸¦ä½¿ç”¨ä»£è¬çµ„å­¸æŠ€è¡“ä¾†è©•ä¼°è…¸é“å…§çš„ä»£è¬è®ŠåŒ–ï¼Œä»¥äº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ã€‚\n\nä¸»è¦çš„ç™¼ç¾æ˜¯ï¼Œè˜¿è””ç¡«ç´ çš„çµ¦äºˆé¡¯è‘—æ”¹å–„äº†å°é¼ çš„è…¸é“ç—…ç†è¡¨ç¾ï¼Œæ¢å¾©äº†è…¸é“å±éšœçš„å®Œæ•´æ€§ï¼Œä¸¦æ¸›å°‘äº†çµè…¸çš„ç‚ç—‡ã€‚æ­¤å¤–ï¼Œè…¸é“å¾®ç”Ÿç‰©ç¾¤çš„åˆ†æé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ èª¿æ•´è…¸é“å¾®ç”Ÿç‰©çš„çµ„æˆï¼Œä¸¦æ”¹å–„èˆ‡è…¸é“ä»£è¬ç›¸é—œçš„è®ŠåŒ–ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ èª¿ç¯€èˆ‡è°·èƒ±ç”˜è‚½ä»£è¬ç›¸é—œçš„ä¿¡è™Ÿé€šè·¯ï¼Œé€™å¯èƒ½æ˜¯å…¶æ”¹å–„è…¸é“åŠŸèƒ½çš„æ©Ÿåˆ¶ä¹‹ä¸€ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ åœ¨æ½°ç˜æ€§çµè…¸ç‚çš„æ²»ç™‚ä¸­å…·æœ‰æ½›åœ¨çš„æ‡‰ç”¨åƒ¹å€¼ã€‚",
    "fb_post": "æ ¹æ“šã€ŠThe Journal of nutritional biochemistryã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒŸä½ çŸ¥é“å—ï¼Ÿè˜¿è””è£¡çš„ç¥å¥‡æˆåˆ†å¯èƒ½å°è…¸é“å¥åº·æœ‰å¹«åŠ©ï¼\n\næœ€è¿‘æœ‰ä¸€é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ ï¼ˆå°±æ˜¯è˜¿è””è£¡çš„é‚£ç¨®ç‡Ÿé¤Šæˆåˆ†ï¼‰åœ¨æ½°ç˜æ€§çµè…¸ç‚ä¸­çš„ä½œç”¨ã€‚é€™ç¨®ç–¾ç—…æœƒè®“è…¸é“ç™¼ç‚ï¼Œå½±éŸ¿æˆ‘å€‘çš„æ¶ˆåŒ–ç³»çµ±ã€‚ç ”ç©¶è€…æƒ³çŸ¥é“ï¼Œè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æ”¹å–„è…¸é“çš„å±éšœåŠŸèƒ½ï¼Œä¸¦æ¸›å°‘å› è…¸é“å¾®ç”Ÿç‰©å¤±è¡¡è€Œå¼•èµ·çš„ç‚ç—‡ã€‚\n\nä»–å€‘åœ¨å¯¦é©—ä¸­ä½¿ç”¨äº†å°é¼ æ¨¡å‹ï¼Œé€™äº›å°é¼ çš„è…¸é“è¢«èª˜å°ç™¼ç‚ï¼Œæ¥è‘—çµ¦äºˆå®ƒå€‘è˜¿è””ç¡«ç´ ï¼Œä¸¦è§€å¯Ÿå…¶æ•ˆæœã€‚çµæœç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ ä¸åƒ…æ”¹å–„äº†å°é¼ çš„è…¸é“å¥åº·ï¼Œé‚„å¹«åŠ©æ¢å¾©äº†è…¸é“çš„å®Œæ•´æ€§ï¼Œæ¸›å°‘äº†ç‚ç—‡ï¼\n\næ›´æœ‰è¶£çš„æ˜¯ï¼Œè˜¿è””ç¡«ç´ é‚„èƒ½èª¿æ•´è…¸é“å…§çš„å¾®ç”Ÿç‰©çµ„æˆï¼Œé€™å°æ–¼è…¸é“çš„å¥åº·éå¸¸é‡è¦ã€‚\n\nğŸ” ç¸½çµä¾†èªªï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„è…¸é“çš„å±éšœåŠŸèƒ½ã€‚\n2. å®ƒèƒ½æ¸›å°‘è…¸é“ç‚ç—‡ï¼Œå°æ½°ç˜æ€§çµè…¸ç‚æœ‰æ½›åœ¨çš„å¥½è™•ã€‚\n3. èª¿æ•´è…¸é“å¾®ç”Ÿç‰©çµ„æˆï¼Œä¿ƒé€²è…¸é“å¥åº·ï¼\n\nå¿«æŠŠé€™å€‹å¥½æ¶ˆæ¯åˆ†äº«çµ¦å®¶äººæœ‹å‹å§ï¼",
    "image_prompt": "Create a flat design infographic explaining the experiment and main results of a study on the effects of sulforaphane (found in radishes) on gut health. Include symbolic illustrations of radishes or broccoli, simplified representations of experimental subjects like mice, arrows or flow lines showing the experimental steps, and a section labeled 'Main Results' highlighting protective effects and changes observed in gut health.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "æ½°ç˜æ€§çµè…¸ç‚ Ulcerative Colitis",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40714240/"
  },
  {
    "id": "41291551",
    "title_en": "Nanoliposome-mediated delivery of sulforaphane suppresses Ehrlich ascites carcinoma growth and improves liver integrity and therapeutic outcomes in a murine model.",
    "pub_date": "2025 Nov",
    "journal": "BMC cancer",
    "abstract_en": "The anticancer activity of sulforaphane (SFN) involves multiple signaling pathways, but its mechanism against Ehrlich Ascites Carcinoma (EAC) in mice remains unclear. This study evaluated the antitumor efficacy of SFN-loaded nanoliposomes (SFN-NLPs). Ninety female Swiss albino mice were allocated into six groups: (1) untreated control, (2) SFN alone (50Â mg/kg/day, orally), (3) SFN-NLPs alone (50Â mg/kg/day, orally), (4) EAC-bearing mice (2.5â€‰Ã—â€‰10â¶ cells, intraperitoneally), (5) EACâ€‰+â€‰SFN, and (6) EACâ€‰+â€‰SFN-NLPs. with treatment lasting 20 days in tumor-bearing groups. SFN-NLPs significantly reduced EAC tumor volume, viable cell count, and tumor marker levels, while prolonging survival more effectively than free SFN. SFN-NLPs modulated key molecular pathways by suppressing inflammatory gene expression (NF-ÎºB, COX-2) and shifting the balance toward apoptosis via upregulation of TP53 and Bax and concomitant downregulation of Bcl-2. Regarding liver integrity, SFN-NLPs significantly reduced DNA fragmentation and hepatic oxidative stress, while modulating systemic inflammation through reductions in total leukocyte count, TNF-Î±, and C-reactive protein. In addition, SFN-NLPs conferred superior protection against both histopathological and ultrastructural liver damage. Furthermore, molecular docking analysis suggested plausible interactions of SFN with proteins associated with antioxidant defense, inflammation regulation, and apoptosis, indicating a potential modulatory role. In conclusion, nanoformulated SFN enhances stability, augments efficacy, and facilitates sustained release and bioavailability, thereby strengthening its antitumor, anti-inflammatory, antioxidant, and pro-apoptotic effects in EAC-bearing mice. These findings highlight the potential of SFN-NLPs to suppress tumor growth by modulating inflammatory and apoptotic gene expression while preserving liver integrity.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨ç™Œç—‡æ²»ç™‚æ–¹é¢ã€‚è˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰æ˜¯ä¸€ç¨®å¾é’èŠ±æ¤°èœä¸­æå–çš„åŒ–åˆç‰©ï¼Œå·²çŸ¥å…·æœ‰æŠ—ç™Œç‰¹æ€§ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œé€éç´ç±³è„‚è³ªé«”åŒ…è£¹çš„è˜¿è””ç¡«ç´ ï¼ˆSFN-NLPsï¼‰å¯èƒ½åœ¨æŠ‘åˆ¶è…«ç˜¤ç”Ÿé•·æ–¹é¢æ¯”å–®ç¨ä½¿ç”¨è˜¿è””ç¡«ç´ æ›´æœ‰æ•ˆã€‚é€™æ„å‘³è‘—ï¼Œæœªä¾†çš„ç™Œç—‡æ²»ç™‚å¯èƒ½æœƒåˆ©ç”¨é€™ç¨®æ–°å‹çš„ç´ç±³æŠ€è¡“ä¾†å¢å¼·è—¥ç‰©çš„æ•ˆæœï¼Œä¸¦æ¸›å°‘å‰¯ä½œç”¨ï¼Œé€²è€Œæ”¹å–„æ‚£è€…çš„ç”Ÿæ´»å“è³ªã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨å°é¼ çš„Ehrlichè…¹æ°´ç™Œï¼ˆEACï¼‰æ¨¡å‹ä¸­çš„æŠ—è…«ç˜¤æ•ˆæœã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œè˜¿è””ç¡«ç´ å¦‚ä½•é€éä¸åŒçš„ä¿¡è™Ÿå‚³å°é€”å¾‘ä¾†å½±éŸ¿è…«ç˜¤çš„ç”Ÿé•·å’Œç™¼å±•ï¼Œç‰¹åˆ¥æ˜¯ä½¿ç”¨ç´ç±³è„‚è³ªé«”ä¾†æé«˜å…¶ç™‚æ•ˆå’Œç©©å®šæ€§ã€‚é€™é …ç ”ç©¶å¸Œæœ›èƒ½å¤ æ­ç¤ºè˜¿è””ç¡«ç´ åœ¨ç™Œç—‡æ²»ç™‚ä¸­çš„æ½›åŠ›ï¼Œä¸¦ç‚ºæœªä¾†çš„è‡¨åºŠæ‡‰ç”¨æä¾›ç§‘å­¸ä¾æ“šã€‚",
    "para3": "å¯¦é©—ä¸­ä½¿ç”¨äº†90éš»é›Œæ€§ç‘å£«ç™½é¼ ï¼Œé€™äº›å°é¼ è¢«åˆ†æˆå…­çµ„ï¼Œåˆ†åˆ¥æ¥å—ä¸åŒçš„è™•ç†ï¼ŒåŒ…æ‹¬æœªæ²»ç™‚çµ„ã€å–®ç¨ä½¿ç”¨è˜¿è””ç¡«ç´ çµ„ã€å–®ç¨ä½¿ç”¨è˜¿è””ç¡«ç´ ç´ç±³è„‚è³ªé«”çµ„ã€EACå°é¼ çµ„ã€EACåŠ è˜¿è””ç¡«ç´ çµ„ï¼Œä»¥åŠEACåŠ è˜¿è””ç¡«ç´ ç´ç±³è„‚è³ªé«”çµ„ã€‚æ²»ç™‚æŒçºŒ20å¤©ï¼Œç ”ç©¶è€…è§€å¯Ÿäº†è…«ç˜¤é«”ç©ã€å­˜æ´»ç‡ã€ä»¥åŠè‚è‡Ÿå¥åº·ç­‰å¤šå€‹æŒ‡æ¨™ï¼Œä¸¦åˆ†æäº†ç›¸é—œçš„åˆ†å­æ©Ÿåˆ¶ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œä½¿ç”¨è˜¿è””ç¡«ç´ ç´ç±³è„‚è³ªé«”çš„çµ„åˆ¥åœ¨æ¸›å°‘è…«ç˜¤é«”ç©ã€æ´»ç´°èƒæ•¸é‡åŠè…«ç˜¤æ¨™è¨˜ç‰©æ°´å¹³æ–¹é¢ï¼Œæ¯”å–®ç¨ä½¿ç”¨è˜¿è””ç¡«ç´ æ›´ç‚ºæœ‰æ•ˆã€‚æ­¤å¤–ï¼Œé€™ç¨®ç´ç±³å½¢å¼çš„è˜¿è””ç¡«ç´ é‚„èƒ½æ”¹å–„è‚è‡Ÿå¥åº·ï¼Œæ¸›å°‘æ°§åŒ–å£“åŠ›å’Œç‚ç—‡åæ‡‰ï¼Œä¸¦ä¸”åœ¨åˆ†å­å±¤é¢ä¸Šèª¿ç¯€äº†èˆ‡ç´°èƒå‡‹äº¡å’Œç‚ç—‡ç›¸é—œçš„åŸºå› è¡¨é”ã€‚é€™äº›çµæœé¡¯ç¤ºï¼Œç´ç±³åŒ…è£¹çš„è˜¿è””ç¡«ç´ å¯èƒ½åœ¨æŠ—è…«ç˜¤å’ŒæŠ—ç‚æ–¹é¢å…·æœ‰æ›´å¼·çš„æ•ˆæœï¼Œä½†ä»éœ€é€²ä¸€æ­¥ç ”ç©¶ä¾†ç¢ºèªå…¶è‡¨åºŠæ‡‰ç”¨çš„æ½›åŠ›ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨ç™Œç—‡æ²»ç™‚æ–¹é¢ã€‚è˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰æ˜¯ä¸€ç¨®å¾é’èŠ±æ¤°èœä¸­æå–çš„åŒ–åˆç‰©ï¼Œå·²çŸ¥å…·æœ‰æŠ—ç™Œç‰¹æ€§ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œé€éç´ç±³è„‚è³ªé«”åŒ…è£¹çš„è˜¿è””ç¡«ç´ ï¼ˆSFN-NLPsï¼‰å¯èƒ½åœ¨æŠ‘åˆ¶è…«ç˜¤ç”Ÿé•·æ–¹é¢æ¯”å–®ç¨ä½¿ç”¨è˜¿è””ç¡«ç´ æ›´æœ‰æ•ˆã€‚é€™æ„å‘³è‘—ï¼Œæœªä¾†çš„ç™Œç—‡æ²»ç™‚å¯èƒ½æœƒåˆ©ç”¨é€™ç¨®æ–°å‹çš„ç´ç±³æŠ€è¡“ä¾†å¢å¼·è—¥ç‰©çš„æ•ˆæœï¼Œä¸¦æ¸›å°‘å‰¯ä½œç”¨ï¼Œé€²è€Œæ”¹å–„æ‚£è€…çš„ç”Ÿæ´»å“è³ªã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨å°é¼ çš„Ehrlichè…¹æ°´ç™Œï¼ˆEACï¼‰æ¨¡å‹ä¸­çš„æŠ—è…«ç˜¤æ•ˆæœã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œè˜¿è””ç¡«ç´ å¦‚ä½•é€éä¸åŒçš„ä¿¡è™Ÿå‚³å°é€”å¾‘ä¾†å½±éŸ¿è…«ç˜¤çš„ç”Ÿé•·å’Œç™¼å±•ï¼Œç‰¹åˆ¥æ˜¯ä½¿ç”¨ç´ç±³è„‚è³ªé«”ä¾†æé«˜å…¶ç™‚æ•ˆå’Œç©©å®šæ€§ã€‚é€™é …ç ”ç©¶å¸Œæœ›èƒ½å¤ æ­ç¤ºè˜¿è””ç¡«ç´ åœ¨ç™Œç—‡æ²»ç™‚ä¸­çš„æ½›åŠ›ï¼Œä¸¦ç‚ºæœªä¾†çš„è‡¨åºŠæ‡‰ç”¨æä¾›ç§‘å­¸ä¾æ“šã€‚\n\nå¯¦é©—ä¸­ä½¿ç”¨äº†90éš»é›Œæ€§ç‘å£«ç™½é¼ ï¼Œé€™äº›å°é¼ è¢«åˆ†æˆå…­çµ„ï¼Œåˆ†åˆ¥æ¥å—ä¸åŒçš„è™•ç†ï¼ŒåŒ…æ‹¬æœªæ²»ç™‚çµ„ã€å–®ç¨ä½¿ç”¨è˜¿è””ç¡«ç´ çµ„ã€å–®ç¨ä½¿ç”¨è˜¿è””ç¡«ç´ ç´ç±³è„‚è³ªé«”çµ„ã€EACå°é¼ çµ„ã€EACåŠ è˜¿è””ç¡«ç´ çµ„ï¼Œä»¥åŠEACåŠ è˜¿è””ç¡«ç´ ç´ç±³è„‚è³ªé«”çµ„ã€‚æ²»ç™‚æŒçºŒ20å¤©ï¼Œç ”ç©¶è€…è§€å¯Ÿäº†è…«ç˜¤é«”ç©ã€å­˜æ´»ç‡ã€ä»¥åŠè‚è‡Ÿå¥åº·ç­‰å¤šå€‹æŒ‡æ¨™ï¼Œä¸¦åˆ†æäº†ç›¸é—œçš„åˆ†å­æ©Ÿåˆ¶ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œä½¿ç”¨è˜¿è””ç¡«ç´ ç´ç±³è„‚è³ªé«”çš„çµ„åˆ¥åœ¨æ¸›å°‘è…«ç˜¤é«”ç©ã€æ´»ç´°èƒæ•¸é‡åŠè…«ç˜¤æ¨™è¨˜ç‰©æ°´å¹³æ–¹é¢ï¼Œæ¯”å–®ç¨ä½¿ç”¨è˜¿è””ç¡«ç´ æ›´ç‚ºæœ‰æ•ˆã€‚æ­¤å¤–ï¼Œé€™ç¨®ç´ç±³å½¢å¼çš„è˜¿è””ç¡«ç´ é‚„èƒ½æ”¹å–„è‚è‡Ÿå¥åº·ï¼Œæ¸›å°‘æ°§åŒ–å£“åŠ›å’Œç‚ç—‡åæ‡‰ï¼Œä¸¦ä¸”åœ¨åˆ†å­å±¤é¢ä¸Šèª¿ç¯€äº†èˆ‡ç´°èƒå‡‹äº¡å’Œç‚ç—‡ç›¸é—œçš„åŸºå› è¡¨é”ã€‚é€™äº›çµæœé¡¯ç¤ºï¼Œç´ç±³åŒ…è£¹çš„è˜¿è””ç¡«ç´ å¯èƒ½åœ¨æŠ—è…«ç˜¤å’ŒæŠ—ç‚æ–¹é¢å…·æœ‰æ›´å¼·çš„æ•ˆæœï¼Œä½†ä»éœ€é€²ä¸€æ­¥ç ”ç©¶ä¾†ç¢ºèªå…¶è‡¨åºŠæ‡‰ç”¨çš„æ½›åŠ›ã€‚",
    "fb_post": "æ ¹æ“šã€ŠBMC cancerã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿé’èŠ±æ¤°èœè£¡çš„è˜¿è””ç¡«ç´ ï¼Œå¯èƒ½æ˜¯å°æŠ—ç™Œç—‡çš„ç§˜å¯†æ­¦å™¨ï¼é€™é …ç ”ç©¶å‘Šè¨´æˆ‘å€‘ï¼Œç´ç±³æŠ€è¡“å¯ä»¥è®“è˜¿è””ç¡«ç´ çš„æ•ˆæœæ›´å¼·å¤§ï¼Œç”šè‡³å¹«åŠ©æ¸›å°‘è…«ç˜¤ç”Ÿé•·ã€‚ç ”ç©¶äººå“¡ä½¿ç”¨å°é¼ ä¾†æ¢è¨è˜¿è””ç¡«ç´ çš„æŠ—è…«ç˜¤æ•ˆæœï¼Œä¸¦ç™¼ç¾é€éç´ç±³è„‚è³ªé«”åŒ…è£¹çš„è˜¿è””ç¡«ç´ ï¼Œèƒ½å¤ æ›´æœ‰æ•ˆåœ°æŠ‘åˆ¶è…«ç˜¤ï¼Œæ”¹å–„è‚è‡Ÿå¥åº·ï¼Œä¸¦æ¸›å°‘ç‚ç—‡ã€‚é€™é …ç ”ç©¶çš„å¯¦é©—ä¸­ï¼Œå°é¼ è¢«åˆ†æˆä¸åŒçµ„åˆ¥ï¼Œæ¥å—å„ç¨®è™•ç†ï¼ŒæŒçºŒ20å¤©è§€å¯Ÿã€‚çµæœé¡¯ç¤ºï¼Œä½¿ç”¨ç´ç±³è„‚è³ªé«”çš„çµ„åˆ¥åœ¨æ¸›å°‘è…«ç˜¤é«”ç©å’Œæ”¹å–„å¥åº·æ–¹é¢ï¼Œæ•ˆæœæ›´ä½³ã€‚é€™äº›ç™¼ç¾è®“æˆ‘å€‘å°æœªä¾†çš„ç™Œç—‡æ²»ç™‚å……æ»¿æœŸå¾…ï¼\n\nğŸ” ä¸»è¦é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æŠ—ç™Œï¼Œå°¤å…¶æ˜¯é€éç´ç±³æŠ€è¡“ã€‚\n2. ä½¿ç”¨ç´ç±³è„‚è³ªé«”çš„è˜¿è””ç¡«ç´ åœ¨æ¸›å°‘è…«ç˜¤å’Œæ”¹å–„è‚è‡Ÿå¥åº·æ–¹é¢æ›´æœ‰æ•ˆã€‚\n3. é€™é …ç ”ç©¶æä¾›äº†æœªä¾†ç™Œç—‡æ²»ç™‚çš„æ–°æ–¹å‘ã€‚",
    "image_prompt": "Create an informative flat design illustration explaining the experiment and main results of a study on sulforaphane (SFN) from broccoli. Include symbols for broccoli and sulforaphane, simplified representations of experimental subjects like mice or cells, arrows or flow lines to indicate experimental steps, and a section clearly labeled 'Main Results' highlighting protective effects or changes observed.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "è…¹æ°´ç™Œ Ehrlich Ascites Carcinoma",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41291551/"
  },
  {
    "id": "41135276",
    "title_en": "Sulforaphane targets STAT3-CKMT2-AS1 to suppress gastric cancer via PSMB8 downregulation and AIMP1 stabilization.",
    "pub_date": "2025 Nov",
    "journal": "Phytomedicine : international journal of phytotherapy and phytopharmacology",
    "abstract_en": "Gastric cancer (GC) remains one of the most formidable threats to human health with limited therapeutic options. Sulforaphane (SFN), a natural isothiocyanate, exhibits antitumor activity; however, its molecular mechanisms of action in GC remain unclear. To investigate the mechanism of action of SFN in gastric cancer. The antitumor effects of SFN were comprehensively assessed in vitro and in vivo, followed by sequencing analysis to identify the targeted lncRNA. Subsequently, the mechanical verification experiments were carried out to determine the upstream and downstream regulatory components involved in the STAT3-CKMT2-AS1 regulatory axis. We demonstrated that SFN strongly inhibits GC. SFN downregulated the expression of the lncRNA CKMT2-AS1. Elevated expression levels of CKMT2-AS1 in human GC tissues are correlated with poor patient survival rates. Knockdown of CKMT2-AS1 significantly inhibited GC proliferation and migration both in vivo and in vitro, whereas CKMT2-AS1 overexpression enhanced malignant phenotypes. Mechanistically, we identified STAT3 as the transcriptional activator driving CKMT2-AS1 expression, with SFN directly binding to, and inhibiting, STAT3 phosphorylation to decrease its transcriptional activity. Interestingly, cytoplasmic CKMT2-AS1 competitively adsorbs miR-451a, leading to the expression of PSMB8, ultimately promoting the progression of the malignant phenotype of GC. Moreover, we discovered that CKMT2-AS1 directly binds to the RNA-binding protein (RBP) AIMP1, promoting ubiquitination-mediated degradation of AIMP1 protein via the proteasomal pathway. The highly expressed AIMP1 protein, in turn, inhibits the phosphorylation of the PI3K/AKT signaling pathway, which is hyperactivated in virtually all solid tumors. Our findings not only elucidate a novel SFN-mediated tumor-suppressive mechanism via the STAT3/CKMT2-AS1 regulatory axis, but also validate CKMT2-AS1 as a promising therapeutic target for GC intervention.",
    "para1": "èƒƒç™Œæ˜¯å°äººé¡å¥åº·çš„ä¸€å¤§å¨è„…ï¼Œç›®å‰æ²»ç™‚é¸æ“‡æœ‰é™ã€‚é€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ åœ¨èƒƒç™Œä¸­çš„ä½œç”¨ï¼Œå¯èƒ½ç‚ºé é˜²å’Œæ²»ç™‚èƒƒç™Œæä¾›æ–°çš„æ€è·¯ã€‚é€éäº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ï¼Œæœªä¾†æœ‰æœ›é–‹ç™¼å‡ºæ›´æœ‰æ•ˆçš„æ²»ç™‚æ–¹æ³•ï¼Œæ”¹å–„æ‚£è€…çš„ç”Ÿå­˜ç‡å’Œç”Ÿæ´»å“è³ªã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯è˜¿è””ç¡«ç´ åœ¨èƒƒç™Œä¸­çš„æŠ—è…«ç˜¤ä½œç”¨åŠå…¶åˆ†å­æ©Ÿåˆ¶ã€‚ç ”ç©¶è€…å¸Œæœ›æ­ç¤ºè˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿èƒƒç™Œç´°èƒçš„ç”Ÿé•·å’Œæ“´æ•£ï¼Œä¸¦æ‰¾å‡ºç›¸é—œçš„åˆ†å­æ¨™é¶ï¼Œé€™å°æ–¼é–‹ç™¼æ–°çš„æ²»ç™‚ç­–ç•¥è‡³é—œé‡è¦ã€‚",
    "para3": "ç ”ç©¶åœ˜éšŠé€²è¡Œäº†é«”å…§å’Œé«”å¤–çš„å¯¦é©—ï¼Œä»¥å…¨é¢è©•ä¼°è˜¿è””ç¡«ç´ çš„æŠ—è…«ç˜¤æ•ˆæœã€‚é¦–å…ˆï¼Œä»–å€‘é€²è¡Œäº†åŸºå› æ¸¬åºåˆ†æï¼Œä»¥è­˜åˆ¥ç›®æ¨™é•·éˆéç·¨ç¢¼RNAï¼ˆlncRNAï¼‰ã€‚æ¥è‘—ï¼Œé€²è¡Œäº†æ©Ÿåˆ¶é©—è­‰å¯¦é©—ï¼Œä»¥ç¢ºå®šåƒèˆ‡STAT3-CKMT2-AS1èª¿æ§è»¸çš„ä¸Šæ¸¸å’Œä¸‹æ¸¸èª¿æ§çµ„ä»¶ï¼Œé€™äº›å¯¦é©—å¹«åŠ©ç†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ã€‚",
    "para4": "ç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¼·æ•ˆæŠ‘åˆ¶èƒƒç™Œçš„ç”Ÿé•·ï¼Œä¸¦ä¸‹èª¿äº†lncRNA CKMT2-AS1çš„è¡¨é”ã€‚CKMT2-AS1åœ¨èƒƒç™Œçµ„ç¹”ä¸­çš„é«˜è¡¨é”èˆ‡æ‚£è€…çš„ç”Ÿå­˜ç‡è¼ƒä½ç›¸é—œã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼ŒæŠ‘åˆ¶CKMT2-AS1èƒ½é¡¯è‘—æ¸›å°‘èƒƒç™Œç´°èƒçš„å¢æ®–å’Œé·ç§»ï¼Œè€ŒCKMT2-AS1çš„éåº¦è¡¨é”å‰‡æœƒåŠ åŠ‡è…«ç˜¤çš„æƒ¡æ€§è¡¨ç¾ã€‚é€™äº›ç™¼ç¾ç‚ºè˜¿è””ç¡«ç´ çš„æŠ—è…«ç˜¤æ©Ÿåˆ¶æä¾›äº†æ–°çš„è¦‹è§£ï¼Œä¸¦æŒ‡å‡ºCKMT2-AS1å¯èƒ½æˆç‚ºèƒƒç™Œæ²»ç™‚çš„æ½›åœ¨é¶é»ã€‚",
    "explanation_zh": "èƒƒç™Œæ˜¯å°äººé¡å¥åº·çš„ä¸€å¤§å¨è„…ï¼Œç›®å‰æ²»ç™‚é¸æ“‡æœ‰é™ã€‚é€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ åœ¨èƒƒç™Œä¸­çš„ä½œç”¨ï¼Œå¯èƒ½ç‚ºé é˜²å’Œæ²»ç™‚èƒƒç™Œæä¾›æ–°çš„æ€è·¯ã€‚é€éäº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ï¼Œæœªä¾†æœ‰æœ›é–‹ç™¼å‡ºæ›´æœ‰æ•ˆçš„æ²»ç™‚æ–¹æ³•ï¼Œæ”¹å–„æ‚£è€…çš„ç”Ÿå­˜ç‡å’Œç”Ÿæ´»å“è³ªã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯è˜¿è””ç¡«ç´ åœ¨èƒƒç™Œä¸­çš„æŠ—è…«ç˜¤ä½œç”¨åŠå…¶åˆ†å­æ©Ÿåˆ¶ã€‚ç ”ç©¶è€…å¸Œæœ›æ­ç¤ºè˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿èƒƒç™Œç´°èƒçš„ç”Ÿé•·å’Œæ“´æ•£ï¼Œä¸¦æ‰¾å‡ºç›¸é—œçš„åˆ†å­æ¨™é¶ï¼Œé€™å°æ–¼é–‹ç™¼æ–°çš„æ²»ç™‚ç­–ç•¥è‡³é—œé‡è¦ã€‚\n\nç ”ç©¶åœ˜éšŠé€²è¡Œäº†é«”å…§å’Œé«”å¤–çš„å¯¦é©—ï¼Œä»¥å…¨é¢è©•ä¼°è˜¿è””ç¡«ç´ çš„æŠ—è…«ç˜¤æ•ˆæœã€‚é¦–å…ˆï¼Œä»–å€‘é€²è¡Œäº†åŸºå› æ¸¬åºåˆ†æï¼Œä»¥è­˜åˆ¥ç›®æ¨™é•·éˆéç·¨ç¢¼RNAï¼ˆlncRNAï¼‰ã€‚æ¥è‘—ï¼Œé€²è¡Œäº†æ©Ÿåˆ¶é©—è­‰å¯¦é©—ï¼Œä»¥ç¢ºå®šåƒèˆ‡STAT3-CKMT2-AS1èª¿æ§è»¸çš„ä¸Šæ¸¸å’Œä¸‹æ¸¸èª¿æ§çµ„ä»¶ï¼Œé€™äº›å¯¦é©—å¹«åŠ©ç†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ã€‚\n\nç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¼·æ•ˆæŠ‘åˆ¶èƒƒç™Œçš„ç”Ÿé•·ï¼Œä¸¦ä¸‹èª¿äº†lncRNA CKMT2-AS1çš„è¡¨é”ã€‚CKMT2-AS1åœ¨èƒƒç™Œçµ„ç¹”ä¸­çš„é«˜è¡¨é”èˆ‡æ‚£è€…çš„ç”Ÿå­˜ç‡è¼ƒä½ç›¸é—œã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼ŒæŠ‘åˆ¶CKMT2-AS1èƒ½é¡¯è‘—æ¸›å°‘èƒƒç™Œç´°èƒçš„å¢æ®–å’Œé·ç§»ï¼Œè€ŒCKMT2-AS1çš„éåº¦è¡¨é”å‰‡æœƒåŠ åŠ‡è…«ç˜¤çš„æƒ¡æ€§è¡¨ç¾ã€‚é€™äº›ç™¼ç¾ç‚ºè˜¿è””ç¡«ç´ çš„æŠ—è…«ç˜¤æ©Ÿåˆ¶æä¾›äº†æ–°çš„è¦‹è§£ï¼Œä¸¦æŒ‡å‡ºCKMT2-AS1å¯èƒ½æˆç‚ºèƒƒç™Œæ²»ç™‚çš„æ½›åœ¨é¶é»ã€‚",
    "fb_post": "æ ¹æ“šã€ŠPhytomedicine : international journal of phytotherapy and phytopharmacologyã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸ½ï¸ ä½ çŸ¥é“å—ï¼Ÿæˆ‘å€‘çš„æ—¥å¸¸é£²é£Ÿä¸­æœ‰äº›é£Ÿç‰©å¯èƒ½å°å¥åº·æœ‰æ„æƒ³ä¸åˆ°çš„å¹«åŠ©ï¼æœ€è¿‘æœ‰ç ”ç©¶ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ é€™å€‹æˆåˆ†åœ¨å°æŠ—èƒƒç™Œæ–¹é¢å¯èƒ½æœ‰æ½›åŠ›å“¦ï¼\n\né€™é …ç ”ç©¶ä¸»è¦æ¢è¨è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿èƒƒç™Œç´°èƒçš„ç”Ÿé•·å’Œæ“´æ•£ï¼Œç ”ç©¶åœ˜éšŠé€²è¡Œäº†è¨±å¤šå¯¦é©—ä¾†æ‰¾å‡ºå®ƒçš„ä½œç”¨æ©Ÿåˆ¶ã€‚ä»–å€‘é€éåŸºå› åˆ†æå’Œå¯¦é©—ï¼Œç™¼ç¾è˜¿è””ç¡«ç´ èƒ½æœ‰æ•ˆæŠ‘åˆ¶èƒƒç™Œç´°èƒçš„ç”Ÿé•·ï¼Œä¸¦å½±éŸ¿ä¸€ç¨®å«åšCKMT2-AS1çš„åˆ†å­ï¼Œé€™å€‹åˆ†å­åœ¨èƒƒç™Œä¸­è¡¨ç¾ç•°å¸¸ï¼Œèˆ‡æ‚£è€…çš„ç”Ÿå­˜ç‡æœ‰é—œã€‚\n\né€™é …ç ”ç©¶çš„çµæœè®“æˆ‘å€‘çœ‹åˆ°è˜¿è””ç¡«ç´ çš„æ½›åŠ›ï¼Œæœªä¾†æˆ–è¨±èƒ½æˆç‚ºæ²»ç™‚èƒƒç™Œçš„æ–°æ–¹å‘ï¼\n\nğŸ” é‡é»æ•´ç†ï¼š  \n1. è˜¿è””ç¡«ç´ å¯èƒ½å¹«åŠ©æŠ‘åˆ¶èƒƒç™Œç”Ÿé•·ã€‚  \n2. CKMT2-AS1æ˜¯ä¸€å€‹èˆ‡èƒƒç™Œç”Ÿå­˜ç‡ç›¸é—œçš„åˆ†å­ã€‚  \n3. é€™äº›ç™¼ç¾ç‚ºæœªä¾†çš„æ²»ç™‚æ–¹æ³•æä¾›äº†æ–°çš„æ€è·¯ï¼",
    "image_prompt": "Create a simple and informative illustration explaining the experimental methods and key results of a study on the anti-cancer effects of sulforaphane found in radishes. Use a flat design style with a white or light-colored background and soft colors. Include symbols representing sulforaphane or radishes, simplified icons for experimental subjects like humans, animals, or cells, and arrows or flow lines indicating the experimental steps. Include a section that clearly states the 'Key Results', such as protective effects or changes observed.",
    "is_human_study": true,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "èƒƒç™Œ Gastric Cancer",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41135276/"
  },
  {
    "id": "41275316",
    "title_en": "Investigating the clinical efficacy, safety and molecular mechanism of sulforaphane in autism spectrum disorder: an integrated study combining meta-analysis, network pharmacology, and computational biology.",
    "pub_date": "2025 Nov",
    "journal": "BMC pharmacology & toxicology",
    "abstract_en": "Sulforaphane, a natural antioxidant rich in cruciferous vegetables, has emerged as a promising dietary supplement for autism spectrum disorder (ASD). However, its therapeutic efficacy remains controversial, and the pharmacological mechanisms are not fully elucidated. Eligible randomized controlled trials were retrieved from PubMed, Web of Science, Embase, and Cochrane Library databases. Review Manager 5.4 was used for meta-analysis and bias risk assessment. Network pharmacology, Mendelian randomization, GEO data analyses, molecular docking, and molecular dynamics simulation were employed to explore the mechanisms of sulforaphane in ASD. Six trials involving 333 participants were included in the meta-analysis. Pooled results demonstrated that both 4-5 weeks and 8-10 weeks of sulforaphane supplementation significantly decreased the scores on the Social Responsiveness Scale compared to placebo controls. No significant difference was observed in the incidence of adverse events. Network pharmacology identified 10 core targets of sulforaphane in ASD, including AKT1, EGFR, HSP90AA1, SRC, CASP3, STAT1, MAPK1, MMP9, MAPK8, and JAK2. These targets were implicated in the PI3K-Akt signaling pathway, MAPK signaling pathway, Chemokine signaling pathway, Chemical carcinogenesis - reactive oxygen species, TNF signaling pathway, Th17 cell differentiation, mTOR signaling pathway, and IL-17 signaling pathway. Mendelian randomization further revealed an inverse association between STAT1 levels and ASD risk. GEO transcriptomic data provided independent validation for the network pharmacology predictions. The binding energies between sulforaphane and the top 10 core targets are all â‰¤ -4.0Â kcal/mol. Molecular dynamics simulations further validated the stable interaction between MMP-9 and sulforaphane. Sulforaphane may serve as an efficacious and safe adjunctive therapy for ASD, mediated by its anti-oxidant and anti-inflammatory effects along with the modulation of autophagy. CRD42025635045.",
    "para1": "è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å¤©ç„¶æŠ—æ°§åŒ–åŠ‘ï¼Œä¸»è¦å­˜åœ¨æ–¼åå­—èŠ±ç§‘è”¬èœä¸­ï¼Œæœ€è¿‘è¢«èªç‚ºå¯èƒ½å°è‡ªé–‰ç—‡è­œç³»éšœç¤™ï¼ˆASDï¼‰æœ‰å¹«åŠ©ã€‚é€™é …ç ”ç©¶çš„çµæœå¯èƒ½ç‚ºè‡ªé–‰ç—‡çš„é£²é£Ÿè£œå……ç™‚æ³•æä¾›æ–°çš„æ€è·¯ï¼Œç‰¹åˆ¥æ˜¯åœ¨å¦‚ä½•åˆ©ç”¨å¤©ç„¶æˆåˆ†ä¾†æ”¹å–„è‡ªé–‰ç—‡æ‚£è€…çš„ç¤¾äº¤èƒ½åŠ›æ–¹é¢ã€‚é›–ç„¶é€™äº›çµæœé¡¯ç¤ºè˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘è‡ªé–‰ç—‡çš„æŸäº›ç—‡ç‹€ï¼Œä½†ä»éœ€é€²ä¸€æ­¥ç ”ç©¶ä¾†ç¢ºèªå…¶ç™‚æ•ˆå’Œå®‰å…¨æ€§ï¼Œä»¥ä¾¿ç‚ºæ‚£è€…æä¾›æ›´æœ‰æ•ˆçš„æ²»ç™‚é¸æ“‡ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°è‡ªé–‰ç—‡è­œç³»éšœç¤™ï¼ˆASDï¼‰çš„å½±éŸ¿ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯è˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æ”¹å–„è‡ªé–‰ç—‡æ‚£è€…çš„ç¤¾äº¤åæ‡‰èƒ½åŠ›ï¼Œä»¥åŠå…¶èƒŒå¾Œçš„è—¥ç†æ©Ÿåˆ¶ã€‚ç”±æ–¼ç›®å‰å°æ–¼è˜¿è””ç¡«ç´ çš„ç™‚æ•ˆä»å­˜åœ¨çˆ­è­°ï¼Œå› æ­¤é€™é …ç ”ç©¶å¸Œæœ›èƒ½å¤ é€éç³»çµ±æ€§å›é¡§å’Œåˆ†æï¼Œæä¾›æ›´æ¸…æ™°çš„è­‰æ“šä¾†æ”¯æŒæˆ–åé§è˜¿è””ç¡«ç´ åœ¨è‡ªé–‰ç—‡æ²»ç™‚ä¸­çš„æ½›åœ¨ä½œç”¨ã€‚",
    "para3": "ç ”ç©¶è€…å¾å¤šå€‹è³‡æ–™åº«ä¸­æª¢ç´¢ç¬¦åˆæ¢ä»¶çš„éš¨æ©Ÿå°ç…§è©¦é©—ï¼Œä¸¦ä½¿ç”¨Review Manager 5.4é€²è¡Œçµ±è¨ˆåˆ†æå’Œåå€šé¢¨éšªè©•ä¼°ã€‚é€™é …ç ”ç©¶ç´å…¥äº†å…­å€‹è©¦é©—ï¼Œå…±æœ‰333ååƒèˆ‡è€…ã€‚ç ”ç©¶æ–¹æ³•åŒ…æ‹¬ç¶²çµ¡è—¥ç†å­¸ã€å­Ÿå¾·çˆ¾éš¨æ©ŸåŒ–ã€GEOæ•¸æ“šåˆ†æã€åˆ†å­å°æ¥å’Œåˆ†å­å‹•åŠ›å­¸æ¨¡æ“¬ï¼Œæ—¨åœ¨æ¢è¨è˜¿è””ç¡«ç´ åœ¨è‡ªé–‰ç—‡ä¸­çš„ä½œç”¨æ©Ÿåˆ¶ã€‚é€™äº›æ–¹æ³•çš„çµåˆä½¿ç ”ç©¶è€…èƒ½å¤ æ›´å…¨é¢åœ°ç†è§£è˜¿è””ç¡«ç´ çš„æ½›åœ¨æ•ˆæœã€‚",
    "para4": "ä¸»è¦çš„ç™¼ç¾æ˜¯ï¼Œç¶“é4åˆ°5é€±å’Œ8åˆ°10é€±çš„è˜¿è””ç¡«ç´ è£œå……å¾Œï¼Œåƒèˆ‡è€…åœ¨ç¤¾äº¤åæ‡‰é‡è¡¨ä¸Šçš„å¾—åˆ†é¡¯è‘—ä½æ–¼å®‰æ…°åŠ‘çµ„ï¼Œé¡¯ç¤ºå‡ºè˜¿è””ç¡«ç´ å¯èƒ½å°æ”¹å–„è‡ªé–‰ç—‡æ‚£è€…çš„ç¤¾äº¤èƒ½åŠ›æœ‰æ­£é¢å½±éŸ¿ã€‚æ­¤å¤–ï¼Œç ”ç©¶ä¸­ä¸¦æœªè§€å¯Ÿåˆ°é¡¯è‘—çš„å‰¯ä½œç”¨ç™¼ç”Ÿç‡ã€‚ç¶²çµ¡è—¥ç†å­¸åˆ†æç¢ºå®šäº†è˜¿è””ç¡«ç´ åœ¨è‡ªé–‰ç—‡ä¸­çš„10å€‹æ ¸å¿ƒé¶é»ï¼Œé€™äº›é¶é»èˆ‡å¤šæ¢ä¿¡è™Ÿé€šè·¯ç›¸é—œï¼Œé¡¯ç¤ºå‡ºè˜¿è””ç¡«ç´ å¯èƒ½é€éæŠ—æ°§åŒ–å’ŒæŠ—ç‚ä½œç”¨ä¾†ç™¼æ®æ•ˆæœã€‚é€™äº›çµæœç‚ºæœªä¾†çš„ç ”ç©¶æä¾›äº†é‡è¦çš„åŸºç¤ã€‚",
    "explanation_zh": "è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å¤©ç„¶æŠ—æ°§åŒ–åŠ‘ï¼Œä¸»è¦å­˜åœ¨æ–¼åå­—èŠ±ç§‘è”¬èœä¸­ï¼Œæœ€è¿‘è¢«èªç‚ºå¯èƒ½å°è‡ªé–‰ç—‡è­œç³»éšœç¤™ï¼ˆASDï¼‰æœ‰å¹«åŠ©ã€‚é€™é …ç ”ç©¶çš„çµæœå¯èƒ½ç‚ºè‡ªé–‰ç—‡çš„é£²é£Ÿè£œå……ç™‚æ³•æä¾›æ–°çš„æ€è·¯ï¼Œç‰¹åˆ¥æ˜¯åœ¨å¦‚ä½•åˆ©ç”¨å¤©ç„¶æˆåˆ†ä¾†æ”¹å–„è‡ªé–‰ç—‡æ‚£è€…çš„ç¤¾äº¤èƒ½åŠ›æ–¹é¢ã€‚é›–ç„¶é€™äº›çµæœé¡¯ç¤ºè˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘è‡ªé–‰ç—‡çš„æŸäº›ç—‡ç‹€ï¼Œä½†ä»éœ€é€²ä¸€æ­¥ç ”ç©¶ä¾†ç¢ºèªå…¶ç™‚æ•ˆå’Œå®‰å…¨æ€§ï¼Œä»¥ä¾¿ç‚ºæ‚£è€…æä¾›æ›´æœ‰æ•ˆçš„æ²»ç™‚é¸æ“‡ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°è‡ªé–‰ç—‡è­œç³»éšœç¤™ï¼ˆASDï¼‰çš„å½±éŸ¿ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯è˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æ”¹å–„è‡ªé–‰ç—‡æ‚£è€…çš„ç¤¾äº¤åæ‡‰èƒ½åŠ›ï¼Œä»¥åŠå…¶èƒŒå¾Œçš„è—¥ç†æ©Ÿåˆ¶ã€‚ç”±æ–¼ç›®å‰å°æ–¼è˜¿è””ç¡«ç´ çš„ç™‚æ•ˆä»å­˜åœ¨çˆ­è­°ï¼Œå› æ­¤é€™é …ç ”ç©¶å¸Œæœ›èƒ½å¤ é€éç³»çµ±æ€§å›é¡§å’Œåˆ†æï¼Œæä¾›æ›´æ¸…æ™°çš„è­‰æ“šä¾†æ”¯æŒæˆ–åé§è˜¿è””ç¡«ç´ åœ¨è‡ªé–‰ç—‡æ²»ç™‚ä¸­çš„æ½›åœ¨ä½œç”¨ã€‚\n\nç ”ç©¶è€…å¾å¤šå€‹è³‡æ–™åº«ä¸­æª¢ç´¢ç¬¦åˆæ¢ä»¶çš„éš¨æ©Ÿå°ç…§è©¦é©—ï¼Œä¸¦ä½¿ç”¨Review Manager 5.4é€²è¡Œçµ±è¨ˆåˆ†æå’Œåå€šé¢¨éšªè©•ä¼°ã€‚é€™é …ç ”ç©¶ç´å…¥äº†å…­å€‹è©¦é©—ï¼Œå…±æœ‰333ååƒèˆ‡è€…ã€‚ç ”ç©¶æ–¹æ³•åŒ…æ‹¬ç¶²çµ¡è—¥ç†å­¸ã€å­Ÿå¾·çˆ¾éš¨æ©ŸåŒ–ã€GEOæ•¸æ“šåˆ†æã€åˆ†å­å°æ¥å’Œåˆ†å­å‹•åŠ›å­¸æ¨¡æ“¬ï¼Œæ—¨åœ¨æ¢è¨è˜¿è””ç¡«ç´ åœ¨è‡ªé–‰ç—‡ä¸­çš„ä½œç”¨æ©Ÿåˆ¶ã€‚é€™äº›æ–¹æ³•çš„çµåˆä½¿ç ”ç©¶è€…èƒ½å¤ æ›´å…¨é¢åœ°ç†è§£è˜¿è””ç¡«ç´ çš„æ½›åœ¨æ•ˆæœã€‚\n\nä¸»è¦çš„ç™¼ç¾æ˜¯ï¼Œç¶“é4åˆ°5é€±å’Œ8åˆ°10é€±çš„è˜¿è””ç¡«ç´ è£œå……å¾Œï¼Œåƒèˆ‡è€…åœ¨ç¤¾äº¤åæ‡‰é‡è¡¨ä¸Šçš„å¾—åˆ†é¡¯è‘—ä½æ–¼å®‰æ…°åŠ‘çµ„ï¼Œé¡¯ç¤ºå‡ºè˜¿è””ç¡«ç´ å¯èƒ½å°æ”¹å–„è‡ªé–‰ç—‡æ‚£è€…çš„ç¤¾äº¤èƒ½åŠ›æœ‰æ­£é¢å½±éŸ¿ã€‚æ­¤å¤–ï¼Œç ”ç©¶ä¸­ä¸¦æœªè§€å¯Ÿåˆ°é¡¯è‘—çš„å‰¯ä½œç”¨ç™¼ç”Ÿç‡ã€‚ç¶²çµ¡è—¥ç†å­¸åˆ†æç¢ºå®šäº†è˜¿è””ç¡«ç´ åœ¨è‡ªé–‰ç—‡ä¸­çš„10å€‹æ ¸å¿ƒé¶é»ï¼Œé€™äº›é¶é»èˆ‡å¤šæ¢ä¿¡è™Ÿé€šè·¯ç›¸é—œï¼Œé¡¯ç¤ºå‡ºè˜¿è””ç¡«ç´ å¯èƒ½é€éæŠ—æ°§åŒ–å’ŒæŠ—ç‚ä½œç”¨ä¾†ç™¼æ®æ•ˆæœã€‚é€™äº›çµæœç‚ºæœªä¾†çš„ç ”ç©¶æä¾›äº†é‡è¦çš„åŸºç¤ã€‚",
    "fb_post": "æ ¹æ“šã€ŠBMC pharmacology & toxicologyã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿæˆ‘å€‘çš„æ—¥å¸¸é£²é£Ÿä¸­ï¼Œå…¶å¯¦è—è‘—ä¸€äº›å°å¥åº·æœ‰å¹«åŠ©çš„å¤©ç„¶æˆåˆ†ï¼æœ€è¿‘ï¼Œç§‘å­¸å®¶å€‘ç™¼ç¾äº†ä¸€ç¨®å«åšè˜¿è””ç¡«ç´ çš„å¤©ç„¶æŠ—æ°§åŒ–åŠ‘ï¼Œä¸»è¦å­˜åœ¨æ–¼åƒé’èŠ±æ¤°èœé€™æ¨£çš„åå­—èŠ±ç§‘è”¬èœä¸­ã€‚é€™é …ç ”ç©¶ç‰¹åˆ¥é—œæ³¨è˜¿è””ç¡«ç´ å°è‡ªé–‰ç—‡è­œç³»éšœç¤™ï¼ˆASDï¼‰çš„å½±éŸ¿ï¼Œæƒ³çŸ¥é“å®ƒæ˜¯å¦èƒ½æ”¹å–„è‡ªé–‰ç—‡æ‚£è€…çš„ç¤¾äº¤èƒ½åŠ›ã€‚\n\nç ”ç©¶è€…å¾å¤šå€‹è³‡æ–™åº«ä¸­æ‰¾åˆ°äº†å…­å€‹éš¨æ©Ÿå°ç…§è©¦é©—ï¼Œç¸½å…±æœ‰333ååƒèˆ‡è€…ã€‚ä»–å€‘ä½¿ç”¨å„ç¨®ç§‘å­¸æ–¹æ³•ä¾†åˆ†æè˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ï¼Œä¸¦é€²è¡Œäº†çµ±è¨ˆåˆ†æã€‚çµæœé¡¯ç¤ºï¼Œç¶“é4åˆ°10é€±çš„è˜¿è””ç¡«ç´ è£œå……å¾Œï¼Œåƒèˆ‡è€…çš„ç¤¾äº¤åæ‡‰èƒ½åŠ›æœ‰é¡¯è‘—æ”¹å–„ï¼Œä¸¦ä¸”æ²’æœ‰è§€å¯Ÿåˆ°æ˜é¡¯çš„å‰¯ä½œç”¨ã€‚\n\né€™äº›ç™¼ç¾è®“æˆ‘å€‘å°è˜¿è””ç¡«ç´ çš„æ½›åœ¨ç›Šè™•æœ‰äº†æ–°çš„èªè­˜ï¼Œä½†ä»éœ€è¦æ›´å¤šçš„ç ”ç©¶ä¾†ç¢ºèªå®ƒçš„ç™‚æ•ˆå’Œå®‰å…¨æ€§ã€‚\n\nğŸ” ä¸»è¦é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„è‡ªé–‰ç—‡æ‚£è€…çš„ç¤¾äº¤èƒ½åŠ›ã€‚\n2. ç ”ç©¶ä¸­æœªè§€å¯Ÿåˆ°é¡¯è‘—çš„å‰¯ä½œç”¨ã€‚\n3. ä»éœ€é€²ä¸€æ­¥ç ”ç©¶ä¾†ç¢ºèªå…¶ç™‚æ•ˆå’Œå®‰å…¨æ€§ã€‚",
    "image_prompt": "Create an informative infographic that explains the experiment methods and main results of a study on sulforaphane. The design should feature flat illustrations with a white or light-colored background and soft color palette. Include symbols representing broccoli or sulforaphane, simplified illustrations of experimental subjects (like people or cells), arrows or flow lines to indicate experimental steps, and a section labeled 'Main Results' showcasing protective effects or changes observed.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "è‡ªé–‰ç—‡è­œç³»éšœç¤™ Autism Spectrum Disorder",
    "is_clinical_trial": true,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41275316/"
  },
  {
    "id": "41159773",
    "title_en": "Sulforaphane-Loaded Hydrogel Prolongs Fully MHC-Mismatched Skin Allograft Survival.",
    "pub_date": "2025 Nov",
    "journal": "ACS applied bio materials",
    "abstract_en": "Despite immunosuppression, acute rejection (AR) is still a common setback among transplantation patients and is a risk factor for graft survival. Sulforaphane (SFN), a phytochemical present in crucifers, has been shown to have anti-inflammatory and immunoregulatory properties, yet its influences on immune cell activation as well as in graft survival are still unknown. Thus, the aim was to evaluate SFN's effect, and to improve efficacy, efficiency, and availability, it was incorporated into thermosensitive polymeric hydrogels, to prevent AR in skin transplant (Tx) model mice. A thermosensitive hydrogel containing SFN (0.1%) and hyaluronic acid (HA) (0.5%) dispersed in a poloxamer matrix (PL407 at 20% w/v) was developed (GS-PL407 20%, HA and SFN) and characterized as a liquid-viscous hydrogel. The fully MHC-incompatible skin Tx procedure was performed by using donor skin Balb/c mice, transplanted into C57BL/6 recipient mice. The cytotoxicity test of GS was performed using in vitro assays with bone marrow-derived dendritic cells (BMDC). Treatment of BMDC with GS for 24 h presents no cytotoxicity. Untreated allograft mice present 100% of graft loss at day 9 post Tx. Remarkably, subcutaneous GS injection every 3 days promoted 80% of allograft survival for more than 14 days when compared with untreated recipients (<i>p</i> < 0.001). Histological analysis showed a lower level of inflammatory cells in the skin Tx of GS-treated mice. Flow cytometry analysis of draining lymph nodes at day 5 post Tx revealed that GS treatment reduced the frequency of DC and subtypes and function of the CD4<sup>+</sup> T cells. In vitro GS-treated lipopolysaccharide-activated BMDC present less activation of costimulatory markers. Taken together, GS treatment reduced immune cell activation, postponing AR onset and prolonging allograft survival in Tx animals. This strategy highlights the role of SFN as a promising candidate for further studies in organ transplantation experiments and being tested combined with current immunosuppression protocols.",
    "para1": "åœ¨å™¨å®˜ç§»æ¤ä¸­ï¼Œæ€¥æ€§æ’æ–¥åæ‡‰æ˜¯ä¸€å€‹å¸¸è¦‹çš„å•é¡Œï¼Œå¯èƒ½æœƒå½±éŸ¿ç§»æ¤å™¨å®˜çš„å­˜æ´»ç‡ã€‚é€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ é€™ç¨®æ¤ç‰©åŒ–å­¸ç‰©è³ªçš„æ½›åœ¨ç›Šè™•ï¼Œå› ç‚ºå®ƒå…·æœ‰æŠ—ç™¼ç‚å’Œå…ç–«èª¿ç¯€çš„ç‰¹æ€§ã€‚äº†è§£è˜¿è””ç¡«ç´ å°å…ç–«ç´°èƒæ´»åŒ–çš„å½±éŸ¿ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„ç§»æ¤å¾Œçš„å¥åº·ç‹€æ³ï¼Œä¸¦é™ä½æ€¥æ€§æ’æ–¥åæ‡‰çš„é¢¨éšªï¼Œé€™å°æ–¼æœªä¾†çš„ç–¾ç—…é é˜²å’Œæ²»ç™‚ç­–ç•¥å…·æœ‰é‡è¦æ„ç¾©ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»è¦ç›®çš„æ˜¯è©•ä¼°è˜¿è””ç¡«ç´ åœ¨çš®è†šç§»æ¤æ¨¡å‹ä¸­çš„æ•ˆæœï¼Œç‰¹åˆ¥æ˜¯å®ƒå°æ€¥æ€§æ’æ–¥åæ‡‰çš„å½±éŸ¿ã€‚ç ”ç©¶è€…å¸Œæœ›é€šéå°‡è˜¿è””ç¡«ç´ èˆ‡ç†±æ•èšåˆç‰©æ°´å‡è† çµåˆï¼Œä¾†æé«˜å…¶ç™‚æ•ˆå’Œå¯ç”¨æ€§ã€‚é€™æ¨£çš„ç ”ç©¶ä¸åƒ…æœ‰åŠ©æ–¼äº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ï¼Œé‚„å¯èƒ½ç‚ºæ”¹å–„å™¨å®˜ç§»æ¤å¾Œçš„å…ç–«åæ‡‰æä¾›æ–°çš„æ€è·¯ã€‚",
    "para3": "å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†å°é¼ ä½œç‚ºæ¨¡å‹ï¼Œå°‡è˜¿è””ç¡«ç´ ï¼ˆ0.1%ï¼‰å’Œé€æ˜è³ªé…¸ï¼ˆ0.5%ï¼‰æ··åˆåœ¨ä¸€ç¨®èšåˆç‰©åŸºè³ªä¸­ï¼Œè£½æˆäº†ç†±æ•æ°´å‡è† ã€‚ç„¶å¾Œï¼Œå°‡é€™ç¨®æ°´å‡è† æ³¨å°„åˆ°æ¥å—çš®è†šç§»æ¤çš„å°é¼ èº«ä¸Šã€‚å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…è§€å¯Ÿäº†ç§»æ¤å¾Œçš„å…ç–«åæ‡‰å’Œç§»æ¤å™¨å®˜çš„å­˜æ´»æƒ…æ³ï¼Œä¸¦é€²è¡Œäº†ç´°èƒæ¯’æ€§æ¸¬è©¦ï¼Œä»¥ç¢ºä¿é€™ç¨®æ²»ç™‚æ–¹æ³•çš„å®‰å…¨æ€§ã€‚",
    "para4": "ç ”ç©¶çµæœé¡¯ç¤ºï¼Œæ¥å—è˜¿è””ç¡«ç´ æ²»ç™‚çš„å°é¼ åœ¨ç§»æ¤å¾Œçš„14å¤©å…§ï¼Œæœ‰80%çš„ç§»æ¤å™¨å®˜å­˜æ´»ï¼Œé¡¯è‘—é«˜æ–¼æœªæ¥å—æ²»ç™‚çš„å°é¼ ï¼ˆ100%ç§»æ¤å™¨å®˜åœ¨ç¬¬9å¤©å¤±æ•—ï¼‰ã€‚æ­¤å¤–ï¼Œçµ„ç¹”å­¸åˆ†æé¡¯ç¤ºï¼Œæ¥å—æ²»ç™‚çš„å°é¼ çš®è†šä¸­çš„ç‚ç—‡ç´°èƒæ•¸é‡è¼ƒå°‘ï¼Œé€™è¡¨æ˜è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘å…ç–«ç´°èƒçš„æ´»åŒ–ï¼Œå»¶ç·©æ€¥æ€§æ’æ–¥åæ‡‰çš„ç™¼ç”Ÿã€‚é€™äº›ç™¼ç¾ç‚ºè˜¿è””ç¡«ç´ åœ¨å™¨å®˜ç§»æ¤ä¸­çš„æ‡‰ç”¨æä¾›äº†æ–°çš„ç ”ç©¶æ–¹å‘ã€‚",
    "explanation_zh": "åœ¨å™¨å®˜ç§»æ¤ä¸­ï¼Œæ€¥æ€§æ’æ–¥åæ‡‰æ˜¯ä¸€å€‹å¸¸è¦‹çš„å•é¡Œï¼Œå¯èƒ½æœƒå½±éŸ¿ç§»æ¤å™¨å®˜çš„å­˜æ´»ç‡ã€‚é€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ é€™ç¨®æ¤ç‰©åŒ–å­¸ç‰©è³ªçš„æ½›åœ¨ç›Šè™•ï¼Œå› ç‚ºå®ƒå…·æœ‰æŠ—ç™¼ç‚å’Œå…ç–«èª¿ç¯€çš„ç‰¹æ€§ã€‚äº†è§£è˜¿è””ç¡«ç´ å°å…ç–«ç´°èƒæ´»åŒ–çš„å½±éŸ¿ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„ç§»æ¤å¾Œçš„å¥åº·ç‹€æ³ï¼Œä¸¦é™ä½æ€¥æ€§æ’æ–¥åæ‡‰çš„é¢¨éšªï¼Œé€™å°æ–¼æœªä¾†çš„ç–¾ç—…é é˜²å’Œæ²»ç™‚ç­–ç•¥å…·æœ‰é‡è¦æ„ç¾©ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»è¦ç›®çš„æ˜¯è©•ä¼°è˜¿è””ç¡«ç´ åœ¨çš®è†šç§»æ¤æ¨¡å‹ä¸­çš„æ•ˆæœï¼Œç‰¹åˆ¥æ˜¯å®ƒå°æ€¥æ€§æ’æ–¥åæ‡‰çš„å½±éŸ¿ã€‚ç ”ç©¶è€…å¸Œæœ›é€šéå°‡è˜¿è””ç¡«ç´ èˆ‡ç†±æ•èšåˆç‰©æ°´å‡è† çµåˆï¼Œä¾†æé«˜å…¶ç™‚æ•ˆå’Œå¯ç”¨æ€§ã€‚é€™æ¨£çš„ç ”ç©¶ä¸åƒ…æœ‰åŠ©æ–¼äº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ï¼Œé‚„å¯èƒ½ç‚ºæ”¹å–„å™¨å®˜ç§»æ¤å¾Œçš„å…ç–«åæ‡‰æä¾›æ–°çš„æ€è·¯ã€‚\n\nå¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†å°é¼ ä½œç‚ºæ¨¡å‹ï¼Œå°‡è˜¿è””ç¡«ç´ ï¼ˆ0.1%ï¼‰å’Œé€æ˜è³ªé…¸ï¼ˆ0.5%ï¼‰æ··åˆåœ¨ä¸€ç¨®èšåˆç‰©åŸºè³ªä¸­ï¼Œè£½æˆäº†ç†±æ•æ°´å‡è† ã€‚ç„¶å¾Œï¼Œå°‡é€™ç¨®æ°´å‡è† æ³¨å°„åˆ°æ¥å—çš®è†šç§»æ¤çš„å°é¼ èº«ä¸Šã€‚å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…è§€å¯Ÿäº†ç§»æ¤å¾Œçš„å…ç–«åæ‡‰å’Œç§»æ¤å™¨å®˜çš„å­˜æ´»æƒ…æ³ï¼Œä¸¦é€²è¡Œäº†ç´°èƒæ¯’æ€§æ¸¬è©¦ï¼Œä»¥ç¢ºä¿é€™ç¨®æ²»ç™‚æ–¹æ³•çš„å®‰å…¨æ€§ã€‚\n\nç ”ç©¶çµæœé¡¯ç¤ºï¼Œæ¥å—è˜¿è””ç¡«ç´ æ²»ç™‚çš„å°é¼ åœ¨ç§»æ¤å¾Œçš„14å¤©å…§ï¼Œæœ‰80%çš„ç§»æ¤å™¨å®˜å­˜æ´»ï¼Œé¡¯è‘—é«˜æ–¼æœªæ¥å—æ²»ç™‚çš„å°é¼ ï¼ˆ100%ç§»æ¤å™¨å®˜åœ¨ç¬¬9å¤©å¤±æ•—ï¼‰ã€‚æ­¤å¤–ï¼Œçµ„ç¹”å­¸åˆ†æé¡¯ç¤ºï¼Œæ¥å—æ²»ç™‚çš„å°é¼ çš®è†šä¸­çš„ç‚ç—‡ç´°èƒæ•¸é‡è¼ƒå°‘ï¼Œé€™è¡¨æ˜è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘å…ç–«ç´°èƒçš„æ´»åŒ–ï¼Œå»¶ç·©æ€¥æ€§æ’æ–¥åæ‡‰çš„ç™¼ç”Ÿã€‚é€™äº›ç™¼ç¾ç‚ºè˜¿è””ç¡«ç´ åœ¨å™¨å®˜ç§»æ¤ä¸­çš„æ‡‰ç”¨æä¾›äº†æ–°çš„ç ”ç©¶æ–¹å‘ã€‚",
    "fb_post": "æ ¹æ“šã€ŠACS applied bio materialsã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ± ä½ çŸ¥é“å—ï¼Ÿè˜¿è””è£¡é¢è—è‘—çš„æˆåˆ†å¯èƒ½å°å™¨å®˜ç§»æ¤æœ‰å¹«åŠ©ï¼\n\næœ€è¿‘æœ‰ä¸€é …ç ”ç©¶å°ˆæ³¨æ–¼è˜¿è””ç¡«ç´ é€™ç¨®æ¤ç‰©åŒ–å­¸ç‰©è³ªï¼Œå®ƒè¢«ç™¼ç¾æœ‰æŠ—ç™¼ç‚å’Œèª¿ç¯€å…ç–«çš„ç‰¹æ€§ï¼Œé€™å°æ–¼å™¨å®˜ç§»æ¤å¾Œçš„å¥åº·éå¸¸é‡è¦ã€‚ç ”ç©¶è€…å€‘æƒ³çŸ¥é“ï¼Œè˜¿è””ç¡«ç´ èƒ½å¦å¹«åŠ©æ¸›å°‘æ€¥æ€§æ’æ–¥åæ‡‰ï¼Œè®“ç§»æ¤çš„å™¨å®˜å­˜æ´»å¾—æ›´ä¹…ã€‚\n\nä»–å€‘åœ¨å°é¼ èº«ä¸Šé€²è¡Œäº†å¯¦é©—ï¼Œå°‡è˜¿è””ç¡«ç´ å’Œé€æ˜è³ªé…¸æ··åˆè£½ä½œæˆæ°´å‡è† ï¼Œç„¶å¾Œæ³¨å°„åˆ°æ¥å—çš®è†šç§»æ¤çš„å°é¼ é«”å…§ã€‚å¯¦é©—çµæœé¡¯ç¤ºï¼Œæ¥å—è˜¿è””ç¡«ç´ çš„å°é¼ åœ¨14å¤©å…§ï¼Œæœ‰80%çš„ç§»æ¤å™¨å®˜å­˜æ´»ï¼Œé€™æ¯”æœªæ¥å—æ²»ç™‚çš„å°é¼ è¦å¥½å¾—å¤šï¼è€Œä¸”ï¼Œæ¥å—æ²»ç™‚çš„å°é¼ é«”å…§çš„ç‚ç—‡ç´°èƒä¹Ÿè¼ƒå°‘ï¼Œé€™æ„å‘³è‘—è˜¿è””ç¡«ç´ å¯èƒ½å¹«åŠ©æ¸›å°‘å…ç–«ç³»çµ±çš„éåº¦åæ‡‰ã€‚\n\nğŸ” ç¸½çµä¸€ä¸‹ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼å™¨å®˜ç§»æ¤å¾Œçš„å¥åº·ã€‚\n2. é€™é …ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½æé«˜ç§»æ¤å™¨å®˜çš„å­˜æ´»ç‡ã€‚\n3. æ¸›å°‘å…ç–«ç´°èƒçš„æ´»åŒ–ï¼Œå¯èƒ½æœ‰åŠ©æ–¼å»¶ç·©æ€¥æ€§æ’æ–¥åæ‡‰çš„ç™¼ç”Ÿã€‚\n\næœªä¾†çš„ç ”ç©¶å¯èƒ½æœƒè®“æˆ‘å€‘æ›´äº†è§£é€™å€‹ç¥å¥‡çš„æˆåˆ†ï¼",
    "image_prompt": "Create an infographic that explains the experimental process and main results of a study on the effects of sulforaphane (found in broccoli and radishes) in organ transplantation. Use a flat design style with a white or light-colored background and soft colors. Include simplified illustrations of sulforaphane, experimental subjects like mice, and arrows or flow lines to show the steps of the experiment. Add a section labeled 'Main Results' highlighting the protective effects observed, such as improved organ survival rates.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "å™¨å®˜ç§»æ¤ Organ Transplantation",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41159773/"
  },
  {
    "id": "41196460",
    "title_en": "Sulforaphane: a natural organosulfur having potential to modulate apoptosis and survival signalling in cancer.",
    "pub_date": "2025 Nov",
    "journal": "Discover oncology",
    "abstract_en": "Owing to its ever-growing range of pharmacological advantages, sulforaphane, an isothiocyanate from cruciferous vegetables such as broccoli, is becoming increasingly popular. This review aims to provide a thorough understanding and a current update on the application of sulforaphane in cancer treatment. Sulforaphane interacts with many signaling molecules that control various pathways in malignant cells, including angiogenesis, apoptosis, cell cycle arrest, metastasis, and inflammation pathways. This review examines the effects of this isothiocyanate on inflammatory mediators, caspases, MMPs, cytokines, and the proteins Bax and Bcl-2. Furthermore, the advantages of nanotechnology and synergistic effects in sulforaphane applications are also reviewed. As per evidence, sulforaphane is a shining example of how ethno-pharmacological expertise can be used to create modern medications.",
    "para1": "è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®ä¾†è‡ªé’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘è”¬èœçš„åŒ–åˆç‰©ï¼Œå› å…¶æ½›åœ¨çš„è—¥ç†å„ªå‹¢è€Œå—åˆ°è¶Šä¾†è¶Šå¤šçš„é—œæ³¨ã€‚é€™é …ç ”ç©¶çš„çµæœå¯èƒ½å°å¥åº·å’Œç–¾ç—…é é˜²æœ‰é‡è¦å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨ç™Œç—‡æ²»ç™‚æ–¹é¢ã€‚éš¨è‘—å°è˜¿è””ç¡«ç´ çš„äº†è§£åŠ æ·±ï¼Œæœªä¾†å¯èƒ½æœƒé–‹ç™¼å‡ºæ–°çš„æ²»ç™‚æ–¹æ³•ï¼Œå¹«åŠ©æ¸›å°‘ç™Œç—‡çš„ç™¼ç”Ÿæˆ–æ”¹å–„æ‚£è€…çš„ç”Ÿæ´»å“è³ªã€‚é€™ä¹Ÿæé†’æˆ‘å€‘ï¼Œé£²é£Ÿä¸­å¢åŠ é€™é¡è”¬èœçš„æ”å–ï¼Œå¯èƒ½å°å¥åº·æœ‰æ­£é¢å½±éŸ¿ã€‚",
    "para2": "é€™ç¯‡ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨ç™Œç—‡æ²»ç™‚ä¸­çš„æ‡‰ç”¨ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡ŒåŒ…æ‹¬è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç™Œç´°èƒçš„ä¸åŒç”Ÿç‰©å­¸éç¨‹ï¼Œä¾‹å¦‚è¡€ç®¡ç”Ÿæˆã€ç´°èƒå‡‹äº¡ã€ç´°èƒé€±æœŸåœæ»¯ã€è½‰ç§»å’Œç‚ç—‡ç­‰ã€‚é€™äº›éç¨‹å°æ–¼ç™Œç—‡çš„ç™¼å±•å’Œé€²å±•æœ‰è‘—é‡è¦çš„å½±éŸ¿ï¼Œå› æ­¤æ·±å…¥äº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ï¼Œå°æ–¼é–‹ç™¼æ–°çš„æ²»ç™‚ç­–ç•¥è‡³é—œé‡è¦ã€‚",
    "para3": "åœ¨é€™é …ç ”ç©¶ä¸­ï¼Œç ”ç©¶è€…å›é¡§äº†è˜¿è””ç¡«ç´ å°å¤šç¨®ç”Ÿç‰©æ¨™è¨˜ç‰©çš„å½±éŸ¿ï¼ŒåŒ…æ‹¬ç‚ç—‡ä»‹è³ªã€åŠèƒ±å¤©å†¬é…¶ã€åŸºè³ªé‡‘å±¬è›‹ç™½é…¶ã€ç´°èƒå› å­ä»¥åŠBaxå’ŒBcl-2ç­‰è›‹ç™½è³ªã€‚é€™äº›æ¨™è¨˜ç‰©åœ¨ç™Œç—‡çš„ç™¼å±•ä¸­æ‰®æ¼”è‘—é‡è¦è§’è‰²ã€‚ç ”ç©¶é‚„æ¢è¨äº†ç´ç±³æŠ€è¡“å’Œè˜¿è””ç¡«ç´ çš„å”åŒæ•ˆæ‡‰ï¼Œé€™å¯èƒ½é€²ä¸€æ­¥æå‡å…¶åœ¨æ²»ç™‚ä¸­çš„æ•ˆæœã€‚é€™äº›ç ”ç©¶æ–¹æ³•æä¾›äº†å°è˜¿è””ç¡«ç´ åœ¨ç™Œç—‡æ²»ç™‚ä¸­æ½›åœ¨æ‡‰ç”¨çš„æ·±å…¥è¦‹è§£ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ èˆ‡å¤šç¨®ä¿¡è™Ÿåˆ†å­äº’å‹•ï¼Œå½±éŸ¿ç™Œç´°èƒçš„å¤šå€‹é—œéµé€”å¾‘ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ åœ¨ç™Œç—‡æ²»ç™‚ä¸­å¯èƒ½å…·æœ‰æ½›åœ¨çš„æ‡‰ç”¨åƒ¹å€¼ï¼Œå°¤å…¶æ˜¯åœ¨èª¿æ§ç‚ç—‡å’Œç´°èƒå‡‹äº¡æ–¹é¢ã€‚é›–ç„¶ç›®å‰çš„ç ”ç©¶æä¾›äº†æœ‰å¸Œæœ›çš„çµæœï¼Œä½†ä»éœ€é€²ä¸€æ­¥çš„è‡¨åºŠè©¦é©—ä¾†ç¢ºèªå…¶æ•ˆæœå’Œå®‰å…¨æ€§ï¼Œä¸¦æ¢ç´¢å…¶åœ¨å¯¦éš›æ²»ç™‚ä¸­çš„æ‡‰ç”¨ã€‚",
    "explanation_zh": "è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®ä¾†è‡ªé’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘è”¬èœçš„åŒ–åˆç‰©ï¼Œå› å…¶æ½›åœ¨çš„è—¥ç†å„ªå‹¢è€Œå—åˆ°è¶Šä¾†è¶Šå¤šçš„é—œæ³¨ã€‚é€™é …ç ”ç©¶çš„çµæœå¯èƒ½å°å¥åº·å’Œç–¾ç—…é é˜²æœ‰é‡è¦å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨ç™Œç—‡æ²»ç™‚æ–¹é¢ã€‚éš¨è‘—å°è˜¿è””ç¡«ç´ çš„äº†è§£åŠ æ·±ï¼Œæœªä¾†å¯èƒ½æœƒé–‹ç™¼å‡ºæ–°çš„æ²»ç™‚æ–¹æ³•ï¼Œå¹«åŠ©æ¸›å°‘ç™Œç—‡çš„ç™¼ç”Ÿæˆ–æ”¹å–„æ‚£è€…çš„ç”Ÿæ´»å“è³ªã€‚é€™ä¹Ÿæé†’æˆ‘å€‘ï¼Œé£²é£Ÿä¸­å¢åŠ é€™é¡è”¬èœçš„æ”å–ï¼Œå¯èƒ½å°å¥åº·æœ‰æ­£é¢å½±éŸ¿ã€‚\n\né€™ç¯‡ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨ç™Œç—‡æ²»ç™‚ä¸­çš„æ‡‰ç”¨ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡ŒåŒ…æ‹¬è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç™Œç´°èƒçš„ä¸åŒç”Ÿç‰©å­¸éç¨‹ï¼Œä¾‹å¦‚è¡€ç®¡ç”Ÿæˆã€ç´°èƒå‡‹äº¡ã€ç´°èƒé€±æœŸåœæ»¯ã€è½‰ç§»å’Œç‚ç—‡ç­‰ã€‚é€™äº›éç¨‹å°æ–¼ç™Œç—‡çš„ç™¼å±•å’Œé€²å±•æœ‰è‘—é‡è¦çš„å½±éŸ¿ï¼Œå› æ­¤æ·±å…¥äº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ï¼Œå°æ–¼é–‹ç™¼æ–°çš„æ²»ç™‚ç­–ç•¥è‡³é—œé‡è¦ã€‚\n\nåœ¨é€™é …ç ”ç©¶ä¸­ï¼Œç ”ç©¶è€…å›é¡§äº†è˜¿è””ç¡«ç´ å°å¤šç¨®ç”Ÿç‰©æ¨™è¨˜ç‰©çš„å½±éŸ¿ï¼ŒåŒ…æ‹¬ç‚ç—‡ä»‹è³ªã€åŠèƒ±å¤©å†¬é…¶ã€åŸºè³ªé‡‘å±¬è›‹ç™½é…¶ã€ç´°èƒå› å­ä»¥åŠBaxå’ŒBcl-2ç­‰è›‹ç™½è³ªã€‚é€™äº›æ¨™è¨˜ç‰©åœ¨ç™Œç—‡çš„ç™¼å±•ä¸­æ‰®æ¼”è‘—é‡è¦è§’è‰²ã€‚ç ”ç©¶é‚„æ¢è¨äº†ç´ç±³æŠ€è¡“å’Œè˜¿è””ç¡«ç´ çš„å”åŒæ•ˆæ‡‰ï¼Œé€™å¯èƒ½é€²ä¸€æ­¥æå‡å…¶åœ¨æ²»ç™‚ä¸­çš„æ•ˆæœã€‚é€™äº›ç ”ç©¶æ–¹æ³•æä¾›äº†å°è˜¿è””ç¡«ç´ åœ¨ç™Œç—‡æ²»ç™‚ä¸­æ½›åœ¨æ‡‰ç”¨çš„æ·±å…¥è¦‹è§£ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ èˆ‡å¤šç¨®ä¿¡è™Ÿåˆ†å­äº’å‹•ï¼Œå½±éŸ¿ç™Œç´°èƒçš„å¤šå€‹é—œéµé€”å¾‘ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ åœ¨ç™Œç—‡æ²»ç™‚ä¸­å¯èƒ½å…·æœ‰æ½›åœ¨çš„æ‡‰ç”¨åƒ¹å€¼ï¼Œå°¤å…¶æ˜¯åœ¨èª¿æ§ç‚ç—‡å’Œç´°èƒå‡‹äº¡æ–¹é¢ã€‚é›–ç„¶ç›®å‰çš„ç ”ç©¶æä¾›äº†æœ‰å¸Œæœ›çš„çµæœï¼Œä½†ä»éœ€é€²ä¸€æ­¥çš„è‡¨åºŠè©¦é©—ä¾†ç¢ºèªå…¶æ•ˆæœå’Œå®‰å…¨æ€§ï¼Œä¸¦æ¢ç´¢å…¶åœ¨å¯¦éš›æ²»ç™‚ä¸­çš„æ‡‰ç”¨ã€‚",
    "fb_post": "æ ¹æ“šã€ŠDiscover oncologyã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸ½ï¸ å¤§å®¶çŸ¥é“å—ï¼Ÿæˆ‘å€‘çš„é£²é£Ÿä¸­ç«Ÿç„¶è—è‘—å¯èƒ½å¹«åŠ©æŠ—ç™Œçš„ç§˜å¯†æ­¦å™¨ï¼\n\næœ€è¿‘æœ‰ä¸€é …ç ”ç©¶èšç„¦æ–¼ä¸€ç¨®å«åšè˜¿è””ç¡«ç´ çš„åŒ–åˆç‰©ï¼Œå®ƒä¸»è¦ä¾†è‡ªé’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘çš„è”¬èœã€‚é€™é …ç ”ç©¶æƒ³äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç™Œç´°èƒçš„ç”Ÿé•·éç¨‹ï¼Œåƒæ˜¯è¡€ç®¡ç”Ÿæˆå’Œç´°èƒå‡‹äº¡ï¼ˆç´°èƒæ­»äº¡ï¼‰ã€‚\n\nç ”ç©¶è€…å€‘å›é¡§äº†è˜¿è””ç¡«ç´ å°å¤šç¨®ç”Ÿç‰©æ¨™è¨˜ç‰©çš„å½±éŸ¿ï¼Œé€™äº›æ¨™è¨˜ç‰©åœ¨ç™Œç—‡ç™¼å±•ä¸­æ‰®æ¼”è‘—é‡è¦è§’è‰²ã€‚ä»–å€‘é‚„æ¢è¨äº†è˜¿è””ç¡«ç´ èˆ‡ç´ç±³æŠ€è¡“çš„å”åŒæ•ˆæ‡‰ï¼Œé€™å¯èƒ½é€²ä¸€æ­¥æå‡æ²»ç™‚æ•ˆæœã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ èˆ‡å¤šç¨®ä¿¡è™Ÿåˆ†å­äº’å‹•ï¼Œèª¿æ§ç™Œç´°èƒçš„å¤šå€‹é—œéµé€”å¾‘ã€‚é›–ç„¶ç ”ç©¶çµæœä»¤äººæŒ¯å¥®ï¼Œä½†ä»éœ€é€²ä¸€æ­¥çš„è‡¨åºŠè©¦é©—ä¾†ç¢ºèªæ•ˆæœå’Œå®‰å…¨æ€§ã€‚\n\nğŸ“ ç¸½çµä¸€ä¸‹ï¼š  \n1. è˜¿è””ç¡«ç´ ä¾†è‡ªé’èŠ±æ¤°èœç­‰è”¬èœï¼Œå¯èƒ½å°æŠ—ç™Œæœ‰å¹«åŠ©ã€‚  \n2. ç ”ç©¶ç™¼ç¾è˜¿è””ç¡«ç´ èƒ½å½±éŸ¿ç™Œç´°èƒçš„å¤šå€‹éç¨‹ã€‚  \n3. ä»éœ€æ›´å¤šçš„ç ”ç©¶ä¾†ç¢ºèªå…¶æ•ˆæœå’Œå®‰å…¨æ€§ï¼Œè®“æˆ‘å€‘ä¸€èµ·æœŸå¾…æœªä¾†çš„ç™¼å±•ï¼",
    "image_prompt": "Create an informative illustration to explain the research on sulforaphane. Use a flat design style with a light background and soft colors. Include symbols of broccoli or sulforaphane, simplified representations of experimental subjects like humans or cells, arrows or flow lines showing the experimental steps, and a section labeled 'Main Findings' indicating protective effects or changes observed.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "ç™Œç—‡ Cancer",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41196460/"
  },
  {
    "id": "41184790",
    "title_en": "Efficacy and safety of sulforaphane in schizophrenia: a systematic review and meta-analysis of randomized controlled trials.",
    "pub_date": "2025 Nov",
    "journal": "BMC psychiatry",
    "abstract_en": "Sulforaphane, an isothiocyanate derived from cruciferous vegetables (e.g., broccoli sprouts), has been explored for its antioxidant and anti-inflammatory properties. This is the first systematic review and meta-analysis to explore the therapeutic potentials of sulforaphane in schizophrenia. We searched PubMed, Scopus, Web of Science, and Cochrane Central for studies from inception to April 2025. We included randomized controlled trials (RCTs) evaluating the efficacy of sulforaphane in schizophrenia. The primary outcomes were changes in the Positive and Negative Syndrome Scale (PANSS) total and its subscales. Secondary outcomes included cognitive measures, metabolic markers, and safety. Four RCTs with 369 schizophrenia patients were included. Sulforaphane did not significantly improve PANSS total or positive symptom scores at the latest follow-up (ranging from 24 weeks to 18 weeks) or at a consistent 12-week time point. However, a modest improvement in negative symptoms was found at 12 week- time point (MD= -1.06; 95% CI: -1.95 to -0.16; pâ€‰=â€‰0.02), which was not maintained at the latest follow-up. General psychopathology scores improved significantly (MD= -1.5; 95% CI: -2.78 to -0.23; pâ€‰=â€‰0.02). No cognitive benefits were observed. Sulforaphane led to significant reductions in metabolic markers, including LDL, triglycerides, and cholesterol. Discontinuation rates were lower in the sulforaphane group (RRâ€‰=â€‰0.68; 95% CI: 0.49 to 0.95; pâ€‰=â€‰0.02). The study provides initial insights into sulforaphane's potential therapeutic effects in schizophrenia, showing modest improvements in general psychopathology and negative symptoms, with favorable metabolic changes and lower discontinuation rates. Due to limited data and heterogeneity, the study findings should be interpreted with caution. Not applicable.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨ç²¾ç¥å¥åº·æ–¹é¢ã€‚è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®ä¾†è‡ªåå­—èŠ±ç§‘è”¬èœï¼ˆå¦‚é’èŠ±æ¤°èœï¼‰çš„åŒ–åˆç‰©ï¼Œéå»å·²ç¶“è¢«ç ”ç©¶å…¶æŠ—æ°§åŒ–å’ŒæŠ—ç™¼ç‚çš„ç‰¹æ€§ã€‚é€™æ¬¡çš„ç ”ç©¶å°ˆæ³¨æ–¼è˜¿è””ç¡«ç´ åœ¨ç²¾ç¥åˆ†è£‚ç—‡æ²»ç™‚ä¸­çš„æ½›åŠ›ï¼Œé€™å°æ–¼å°‹æ±‚æ–°ç™‚æ³•çš„æ‚£è€…ä¾†èªªï¼Œå¯èƒ½æ˜¯ä¸€å€‹å€¼å¾—é—œæ³¨çš„æ–¹å‘ã€‚é›–ç„¶çµæœé¡¯ç¤ºè˜¿è””ç¡«ç´ çš„ç™‚æ•ˆæœ‰é™ï¼Œä½†å®ƒåœ¨æ”¹å–„æŸäº›ç—‡ç‹€å’Œä»£è¬æŒ‡æ¨™æ–¹é¢çš„æ½›åŠ›ï¼Œä»ç„¶å€¼å¾—é€²ä¸€æ­¥æ¢ç´¢ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨ç²¾ç¥åˆ†è£‚ç—‡æ‚£è€…ä¸­çš„ç™‚æ•ˆã€‚ç ”ç©¶è€…é€²è¡Œäº†ä¸€å€‹ç³»çµ±æ€§çš„æ–‡ç»å›é¡§å’Œçµ±åˆåˆ†æï¼Œç›®çš„æ˜¯è©•ä¼°è˜¿è””ç¡«ç´ å°æ–¼ç²¾ç¥åˆ†è£‚ç—‡çš„æ²»ç™‚æ•ˆæœã€‚ç ”ç©¶è€…å¾å¤šå€‹è³‡æ–™åº«ä¸­æœå°‹ç›¸é—œçš„éš¨æ©Ÿå°ç…§è©¦é©—ï¼Œä¸¦å°ˆæ³¨æ–¼é€™äº›è©¦é©—ä¸­è˜¿è””ç¡«ç´ çš„æ•ˆæœï¼Œç‰¹åˆ¥æ˜¯å°æ–¼ç²¾ç¥åˆ†è£‚ç—‡çš„ç—‡ç‹€æ”¹å–„å’Œå®‰å…¨æ€§è©•ä¼°ã€‚",
    "para3": "åœ¨é€™é …ç ”ç©¶ä¸­ï¼Œç ”ç©¶è€…ç´å…¥äº†å››é …éš¨æ©Ÿå°ç…§è©¦é©—ï¼Œç¸½å…±369åç²¾ç¥åˆ†è£‚ç—‡æ‚£è€…åƒèˆ‡äº†é€™äº›è©¦é©—ã€‚ç ”ç©¶ä¸»è¦è©•ä¼°äº†è˜¿è””ç¡«ç´ å°æ–¼æ‚£è€…çš„æ­£è² ç—‡ç‹€é‡è¡¨ï¼ˆPANSSï¼‰çš„å½±éŸ¿ï¼Œä¸¦ä¸”é‚„è€ƒé‡äº†èªçŸ¥æ¸¬é‡ã€ä»£è¬æŒ‡æ¨™å’Œå®‰å…¨æ€§ç­‰æ¬¡è¦çµæœã€‚é€™äº›è©¦é©—çš„éš¨è¨ªæ™‚é–“å¾24é€±åˆ°18é€±ä¸ç­‰ï¼Œä¸¦åœ¨12é€±çš„æ™‚é–“é»é€²è¡Œäº†è©•ä¼°ã€‚",
    "para4": "ç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨æ”¹å–„PANSSç¸½åˆ†å’Œæ­£ç—‡ç‹€æ–¹é¢ä¸¦æœªé¡¯è‘—æœ‰æ•ˆï¼Œä½†åœ¨12é€±çš„æ™‚é–“é»ä¸Šï¼Œå°æ–¼è² ç—‡ç‹€æœ‰è¼•å¾®æ”¹å–„ã€‚ä¸€èˆ¬ç²¾ç¥ç—…ç†å­¸çš„è©•åˆ†ä¹Ÿæœ‰é¡¯è‘—æ”¹å–„ï¼Œé¡¯ç¤ºå‡ºè˜¿è””ç¡«ç´ åœ¨æŸäº›æ–¹é¢çš„æ½›åŠ›ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ é‚„èƒ½é¡¯è‘—é™ä½ä¸€äº›ä»£è¬æŒ‡æ¨™ï¼Œå¦‚ä½å¯†åº¦è„‚è›‹ç™½ï¼ˆLDLï¼‰ã€ä¸‰é…¸ç”˜æ²¹è„‚å’Œè†½å›ºé†‡ï¼Œä¸¦ä¸”åœ¨è˜¿è””ç¡«ç´ çµ„çš„æ‚£è€…ä¸­ï¼Œåœè—¥ç‡è¼ƒä½ã€‚ç„¶è€Œï¼Œç”±æ–¼æ•¸æ“šæœ‰é™ä¸”å­˜åœ¨ç•°è³ªæ€§ï¼Œé€™äº›çµæœéœ€è¦è¬¹æ…è§£è®€ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨ç²¾ç¥å¥åº·æ–¹é¢ã€‚è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®ä¾†è‡ªåå­—èŠ±ç§‘è”¬èœï¼ˆå¦‚é’èŠ±æ¤°èœï¼‰çš„åŒ–åˆç‰©ï¼Œéå»å·²ç¶“è¢«ç ”ç©¶å…¶æŠ—æ°§åŒ–å’ŒæŠ—ç™¼ç‚çš„ç‰¹æ€§ã€‚é€™æ¬¡çš„ç ”ç©¶å°ˆæ³¨æ–¼è˜¿è””ç¡«ç´ åœ¨ç²¾ç¥åˆ†è£‚ç—‡æ²»ç™‚ä¸­çš„æ½›åŠ›ï¼Œé€™å°æ–¼å°‹æ±‚æ–°ç™‚æ³•çš„æ‚£è€…ä¾†èªªï¼Œå¯èƒ½æ˜¯ä¸€å€‹å€¼å¾—é—œæ³¨çš„æ–¹å‘ã€‚é›–ç„¶çµæœé¡¯ç¤ºè˜¿è””ç¡«ç´ çš„ç™‚æ•ˆæœ‰é™ï¼Œä½†å®ƒåœ¨æ”¹å–„æŸäº›ç—‡ç‹€å’Œä»£è¬æŒ‡æ¨™æ–¹é¢çš„æ½›åŠ›ï¼Œä»ç„¶å€¼å¾—é€²ä¸€æ­¥æ¢ç´¢ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨ç²¾ç¥åˆ†è£‚ç—‡æ‚£è€…ä¸­çš„ç™‚æ•ˆã€‚ç ”ç©¶è€…é€²è¡Œäº†ä¸€å€‹ç³»çµ±æ€§çš„æ–‡ç»å›é¡§å’Œçµ±åˆåˆ†æï¼Œç›®çš„æ˜¯è©•ä¼°è˜¿è””ç¡«ç´ å°æ–¼ç²¾ç¥åˆ†è£‚ç—‡çš„æ²»ç™‚æ•ˆæœã€‚ç ”ç©¶è€…å¾å¤šå€‹è³‡æ–™åº«ä¸­æœå°‹ç›¸é—œçš„éš¨æ©Ÿå°ç…§è©¦é©—ï¼Œä¸¦å°ˆæ³¨æ–¼é€™äº›è©¦é©—ä¸­è˜¿è””ç¡«ç´ çš„æ•ˆæœï¼Œç‰¹åˆ¥æ˜¯å°æ–¼ç²¾ç¥åˆ†è£‚ç—‡çš„ç—‡ç‹€æ”¹å–„å’Œå®‰å…¨æ€§è©•ä¼°ã€‚\n\nåœ¨é€™é …ç ”ç©¶ä¸­ï¼Œç ”ç©¶è€…ç´å…¥äº†å››é …éš¨æ©Ÿå°ç…§è©¦é©—ï¼Œç¸½å…±369åç²¾ç¥åˆ†è£‚ç—‡æ‚£è€…åƒèˆ‡äº†é€™äº›è©¦é©—ã€‚ç ”ç©¶ä¸»è¦è©•ä¼°äº†è˜¿è””ç¡«ç´ å°æ–¼æ‚£è€…çš„æ­£è² ç—‡ç‹€é‡è¡¨ï¼ˆPANSSï¼‰çš„å½±éŸ¿ï¼Œä¸¦ä¸”é‚„è€ƒé‡äº†èªçŸ¥æ¸¬é‡ã€ä»£è¬æŒ‡æ¨™å’Œå®‰å…¨æ€§ç­‰æ¬¡è¦çµæœã€‚é€™äº›è©¦é©—çš„éš¨è¨ªæ™‚é–“å¾24é€±åˆ°18é€±ä¸ç­‰ï¼Œä¸¦åœ¨12é€±çš„æ™‚é–“é»é€²è¡Œäº†è©•ä¼°ã€‚\n\nç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨æ”¹å–„PANSSç¸½åˆ†å’Œæ­£ç—‡ç‹€æ–¹é¢ä¸¦æœªé¡¯è‘—æœ‰æ•ˆï¼Œä½†åœ¨12é€±çš„æ™‚é–“é»ä¸Šï¼Œå°æ–¼è² ç—‡ç‹€æœ‰è¼•å¾®æ”¹å–„ã€‚ä¸€èˆ¬ç²¾ç¥ç—…ç†å­¸çš„è©•åˆ†ä¹Ÿæœ‰é¡¯è‘—æ”¹å–„ï¼Œé¡¯ç¤ºå‡ºè˜¿è””ç¡«ç´ åœ¨æŸäº›æ–¹é¢çš„æ½›åŠ›ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ é‚„èƒ½é¡¯è‘—é™ä½ä¸€äº›ä»£è¬æŒ‡æ¨™ï¼Œå¦‚ä½å¯†åº¦è„‚è›‹ç™½ï¼ˆLDLï¼‰ã€ä¸‰é…¸ç”˜æ²¹è„‚å’Œè†½å›ºé†‡ï¼Œä¸¦ä¸”åœ¨è˜¿è””ç¡«ç´ çµ„çš„æ‚£è€…ä¸­ï¼Œåœè—¥ç‡è¼ƒä½ã€‚ç„¶è€Œï¼Œç”±æ–¼æ•¸æ“šæœ‰é™ä¸”å­˜åœ¨ç•°è³ªæ€§ï¼Œé€™äº›çµæœéœ€è¦è¬¹æ…è§£è®€ã€‚",
    "fb_post": "æ ¹æ“šã€ŠBMC psychiatryã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿä¾†è‡ªé’èŠ±æ¤°èœçš„è˜¿è””ç¡«ç´ ï¼Œå¯èƒ½å°ç²¾ç¥å¥åº·æœ‰ä¸€äº›æ„æƒ³ä¸åˆ°çš„å¹«åŠ©ï¼æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶å°ˆæ³¨æ–¼æ¢è¨è˜¿è””ç¡«ç´ åœ¨ç²¾ç¥åˆ†è£‚ç—‡æ‚£è€…ä¸­çš„æ•ˆæœï¼Œé€™å°æ–¼å°‹æ±‚æ–°ç™‚æ³•çš„æœ‹å‹å€‘ä¾†èªªï¼Œæˆ–è¨±æ˜¯ä¸€å€‹æœ‰è¶£çš„æ–¹å‘ã€‚ é€™é …ç ”ç©¶é€²è¡Œäº†ä¸€å€‹ç³»çµ±æ€§çš„æ–‡ç»å›é¡§ï¼Œåˆ†æäº†å¤šå€‹éš¨æ©Ÿå°ç…§è©¦é©—ï¼Œç¸½å…±369åç²¾ç¥åˆ†è£‚ç—‡æ‚£è€…åƒèˆ‡äº†é€™äº›è©¦é©—ã€‚ç ”ç©¶è€…ä¸»è¦é—œæ³¨è˜¿è””ç¡«ç´ å°æ–¼æ‚£è€…çš„ç—‡ç‹€æ”¹å–„å’Œå®‰å…¨æ€§ã€‚ çµæœé¡¯ç¤ºï¼Œé›–ç„¶è˜¿è””ç¡«ç´ åœ¨æ”¹å–„æŸäº›ç—‡ç‹€ä¸Šä¸¦æœªé¡¯è‘—æœ‰æ•ˆï¼Œä½†åœ¨è² ç—‡ç‹€æ–¹é¢æœ‰è¼•å¾®æ”¹å–„ï¼Œä¸¦ä¸”é‚„èƒ½é™ä½ä¸€äº›ä»£è¬æŒ‡æ¨™ï¼Œå¦‚å£è†½å›ºé†‡ï¼ˆLDLï¼‰å’Œä¸‰é…¸ç”˜æ²¹è„‚ã€‚æ­¤å¤–ï¼ŒåƒåŠ è˜¿è””ç¡«ç´ çµ„çš„æ‚£è€…åœè—¥ç‡è¼ƒä½ã€‚ ä¸éï¼Œå› ç‚ºæ•¸æ“šæœ‰é™ä¸”çµæœå­˜åœ¨å·®ç•°ï¼Œæˆ‘å€‘é‚„æ˜¯è¦è¬¹æ…è§£è®€é€™äº›ç™¼ç¾ã€‚ ç¸½çµä¾†èªªï¼š 1. è˜¿è””ç¡«ç´ å¯èƒ½å°ç²¾ç¥åˆ†è£‚ç—‡æ‚£è€…æœ‰äº›å¹«åŠ©ï¼Œä½†æ•ˆæœæœ‰é™ã€‚ 2. å®ƒèƒ½æ”¹å–„æŸäº›è² é¢ç—‡ç‹€ï¼Œä¸¦é™ä½ä»£è¬æŒ‡æ¨™ã€‚ 3. é€™é …ç ”ç©¶å€¼å¾—é€²ä¸€æ­¥æ¢ç´¢ï¼Œæœªä¾†å¯èƒ½æœ‰æ›´å¤šçš„ç™¼ç¾ï¼",
    "image_prompt": "Create an infographic that explains the experiment and main results of a study on sulforaphane, a compound from broccoli, and its effects on schizophrenia. The design should be flat and minimalistic, with a white or light-colored background and soft color palette. Include symbols representing broccoli or sulforaphane, simplified illustrations of experiment subjects (like people or cells), and arrows or flow lines indicating the steps of the experiment. There should also be a section clearly labeled 'Main Results' highlighting the protective effects and any observed changes.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "ç²¾ç¥åˆ†è£‚ç—‡ Schizophrenia",
    "is_clinical_trial": true,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41184790/"
  },
  {
    "id": "41604557",
    "title_en": "Sulforaphane Adjunct to Methylphenidate for Attention-deficit/Hyperactivity Disorder: A Randomized, Double-blind, Placebo-controlled Trial.",
    "pub_date": "2025 Nov-Dec 01",
    "journal": "Clinical neuropharmacology",
    "abstract_en": "Available treatment strategies for attention-deficit/hyperactivity disorder (ADHD) encounter significant limitations and, thus, necessitate novel therapeutic approaches. In this regard, this study investigated the effects of sulforaphane due to its neuroprotective, anti-inflammatory, and antioxidant properties. Seventy ADHD outpatients aged 6 to 11 were equally assigned to receive methylphenidate (0.3 to 1.5Â mg/kg/d) plus either sulforaphane 30Â mg/d or matched placebo for 8 weeks. The teacher and parent ADHD rating scale (ADHD-RS) was used to assess their symptoms at baseline and weeks 4 and 8. The patients were also evaluated for side effects. Thirty-two patients in the sulforaphane group and 31 in the placebo group completed the study with comparable baseline demographic and clinical characteristics (Ps>0.05). There were significant time-treatment interaction effects on the ADHD-RS total, inattention, and hyperactivity-impulsivity scores rated by teachers (=0.245, 0.203, and 0.246, respectively) and parents (=0.265, 0.283, and 0.159, respectively). Affirmatively, their reductions were significantly greater in the sulforaphane group until the endpoint rated by teachers (Cohen ds=1.192, 1.055, and 1.220, respectively) and parents (Cohen's ds=1.344, 1.446, and 0.966, respectively). Better response to treatment (â‰¥40% reduction in ADHD-RS total scores), robust improvement (â‰¥50% reduction in ADHD-RS total scores), and remission (an ADHD-RS total score of â‰¤18) rates were obtained in the sulforaphane group until the endpoint (Ps<0.001). The side effect frequencies were comparable between the groups (Ps>0.05). Sulforaphane adjunct to methylphenidate was beneficial for inattention, hyperactivity-impulsivity, and total symptoms of children with ADHD safely and tolerably.",
    "para1": "é€™é …ç ”ç©¶å°æ–¼æ³¨æ„åŠ›ä¸è¶³éå‹•ç—‡ï¼ˆADHDï¼‰çš„æ²»ç™‚æä¾›äº†æ–°çš„æ€è·¯ã€‚ç¾æœ‰çš„æ²»ç™‚æ–¹æ³•æœ‰å…¶é™åˆ¶ï¼Œå› æ­¤éœ€è¦å°‹æ‰¾æ–°çš„ç™‚æ³•ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½å…·æœ‰ç¥ç¶“ä¿è­·ã€æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–çš„ç‰¹æ€§ï¼Œé€™äº›ç‰¹æ€§å¯èƒ½å°æ”¹å–„ADHDç—‡ç‹€æœ‰å¹«åŠ©ã€‚é€™å°æ–¼å®¶é•·å’Œé†«ç™‚å°ˆæ¥­äººå“¡ä¾†èªªï¼Œå¯èƒ½æ˜¯ä¸€å€‹å€¼å¾—é—œæ³¨çš„é¸é …ï¼Œå°¤å…¶æ˜¯åœ¨ç¾æœ‰è—¥ç‰©æ•ˆæœä¸ä½³æˆ–æœ‰å‰¯ä½œç”¨çš„æƒ…æ³ä¸‹ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°æ³¨æ„åŠ›ä¸è¶³éå‹•ç—‡ï¼ˆADHDï¼‰æ‚£è€…çš„å½±éŸ¿ã€‚ADHDæ˜¯ä¸€ç¨®å¸¸è¦‹çš„ç¥ç¶“ç™¼å±•éšœç¤™ï¼Œé€šå¸¸åœ¨å…’ç«¥ä¸­è¢«è¨ºæ–·å‡ºä¾†ï¼Œå½±éŸ¿ä»–å€‘çš„æ³¨æ„åŠ›å’Œè¡Œç‚ºã€‚ç ”ç©¶æ—¨åœ¨è©•ä¼°è˜¿è””ç¡«ç´ èˆ‡å‚³çµ±è—¥ç‰©ç”²åŸºè‹¯ä¸™èƒºï¼ˆmethylphenidateï¼‰è¯åˆä½¿ç”¨çš„æ•ˆæœï¼Œä¸¦äº†è§£é€™ç¨®æ–°ç™‚æ³•æ˜¯å¦èƒ½æ”¹å–„ADHDçš„ç—‡ç‹€ã€‚",
    "para3": "ç ”ç©¶å°è±¡ç‚º70åå¹´é½¡åœ¨6åˆ°11æ­²ä¹‹é–“çš„ADHDæ‚£è€…ï¼Œé€™äº›æ‚£è€…è¢«éš¨æ©Ÿåˆ†ç‚ºå…©çµ„ï¼Œä¸€çµ„æ¥å—ç”²åŸºè‹¯ä¸™èƒºåŠ ä¸Šæ¯æ—¥30æ¯«å…‹çš„è˜¿è””ç¡«ç´ ï¼Œå¦ä¸€çµ„å‰‡æ¥å—ç›¸åŒåŠ‘é‡çš„å®‰æ…°åŠ‘ï¼Œç‚ºæœŸ8é€±ã€‚ç ”ç©¶ä½¿ç”¨æ•™å¸«å’Œå®¶é•·çš„ADHDè©•åˆ†é‡è¡¨ä¾†è©•ä¼°æ‚£è€…çš„ç—‡ç‹€ï¼Œä¸¦åœ¨ç ”ç©¶é–‹å§‹æ™‚åŠç¬¬4é€±å’Œç¬¬8é€±é€²è¡Œè©•ä¼°ã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„è©•ä¼°äº†æ‚£è€…çš„å‰¯ä½œç”¨æƒ…æ³ï¼Œä»¥ç¢ºä¿æ²»ç™‚çš„å®‰å…¨æ€§ã€‚",
    "para4": "ç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ çµ„åœ¨ADHDè©•åˆ†é‡è¡¨çš„ç¸½åˆ†ã€æ³¨æ„åŠ›ä¸é›†ä¸­å’Œéå‹•-è¡å‹•çš„è©•åˆ†ä¸Šï¼Œèˆ‡å®‰æ…°åŠ‘çµ„ç›¸æ¯”æœ‰é¡¯è‘—çš„æ”¹å–„ã€‚ç‰¹åˆ¥æ˜¯åœ¨æ•™å¸«çš„è©•åˆ†ä¸­ï¼Œè˜¿è””ç¡«ç´ çµ„çš„æ”¹å–„å¹…åº¦æ›´å¤§ï¼Œä¸”å‰¯ä½œç”¨çš„ç™¼ç”Ÿç‡åœ¨å…©çµ„ä¹‹é–“ç›¸ä¼¼ã€‚é€™è¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ ä½œç‚ºè¼”åŠ©ç™‚æ³•ï¼Œå¯èƒ½å°ADHDå…’ç«¥çš„æ³¨æ„åŠ›ä¸é›†ä¸­ã€éå‹•å’Œç¸½é«”ç—‡ç‹€æœ‰æ­£é¢çš„å½±éŸ¿ï¼Œä¸”åœ¨å®‰å…¨æ€§ä¸Šä¹Ÿè¡¨ç¾è‰¯å¥½ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°æ–¼æ³¨æ„åŠ›ä¸è¶³éå‹•ç—‡ï¼ˆADHDï¼‰çš„æ²»ç™‚æä¾›äº†æ–°çš„æ€è·¯ã€‚ç¾æœ‰çš„æ²»ç™‚æ–¹æ³•æœ‰å…¶é™åˆ¶ï¼Œå› æ­¤éœ€è¦å°‹æ‰¾æ–°çš„ç™‚æ³•ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½å…·æœ‰ç¥ç¶“ä¿è­·ã€æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–çš„ç‰¹æ€§ï¼Œé€™äº›ç‰¹æ€§å¯èƒ½å°æ”¹å–„ADHDç—‡ç‹€æœ‰å¹«åŠ©ã€‚é€™å°æ–¼å®¶é•·å’Œé†«ç™‚å°ˆæ¥­äººå“¡ä¾†èªªï¼Œå¯èƒ½æ˜¯ä¸€å€‹å€¼å¾—é—œæ³¨çš„é¸é …ï¼Œå°¤å…¶æ˜¯åœ¨ç¾æœ‰è—¥ç‰©æ•ˆæœä¸ä½³æˆ–æœ‰å‰¯ä½œç”¨çš„æƒ…æ³ä¸‹ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°æ³¨æ„åŠ›ä¸è¶³éå‹•ç—‡ï¼ˆADHDï¼‰æ‚£è€…çš„å½±éŸ¿ã€‚ADHDæ˜¯ä¸€ç¨®å¸¸è¦‹çš„ç¥ç¶“ç™¼å±•éšœç¤™ï¼Œé€šå¸¸åœ¨å…’ç«¥ä¸­è¢«è¨ºæ–·å‡ºä¾†ï¼Œå½±éŸ¿ä»–å€‘çš„æ³¨æ„åŠ›å’Œè¡Œç‚ºã€‚ç ”ç©¶æ—¨åœ¨è©•ä¼°è˜¿è””ç¡«ç´ èˆ‡å‚³çµ±è—¥ç‰©ç”²åŸºè‹¯ä¸™èƒºï¼ˆmethylphenidateï¼‰è¯åˆä½¿ç”¨çš„æ•ˆæœï¼Œä¸¦äº†è§£é€™ç¨®æ–°ç™‚æ³•æ˜¯å¦èƒ½æ”¹å–„ADHDçš„ç—‡ç‹€ã€‚\n\nç ”ç©¶å°è±¡ç‚º70åå¹´é½¡åœ¨6åˆ°11æ­²ä¹‹é–“çš„ADHDæ‚£è€…ï¼Œé€™äº›æ‚£è€…è¢«éš¨æ©Ÿåˆ†ç‚ºå…©çµ„ï¼Œä¸€çµ„æ¥å—ç”²åŸºè‹¯ä¸™èƒºåŠ ä¸Šæ¯æ—¥30æ¯«å…‹çš„è˜¿è””ç¡«ç´ ï¼Œå¦ä¸€çµ„å‰‡æ¥å—ç›¸åŒåŠ‘é‡çš„å®‰æ…°åŠ‘ï¼Œç‚ºæœŸ8é€±ã€‚ç ”ç©¶ä½¿ç”¨æ•™å¸«å’Œå®¶é•·çš„ADHDè©•åˆ†é‡è¡¨ä¾†è©•ä¼°æ‚£è€…çš„ç—‡ç‹€ï¼Œä¸¦åœ¨ç ”ç©¶é–‹å§‹æ™‚åŠç¬¬4é€±å’Œç¬¬8é€±é€²è¡Œè©•ä¼°ã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„è©•ä¼°äº†æ‚£è€…çš„å‰¯ä½œç”¨æƒ…æ³ï¼Œä»¥ç¢ºä¿æ²»ç™‚çš„å®‰å…¨æ€§ã€‚\n\nç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ çµ„åœ¨ADHDè©•åˆ†é‡è¡¨çš„ç¸½åˆ†ã€æ³¨æ„åŠ›ä¸é›†ä¸­å’Œéå‹•-è¡å‹•çš„è©•åˆ†ä¸Šï¼Œèˆ‡å®‰æ…°åŠ‘çµ„ç›¸æ¯”æœ‰é¡¯è‘—çš„æ”¹å–„ã€‚ç‰¹åˆ¥æ˜¯åœ¨æ•™å¸«çš„è©•åˆ†ä¸­ï¼Œè˜¿è””ç¡«ç´ çµ„çš„æ”¹å–„å¹…åº¦æ›´å¤§ï¼Œä¸”å‰¯ä½œç”¨çš„ç™¼ç”Ÿç‡åœ¨å…©çµ„ä¹‹é–“ç›¸ä¼¼ã€‚é€™è¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ ä½œç‚ºè¼”åŠ©ç™‚æ³•ï¼Œå¯èƒ½å°ADHDå…’ç«¥çš„æ³¨æ„åŠ›ä¸é›†ä¸­ã€éå‹•å’Œç¸½é«”ç—‡ç‹€æœ‰æ­£é¢çš„å½±éŸ¿ï¼Œä¸”åœ¨å®‰å…¨æ€§ä¸Šä¹Ÿè¡¨ç¾è‰¯å¥½ã€‚",
    "fb_post": "æ ¹æ“šã€ŠClinical neuropharmacologyã€‹æ–¼ 2025 å¹´ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒŸ æƒ³çŸ¥é“è˜¿è””ä¹Ÿèƒ½å¹«åŠ©æ”¹å–„æ³¨æ„åŠ›ä¸è¶³éå‹•ç—‡ï¼ˆADHDï¼‰å—ï¼Ÿé€™æ˜¯ä¸€å€‹è®“äººé©šå–œçš„ç ”ç©¶ï¼\n\næœ€è¿‘çš„ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ ï¼ˆä¾†è‡ªé’èŠ±æ¤°èœå’Œè˜¿è””çš„æˆåˆ†ï¼‰å°ADHDçš„å½±éŸ¿ï¼Œé€™æ˜¯ä¸€ç¨®å½±éŸ¿å­©å­æ³¨æ„åŠ›å’Œè¡Œç‚ºçš„å¸¸è¦‹å•é¡Œã€‚ç¾æœ‰çš„æ²»ç™‚æ–¹æ³•æœ‰æ™‚æ•ˆæœä¸ä½³ï¼Œå› æ­¤ç§‘å­¸å®¶å€‘å¸Œæœ›æ‰¾åˆ°æ–°çš„è§£æ±ºæ–¹æ¡ˆã€‚\n\nåœ¨é€™é …ç ”ç©¶ä¸­ï¼Œ70å6åˆ°11æ­²çš„ADHDå­©å­è¢«éš¨æ©Ÿåˆ†æˆå…©çµ„ï¼Œä¸€çµ„ä½¿ç”¨å‚³çµ±è—¥ç‰©ç”²åŸºè‹¯ä¸™èƒºï¼ˆmethylphenidateï¼‰åŠ ä¸Šæ¯å¤©30æ¯«å…‹çš„è˜¿è””ç¡«ç´ ï¼Œå¦ä¸€çµ„å‰‡ä½¿ç”¨å®‰æ…°åŠ‘ã€‚ç ”ç©¶æŒçºŒäº†8é€±ï¼Œç ”ç©¶äººå“¡é€éè€å¸«å’Œå®¶é•·çš„è©•åˆ†ä¾†è©•ä¼°å­©å­çš„ç—‡ç‹€è®ŠåŒ–ã€‚\n\nçµæœé¡¯ç¤ºï¼Œæ¥å—è˜¿è””ç¡«ç´ çš„å­©å­åœ¨æ³¨æ„åŠ›ä¸é›†ä¸­å’Œéå‹•-è¡å‹•çš„è©•åˆ†ä¸Šæœ‰é¡¯è‘—æ”¹å–„ï¼Œç‰¹åˆ¥æ˜¯åœ¨è€å¸«çš„è©•åˆ†ä¸­ï¼Œæ•ˆæœæ›´æ˜é¡¯ã€‚æ­¤å¤–ï¼Œå…©çµ„çš„å‰¯ä½œç”¨ç™¼ç”Ÿç‡ç›¸ä¼¼ï¼Œé¡¯ç¤ºè˜¿è””ç¡«ç´ çš„å®‰å…¨æ€§ä¹Ÿä¸éŒ¯ã€‚\n\nğŸ” ç¸½çµä¾†èªªï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½å°æ”¹å–„ADHDç—‡ç‹€æœ‰æ­£é¢å½±éŸ¿ã€‚\n2. ç ”ç©¶é¡¯ç¤ºå®ƒçš„å®‰å…¨æ€§èˆ‡å‚³çµ±è—¥ç‰©ç›¸ç•¶ã€‚\n3. å°æ–¼æ•ˆæœä¸ä½³çš„å­©å­ï¼Œé€™å¯èƒ½æ˜¯ä¸€å€‹å€¼å¾—è€ƒæ…®çš„æ–°é¸æ“‡ï¼",
    "image_prompt": "Create an infographic explaining the experiment and main results of a study on the effects of sulforaphane on ADHD. Use a flat design style with a white or light-colored background and soft color palette. Include symbols representing broccoli or sulforaphane, simplified illustrations of human subjects (children), arrows or flow lines showing the experimental steps, and a section highlighting the main results, such as protective effects and observed improvements.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "æ³¨æ„åŠ›ä¸è¶³éå‹•ç—‡ Attention-Deficit/Hyperactivity Disorder",
    "is_clinical_trial": true,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41604557/"
  },
  {
    "id": "40992247",
    "title_en": "Assessing the transplacental passage and breastmilk levels of broccoli sprout-derived sulforaphane.",
    "pub_date": "2025 Nov",
    "journal": "Placenta",
    "abstract_en": "Preeclampsia is characterised by hypertension with maternal end-organ dysfunction and/or fetal growth restriction. Sulforaphane, an antioxidant found in broccoli sprouts, has potential as a future therapeutic. With its ability to attenuate the injurious impacts of endothelial dysfunction in vitro, sulforaphane is uniquely positioned to protect against the harmful effects of preeclampsia. However, the transferability of sulforaphane from mother to fetus/baby remains unknown in humans. Uncomplicated pregnant patients (nÂ =Â 8) scheduled for elective caesarean sections (>37 weeks gestation) provided written and informed consent. A single oral dose of EnduraCell, a broccoli sprout extract (equivalent to 21Â mg of sulforaphane), was administered prior to caesarean section. Baseline blood pressure, blood and urine were collected and again at time of operation, alongside umbilical cord blood (vein and artery) and placental samples. 2-4 days post-delivery, a second dose was administered. Two hours later, maternal bloods and breast milk were collected. Samples were processed and analysed by liquid-chromatography mass-spectrometry to measure sulforaphane. Besides an increase in peripheral diastolic blood pressure on the day of caesarean section (pÂ =Â 0.028), there were no changes in maternal blood pressure or heart rate after ingestion of EnduraCell. Sulforaphane was found in maternal serum (70.10Â ng/mlÂ Â±Â 11.90), umbilical cord blood (vein: 25.18Â ng/mLÂ Â±Â 3.11, artery: 18.81Â ng/mLÂ Â±Â 2.36), urine (5726.00Â ng/mLÂ Â±Â 1175.00), placental tissue (10.99Â ng/mgÂ Â±Â 2.11) and breast milk (1.33Â ng/mLÂ Â±Â 2.29). Sulforaphane is present in the umbilical cord and breast milk, providing the world's first evidence of sulforaphane maternal-fetal transfer in humans, and opening avenues for future research into relevant fetal implications.",
    "para1": "é€™é …ç ”ç©¶å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›å¯èƒ½çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨å¦Šå¨ é«˜è¡€å£“ç—‡ï¼ˆå­ç™²å‰ç—‡ï¼‰çš„æƒ…æ³ä¸‹ã€‚å­ç™²å‰ç—‡æ˜¯ä¸€ç¨®å¦Šå¨ æœŸé–“å¯èƒ½å‡ºç¾çš„é«˜è¡€å£“ç–¾ç—…ï¼Œæœƒå½±éŸ¿æ¯é«”å’Œèƒå…’çš„å¥åº·ã€‚ç ”ç©¶æŒ‡å‡ºï¼Œè˜¿è””ç¡«ç´ é€™ç¨®å­˜åœ¨æ–¼é’èŠ±æ¤°èœä¸­çš„æŠ—æ°§åŒ–åŠ‘ï¼Œå¯èƒ½å°æ–¼æ¸›è¼•å­ç™²å‰ç—‡çš„æœ‰å®³å½±éŸ¿æœ‰æ½›åœ¨çš„ç™‚æ•ˆã€‚é€™æ„å‘³è‘—ï¼Œé€éé£²é£Ÿä¸­çš„å¤©ç„¶æˆåˆ†ï¼Œæˆ–è¨±èƒ½å¤ åœ¨æœªä¾†å¹«åŠ©æ”¹å–„å¦Šå¨ é«˜è¡€å£“çš„æƒ…æ³ï¼Œé€²è€Œä¿è­·æ¯å¬°å¥åº·ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨å¦Šå¨ é«˜è¡€å£“ç—‡ä¸­çš„æ½›åœ¨æ‡‰ç”¨ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½å¤ å¾æ¯é«”è½‰ç§»åˆ°èƒå…’ï¼Œä¸¦ä¸”åœ¨å¦Šå¨ éç¨‹ä¸­æ˜¯å¦èƒ½å¤ ç™¼æ®ä¿è­·ä½œç”¨ã€‚ç”±æ–¼å­ç™²å‰ç—‡æœƒå°è‡´æ¯é«”å’Œèƒå…’çš„å¥åº·é¢¨éšªï¼Œå› æ­¤äº†è§£é€™ç¨®å¤©ç„¶åŒ–åˆç‰©çš„è½‰ç§»å’Œä½œç”¨æ©Ÿåˆ¶ï¼Œå°æ–¼æœªä¾†çš„æ²»ç™‚ç­–ç•¥å…·æœ‰é‡è¦æ„ç¾©ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…æ‹›å‹Ÿäº†8ä½å¥åº·çš„å­•å©¦ï¼Œé€™äº›å­•å©¦åœ¨æ‡·å­•è¶…é37é€±æ™‚ï¼Œè¨ˆåŠƒé€²è¡Œå‰–è…¹ç”¢æ‰‹è¡“ã€‚é€™äº›å­•å©¦åœ¨æ‰‹è¡“å‰æ¥å—äº†æ›¸é¢åŒæ„ï¼Œä¸¦åœ¨æ‰‹è¡“å‰å£æœäº†ä¸€åŠ‘å«æœ‰21æ¯«å…‹è˜¿è””ç¡«ç´ çš„é’èŠ±æ¤°èœèƒå–ç‰©ã€‚ç ”ç©¶è€…åœ¨æ‰‹è¡“å‰å’Œæ‰‹è¡“æ™‚æ”¶é›†äº†æ¯é«”çš„è¡€å£“ã€è¡€æ¶²å’Œå°¿æ¶²æ¨£æœ¬ï¼Œä¸¦æ”¶é›†äº†è‡å¸¶è¡€å’Œèƒç›¤æ¨£æœ¬ã€‚æ‰‹è¡“å¾Œ2è‡³4å¤©ï¼Œå­•å©¦å†æ¬¡æœç”¨è˜¿è””ç¡«ç´ ï¼Œä¸¦åœ¨å…©å°æ™‚å¾Œæ”¶é›†æ¯é«”è¡€æ¶²å’Œæ¯ä¹³æ¨£æœ¬ï¼Œé€²è¡Œåˆ†æã€‚",
    "para4": "ç ”ç©¶çš„ä¸»è¦ç™¼ç¾æ˜¯ï¼Œè˜¿è””ç¡«ç´ åœ¨æ¯é«”è¡€æ¸…ã€è‡å¸¶è¡€ã€å°¿æ¶²ã€èƒç›¤çµ„ç¹”å’Œæ¯ä¹³ä¸­å‡æœ‰æª¢æ¸¬åˆ°ï¼Œé€™æ˜¯äººé¡ä¸­é¦–æ¬¡è­‰å¯¦è˜¿è””ç¡«ç´ èƒ½å¤ å¾æ¯é«”è½‰ç§»åˆ°èƒå…’ã€‚é›–ç„¶åœ¨å‰–è…¹ç”¢ç•¶å¤©ï¼Œå­•å©¦çš„å‘¨é‚Šèˆ’å¼µå£“æœ‰æ‰€ä¸Šå‡ï¼Œä½†æ•´é«”ä¸Šï¼Œæ¯é«”çš„è¡€å£“å’Œå¿ƒç‡åœ¨æœç”¨è˜¿è””ç¡«ç´ å¾Œä¸¦æœªç™¼ç”Ÿé¡¯è‘—è®ŠåŒ–ã€‚é€™äº›çµæœç‚ºæœªä¾†ç ”ç©¶è˜¿è””ç¡«ç´ åœ¨å¦Šå¨ ä¸­çš„æ½›åœ¨å½±éŸ¿æä¾›äº†æ–°çš„æ–¹å‘ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›å¯èƒ½çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨å¦Šå¨ é«˜è¡€å£“ç—‡ï¼ˆå­ç™²å‰ç—‡ï¼‰çš„æƒ…æ³ä¸‹ã€‚å­ç™²å‰ç—‡æ˜¯ä¸€ç¨®å¦Šå¨ æœŸé–“å¯èƒ½å‡ºç¾çš„é«˜è¡€å£“ç–¾ç—…ï¼Œæœƒå½±éŸ¿æ¯é«”å’Œèƒå…’çš„å¥åº·ã€‚ç ”ç©¶æŒ‡å‡ºï¼Œè˜¿è””ç¡«ç´ é€™ç¨®å­˜åœ¨æ–¼é’èŠ±æ¤°èœä¸­çš„æŠ—æ°§åŒ–åŠ‘ï¼Œå¯èƒ½å°æ–¼æ¸›è¼•å­ç™²å‰ç—‡çš„æœ‰å®³å½±éŸ¿æœ‰æ½›åœ¨çš„ç™‚æ•ˆã€‚é€™æ„å‘³è‘—ï¼Œé€éé£²é£Ÿä¸­çš„å¤©ç„¶æˆåˆ†ï¼Œæˆ–è¨±èƒ½å¤ åœ¨æœªä¾†å¹«åŠ©æ”¹å–„å¦Šå¨ é«˜è¡€å£“çš„æƒ…æ³ï¼Œé€²è€Œä¿è­·æ¯å¬°å¥åº·ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨å¦Šå¨ é«˜è¡€å£“ç—‡ä¸­çš„æ½›åœ¨æ‡‰ç”¨ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½å¤ å¾æ¯é«”è½‰ç§»åˆ°èƒå…’ï¼Œä¸¦ä¸”åœ¨å¦Šå¨ éç¨‹ä¸­æ˜¯å¦èƒ½å¤ ç™¼æ®ä¿è­·ä½œç”¨ã€‚ç”±æ–¼å­ç™²å‰ç—‡æœƒå°è‡´æ¯é«”å’Œèƒå…’çš„å¥åº·é¢¨éšªï¼Œå› æ­¤äº†è§£é€™ç¨®å¤©ç„¶åŒ–åˆç‰©çš„è½‰ç§»å’Œä½œç”¨æ©Ÿåˆ¶ï¼Œå°æ–¼æœªä¾†çš„æ²»ç™‚ç­–ç•¥å…·æœ‰é‡è¦æ„ç¾©ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…æ‹›å‹Ÿäº†8ä½å¥åº·çš„å­•å©¦ï¼Œé€™äº›å­•å©¦åœ¨æ‡·å­•è¶…é37é€±æ™‚ï¼Œè¨ˆåŠƒé€²è¡Œå‰–è…¹ç”¢æ‰‹è¡“ã€‚é€™äº›å­•å©¦åœ¨æ‰‹è¡“å‰æ¥å—äº†æ›¸é¢åŒæ„ï¼Œä¸¦åœ¨æ‰‹è¡“å‰å£æœäº†ä¸€åŠ‘å«æœ‰21æ¯«å…‹è˜¿è””ç¡«ç´ çš„é’èŠ±æ¤°èœèƒå–ç‰©ã€‚ç ”ç©¶è€…åœ¨æ‰‹è¡“å‰å’Œæ‰‹è¡“æ™‚æ”¶é›†äº†æ¯é«”çš„è¡€å£“ã€è¡€æ¶²å’Œå°¿æ¶²æ¨£æœ¬ï¼Œä¸¦æ”¶é›†äº†è‡å¸¶è¡€å’Œèƒç›¤æ¨£æœ¬ã€‚æ‰‹è¡“å¾Œ2è‡³4å¤©ï¼Œå­•å©¦å†æ¬¡æœç”¨è˜¿è””ç¡«ç´ ï¼Œä¸¦åœ¨å…©å°æ™‚å¾Œæ”¶é›†æ¯é«”è¡€æ¶²å’Œæ¯ä¹³æ¨£æœ¬ï¼Œé€²è¡Œåˆ†æã€‚\n\nç ”ç©¶çš„ä¸»è¦ç™¼ç¾æ˜¯ï¼Œè˜¿è””ç¡«ç´ åœ¨æ¯é«”è¡€æ¸…ã€è‡å¸¶è¡€ã€å°¿æ¶²ã€èƒç›¤çµ„ç¹”å’Œæ¯ä¹³ä¸­å‡æœ‰æª¢æ¸¬åˆ°ï¼Œé€™æ˜¯äººé¡ä¸­é¦–æ¬¡è­‰å¯¦è˜¿è””ç¡«ç´ èƒ½å¤ å¾æ¯é«”è½‰ç§»åˆ°èƒå…’ã€‚é›–ç„¶åœ¨å‰–è…¹ç”¢ç•¶å¤©ï¼Œå­•å©¦çš„å‘¨é‚Šèˆ’å¼µå£“æœ‰æ‰€ä¸Šå‡ï¼Œä½†æ•´é«”ä¸Šï¼Œæ¯é«”çš„è¡€å£“å’Œå¿ƒç‡åœ¨æœç”¨è˜¿è””ç¡«ç´ å¾Œä¸¦æœªç™¼ç”Ÿé¡¯è‘—è®ŠåŒ–ã€‚é€™äº›çµæœç‚ºæœªä¾†ç ”ç©¶è˜¿è””ç¡«ç´ åœ¨å¦Šå¨ ä¸­çš„æ½›åœ¨å½±éŸ¿æä¾›äº†æ–°çš„æ–¹å‘ã€‚",
    "fb_post": "æ ¹æ“šã€ŠPlacentaã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ±ä½ çŸ¥é“å—ï¼Ÿé’èŠ±æ¤°èœè£¡çš„è˜¿è””ç¡«ç´ ï¼Œå¯èƒ½å°å­•å©¦çš„å¥åº·æœ‰æ„æƒ³ä¸åˆ°çš„å¥½è™•ï¼é€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ åœ¨å¦Šå¨ é«˜è¡€å£“ç—‡ï¼ˆå­ç™²å‰ç—‡ï¼‰ä¸­çš„æ½›åœ¨æ‡‰ç”¨ï¼Œé€™æ˜¯ä¸€ç¨®å¦Šå¨ æ™‚å¯èƒ½å‡ºç¾çš„é«˜è¡€å£“å•é¡Œï¼Œæœƒå½±éŸ¿åˆ°åª½åª½å’Œå¯¶å¯¶çš„å¥åº·ã€‚ç ”ç©¶è€…æƒ³çŸ¥é“ï¼Œé€™ç¨®å¤©ç„¶æˆåˆ†èƒ½å¦å¾åª½åª½çš„èº«é«”è½‰ç§»åˆ°èƒå…’ï¼Œä¸¦æä¾›ä¿è­·ã€‚  \n  \nåœ¨å¯¦é©—ä¸­ï¼Œ8ä½å¥åº·çš„å­•å©¦åœ¨å‰–è…¹ç”¢å‰ï¼Œå£æœäº†å«æœ‰21æ¯«å…‹è˜¿è””ç¡«ç´ çš„é’èŠ±æ¤°èœèƒå–ç‰©ã€‚æ‰‹è¡“å‰å¾Œï¼Œç ”ç©¶è€…æ”¶é›†äº†ä»–å€‘çš„è¡€å£“ã€è¡€æ¶²ã€å°¿æ¶²æ¨£æœ¬ï¼Œé‚„æœ‰è‡å¸¶è¡€å’Œèƒç›¤æ¨£æœ¬ã€‚çµæœç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ åœ¨åª½åª½çš„è¡€æ¸…ã€è‡å¸¶è¡€ã€å°¿æ¶²ç­‰å¤šç¨®æ¨£æœ¬ä¸­éƒ½æœ‰æª¢æ¸¬åˆ°ï¼Œé€™æ˜¯é¦–æ¬¡è­‰å¯¦å®ƒèƒ½å¤ å¾åª½åª½è½‰ç§»åˆ°å¯¶å¯¶èº«ä¸Šï¼é›–ç„¶å­•å©¦çš„è¡€å£“ç•¥æœ‰ä¸Šå‡ï¼Œä½†æ•´é«”ä¸Šä¸¦æœªæœ‰æ˜é¡¯çš„è®ŠåŒ–ã€‚  \n  \nâœ¨é€™é …ç ”ç©¶çš„é‡é»ï¼š  \n1. è˜¿è””ç¡«ç´ å¯èƒ½å°å¦Šå¨ é«˜è¡€å£“ç—‡æœ‰æ­£é¢å½±éŸ¿ã€‚  \n2. å®ƒèƒ½å¤ å¾æ¯é«”è½‰ç§»åˆ°èƒå…’ï¼Œé€™æ˜¯å€‹å¥½æ¶ˆæ¯ï¼  \n3. æœªä¾†ç ”ç©¶å¯èƒ½æœƒç‚ºå­•å©¦çš„å¥åº·å¸¶ä¾†æ–°çš„æ²»ç™‚æ–¹å‘ï¼",
    "image_prompt": "Create an infographic that explains the experiment and main results of a study on sulforaphane, a compound found in broccoli, and its potential effects on pregnancy hypertension. Use flat design style with a white or light-colored background and soft color palette. Include symbols representing broccoli or sulforaphane, simplified illustrations of the experiment subjects like pregnant women, and arrows or flow lines showing the steps of the experiment. Add a section highlighting the main results, such as the protective effects observed and the transfer of sulforaphane from mother to fetus.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "å¦Šå¨ é«˜è¡€å£“ç—‡ Preeclampsia",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40992247/"
  }
]